[
  {
    "title": "\"Murder In Boston\" Reopens The City's Troubled History Of Race Relations: One Path Forward",
    "url": "https://www.forbes.com/sites/sachinjain/2024/01/01/murder-in-boston-reopens-the-citys-troubled-history-of-race-relations-one-path-forward/",
    "time_published": "20240101T174137",
    "authors": [
      "Sachin H. Jain"
    ],
    "summary": "Charles Stuart shot his pregnant wife Carol and himself on the way out of a birthing class at the Brigham and Women's Hospital. When Stuart, a white man, called 911 for assistance, he implicated a fictitious \"black man\" who fled into Boston's Mission Hill neighborhood.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65923b81ddab975226978df2/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.173835,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.027667",
        "ticker_sentiment_score": "0.155307",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WBD",
        "relevance_score": "0.027667",
        "ticker_sentiment_score": "-0.08895",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 No-Brainer Growth Stocks to Buy for Less Than $100",
    "url": "https://www.fool.com/investing/2024/01/01/3-no-brainer-growth-stocks-to-buy-for-less-than-10/",
    "time_published": "20240101T140500",
    "authors": [
      "David Jagielski"
    ],
    "summary": "These businesses have promising futures and make for great investment options today.",
    "banner_image": "https://g.foolcdn.com/editorial/images/759494/an-excited-investor-looking-at-a-chart.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999612"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.95493"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.313856,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PYPL",
        "relevance_score": "0.244109",
        "ticker_sentiment_score": "0.230309",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.061949",
        "ticker_sentiment_score": "0.117349",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PLTR",
        "relevance_score": "0.123526",
        "ticker_sentiment_score": "0.245392",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Prediction: These 3 Stocks Will Soar in 2024",
    "url": "https://www.fool.com/investing/2024/01/01/prediction-these-3-stocks-will-soar-in-2024/",
    "time_published": "20240101T115000",
    "authors": [
      "Keith Speights",
      "David Jagielski",
      "and Prosper Junior Bakiny"
    ],
    "summary": "Investors could enjoy an especially happy new year with these great stocks.",
    "banner_image": "https://g.foolcdn.com/editorial/images/759462/cheering-person-with-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.196612,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.121241",
        "ticker_sentiment_score": "0.009226",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.040553",
        "ticker_sentiment_score": "0.035663",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.278109",
        "ticker_sentiment_score": "0.148716",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXSM",
        "relevance_score": "0.200688",
        "ticker_sentiment_score": "0.14049",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "A Closer Look at CRISPR Therapeutics's Options Market Dynamics - CRISPR Therapeutics  ( NASDAQ:CRSP ) ",
    "url": "https://www.benzinga.com/markets/options/24/01/36456642/a-closer-look-at-crispr-therapeuticss-options-market-dynamics",
    "time_published": "20240102T180116",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "High-rolling investors have positioned themselves bearish on CRISPR Therapeutics CRSP, and it's important for retail traders to take note. \\This activity came to our attention today through Benzinga's tracking of publicly available options data.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.955357"
      }
    ],
    "overall_sentiment_score": 0.184336,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.073546",
        "ticker_sentiment_score": "0.154411",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Editas  ( EDIT )  Stock Gains 23% in the Past 6 Months: Here's Why",
    "url": "https://www.zacks.com/stock/news/2204495/editas-edit-stock-gains-23-in-the-past-6-months-heres-why",
    "time_published": "20240102T151500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Editas (EDIT) shares have gained 23% in the past six months, driven by encouraging findings from the EDIT-301 studies in SCD and TDT, along with a licensing deal for its CAS9 gene-editing tool with Vertex.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7b/850.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.19702,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.089629",
        "ticker_sentiment_score": "0.121267",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BLUE",
        "relevance_score": "0.17813",
        "ticker_sentiment_score": "-0.007337",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EDIT",
        "relevance_score": "0.306416",
        "ticker_sentiment_score": "0.110989",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "InnovationRx: TikTok's Parent Company Is Moving Into Pharma",
    "url": "https://www.forbes.com/sites/katiejennings/2024/01/03/innovationrx-tiktoks-parent-company-is-moving-into-pharma/",
    "time_published": "20240103T225426",
    "authors": [
      "Alex Knapp"
    ],
    "summary": "InnovationRx is your weekly digest of healthcare news. To get it in your inbox, subscribe here.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6595e262535a2a6b7e7d0520/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.121447,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.062597",
        "ticker_sentiment_score": "0.059009",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.062597",
        "ticker_sentiment_score": "0.072015",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RADCQ",
        "relevance_score": "0.062597",
        "ticker_sentiment_score": "-0.092344",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( VRTX )  Stock Moves -0.05%: What You Should Know",
    "url": "https://www.zacks.com/stock/news/2205305/vertex-pharmaceuticals-vrtx-stock-moves--005-what-you-should-know",
    "time_published": "20240103T225017",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $410.71, signifying a -0.05% move from its prior day's close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default110.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.214612,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.571903",
        "ticker_sentiment_score": "0.262764",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Voyager  ( VYGR )  Gains on Gene Therapy Deal With Novartis",
    "url": "https://www.zacks.com/stock/news/2205112/voyager-vygr-gains-on-gene-therapy-deal-with-novartis",
    "time_published": "20240103T161500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Voyager (VYGR) enters into a capsid license agreement with Novartis for Huntington's disease and spinal muscular atrophy. The infusion of cash will extend the company's cash runway.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2e/972.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.154057,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.059785",
        "ticker_sentiment_score": "0.073998",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DVAX",
        "relevance_score": "0.235823",
        "ticker_sentiment_score": "0.083852",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRDA",
        "relevance_score": "0.178021",
        "ticker_sentiment_score": "0.073644",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VYGR",
        "relevance_score": "0.178021",
        "ticker_sentiment_score": "0.020082",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Invesco Biotechnology & Genome ETF  ( PBE )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2204768/is-invesco-biotechnology-genome-etf-pbe-a-strong-etf-right-now",
    "time_published": "20240103T112007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default111.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999994"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.279971,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.116631",
        "ticker_sentiment_score": "0.066983",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.230782",
        "ticker_sentiment_score": "0.218856",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.116631",
        "ticker_sentiment_score": "0.066983",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.116631",
        "ticker_sentiment_score": "0.066983",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "January Has Been 1 of the Worst Months for the S&P 500 Over the Last 20 Years. Here Are 3 Stocks to Buy Anyway.",
    "url": "https://www.fool.com/investing/2024/01/03/january-worst-month-sp-500-stocks-buy/",
    "time_published": "20240103T105000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "These stocks are smart picks to buy now, regardless of whether the S&P 500 stocks start off 2024 poorly.",
    "banner_image": "https://g.foolcdn.com/editorial/images/759884/young-woman-looking-at-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.193821,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BEP",
        "relevance_score": "0.31006",
        "ticker_sentiment_score": "0.325769",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.126784",
        "ticker_sentiment_score": "0.139505",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MELI",
        "relevance_score": "0.31006",
        "ticker_sentiment_score": "0.266519",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Stran & Company Appoints Ian Thomas Wall as Chief Information Officer",
    "url": "https://www.globenewswire.com/news-release/2024/01/04/2804023/0/en/Stran-Company-Appoints-Ian-Thomas-Wall-as-Chief-Information-Officer.html",
    "time_published": "20240104T140000",
    "authors": [
      "Inc.",
      "Stran & Company"
    ],
    "summary": "Quincy, MA, Jan. 04, 2024 ( GLOBE NEWSWIRE ) -- Stran & Company, Inc. ( \"Stran\" or the \"Company\" ) ( NASDAQ: SWAG. SWAGW ) , a leading outsourced marketing solutions provider that leverages its promotional products and loyalty incentive expertise, announces that it has appointed Ian Thomas Wall ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/b48087c7-1d09-44f4-b051-176a3ab4efaf",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.285414,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.04794",
        "ticker_sentiment_score": "0.073616",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWAG",
        "relevance_score": "0.369456",
        "ticker_sentiment_score": "0.569935",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.04794",
        "ticker_sentiment_score": "0.073616",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Best Stocks to Invest $1,000 in Right Now",
    "url": "https://www.fool.com/investing/2024/01/04/the-best-stocks-to-invest-1000-in-right-now/",
    "time_published": "20240104T140000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "It's not too late to get in on these market beaters.",
    "banner_image": "https://g.foolcdn.com/editorial/images/759414/pharmacist-talking-to-patient.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.858979"
      }
    ],
    "overall_sentiment_score": 0.270989,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.276491",
        "ticker_sentiment_score": "0.36389",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.168099",
        "ticker_sentiment_score": "0.264564",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.3796",
        "ticker_sentiment_score": "0.27009",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Here's Why 2024 Could Be a Big Year for CRISPR Therapeutics",
    "url": "https://www.fool.com/investing/2024/01/04/heres-why-2024-could-be-a-big-year-for-crispr-ther/",
    "time_published": "20240104T100000",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "CRISPR Therapeutics' shares climbed considerably last year -- but more gains could be just ahead.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F759122%2Fscientists-high-five-smile.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.33254,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.061949",
        "ticker_sentiment_score": "0.062005",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "StockNews.com Downgrades Vertex Pharmaceuticals  ( NASDAQ:VRTX )  to Buy",
    "url": "https://www.defenseworld.net/2024/01/04/stocknews-com-downgrades-vertex-pharmaceuticals-nasdaqvrtx-to-buy.html",
    "time_published": "20240104T062445",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Vertex Pharmaceuticals ( NASDAQ:VRTX - Get Free Report ) was downgraded by equities research analysts at StockNews.com from a \"strong-buy\" rating to a \"buy\" rating in a research note issued to investors on Thursday.",
    "banner_image": "https://www.marketbeat.com/logos/vertex-pharmaceuticals-incorporated-logo.png?v=20231228113929",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.990786"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.297567,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TFC",
        "relevance_score": "0.042346",
        "ticker_sentiment_score": "0.058743",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.042346",
        "ticker_sentiment_score": "0.058743",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.042346",
        "ticker_sentiment_score": "0.058743",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.735169",
        "ticker_sentiment_score": "0.465748",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "SEIC",
        "relevance_score": "0.084572",
        "ticker_sentiment_score": "0.219221",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNV",
        "relevance_score": "0.084572",
        "ticker_sentiment_score": "0.219221",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RBCPF",
        "relevance_score": "0.042346",
        "ticker_sentiment_score": "0.058743",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "It's Been An Abysmal Two Years. But Biotech Is Looking Up.",
    "url": "https://www.investors.com/news/technology/biotech-stocks-pharma-heat-up-in-2024-as-buyouts-obesity-ai-drive-excitement/",
    "time_published": "20240105T140000",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "Biotech Stocks, Pharma Heat Up In 2024 As Buyouts, Obesity And AI Drive Excitement Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/01/A1-010824-biotech-Gash.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.12567,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NVO",
        "relevance_score": "0.035679",
        "ticker_sentiment_score": "0.069333",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NBIX",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.14181",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KRTX",
        "relevance_score": "0.035679",
        "ticker_sentiment_score": "0.037838",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IONS",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.084592",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RYZB",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARWR",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALEC",
        "relevance_score": "0.09495",
        "ticker_sentiment_score": "0.150269",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.153696",
        "ticker_sentiment_score": "0.053027",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VERV",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.006781",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OMGA",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.079056",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NTLA",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "-0.008781",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BHVN",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "-0.001871",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.067127",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.035679",
        "ticker_sentiment_score": "0.017905",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CPRX",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.14181",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BEAM",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.057997",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GRCL",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CLNN",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "-0.020246",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GPCR",
        "relevance_score": "0.035679",
        "ticker_sentiment_score": "0.08972",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMPH",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.14181",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARGX",
        "relevance_score": "0.011896",
        "ticker_sentiment_score": "-0.115274",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.067127",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "-0.042606",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.035679",
        "ticker_sentiment_score": "0.064761",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.059429",
        "ticker_sentiment_score": "0.106048",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Biotech Stocks With Huge Catalysts in 2024",
    "url": "https://www.fool.com/investing/2024/01/05/2-biotech-stocks-with-huge-catalysts-in-2024/",
    "time_published": "20240105T103400",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "Important clinical-trial readouts on the way could send these stocks soaring in early 2024.",
    "banner_image": "https://g.foolcdn.com/editorial/images/760000/two-people-use-devices-at-home-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.075292,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.160633",
        "ticker_sentiment_score": "0.150694",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMLX",
        "relevance_score": "0.160633",
        "ticker_sentiment_score": "-0.051537",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Vertex Pharmaceuticals Stock a Buy Now?",
    "url": "https://www.fool.com/investing/2024/01/06/is-vertex-pharmaceuticals-stock-a-buy-now/",
    "time_published": "20240106T134500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The biotech's prospects keep improving.",
    "banner_image": "https://g.foolcdn.com/editorial/images/759939/physician-talking-to-patient.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.217359,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.475618",
        "ticker_sentiment_score": "0.430073",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BLUE",
        "relevance_score": "0.063425",
        "ticker_sentiment_score": "0.097054",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "5 Top Stocks to Buy in January",
    "url": "https://www.fool.com/investing/2024/01/07/5-top-stocks-to-buy-in-january/",
    "time_published": "20240107T104500",
    "authors": [
      "Keith Speights",
      "Anders Bylund",
      "Demitri Kalogeropoulos",
      "and Neha Chamaria",
      "Daniel Foelber"
    ],
    "summary": "Start the year off right by investing in these quality businesses.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F760264%2Fgettyimages-618335432-1201x801-d21b45d.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.967321"
      }
    ],
    "overall_sentiment_score": 0.302481,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.1294",
        "ticker_sentiment_score": "0.205403",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.086478",
        "ticker_sentiment_score": "0.156576",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.021659",
        "ticker_sentiment_score": "0.039331",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SBUX",
        "relevance_score": "0.374937",
        "ticker_sentiment_score": "0.435517",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BIPC",
        "relevance_score": "0.234787",
        "ticker_sentiment_score": "0.15869",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IBM",
        "relevance_score": "0.171943",
        "ticker_sentiment_score": "0.146872",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nuvation Bio Announces Appointment of Dr. Robert Mashal to its Board of Directors",
    "url": "https://investingnews.com/nuvation-bio-announces-appointment-of-dr-robert-mashal-to-its-board-of-directors/",
    "time_published": "20240108T221451",
    "authors": [
      "Investing News Network"
    ],
    "summary": "Nuvation Bio Inc. ( NYSE: NUVB ) , a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of Robert Mashal, M.D. to its Board of Directors.",
    "banner_image": "https://investingnews.com/media-library/image.jpg?id=30128384&width=1200&height=600",
    "source": "Investing News Network",
    "category_within_source": "n/a",
    "source_domain": "investingnews.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.167531,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.095899",
        "ticker_sentiment_score": "-0.008432",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NUVB",
        "relevance_score": "0.60098",
        "ticker_sentiment_score": "0.388595",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.095899",
        "ticker_sentiment_score": "-0.008432",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results",
    "url": "https://www.globenewswire.com/news-release/2024/01/08/2805839/0/en/MaxCyte-Announces-Preliminary-Unaudited-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html",
    "time_published": "20240108T210500",
    "authors": [
      "Inc.",
      "MaxCyte"
    ],
    "summary": "ROCKVILLE, MD, January 8, 2024 - MaxCyte, Inc., ( NASDAQ: MXCT.",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/ca8c6b64-4f99-4a88-86a6-5c0b5f3d49fe",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999982"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      }
    ],
    "overall_sentiment_score": 0.185878,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MXCT",
        "relevance_score": "0.270202",
        "ticker_sentiment_score": "0.358072",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.039353",
        "ticker_sentiment_score": "0.252586",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results",
    "url": "https://www.globenewswire.com/news-release/2024/01/08/2805846/0/en/MaxCyte-Announces-Preliminary-Unaudited-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html",
    "time_published": "20240108T210500",
    "authors": [
      "Inc",
      "MaxCyte"
    ],
    "summary": "ROCKVILLE, Md., Jan. 08, 2024 ( GLOBE NEWSWIRE ) -- MaxCyte, Inc., ( NASDAQ: MXCT. LSE: MXCT ) , a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/8f0f0d48-fc4f-4d03-ac70-f4d096a780bd",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999982"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      }
    ],
    "overall_sentiment_score": 0.185876,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MXCT",
        "relevance_score": "0.269351",
        "ticker_sentiment_score": "0.355437",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.039224",
        "ticker_sentiment_score": "0.252519",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results - MaxCyte  ( NASDAQ:MXCT ) ",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36544610/maxcyte-announces-preliminary-unaudited-fourth-quarter-and-full-year-2023-financial-results",
    "time_published": "20240108T210500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "ROCKVILLE, Md., Jan. 08, 2024 ( GLOBE NEWSWIRE ) -- MaxCyte, Inc., MXCTMXCT ) ) , a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999982"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.744043"
      }
    ],
    "overall_sentiment_score": 0.183564,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MXCT",
        "relevance_score": "0.192387",
        "ticker_sentiment_score": "0.27462",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.038843",
        "ticker_sentiment_score": "0.252315",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "$1000 Invested In This Stock 15 Years Ago Would Be Worth $14,000 Today - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/news/24/01/36539655/1000-invested-in-this-stock-15-years-ago-would-be-worth-14-000-today",
    "time_published": "20240108T173015",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Vertex Pharmaceuticals VRTX has outperformed the market over the past 15 years by 6.9% on an annualized basis producing an average annual return of 18.8%. Currently, Vertex Pharmaceuticals has a market capitalization of $106.68 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_4.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.160819,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.980595",
        "ticker_sentiment_score": "0.386944",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Will Vertex  ( VRTX )  Beat Estimates Again in Its Next Earnings Report?",
    "url": "https://www.zacks.com/stock/news/2207133/will-vertex-vrtx-beat-estimates-again-in-its-next-earnings-report",
    "time_published": "20240108T171011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default15.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.99989"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.312447,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.173958",
        "ticker_sentiment_score": "0.210994",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "PBYI vs. VRTX: Which Stock Is the Better Value Option?",
    "url": "https://www.zacks.com/stock/news/2207091/pbyi-vs-vrtx-which-stock-is-the-better-value-option",
    "time_published": "20240108T164012",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Puma Biotech ( PBYI Quick QuotePBYI - ) and Vertex Pharmaceuticals ( VRTX Quick QuoteVRTX - ) . But which of these two stocks offers value investors a better bang for their buck right now?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default112.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.455342,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.68471",
        "ticker_sentiment_score": "0.522443",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference - Editas Medicine  ( NASDAQ:EDIT ) ",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36532383/editas-medicine-highlights-2024-anticipated-milestones-and-strategic-priorities-at-the-j-p-morgan-",
    "time_published": "20240108T131500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Anticipated 2024 milestones include: present reni-cel clinical data updates mid-year and year-end, initiate the RUBY clinical trial adolescent cohort, establish in vivo preclinical proof-of-concept for an undisclosed indication, and continue to sublicense foundational IP",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.152988,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.04531",
        "ticker_sentiment_score": "0.102362",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EDIT",
        "relevance_score": "0.350564",
        "ticker_sentiment_score": "0.127243",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference",
    "url": "https://www.globenewswire.com/news-release/2024/01/08/2805430/0/en/Editas-Medicine-Highlights-2024-Anticipated-Milestones-and-Strategic-Priorities-at-the-J-P-Morgan-Healthcare-Conference.html",
    "time_published": "20240108T131500",
    "authors": [
      "Editas Medicine",
      "Inc."
    ],
    "summary": "Anticipated 2024 milestones include: present reni-cel clinical data updates mid-year and year-end, initiate the RUBY clinical trial adolescent cohort, establish in vivo preclinical proof-of-concept for an undisclosed indication, and continue to sublicense foundational IP ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/03686b66-5cbc-40b5-9dfa-be0e7858ac97",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.576289"
      }
    ],
    "overall_sentiment_score": 0.132441,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.031079",
        "ticker_sentiment_score": "0.051041",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EDIT",
        "relevance_score": "0.214937",
        "ticker_sentiment_score": "0.089716",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics",
    "url": "https://www.fool.com/investing/2024/01/08/better-gene-editing-stock-editas-medicine-vs-intel/",
    "time_published": "20240108T124500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "These two are at very different stages of the clinical trials process.",
    "banner_image": "https://g.foolcdn.com/editorial/images/759688/scientist-configures-tilting-machine.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.972756"
      }
    ],
    "overall_sentiment_score": 0.244538,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.056674",
        "ticker_sentiment_score": "0.075978",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EDIT",
        "relevance_score": "0.113062",
        "ticker_sentiment_score": "0.155062",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BLUE",
        "relevance_score": "0.056674",
        "ticker_sentiment_score": "-0.029015",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NTLA",
        "relevance_score": "0.113062",
        "ticker_sentiment_score": "0.155062",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "The Ultimate Growth Stock to Buy With $1,000 Right Now",
    "url": "https://www.fool.com/investing/2024/01/08/the-ultimate-growth-stock-to-buy-with-1000-now/",
    "time_published": "20240108T100000",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "The stock, trading for about $60, has plenty of room to run.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F760286%2Fgettyimages-519517489-1.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.989041"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.312875,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.055751",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.055751",
        "ticker_sentiment_score": "0.138",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Clarivate Identifies Thirteen Potential Blockbuster Drugs and Gamechangers in Annual Drugs to Watch Report",
    "url": "https://www.prnewswire.com/news-releases/clarivate-identifies-thirteen-potential-blockbuster-drugs-and-gamechangers-in-annual-drugs-to-watch-report-302027294.html",
    "time_published": "20240108T080000",
    "authors": [
      "Clarivate Plc"
    ],
    "summary": "Therapeutic advancements for sickle cell disease, RSV, breast cancer, Crohn's and other ailments poised to advance patient health despite urgent challenges facing life science companies",
    "banner_image": "https://mma.prnewswire.com/media/1159266/Clarivate_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.242731,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLUE",
        "relevance_score": "0.020266",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "III",
        "relevance_score": "0.020266",
        "ticker_sentiment_score": "0.240962",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.020266",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SKXJF",
        "relevance_score": "0.040519",
        "ticker_sentiment_score": "-0.030752",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSKYF",
        "relevance_score": "0.040519",
        "ticker_sentiment_score": "-0.030752",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.020266",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.020266",
        "ticker_sentiment_score": "-0.125978",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CLVT",
        "relevance_score": "0.239502",
        "ticker_sentiment_score": "0.270064",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.020266",
        "ticker_sentiment_score": "-0.125978",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIOVF",
        "relevance_score": "0.020266",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.020266",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GSK",
        "relevance_score": "0.040519",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.020266",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Clarivate Identifies Thirteen Potential Blockbuster Drugs and Gamechangers in Annual Drugs to Watch Report",
    "url": "https://www.newswire.ca/news-releases/clarivate-identifies-thirteen-potential-blockbuster-drugs-and-gamechangers-in-annual-drugs-to-watch-report-802561925.html",
    "time_published": "20240108T080000",
    "authors": [
      "Clarivate Plc"
    ],
    "summary": "Therapeutic advancements for sickle cell disease, RSV, breast cancer, Crohn's and other ailments poised to advance patient health despite urgent challenges facing life science companies",
    "banner_image": "https://mma.prnewswire.com/media/1159266/Clarivate_Logo.jpg?p=facebook",
    "source": "Canada Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.newswire.ca",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.242731,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLUE",
        "relevance_score": "0.020266",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "III",
        "relevance_score": "0.020266",
        "ticker_sentiment_score": "0.240962",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.020266",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SKXJF",
        "relevance_score": "0.040519",
        "ticker_sentiment_score": "-0.030752",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSKYF",
        "relevance_score": "0.040519",
        "ticker_sentiment_score": "-0.030752",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.020266",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.020266",
        "ticker_sentiment_score": "-0.125978",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CLVT",
        "relevance_score": "0.239502",
        "ticker_sentiment_score": "0.270064",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.020266",
        "ticker_sentiment_score": "-0.125978",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIOVF",
        "relevance_score": "0.020266",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.020266",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GSK",
        "relevance_score": "0.040519",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.020266",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's How Much You'd Have If You Invested $1000 in Vertex Pharmaceuticals a Decade Ago",
    "url": "https://www.zacks.com/stock/news/2207791/heres-how-much-youd-have-if-you-invested-1000-in-vertex-pharmaceuticals-a-decade-ago",
    "time_published": "20240109T225434",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default90.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      }
    ],
    "overall_sentiment_score": 0.155139,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.422493",
        "ticker_sentiment_score": "0.202301",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( VRTX )  Ascends While Market Falls: Some Facts to Note",
    "url": "https://www.zacks.com/stock/news/2207797/vertex-pharmaceuticals-vrtx-ascends-while-market-falls-some-facts-to-note",
    "time_published": "20240109T225020",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $421.01, indicating a +0.45% shift from the previous trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default131.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.201034,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.561606",
        "ticker_sentiment_score": "0.216119",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "What Makes Vertex Pharmaceuticals  ( VRTX )  a Strong Momentum Stock: Buy Now?",
    "url": "https://www.zacks.com/stock/news/2207704/what-makes-vertex-pharmaceuticals-vrtx-a-strong-momentum-stock-buy-now",
    "time_published": "20240109T215602",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Does Vertex Pharmaceuticals (VRTX) have what it takes to be a top stock pick for momentum investors? Let's find out.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default118.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      }
    ],
    "overall_sentiment_score": 0.274814,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.596651",
        "ticker_sentiment_score": "0.351022",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Should You Invest in the Invesco Biotechnology & Genome ETF  ( PBE ) ?",
    "url": "https://www.zacks.com/stock/news/2207718/should-you-invest-in-the-invesco-biotechnology-genome-etf-pbe",
    "time_published": "20240109T215449",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default27.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.202758,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.128135",
        "ticker_sentiment_score": "0.069783",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.19117",
        "ticker_sentiment_score": "0.112309",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ILMN",
        "relevance_score": "0.128135",
        "ticker_sentiment_score": "0.069783",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NBIX",
        "relevance_score": "0.128135",
        "ticker_sentiment_score": "0.069783",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Biotech ETFs Stage Solid Comeback at the Start of 2024",
    "url": "https://www.zacks.com/stock/news/2207551/biotech-etfs-stage-solid-comeback-at-the-start-of-2024",
    "time_published": "20240109T160500",
    "authors": [
      "Sweta Killa"
    ],
    "summary": "The biotech space staged a strong comeback at the start of 2024, driven by multi-billion dollar deals, upbeat clinical results and cutting-edge medical advances like CRISPR gene-editing hitting prime-time.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7b/850.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.147642,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NVO",
        "relevance_score": "0.133346",
        "ticker_sentiment_score": "0.162037",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "0.084886",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KRTX",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "0.058856",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "0.084886",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RYZB",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "0.058856",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "0.058856",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.133346",
        "ticker_sentiment_score": "0.06769",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "0.058856",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GRCL",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "0.058856",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HARP",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "0.084886",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.133346",
        "ticker_sentiment_score": "0.162037",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.133346",
        "ticker_sentiment_score": "0.071668",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OMGA",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "0.140918",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "A Look Into Vertex Pharmaceuticals Inc's Price Over Earnings - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/news/24/01/36557818/a-look-into-vertex-pharmaceuticals-incs-price-over-earnings",
    "time_published": "20240109T144515",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "In the current session, the stock is trading at $419.65, after a 0.13% increase. Over the past month, Vertex Pharmaceuticals Inc. VRTX stock increased by 17.04%, and in the past year, by 43.26%.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      }
    ],
    "overall_sentiment_score": 0.130669,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.412298",
        "ticker_sentiment_score": "0.116901",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Focal Segmental Glomerulosclerosis Market to Observe Impressive Growth by 2032, Predicts DelveInsight | Leading Companies - ACELYRIN, Genentech, ChemoCentryx, Travere Therapeutics, Boehringer Ingelheim, Chinook Therapeutics",
    "url": "https://www.prnewswire.com/news-releases/focal-segmental-glomerulosclerosis-market-to-observe-impressive-growth-by-2032-predicts-delveinsight--leading-companies---acelyrin-genentech-chemocentryx-travere-therapeutics-boehringer-ingelheim-chinook-therapeutics-302030785.html",
    "time_published": "20240110T220100",
    "authors": [
      "DelveInsight Business Research",
      "LLP"
    ],
    "summary": "Focal Segmental Glomerulosclerosis Market to Observe Impressive Growth by 2032, Predicts DelveInsight | Leading ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.106846,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ZVSA",
        "relevance_score": "0.028321",
        "ticker_sentiment_score": "0.038274",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALDX",
        "relevance_score": "0.028321",
        "ticker_sentiment_score": "0.086235",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TVTX",
        "relevance_score": "0.084821",
        "ticker_sentiment_score": "0.088295",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.056607",
        "ticker_sentiment_score": "-0.017",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KDNY",
        "relevance_score": "0.056607",
        "ticker_sentiment_score": "0.085954",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.028321",
        "ticker_sentiment_score": "0.038274",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DMAC",
        "relevance_score": "0.028321",
        "ticker_sentiment_score": "0.002769",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.028321",
        "ticker_sentiment_score": "0.038274",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LXRX",
        "relevance_score": "0.028321",
        "ticker_sentiment_score": "0.002769",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SLRN",
        "relevance_score": "0.028321",
        "ticker_sentiment_score": "0.086235",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.028321",
        "ticker_sentiment_score": "0.002769",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PROK",
        "relevance_score": "0.056607",
        "ticker_sentiment_score": "-0.017",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.028321",
        "ticker_sentiment_score": "0.002769",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Red Flags for Bluebird Bio Stock",
    "url": "https://www.fool.com/investing/2024/01/10/2-red-flags-for-bluebird-bio-stock/",
    "time_published": "20240110T115500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The biotech's struggles may continue.",
    "banner_image": "https://g.foolcdn.com/editorial/images/760285/patient-sitting-on-hospital-bed.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.043943,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.123526",
        "ticker_sentiment_score": "-0.029978",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BLUE",
        "relevance_score": "0.359014",
        "ticker_sentiment_score": "0.173967",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "These 3 Stocks Have Beaten the S&P Average Return for Years and Are Likely to Continue That Trend",
    "url": "https://www.fool.com/investing/2024/01/10/these-3-stocks-have-beaten-the-sp-average-return-f/",
    "time_published": "20240110T105100",
    "authors": [
      "Keith Speights"
    ],
    "summary": "These winners seem likely to keep up their winning ways.",
    "banner_image": "https://g.foolcdn.com/editorial/images/760612/smiling-person-looking-at-a-monitor-with-stock-chart.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.795202"
      }
    ],
    "overall_sentiment_score": 0.345138,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AXON",
        "relevance_score": "0.110462",
        "ticker_sentiment_score": "0.152537",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.110462",
        "ticker_sentiment_score": "-0.147233",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.055364",
        "ticker_sentiment_score": "0.247979",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TTD",
        "relevance_score": "0.218817",
        "ticker_sentiment_score": "0.253948",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "ESG Is Under Fire. How These 5 Funds Still Beat the Market.",
    "url": "https://www.barrons.com/amp/articles/top-esg-funds-nvidia-active-f851057c",
    "time_published": "20240110T073000",
    "authors": [
      "Lauren Foster"
    ],
    "summary": "The Top ESG Funds Held Nvidia and Other ...",
    "banner_image": "https://images.barrons.com/im-37596237/social",
    "source": "Barrons",
    "category_within_source": "n/a",
    "source_domain": "www.barrons.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999997"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.372991,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.275832",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMDUF",
        "relevance_score": "0.042122",
        "ticker_sentiment_score": "0.036696",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LULU",
        "relevance_score": "0.042122",
        "ticker_sentiment_score": "0.027664",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.208285",
        "ticker_sentiment_score": "0.312065",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GWRE",
        "relevance_score": "0.042122",
        "ticker_sentiment_score": "0.027664",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NOW",
        "relevance_score": "0.042122",
        "ticker_sentiment_score": "0.186886",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.042122",
        "ticker_sentiment_score": "0.195868",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MORN",
        "relevance_score": "0.042122",
        "ticker_sentiment_score": "0.249905",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SPLK",
        "relevance_score": "0.042122",
        "ticker_sentiment_score": "0.027664",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.042122",
        "ticker_sentiment_score": "0.156017",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MLM",
        "relevance_score": "0.042122",
        "ticker_sentiment_score": "0.102216",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Unpacking the Latest Options Trading Trends in Vertex Pharmaceuticals - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/markets/options/24/01/36598743/unpacking-the-latest-options-trading-trends-in-vertex-pharmaceuticals",
    "time_published": "20240111T174648",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Whales with a lot of money to spend have taken a noticeably bearish stance on Vertex Pharmaceuticals. Looking at options history for Vertex Pharmaceuticals VRTX we detected 8 trades. If we consider the specifics of each trade, it is accurate to state that 25% of the investors opened trades with ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.066955,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.592095",
        "ticker_sentiment_score": "0.028215",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "State Economics - Spotlight on New England: The Kiplinger Letter",
    "url": "https://www.kiplinger.com/personal-finance/job-search/state-economics-new-england-the-kiplinger-letter",
    "time_published": "20240111T124728",
    "authors": [
      "David Payne"
    ],
    "summary": "After the 2023 boom, New England states see modest employment growth Kiplinger's Personal Finance ...",
    "banner_image": "https://cdn.mos.cms.futurecdn.net/TtbbcgnxqkMad2zGHHTYXa-1200-80.jpg",
    "source": "Kiplinger",
    "category_within_source": "n/a",
    "source_domain": "www.kiplinger.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.252829,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.047465",
        "ticker_sentiment_score": "0.209683",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GE",
        "relevance_score": "0.047465",
        "ticker_sentiment_score": "0.209683",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Uber, Abbott Laboratories, Vertex Pharmaceuticals And More On CNBC's 'Final Trades' - Abbott Laboratories  ( NYSE:ABT ) , Uber Technologies  ( NYSE:UBER ) ",
    "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/01/36606668/uber-abbott-laboratories-vertex-pharmaceuticals-and-more-on-cnbcs-final-trades",
    "time_published": "20240112T135103",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "On CNBC's \"Halftime Report Final Trades,\" Joshua Brown of Ritholtz Wealth Management said Uber Technologies, Inc. UBER shares hit an all-time high on Thursday above the Feb. 2021 high. He remains long on the stock and still loves it.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/12/uber_-logo.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      }
    ],
    "overall_sentiment_score": 0.29394,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.436009",
        "ticker_sentiment_score": "0.618511",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.558244",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.152499",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.558244",
        "ticker_sentiment_score": "0.571354",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Arena BioWorks Launches as a Privately Funded, Fully Independent Biomedical Institute to Shorten the Path from Insight to Therapeutics",
    "url": "https://www.prnewswire.com/news-releases/arena-bioworks-launches-as-a-privately-funded-fully-independent-biomedical-institute-to-shorten-the-path-from-insight-to-therapeutics-302033563.html",
    "time_published": "20240112T113000",
    "authors": [
      "Arena BioWorks"
    ],
    "summary": "Arena BioWorks Launches as a Privately Funded, Fully Independent Biomedical Institute to Shorten the Path from ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/2279495/Arena_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.268175,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.019026",
        "ticker_sentiment_score": "0.046462",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CORZQ",
        "relevance_score": "0.03804",
        "ticker_sentiment_score": "0.049775",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.019026",
        "ticker_sentiment_score": "0.055053",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HHH",
        "relevance_score": "0.019026",
        "ticker_sentiment_score": "0.055053",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EDIT",
        "relevance_score": "0.019026",
        "ticker_sentiment_score": "0.090388",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRI",
        "relevance_score": "0.019026",
        "ticker_sentiment_score": "0.090388",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BEAM",
        "relevance_score": "0.019026",
        "ticker_sentiment_score": "0.090388",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSNLF",
        "relevance_score": "0.019026",
        "ticker_sentiment_score": "0.090388",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CLVT",
        "relevance_score": "0.019026",
        "ticker_sentiment_score": "0.090388",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VERV",
        "relevance_score": "0.019026",
        "ticker_sentiment_score": "0.090388",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DELL",
        "relevance_score": "0.019026",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PRME",
        "relevance_score": "0.019026",
        "ticker_sentiment_score": "0.073128",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.019026",
        "ticker_sentiment_score": "0.046462",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Want to Get Richer? 2 Stocks to Buy and Hold for 10 Years",
    "url": "https://www.fool.com/investing/2024/01/13/want-to-get-richer-2-stocks-to-buy-and-hold-for-10/",
    "time_published": "20240113T130000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "These companies are leaders in their respective fields.",
    "banner_image": "https://g.foolcdn.com/editorial/images/760535/physicians-in-an-operating-room.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.226875,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SHOP",
        "relevance_score": "0.53784",
        "ticker_sentiment_score": "0.344138",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.116914",
        "ticker_sentiment_score": "0.081648",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BLUE",
        "relevance_score": "0.058615",
        "ticker_sentiment_score": "0.069982",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Unstoppable Stocks to Buy in 2024",
    "url": "https://www.fool.com/investing/2024/01/13/3-unstoppable-stocks-to-buy-in-2024/",
    "time_published": "20240113T124800",
    "authors": [
      "Keith Speights",
      "David Jagielski",
      "and Prosper Junior Bakiny"
    ],
    "summary": "These stocks appear to be on a clear path to continued growth.",
    "banner_image": "https://g.foolcdn.com/editorial/images/761021/scientists-in-a-lab-smiling.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.25543,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.266343",
        "ticker_sentiment_score": "0.049266",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.349945",
        "ticker_sentiment_score": "0.133208",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MORN",
        "relevance_score": "0.045224",
        "ticker_sentiment_score": "0.143626",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.308614",
        "ticker_sentiment_score": "0.308668",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FOREX:DKK",
        "relevance_score": "0.045224",
        "ticker_sentiment_score": "0.270178",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FOREX:NOK",
        "relevance_score": "0.045224",
        "ticker_sentiment_score": "0.270178",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Cathie Wood Goes Bargain Hunting: 3 Stocks She Bought This Week",
    "url": "https://www.fool.com/investing/2024/01/13/cathie-wood-bargain-hunts-3-stocks-she-bought/",
    "time_published": "20240113T102000",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "These companies could stand out thanks to game-changing technology.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F761087%2Fgettyimages-904880170.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.967645"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.298602,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.04583",
        "ticker_sentiment_score": "0.174802",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RXRX",
        "relevance_score": "0.136888",
        "ticker_sentiment_score": "0.071337",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TOST",
        "relevance_score": "0.472733",
        "ticker_sentiment_score": "0.352021",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "What Does It Mean for Investors if CRISPR Therapeutics Gets Bought Out in 2024?",
    "url": "https://www.fool.com/investing/2024/01/14/what-does-it-mean-if-crispr-gets-bought-out/",
    "time_published": "20240114T183000",
    "authors": [
      "David Jagielski"
    ],
    "summary": "An acquisition could be both a blessing and a curse for long-term investors.",
    "banner_image": "https://g.foolcdn.com/editorial/images/760422/people-agreeing-on-a-deal.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999701"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.838487"
      }
    ],
    "overall_sentiment_score": 0.26526,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.053035",
        "ticker_sentiment_score": "0.170688",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "My 3 Highest-Conviction Growth Stocks to Buy in 2024",
    "url": "https://www.fool.com/investing/2024/01/14/my-3-highest-conviction-growth-stocks-to-buy-in-20/",
    "time_published": "20240114T151300",
    "authors": [
      "Keith Speights"
    ],
    "summary": "Simply put, these stocks inspire confidence.",
    "banner_image": "https://g.foolcdn.com/editorial/images/760970/solar-panels-and-workers.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.296196,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.096866",
        "ticker_sentiment_score": "0.071053",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.048523",
        "ticker_sentiment_score": "0.069022",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BEP",
        "relevance_score": "0.23907",
        "ticker_sentiment_score": "0.217306",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.048523",
        "ticker_sentiment_score": "0.085103",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.19231",
        "ticker_sentiment_score": "0.192281",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Growth Stocks to Buy That Could Be Massive Long-Term Winners",
    "url": "https://www.fool.com/investing/2024/01/14/3-growth-stocks-to-buy-that-could-be-massive-long/",
    "time_published": "20240114T140000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "These stocks appear to have what it takes to keep up their winning ways.",
    "banner_image": "https://g.foolcdn.com/editorial/images/760683/artificial-intelligence-investing-algorithms.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      }
    ],
    "overall_sentiment_score": 0.248026,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.116067",
        "ticker_sentiment_score": "0.159005",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.173333",
        "ticker_sentiment_score": "-0.022476",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MELI",
        "relevance_score": "0.284861",
        "ticker_sentiment_score": "0.129709",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "My 5 Top Growth Stocks to Buy Hand Over Fist for 2024",
    "url": "https://www.fool.com/investing/2024/01/14/my-5-top-growth-stocks-to-buy-for-2024/",
    "time_published": "20240114T101000",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "2024 could be a year of growth.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F760878%2Fgettyimages-three-business-people-use-tablets.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999994"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.429002,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CHWY",
        "relevance_score": "0.252987",
        "ticker_sentiment_score": "0.243893",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.036756",
        "ticker_sentiment_score": "0.277177",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TDOC",
        "relevance_score": "0.073434",
        "ticker_sentiment_score": "0.255571",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ETSY",
        "relevance_score": "0.18223",
        "ticker_sentiment_score": "0.091942",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.217834",
        "ticker_sentiment_score": "0.4119",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Here's Why CRISPR Therapeutics Stock Rose 54% Last Year",
    "url": "https://www.fool.com/investing/2024/01/15/heres-why-crispr-therapeutics-stock-rose-54-last-y/",
    "time_published": "20240115T215600",
    "authors": [
      "Ryan Downie"
    ],
    "summary": "Key regulatory developments sent this biotech stock higher.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F761374%2Fdna-genetic-sequencing-biotech.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.134919,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.139669",
        "ticker_sentiment_score": "0.117333",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.070105",
        "ticker_sentiment_score": "0.079486",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Down 88%, Could Editas Medicine Be a Good Investment Now?",
    "url": "https://www.fool.com/investing/2024/01/15/down-88-could-editas-medicine-be-a-good-investment/",
    "time_published": "20240115T101900",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "The past few years have been difficult ones, but shares of the gene editor are far more attractive now that a CRISPR medicine has passed regulatory hurdles.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F761086%2Fsmart-investor-looking-for-stocks-to-buy-getty.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.142489,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.24289",
        "ticker_sentiment_score": "0.207009",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "EDIT",
        "relevance_score": "0.463792",
        "ticker_sentiment_score": "0.176254",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "FDA Approves New CRISPR Gene-Editing Treatment",
    "url": "https://www.forbes.com/sites/jamesfarrell/2024/01/16/fda-approves-new-crispr-gene-editing-treatment/",
    "time_published": "20240116T225905",
    "authors": [
      "James Farrell"
    ],
    "summary": "The Food and Drug Administration approved the use of Casgevy, a therapy from Vertex Pharmaceuticals and CRISPR Therapeutics that uses CRISPR gene-editing to treat the serious blood disorder transfusion-dependent beta thalassemia-marking the second major U.S. regulatory approval for the emerging ...",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65a70a106171deb3993b76ee/0x0.jpg?format=jpg&crop=2614,1469,x0,y135,safe&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.202184,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.102013",
        "ticker_sentiment_score": "0.109846",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "CRISPR Therapeutics Announces U.S. Food and Drug Administration  ( FDA )  Approval of CASGEVY\u2122  ( exagamglogene autotemcel )  for the Treatment of Transfusion-Dependent Beta Thalassemia - CRISPR Therapeutics  ( NASDAQ:CRSP ) ",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36649789/crispr-therapeutics-announces-u-s-food-and-drug-administration-fda-approval-of-casgevy-exagamgloge",
    "time_published": "20240116T210100",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "- Approximately 1,000 patients in the U.S. 12 years of age and older are now eligible for this one-time treatment- ZUG, Switzerland and BOSTON, Jan. 16, 2024 ( GLOBE NEWSWIRE ) -- CRISPR Therapeutics CRSP, a biopharmaceutical company focused on creating transformative gene-based medicines for ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.118577,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.11894",
        "ticker_sentiment_score": "0.096945",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRSP",
        "relevance_score": "0.089351",
        "ticker_sentiment_score": "0.105743",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex's Warpath Continues With A Second Crispr Gene-Editing OK",
    "url": "https://www.investors.com/news/technology/crsp-stock-dips-despite-snagging-a-second-gene-editing-ok-vrtx-stock-continues-on-its-warpath/",
    "time_published": "20240116T202100",
    "authors": [
      "ALLISON GATLIN",
      "Investor's Business Daily"
    ],
    "summary": "CRSP Stock Dips Despite Snagging A Second Gene-Editing OK. VRTX Stock Continues On Its Warpath Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2023/11/Stock-crispr-dna-03-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99977"
      }
    ],
    "overall_sentiment_score": 0.293283,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.47147",
        "ticker_sentiment_score": "-0.076163",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.100308",
        "ticker_sentiment_score": "0.125644",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "These 2 Stocks Carry a Lot of Risk, but Their Upside Is Huge",
    "url": "https://www.fool.com/investing/2024/01/16/these-2-stocks-carry-lot-of-risk-but-their-upside/",
    "time_published": "20240116T131500",
    "authors": [
      "Ryan Downie"
    ],
    "summary": "These risky stocks can deliver big returns for investors.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F761175%2Fgettyimages-1214328228.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.126185,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.045569",
        "ticker_sentiment_score": "0.030929",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.045569",
        "ticker_sentiment_score": "-0.012901",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.045569",
        "ticker_sentiment_score": "0.030929",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( VRTX )  Declines More Than Market: Some Information for Investors",
    "url": "https://www.zacks.com/stock/news/2211744/vertex-pharmaceuticals-vrtx-declines-more-than-market-some-information-for-investors",
    "time_published": "20240117T225017",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $433.76, signifying a -0.85% move from its prior day's close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default7.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.197661,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.55992",
        "ticker_sentiment_score": "0.204315",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Beta-thalassemia Market to Witness Upsurge in Growth During the Study Period  ( 2019-2032 ) , Evaluates DelveInsight | Leading Companies - Vertex Pharmaceuticals, CRISPR Therapeutics, Agios Pharmaceuticals, Celgene, Forma Therapeutics",
    "url": "https://www.prnewswire.com/news-releases/beta-thalassemia-market-to-witness-upsurge-in-growth-during-the-study-period-20192032-evaluates-delveinsight--leading-companies---vertex-pharmaceuticals-crispr-therapeutics-agios-pharmaceuticals-celgene-forma-therapeutics-302034997.html",
    "time_published": "20240117T220100",
    "authors": [
      "LLP",
      "DelveInsight Business Research"
    ],
    "summary": "Beta-thalassemia Market to Witness Upsurge in Growth During the Study Period ( 2019-2032 ) , Evaluates DelveInsight ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.178567,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BEAM",
        "relevance_score": "0.027257",
        "ticker_sentiment_score": "0.038951",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AGIO",
        "relevance_score": "0.054483",
        "ticker_sentiment_score": "0.093789",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GMDA",
        "relevance_score": "0.027257",
        "ticker_sentiment_score": "0.043538",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SLN",
        "relevance_score": "0.054483",
        "ticker_sentiment_score": "0.044844",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.027257",
        "ticker_sentiment_score": "0.096627",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FULC",
        "relevance_score": "0.027257",
        "ticker_sentiment_score": "0.038951",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.027257",
        "ticker_sentiment_score": "0.096627",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IONS",
        "relevance_score": "0.027257",
        "ticker_sentiment_score": "0.043538",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EDIT",
        "relevance_score": "0.081645",
        "ticker_sentiment_score": "0.095821",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IRON",
        "relevance_score": "0.027257",
        "ticker_sentiment_score": "0.038951",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Market Whales and Their Recent Bets on VRTX Options - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/markets/options/24/01/36666930/market-whales-and-their-recent-bets-on-vrtx-options",
    "time_published": "20240117T200041",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bullish stance on Vertex Pharmaceuticals VRTX. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.111783,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.623976",
        "ticker_sentiment_score": "0.156892",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Vertex  ( VRTX ) , CRSP's Casgevy Gets FDA Nod for Thalassemia",
    "url": "https://www.zacks.com/stock/news/2211622/vertex-vrtx-crsps-casgevy-gets-fda-nod-for-thalassemia",
    "time_published": "20240117T170400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "This is the second approval granted to Vertex (VRTX)/CRISPR's (CRSP) gene therapy Casgevy and comes just a month after the FDA approved the therapy for sickle cell disease.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7b/850.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.12538,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.241684",
        "ticker_sentiment_score": "0.091496",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRSP",
        "relevance_score": "0.182506",
        "ticker_sentiment_score": "0.073526",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BLUE",
        "relevance_score": "0.182506",
        "ticker_sentiment_score": "0.148808",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SRPT",
        "relevance_score": "0.122269",
        "ticker_sentiment_score": "0.055742",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Best Stock to Invest $1,000 in Right Now",
    "url": "https://www.fool.com/investing/2024/01/17/the-best-stock-to-invest-1000-in-right-now/",
    "time_published": "20240117T105000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "This stock has what it takes to be a big winner.",
    "banner_image": "https://g.foolcdn.com/editorial/images/761362/happy-stock-investor-holding-smartphone.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99676"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.20789,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.060694",
        "ticker_sentiment_score": "0.103004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.060694",
        "ticker_sentiment_score": "0.15826",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.121037",
        "ticker_sentiment_score": "0.238791",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Alpha-1 Antitrypsin Deficiency Market to Register Incremental Growth by 2032, Assesses DelveInsight | Key Companies - Kamada Pharmaceuticals, Arrowhead Pharmaceuticals, Takeda, Mereo BioPharma, AstraZeneca, Inhibrx, Novo Nordisk",
    "url": "https://www.prnewswire.com/news-releases/alpha-1-antitrypsin-deficiency-market-to-register-incremental-growth-by-2032-assesses-delveinsight--key-companies---kamada-pharmaceuticals-arrowhead-pharmaceuticals-takeda-mereo-biopharma-astrazeneca-inhibrx-novo-nordisk-302038155.html",
    "time_published": "20240118T220100",
    "authors": [
      "LLP",
      "DelveInsight Business Research"
    ],
    "summary": "Alpha-1 Antitrypsin Deficiency Market to Register Incremental Growth by 2032, Assesses DelveInsight | Key ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.111042,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ARWR",
        "relevance_score": "0.095044",
        "ticker_sentiment_score": "0.027938",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.047607",
        "ticker_sentiment_score": "0.031954",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.023814",
        "ticker_sentiment_score": "0.037329",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CNTA",
        "relevance_score": "0.023814",
        "ticker_sentiment_score": "-0.018133",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WVE",
        "relevance_score": "0.023814",
        "ticker_sentiment_score": "-0.018133",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALNY",
        "relevance_score": "0.047607",
        "ticker_sentiment_score": "-0.02087",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.071357",
        "ticker_sentiment_score": "0.032536",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GRFS",
        "relevance_score": "0.023814",
        "ticker_sentiment_score": "0.164769",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "INBX",
        "relevance_score": "0.023814",
        "ticker_sentiment_score": "0.037329",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MREO",
        "relevance_score": "0.071357",
        "ticker_sentiment_score": "0.040684",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.023814",
        "ticker_sentiment_score": "-0.020993",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "List Price Of Ozempic And Other Drugs Reportedly Rise: Here's What That Means For Consumers",
    "url": "https://www.forbes.com/sites/ariannajohnson/2024/01/18/list-price-of-ozempic-and-other-drugs-reportedly-rise-heres-what-that-means-for-consumers/",
    "time_published": "20240118T194930",
    "authors": [
      "Arianna Johnson"
    ],
    "summary": "Almost 800 medications-including Ozempic and Mounjaro-had a median list price increase of 4.5% this month, according to a Wall Street Journal report, meaning copays may increase for consumers.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/651ed914b753a9b834db1a57/0x0.jpg?format=jpg&crop=3317,1864,x0,y171,safe&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.061908,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.113329",
        "ticker_sentiment_score": "0.068214",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.056808",
        "ticker_sentiment_score": "0.046999",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.113329",
        "ticker_sentiment_score": "0.052573",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.056808",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.113329",
        "ticker_sentiment_score": "0.052573",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Biotech Stock Roundup: VRTX/CRSP Gene Therapy Label Expansion, ALLK Falls on Update",
    "url": "https://www.zacks.com/stock/news/2212227/biotech-stock-roundup-vrtxcrsp-gene-therapy-label-expansion-allk-falls-on-update",
    "time_published": "20240118T152100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex (VRTX), CRSP and Allakos are in the spotlight on regulatory and pipeline updates.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/66/1019.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.168993,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ALLK",
        "relevance_score": "0.359014",
        "ticker_sentiment_score": "-0.066483",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.123526",
        "ticker_sentiment_score": "0.137767",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SLDB",
        "relevance_score": "0.302429",
        "ticker_sentiment_score": "0.235638",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Charles River's  ( CRL )  New Launch to Boost Gene Therapy Programs",
    "url": "https://www.zacks.com/stock/news/2212039/charles-rivers-crl-new-launch-to-boost-gene-therapy-programs",
    "time_published": "20240118T141000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Charles River's (CRL) latest offering is likely to complete a comprehensive range of off-the-shelf plasmid products and simplify gene therapy supply chains with immediate availability.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7b/850.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.189454,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.060694",
        "ticker_sentiment_score": "0.040071",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MMSI",
        "relevance_score": "0.121037",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRL",
        "relevance_score": "0.121037",
        "ticker_sentiment_score": "-0.094236",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ITGR",
        "relevance_score": "0.239305",
        "ticker_sentiment_score": "0.149442",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DVA",
        "relevance_score": "0.180685",
        "ticker_sentiment_score": "0.133374",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Postoperative Acute Pain Market to Grow Immensely at a CAGR of 7.9% During the Study Period  ( 2019-2032 )  | DelveInsight",
    "url": "https://www.prnewswire.com/news-releases/postoperative-acute-pain-market-to-grow-immensely-at-a-cagr-of-7-9-during-the-study-period-20192032--delveinsight-302039152.html",
    "time_published": "20240119T223000",
    "authors": [
      "DelveInsight Business Research",
      "LLP"
    ],
    "summary": "Postoperative Acute Pain Market to Grow Immensely at a CAGR of 7.9% During the Study Period ( 2019-2032 ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.089195,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.073924",
        "ticker_sentiment_score": "-0.042775",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PRFX",
        "relevance_score": "0.024673",
        "ticker_sentiment_score": "-0.092473",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ATXI",
        "relevance_score": "0.024673",
        "ticker_sentiment_score": "-0.019709",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Unstoppable Growth Stocks That Can Make You Richer in 2024",
    "url": "https://www.fool.com/investing/2024/01/20/3-unstoppable-growth-stocks-that-can-make-you-rich/",
    "time_published": "20240120T175000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "These big winners of 2023 could keep their momentum going in the new year.",
    "banner_image": "https://g.foolcdn.com/editorial/images/761599/getty-happy-person-with-cash-money.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.32127,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.121343",
        "ticker_sentiment_score": "0.028017",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MELI",
        "relevance_score": "0.297301",
        "ticker_sentiment_score": "0.186138",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.060848",
        "ticker_sentiment_score": "0.100005",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.353059",
        "ticker_sentiment_score": "0.324885",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "These 2 Phenomenal Growth Stocks Can Make You Richer in 2024",
    "url": "https://www.fool.com/investing/2024/01/20/these-2-phenomenal-growth-stocks-can-make-you-rich/",
    "time_published": "20240120T115500",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "One market-beating stock and one beaten-down stock look like tempting buys for very different reasons.",
    "banner_image": "https://g.foolcdn.com/editorial/images/761556/family-together-father-and-son.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.94762"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.918141"
      }
    ],
    "overall_sentiment_score": 0.199366,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.102741",
        "ticker_sentiment_score": "0.123755",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ETSY",
        "relevance_score": "0.236808",
        "ticker_sentiment_score": "0.114489",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 High-Flying Stocks That Could Soar Even More in 2024",
    "url": "https://www.fool.com/investing/2024/01/20/3-high-flying-stocks-that-could-soar-even-more-in/",
    "time_published": "20240120T115000",
    "authors": [
      "David Jagielski",
      "Keith Speights",
      "and Prosper Junior Bakiny"
    ],
    "summary": "These big winners could keep the momentum going.",
    "banner_image": "https://g.foolcdn.com/editorial/images/761822/dna-on-monitor-scientists.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.284698,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.260652",
        "ticker_sentiment_score": "0.195213",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.044222",
        "ticker_sentiment_score": "0.26179",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.044222",
        "ticker_sentiment_score": "0.056817",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.30211",
        "ticker_sentiment_score": "0.160317",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.044222",
        "ticker_sentiment_score": "-0.005924",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Could Editas Medicine Become the Next CRISPR Therapeutics?",
    "url": "https://www.fool.com/investing/2024/01/21/could-editas-medicine-become-the-next-crispr/",
    "time_published": "20240121T143700",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "The similarities between the pair are striking, but it might not be enough.",
    "banner_image": "https://g.foolcdn.com/editorial/images/761796/scientist-studies-test-tube.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.272921,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.047654",
        "ticker_sentiment_score": "0.080991",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EDIT",
        "relevance_score": "0.095138",
        "ticker_sentiment_score": "0.03834",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BLUE",
        "relevance_score": "0.047654",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.047654",
        "ticker_sentiment_score": "0.080991",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Better Growth Stock: Intellia Therapeutics vs. CRISPR Therapeutics",
    "url": "https://www.fool.com/investing/2024/01/21/better-growth-stock-intellia-vs-crispr/",
    "time_published": "20240121T130000",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Both companies are going to continue doing high-impact science in 2024.",
    "banner_image": "https://g.foolcdn.com/editorial/images/760860/two-investors-look-at-figures.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.167748,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.049526",
        "ticker_sentiment_score": "0.10518",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NTLA",
        "relevance_score": "0.33628",
        "ticker_sentiment_score": "0.18016",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Smart Growth Stocks to Buy Hand Over Fist in 2024",
    "url": "https://www.fool.com/investing/2024/01/21/2-smart-growth-stocks-to-buy-hand-over-fist/",
    "time_published": "20240121T121500",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "These businesses are on paths to extremely bright futures.",
    "banner_image": "https://g.foolcdn.com/editorial/images/761396/counting-money-smiling-in-a-shop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.955357"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.905476"
      }
    ],
    "overall_sentiment_score": 0.167871,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.079",
        "ticker_sentiment_score": "0.02992",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.079",
        "ticker_sentiment_score": "0.047636",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DBTX",
        "relevance_score": "0.039548",
        "ticker_sentiment_score": "-0.050059",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.079",
        "ticker_sentiment_score": "-0.004094",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VTRS",
        "relevance_score": "0.039548",
        "ticker_sentiment_score": "0.041695",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "A New S&P 500 Bull Market Just Began: 3 No-Brainer Stocks to Buy Hand Over Fist",
    "url": "https://www.fool.com/investing/2024/01/22/sp-500-bull-market-no-brainer-stocks-to-buy/",
    "time_published": "20240122T192300",
    "authors": [
      "Keith Speights"
    ],
    "summary": "These stocks seem likely to keep up their winning ways.",
    "banner_image": "https://g.foolcdn.com/editorial/images/762094/family-and-contractor-new-build-new-home-real-estate.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.288208,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.108466",
        "ticker_sentiment_score": "-0.089797",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.162073",
        "ticker_sentiment_score": "0.139872",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Highlights From the 2024 JPMorgan Health Care Conference",
    "url": "https://www.fool.com/investing/2024/01/22/highlights-from-the-2024-jpmorgan-health-care-conf/",
    "time_published": "20240122T183900",
    "authors": [
      "Motley Fool Staff"
    ],
    "summary": "Weight loss drugs are taking center spotlight, but other developing treatments could change how we live.",
    "banner_image": "https://g.foolcdn.com/editorial/images/762063/mfm_0120.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.116608,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.039532",
        "ticker_sentiment_score": "0.033798",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JPM",
        "relevance_score": "0.009887",
        "ticker_sentiment_score": "-0.122802",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.019772",
        "ticker_sentiment_score": "0.081833",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.009887",
        "ticker_sentiment_score": "-0.122802",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.019772",
        "ticker_sentiment_score": "0.091155",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNTX",
        "relevance_score": "0.029654",
        "ticker_sentiment_score": "0.09583",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVCR",
        "relevance_score": "0.019772",
        "ticker_sentiment_score": "0.0243",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GPCR",
        "relevance_score": "0.009887",
        "ticker_sentiment_score": "0.082574",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.019772",
        "ticker_sentiment_score": "0.081056",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.009887",
        "ticker_sentiment_score": "0.057158",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GE",
        "relevance_score": "0.019772",
        "ticker_sentiment_score": "0.036967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.009887",
        "ticker_sentiment_score": "0.057158",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.009887",
        "ticker_sentiment_score": "0.08523",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's How Much $1000 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/insights/news/24/01/36719767/heres-how-much-1000-invested-in-vertex-pharmaceuticals-10-years-ago-would-be-worth-today",
    "time_published": "20240122T170037",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 8.29% on an annualized basis producing an average annual return of 18.73%. Currently, Vertex Pharmaceuticals has a market capitalization of $112.76 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.160819,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.980595",
        "ticker_sentiment_score": "0.386944",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "If You Invested $10,000 in Vertex Pharmaceuticals in 2018, This Is How Much You Would Have Today",
    "url": "https://www.fool.com/investing/2024/01/22/if-you-invested-10000-in-vertex-pharma-2018/",
    "time_published": "20240122T140000",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Has investing in Vertex been a better option than just putting your money in the S&P 500?",
    "banner_image": "https://media.ycharts.com/charts/13e4b6af641fa2204465bdd2f377de68.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.658903"
      }
    ],
    "overall_sentiment_score": 0.39428,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.195287",
        "ticker_sentiment_score": "0.17001",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Cathie Wood's ARKK ETF Is Taking On Water. The Reason Is Simple.",
    "url": "https://www.investors.com/news/cathie-wood-flagship-arkk-etf-is-taking-on-water-due-to-coinbase-tesla/",
    "time_published": "20240122T125100",
    "authors": [
      "Investor's Business Daily",
      "ED CARSON"
    ],
    "summary": "Cathie Wood Flagship ARKK ETF Is Taking On Water Due To Coinbase, Tesla, These Stocks Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2021/11/Stock-CathieWoods-company.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.947132"
      }
    ],
    "overall_sentiment_score": 0.053115,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "PATH",
        "relevance_score": "0.186738",
        "ticker_sentiment_score": "-0.031397",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ROKU",
        "relevance_score": "0.112709",
        "ticker_sentiment_score": "0.080265",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.259135",
        "ticker_sentiment_score": "0.108614",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ZM",
        "relevance_score": "0.259135",
        "ticker_sentiment_score": "-0.037627",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "U",
        "relevance_score": "0.186738",
        "ticker_sentiment_score": "0.039357",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.075279",
        "ticker_sentiment_score": "0.161923",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RBLX",
        "relevance_score": "0.149889",
        "ticker_sentiment_score": "0.032553",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COIN",
        "relevance_score": "0.259135",
        "ticker_sentiment_score": "0.047463",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SQ",
        "relevance_score": "0.112709",
        "ticker_sentiment_score": "0.079399",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.186738",
        "ticker_sentiment_score": "-0.010799",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Could CRISPR Therapeutics Stock Help You Become a Millionaire?",
    "url": "https://www.fool.com/investing/2024/01/22/could-crispr-therapeutics-help-make-you-rich/",
    "time_published": "20240122T100500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "CRISPR Therapeutics shares have soared 39% over the past three months.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F761747%2Fgettyimages-476196983.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.195939,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.055881",
        "ticker_sentiment_score": "0.157001",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.055881",
        "ticker_sentiment_score": "0.105888",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( VRTX )  Stock Dips While Market Gains: Key Facts",
    "url": "https://www.zacks.com/stock/news/2214594/vertex-pharmaceuticals-vrtx-stock-dips-while-market-gains-key-facts",
    "time_published": "20240123T225019",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex Pharmaceuticals (VRTX) reachead $439.70 at the closing of the latest trading day, reflecting a -0.09% change compared to its last close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default179.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.875462"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.260931,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.656549",
        "ticker_sentiment_score": "0.350752",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "A Look Into Vertex Pharmaceuticals Inc's Price Over Earnings - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/insights/news/24/01/36742045/a-look-into-vertex-pharmaceuticals-incs-price-over-earnings",
    "time_published": "20240123T164517",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "In the current market session, Vertex Pharmaceuticals Inc. VRTX stock price is at $438.11, after a 0.45% drop. However, over the past month, the company's stock spiked by 7.36%, and in the past year, by 38.81%.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      }
    ],
    "overall_sentiment_score": -0.075301,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.428632",
        "ticker_sentiment_score": "-0.048765",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "1 Setback and 1 Opportunity for CRISPR Therapeutics Stock",
    "url": "https://www.fool.com/investing/2024/01/23/1-setback-and-1-opportunity-for-crispr-therapeutic/",
    "time_published": "20240123T143000",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Despite A bump in the road, the biotech's future looks sunny.",
    "banner_image": "https://g.foolcdn.com/editorial/images/761794/two-scientists-review-data-in-lab-bench.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.191425,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.111747",
        "ticker_sentiment_score": "0.108935",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Slow Market Penetration For Biogen's Another Alzheimer's Drug: UBS Highlights Risks, Forecasts - Biogen  ( NASDAQ:BIIB ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/01/36766392/slow-market-penetration-for-biogens-another-alzheimers-drug-ubs-highlights-risks-fo",
    "time_published": "20240124T195514",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "UBS has downgraded Biogen Inc BIIB, noting inflection for its second Alzheimer's drug Leqembi ( lecanemab ) will take longer than anticipated.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/BIIB.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.137865,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "REGN",
        "relevance_score": "0.214937",
        "ticker_sentiment_score": "0.122634",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.214937",
        "ticker_sentiment_score": "0.122634",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.586747",
        "ticker_sentiment_score": "0.128726",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "PBYI or VRTX: Which Is the Better Value Stock Right Now?",
    "url": "https://www.zacks.com/stock/news/2215148/pbyi-or-vrtx-which-is-the-better-value-stock-right-now",
    "time_published": "20240124T164010",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "PBYI vs. VRTX: Which Stock Is the Better Value Option?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default73.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.46109,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.614479",
        "ticker_sentiment_score": "0.526631",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Where Will CRISPR Therapeutics Be in 5 Years?",
    "url": "https://www.fool.com/investing/2024/01/24/where-will-crispr-therapeutics-be-in-5-years/",
    "time_published": "20240124T144500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The company could maintain the momentum it gained last year.",
    "banner_image": "https://g.foolcdn.com/editorial/images/761459/patient-sitting-on-hospital-bed.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.286427,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.116914",
        "ticker_sentiment_score": "0.117678",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BLUE",
        "relevance_score": "0.058615",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Wall Street Bulls Look Optimistic About Vertex  ( VRTX ) : Should You Buy?",
    "url": "https://www.zacks.com/stock/news/2214956/wall-street-bulls-look-optimistic-about-vertex-vrtx-should-you-buy",
    "time_published": "20240124T143005",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "According to the average brokerage recommendation (ABR), one should invest in Vertex (VRTX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?",
    "banner_image": "https://staticx-tuner.zacks.com/images/yesopchart/brokerage_bar/VRTX_01242024.png",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.938238"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      }
    ],
    "overall_sentiment_score": 0.30119,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.05387",
        "ticker_sentiment_score": "0.14275",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Netflix To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday - Endava  ( NYSE:DAVA ) , Apellis Pharmaceuticals  ( NASDAQ:APLS ) ",
    "url": "https://www.benzinga.com/news/24/01/36755283/netflix-to-rally-around-18-here-are-10-top-analyst-forecasts-for-wednesday",
    "time_published": "20240124T121830",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Keybanc raised Texas Instruments Incorporated TXN price target from $180 to $200.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/24/netfliximage.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.752319"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.098324,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.242084",
        "ticker_sentiment_score": "0.105024",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.162802",
        "ticker_sentiment_score": "0.140919",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JPM",
        "relevance_score": "0.162802",
        "ticker_sentiment_score": "-0.095343",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.162802",
        "ticker_sentiment_score": "-0.039827",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "APLS",
        "relevance_score": "0.242084",
        "ticker_sentiment_score": "0.109592",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.242084",
        "ticker_sentiment_score": "-0.037199",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WBS",
        "relevance_score": "0.242084",
        "ticker_sentiment_score": "0.1781",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PLUG",
        "relevance_score": "0.242084",
        "ticker_sentiment_score": "0.10555",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TXN",
        "relevance_score": "0.242084",
        "ticker_sentiment_score": "-0.156489",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "CCORF",
        "relevance_score": "0.162802",
        "ticker_sentiment_score": "-0.027554",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SUN",
        "relevance_score": "0.242084",
        "ticker_sentiment_score": "0.188992",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DXC",
        "relevance_score": "0.242084",
        "ticker_sentiment_score": "-0.128357",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DAVA",
        "relevance_score": "0.242084",
        "ticker_sentiment_score": "-0.053693",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Super Stocks You'll Wish 5 Years From Now That You'd Bought Today",
    "url": "https://www.fool.com/investing/2024/01/24/2-super-stocks-youll-wish-youd-bought-today-5-year/",
    "time_published": "20240124T101500",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "These powerhouse stocks still have plenty of growth catalysts to tap into over the coming years.",
    "banner_image": "https://g.foolcdn.com/editorial/images/761966/two-men-sitting-at-desk-speaking-to-woman-in-business-attire-gay-couple-financial-advisor-broker-lgbtq-poc.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.989041"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.224151,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.249106",
        "ticker_sentiment_score": "0.170358",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.094762",
        "ticker_sentiment_score": "0.152512",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.031654",
        "ticker_sentiment_score": "0.040855",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FNF",
        "relevance_score": "0.031654",
        "ticker_sentiment_score": "0.049275",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Where Will Vertex Pharmaceuticals Be in 10 Years?",
    "url": "https://www.fool.com/investing/2024/01/25/where-will-vertex-pharmaceuticals-be-in-10-years/",
    "time_published": "20240125T170000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "As the adage goes, winners keep winning.",
    "banner_image": "https://media.ycharts.com/charts/b099a4d643e6f0836267723763fc9490.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.237018,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.359014",
        "ticker_sentiment_score": "0.36705",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Could Sarepta Therapeutics Become the Next Vertex Pharmaceuticals?",
    "url": "https://www.fool.com/investing/2024/01/25/could-sarepta-therapeutics-become-the-next-vertex/",
    "time_published": "20240125T144500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "It's always tough to be compared to a giant.",
    "banner_image": "https://g.foolcdn.com/editorial/images/761906/person-working-at-a-desk.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.203215,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.217834",
        "ticker_sentiment_score": "0.100139",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SRPT",
        "relevance_score": "0.510588",
        "ticker_sentiment_score": "0.286101",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Here's My Top Growth Stock to Buy Right Now",
    "url": "https://www.fool.com/investing/2024/01/27/heres-my-top-growth-stock-to-buy-right-now/",
    "time_published": "20240127T165000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "There doesn't appear to be a weak link with this great stock.",
    "banner_image": "https://g.foolcdn.com/editorial/images/762404/scientist-monitors-with-dna.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.260328,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.047654",
        "ticker_sentiment_score": "0.090923",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.047654",
        "ticker_sentiment_score": "0.058907",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.095138",
        "ticker_sentiment_score": "0.133342",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Magnificent Stocks to Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/01/27/3-magnificent-stocks-to-buy-and-hold-forever/",
    "time_published": "20240127T125400",
    "authors": [
      "Keith Speights",
      "and Prosper Junior Bakiny",
      "David Jagielski"
    ],
    "summary": "Many investors will want to consider owning these stocks for a long time.",
    "banner_image": "https://g.foolcdn.com/editorial/images/762671/hands-behind-head-young-man.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.349365,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.16849",
        "ticker_sentiment_score": "0.001473",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.126784",
        "ticker_sentiment_score": "0.228318",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.367865",
        "ticker_sentiment_score": "0.28224",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NTLA",
        "relevance_score": "0.042421",
        "ticker_sentiment_score": "0.085851",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "If You Invested $1,000 in Bluebird Bio in 2019, This Is How Much You Would Have Today",
    "url": "https://www.fool.com/investing/2024/01/27/if-you-invested-1000-in-bluebird-bio-in-2019/",
    "time_published": "20240127T122800",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The answer hardly inspires confidence.",
    "banner_image": "https://g.foolcdn.com/editorial/images/761882/physician-giving-a-high-five-to-a-young-patient.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.174762,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.135347",
        "ticker_sentiment_score": "0.058736",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BLUE",
        "relevance_score": "0.201803",
        "ticker_sentiment_score": "0.198199",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Under-the-Radar Stocks With Incredible Upside Potential",
    "url": "https://www.fool.com/investing/2024/01/28/2-under-the-radar-stocks-with-incredible-upside/",
    "time_published": "20240128T134500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "It's also important to consider their downsides.",
    "banner_image": "https://g.foolcdn.com/editorial/images/762022/physician-shaking-patients-hand.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.304616,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.060848",
        "ticker_sentiment_score": "0.113628",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.060848",
        "ticker_sentiment_score": "0.247073",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "EDIT",
        "relevance_score": "0.458593",
        "ticker_sentiment_score": "0.415686",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "RXRX",
        "relevance_score": "0.239895",
        "ticker_sentiment_score": "0.373771",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Cathie Wood Goes Bargain Hunting: 3 Stocks She Bought Last Week",
    "url": "https://www.fool.com/investing/2024/01/28/cathie-wood-bargain-hunts-3-stocks-she-bought/",
    "time_published": "20240128T101000",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Wood added to her existing positions in these three exciting companies.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F762836%2Fgettyimages-998452928.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.918141"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.340189,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PGPGF",
        "relevance_score": "0.046006",
        "ticker_sentiment_score": "0.081695",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.046006",
        "ticker_sentiment_score": "0.254375",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.137409",
        "ticker_sentiment_score": "0.215652",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DNA",
        "relevance_score": "0.09186",
        "ticker_sentiment_score": "0.086331",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.09186",
        "ticker_sentiment_score": "0.088233",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( VRTX )  Laps the Stock Market: Here's Why",
    "url": "https://www.zacks.com/stock/news/2217475/vertex-pharmaceuticals-vrtx-laps-the-stock-market-heres-why",
    "time_published": "20240129T225018",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex Pharmaceuticals (VRTX) closed at $435.82 in the latest trading session, marking a +1.31% move from the prior day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default182.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.95493"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.28345,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.556576",
        "ticker_sentiment_score": "0.379114",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Vertex non-opioid painkiller shows positive results in critical late-stage trial on acute pain",
    "url": "https://www.cnbc.com/2024/01/30/vertex-non-opioid-painkiller-shows-positive-late-stage-trial-results.html",
    "time_published": "20240130T213125",
    "authors": [
      "Annika Kim Constantino"
    ],
    "summary": "The trial results bring the biotech company one step closer to developing a drug that can provide strong pain relief without the addictive potential of opioids.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107347177-17024876422019-10-23t192640z_180367507_rc14151b5800_rtrmadp_0_vertex-pharms-fda.jpeg?v=1702493101&w=1920&h=1080",
    "source": "CNBC",
    "category_within_source": "Business",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.034838,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.077593",
        "ticker_sentiment_score": "-0.126738",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Charles River  ( CRL )  Launches Animal-Free Endotoxin Test",
    "url": "https://www.zacks.com/stock/news/2218218/charles-river-crl-launches-animal-free-endotoxin-test",
    "time_published": "20240130T183900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Charles River's (CRL) latest launch expands on Charles River's existing Trillium rCR vial product.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.234964,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.051221",
        "ticker_sentiment_score": "0.038965",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UHS",
        "relevance_score": "0.20279",
        "ticker_sentiment_score": "0.146821",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ACHC",
        "relevance_score": "0.152821",
        "ticker_sentiment_score": "0.056264",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ITGR",
        "relevance_score": "0.20279",
        "ticker_sentiment_score": "0.073581",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Exelixis  ( EXEL )  Reports Next Week: Wall Street Expects Earnings Growth",
    "url": "https://www.zacks.com/stock/news/2217975/exelixis-exel-reports-next-week-wall-street-expects-earnings-growth",
    "time_published": "20240130T150058",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default225.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.130823,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.087985",
        "ticker_sentiment_score": "0.038079",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXEL",
        "relevance_score": "0.259727",
        "ticker_sentiment_score": "0.057277",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Is Vertex Pharmaceuticals Stock Sliding Today? - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/general/biotech/24/01/36846814/why-is-vertex-pharmaceuticals-stock-sliding-today",
    "time_published": "20240130T145107",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Tuesday, Vertex Pharmaceuticals Incorporated VRTX announced results from its Phase 3 program ( two Phase 3 trials ) for the selective NaV1.8 inhibitor, VX-548, for moderate-to-severe acute pain.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/VRTX.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.176732,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.331765",
        "ticker_sentiment_score": "-0.022013",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Skids - Its Opioid Alternative Is 'Not A Game-Changer'",
    "url": "https://www.investors.com/news/technology/vrtx-stock-skids-its-alternative-to-opioids-is-not-a-game-changer-says-analyst/",
    "time_published": "20240130T144100",
    "authors": [
      "ALLISON GATLIN",
      "Investor's Business Daily"
    ],
    "summary": "Vertex Pharmaceuticals' ( VRTX ) alternative to opioids in pain treatment is \"not a game-changer,\" an analyst said Tuesday as VRTX stock slipped on the company's Phase 3 test results.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2023/10/Stock-Vertex-tech-company.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      }
    ],
    "overall_sentiment_score": 0.002408,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.666827",
        "ticker_sentiment_score": "-0.470915",
        "ticker_sentiment_label": "Bearish"
      }
    ]
  },
  {
    "title": "Is CRISPR Therapeutics a Buy in the New Bull Market?",
    "url": "https://www.fool.com/investing/2024/01/30/is-crispr-therapeutics-a-buy-in-new-bull-market/",
    "time_published": "20240130T100200",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "CRISPR Therapeutics is a specialist in the hot technology of gene editing.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F763021%2Fgettyimages-1096502340.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.354424,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.055881",
        "ticker_sentiment_score": "0.22298",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Vertex's  ( VRTX )  Non-Opioid Pain Drug Meets Primary Goal",
    "url": "https://www.zacks.com/stock/news/2218984/vertexs-vrtx-non-opioid-pain-drug-meets-primary-goal",
    "time_published": "20240131T171800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Three late-stage studies data show that Vertex's (VRTX) experimental non-opioid drug reduced pain across a 48-hour period. Based on this data, VRTX intends to submit an FDA filing by mid-2024.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.017155,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.211652",
        "ticker_sentiment_score": "-0.012561",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SRPT",
        "relevance_score": "0.106778",
        "ticker_sentiment_score": "0.046451",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVXL",
        "relevance_score": "0.159569",
        "ticker_sentiment_score": "0.07587",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Check Out What Whales Are Doing With VRTX - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/insights/options/24/01/36869793/check-out-what-whales-are-doing-with-vrtx",
    "time_published": "20240131T160124",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Financial giants have made a conspicuous bearish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex Pharmaceuticals VRTX revealed 9 unusual trades. Delving into the details, we found 33% of traders were bullish, while 66% showed bearish tendencies.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.067146,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.68471",
        "ticker_sentiment_score": "-0.101506",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stay Ahead of the Game With Vertex  ( VRTX )  Q4 Earnings: Wall Street's Insights on Key Metrics",
    "url": "https://www.zacks.com/stock/news/2218636/stay-ahead-of-the-game-with-vertex-vrtx-q4-earnings-wall-streets-insights-on-key-metrics",
    "time_published": "20240131T141517",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Beyond analysts' top -and-bottom-line estimates for Vertex (VRTX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default30.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.947132"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.158543,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.227007",
        "ticker_sentiment_score": "0.195855",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Jim Cramer Says It's 'Still Not Too Late' To Buy This Energy Stock - CRISPR Therapeutics  ( NASDAQ:CRSP ) , DigitalOcean Holdings  ( NYSE:DOCN ) ",
    "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/01/36860627/jim-cramer-says-its-still-not-too-late-to-buy-this-energy-stock",
    "time_published": "20240131T125743",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "On CNBC's \"Mad Money Lightning Round,\" Jim Cramer said he is taking a \"hard pass\" on Surgery Partners, Inc. SGRY. \"That industry has been up and down and up and down,\" he added. Surgery Partners recently reaffirmed its 2023 adjusted EBITDA guidance of $436 million to $440 million and revenue ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/31/jim_cramer_nyse_shutter.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": -0.034059,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.111488",
        "ticker_sentiment_score": "0.06475",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRSP",
        "relevance_score": "0.220809",
        "ticker_sentiment_score": "-0.447299",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "MP",
        "relevance_score": "0.325924",
        "ticker_sentiment_score": "-0.076966",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DOCN",
        "relevance_score": "0.42503",
        "ticker_sentiment_score": "0.192987",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.111488",
        "ticker_sentiment_score": "0.093442",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VOD",
        "relevance_score": "0.42503",
        "ticker_sentiment_score": "0.005886",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SGRY",
        "relevance_score": "0.42503",
        "ticker_sentiment_score": "-0.058307",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ET",
        "relevance_score": "0.42503",
        "ticker_sentiment_score": "0.287745",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why Vertex Pharmaceuticals Stock Topped the Market Today",
    "url": "https://www.fool.com/investing/2024/01/30/why-vertex-pharmaceuticals-stock-topped-the-market/",
    "time_published": "20240131T001016",
    "authors": [
      "Eric Volkman"
    ],
    "summary": "The company reported that it met its primary endpoint in a study for its non-opioid pain drug.",
    "banner_image": "https://g.foolcdn.com/editorial/images/763301/two-people-seated-at-a-lab-desk-featuring-a-pc-screen-and-microscope.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.085973,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.272788",
        "ticker_sentiment_score": "0.493625",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "InnovationRx: Show Me The Healthcare Savings",
    "url": "https://www.forbes.com/sites/katiejennings/2024/02/01/innovationrx-welltheory-healthcare-savings/",
    "time_published": "20240201T150012",
    "authors": [
      "Katie Jennings"
    ],
    "summary": "InnovationRx is your weekly digest of healthcare news. To get it in your inbox, subscribe here. here were a whopping two healthtech startups that hit billion-dollar valuations in 2023, compared to 52 unicorns minted during the two years prior, according to a PitchBook analysis.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65bbabdc914b96812cb02bf8/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.152677,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SCI",
        "relevance_score": "0.041323",
        "ticker_sentiment_score": "0.118104",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.041323",
        "ticker_sentiment_score": "0.11689",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HUM",
        "relevance_score": "0.041323",
        "ticker_sentiment_score": "-0.009886",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.041323",
        "ticker_sentiment_score": "0.197529",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.041323",
        "ticker_sentiment_score": "0.124483",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.041323",
        "ticker_sentiment_score": "0.233516",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "EnteroBiotix Strengthens its Executive Team, Appoints COO and CFO",
    "url": "https://www.benzinga.com/pressreleases/24/02/g36882398/enterobiotix-strengthens-its-executive-team-appoints-coo-and-cfo",
    "time_published": "20240201T082728",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "GLASGOW, Scotland, Feb. 01, 2024 ( GLOBE NEWSWIRE ) -- EnteroBiotix Limited ( \"EBX\" ) , a clinical stage biopharmaceutical company with the premier platform for full-spectrum microbiome therapeutics, today announced the appointments of Dr James Barnes as Chief Operating Officer ( \"COO\" ) and ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.233184,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.083251",
        "ticker_sentiment_score": "0.066094",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals May Be About to Solve a Common Health Problem. Is the Stock a Buy?",
    "url": "https://www.fool.com/investing/2024/02/02/vertex-to-solve-common-health-problem/",
    "time_published": "20240202T211200",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Vertex shares recently reached an all-time high.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F763503%2Fgettyimages-scientists-in-lab01.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.04186,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.119235",
        "ticker_sentiment_score": "0.327133",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Stocks Handle Huge Earnings, Fed, Jobs Report: Weekly Review",
    "url": "https://www.investors.com/news/stock-market-handles-huge-earnings-week-fed-powell-jobs-report-weekly-review/",
    "time_published": "20240202T171500",
    "authors": [
      "IBD STAFF",
      "Investor's Business Daily"
    ],
    "summary": "Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/04/SSA-040816-shutterstock.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99977"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.142857"
      }
    ],
    "overall_sentiment_score": 0.029434,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MXL",
        "relevance_score": "0.033236",
        "ticker_sentiment_score": "0.01579",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.099476",
        "ticker_sentiment_score": "0.026313",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "-0.145994",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.066414",
        "ticker_sentiment_score": "0.045467",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.016621",
        "ticker_sentiment_score": "-0.013684",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NYCB",
        "relevance_score": "0.082963",
        "ticker_sentiment_score": "-0.121209",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "-0.136008",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALGM",
        "relevance_score": "0.033236",
        "ticker_sentiment_score": "0.01579",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.099476",
        "ticker_sentiment_score": "0.050168",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SHOP",
        "relevance_score": "0.033236",
        "ticker_sentiment_score": "-0.154811",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.033236",
        "ticker_sentiment_score": "0.007675",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MA",
        "relevance_score": "0.016621",
        "ticker_sentiment_score": "0.113074",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QCOM",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "0.016017",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.033236",
        "ticker_sentiment_score": "-0.109096",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMD",
        "relevance_score": "0.099476",
        "ticker_sentiment_score": "0.005554",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NXT(EXP20091224)",
        "relevance_score": "0.016621",
        "ticker_sentiment_score": "0.155736",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.066414",
        "ticker_sentiment_score": "-0.024213",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.082963",
        "ticker_sentiment_score": "0.120391",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.033236",
        "ticker_sentiment_score": "0.158384",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "0.161989",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GM",
        "relevance_score": "0.099476",
        "ticker_sentiment_score": "0.036073",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LSTR",
        "relevance_score": "0.033236",
        "ticker_sentiment_score": "-0.014716",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "0.16469",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "-0.069943",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "-0.136008",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MANH",
        "relevance_score": "0.033236",
        "ticker_sentiment_score": "-0.154811",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.033236",
        "ticker_sentiment_score": "-0.133526",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "POWL",
        "relevance_score": "0.033236",
        "ticker_sentiment_score": "0.053581",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DECK",
        "relevance_score": "0.033236",
        "ticker_sentiment_score": "0.092797",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.033236",
        "ticker_sentiment_score": "-0.142727",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SOFI",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "0.010999",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RCL",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "-0.059814",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WOLF",
        "relevance_score": "0.033236",
        "ticker_sentiment_score": "0.01579",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.033236",
        "ticker_sentiment_score": "-0.133526",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SBNY",
        "relevance_score": "0.016621",
        "ticker_sentiment_score": "-0.102369",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "0.028998",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.066414",
        "ticker_sentiment_score": "0.004048",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ODFL",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "-0.015004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:NXT",
        "relevance_score": "0.016621",
        "ticker_sentiment_score": "0.155736",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Vertex  ( VRTX )  to Report Q4 Earnings: What's in the Cards?",
    "url": "https://www.zacks.com/stock/news/2220380/vertex-vrtx-to-report-q4-earnings-whats-in-the-cards",
    "time_published": "20240202T154700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "On Vertex's (VRTX) fourth-quarter 2023 earnings call, investors' focus is likely to be on the sales numbers of its lead drug, Trikafta/Kaftrio, and progress with other pipeline candidates.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/37/2337.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.99998"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.082934,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.194632",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SRPT",
        "relevance_score": "0.146618",
        "ticker_sentiment_score": "0.056138",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BPMC",
        "relevance_score": "0.288327",
        "ticker_sentiment_score": "0.062125",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Got $100? 2 Top Cathie Wood Stocks to Buy and Hold.",
    "url": "https://www.fool.com/investing/2024/02/04/got-100-2-top-cathie-wood-stocks-to-buy-and-hold/",
    "time_published": "20240204T193500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "These stocks are steals right now.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F763515%2Fcrsp_getty-images.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.967645"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.358644,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.060694",
        "ticker_sentiment_score": "0.077001",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TDOC",
        "relevance_score": "0.121037",
        "ticker_sentiment_score": "0.245556",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( VRTX )  Q4 Earnings and Revenues Top Estimates",
    "url": "https://www.zacks.com/stock/news/2221313/vertex-pharmaceuticals-vrtx-q4-earnings-and-revenues-top-estimates",
    "time_published": "20240205T222004",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex (VRTX) delivered earnings and revenue surprises of 2.44% and 0.76%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default25.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999992"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.171037,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.140896",
        "ticker_sentiment_score": "0.09672",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STOK",
        "relevance_score": "0.20997",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Scores Big With Its Next-Gen Cystic Fibrosis Drug",
    "url": "https://www.investors.com/news/technology/vrtx-stock-vertex-earnings-q4-2023/",
    "time_published": "20240205T212000",
    "authors": [
      "ALLISON GATLIN",
      "Investor's Business Daily"
    ],
    "summary": "VRTX Stock Rises On Quarterly Beat As Next-Gen CF Drug Scores Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2020/04/Stock-Vertex-04-shutt.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      }
    ],
    "overall_sentiment_score": 0.26355,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.6338",
        "ticker_sentiment_score": "0.274514",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.143415",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stocks Fall As Traders Dial Back Rate Cut Bets; Dollar, Treasury Yields Rise: What's Driving Markets Monday? - Air Products & Chemicals  ( NYSE:APD ) , Caterpillar  ( NYSE:CAT ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/02/36939189/stocks-fall-as-traders-dial-back-rate-cut-bets-dollar-treasury-yields-rise-whats-dr",
    "time_published": "20240205T191208",
    "authors": [
      "Piero Cingari"
    ],
    "summary": "After enjoying 13 out of 14 positive weeks, Wall Street kicked off Monday on a weaker note as traders revise down their expectations regarding Fed interest rate cuts.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Wall-Street-sign_5.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.976913"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": -0.007286,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.130926",
        "ticker_sentiment_score": "-0.253202",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.130926",
        "ticker_sentiment_score": "0.215223",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MDNDF",
        "relevance_score": "0.065685",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.130926",
        "ticker_sentiment_score": "0.107177",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.130926",
        "ticker_sentiment_score": "0.107177",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.130926",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPG",
        "relevance_score": "0.130926",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.065685",
        "ticker_sentiment_score": "0.182451",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.065685",
        "ticker_sentiment_score": "0.115979",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNAP",
        "relevance_score": "0.130926",
        "ticker_sentiment_score": "-0.33349",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "MCD",
        "relevance_score": "0.130926",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "APD",
        "relevance_score": "0.130926",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.130926",
        "ticker_sentiment_score": "0.338185",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IDXX",
        "relevance_score": "0.130926",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ON",
        "relevance_score": "0.065685",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PLTR",
        "relevance_score": "0.130926",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.065685",
        "ticker_sentiment_score": "0.184461",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals Gears Up For Q4 Print; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/news/earnings/24/02/36935401/vertex-pharmaceuticals-gears-up-for-q4-print-these-most-accurate-analysts-revise-forecasts-ahead-of",
    "time_published": "20240205T155940",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "Vertex Pharmaceuticals Incorporated VRTX is expected to release earnings results for its fourth quarter, after the closing bell on Feb. 5, 2024. Analysts expect the company to report quarterly earnings at $4.10 per share, up from year-ago earnings of $3.76 per share.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.070368,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CCORF",
        "relevance_score": "0.129516",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.485711",
        "ticker_sentiment_score": "-0.17205",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Will Jerome Powell Spoil Wall Street's Party? US Stock Futures Slip As Fed Chief Maintains Hawkish Tone Ahead Of More Earnings - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ",
    "url": "https://www.benzinga.com/news/earnings/24/02/36930088/will-jerome-powell-spoil-wall-streets-party-us-stock-futures-slip-as-fed-chief-maintains-hawkish-to",
    "time_published": "20240205T122645",
    "authors": [
      "Shanthi Rexaline"
    ],
    "summary": "U.S. stock futures experienced a dip in Monday's premarket session as investors brace for an earnings-heavy week. Federal Reserve Chair Jerome Powell, in a \"60 Minutes\" interview, maintained his hawkish stance, emphasizing the central bank's cautious approach toward potential rate cuts this year.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/powell-wall-street-flickr_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.972756"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      }
    ],
    "overall_sentiment_score": -0.030873,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.121343",
        "ticker_sentiment_score": "0.090407",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.121343",
        "ticker_sentiment_score": "0.090407",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.121343",
        "ticker_sentiment_score": "0.090407",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDNDF",
        "relevance_score": "0.060848",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NXPI",
        "relevance_score": "0.121343",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.121343",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RMBS",
        "relevance_score": "0.121343",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.060848",
        "ticker_sentiment_score": "0.129809",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSN",
        "relevance_score": "0.121343",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MCD",
        "relevance_score": "0.121343",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JJSF",
        "relevance_score": "0.121343",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "APD",
        "relevance_score": "0.121343",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.121343",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.060848",
        "ticker_sentiment_score": "0.062",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.121343",
        "ticker_sentiment_score": "0.090407",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ON",
        "relevance_score": "0.060848",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PLTR",
        "relevance_score": "0.121343",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Fate of the Mag 7 depends on their ability to deliver rapid revenue growth in 2024, says Goldman Sachs",
    "url": "https://www.marketwatch.com/story/fate-of-the-mag-7-depends-on-their-ability-to-deliver-rapid-revenue-growth-in-2024-says-goldman-sachs-57b43604",
    "time_published": "20240205T114600",
    "authors": [
      "Jamie Chisholm"
    ],
    "summary": "Mag 7 valuations are not extreme but they must deliver the forecast revenue growth ...",
    "banner_image": "https://images.mktw.net/im-37755619?width=700&height=481",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990893"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.857896"
      }
    ],
    "overall_sentiment_score": 0.166282,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.077094",
        "ticker_sentiment_score": "0.23679",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.115416",
        "ticker_sentiment_score": "0.204829",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.15347",
        "ticker_sentiment_score": "0.140498",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CSCO",
        "relevance_score": "0.077094",
        "ticker_sentiment_score": "0.036381",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDNDF",
        "relevance_score": "0.038592",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.038592",
        "ticker_sentiment_score": "0.046983",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NXPI",
        "relevance_score": "0.077094",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.077094",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.038592",
        "ticker_sentiment_score": "0.228167",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.115416",
        "ticker_sentiment_score": "0.160906",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.15347",
        "ticker_sentiment_score": "0.168806",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.077094",
        "ticker_sentiment_score": "0.036381",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.077094",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.077094",
        "ticker_sentiment_score": "0.036381",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IDXX",
        "relevance_score": "0.077094",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GE",
        "relevance_score": "0.077094",
        "ticker_sentiment_score": "0.036381",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PLTR",
        "relevance_score": "0.077094",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.038592",
        "ticker_sentiment_score": "0.04419",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Investor Optimism Improves Following Tech Earnings, Jobs Data; S&P 500 Gains For 4th Week - Apple  ( NASDAQ:AAPL ) , Amazon.com  ( NASDAQ:AMZN ) ",
    "url": "https://www.benzinga.com/news/earnings/24/02/36927010/investor-optimism-improves-following-tech-earnings-jobs-data-s-p-500-gains-for-4th-week",
    "time_published": "20240205T081911",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "The CNN Money Fear and Greed index showed an improvement in the overall market sentiment, while the index remained in the \"Greed\" zone on Friday. U.S. stocks closed higher on Friday, with the S&P 500 index hitting a new record high during the session.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/02/05/image21.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.795202"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.058123,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.379119",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.422161",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "MDNDF",
        "relevance_score": "0.107495",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WBD",
        "relevance_score": "0.107495",
        "ticker_sentiment_score": "-0.171284",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "TSN",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex's Next-Generation Cystic Fibrosis Program Shows Efficacy With Reduced Burden, Provides Growth Opportunity: Goldman Sachs - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/02/36964644/vertexs-next-generation-cystic-fibrosis-program-shows-efficacy-with-reduced-burden-",
    "time_published": "20240206T195519",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Monday, Vertex Pharmaceuticals Incorporated VRTX released results from its once-daily vanzacaftor/tezacaftor/deutivacaftor ( vanza triple ) program for cystic fibrosis ( CF ) , a progressive, multi-organ disease caused by dysfunction of the CFTR protein.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/VRTX_1.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.06931,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.101582",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.298264",
        "ticker_sentiment_score": "0.061706",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex's  ( VRTX )  Q4 Earnings and Sales Surpass Estimates",
    "url": "https://www.zacks.com/stock/news/2221892/vertexs-vrtx-q4-earnings-and-sales-surpass-estimates",
    "time_published": "20240206T152600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex's (VRTX) fourth-quarter earnings and revenues surpass estimates. The company reports encouraging data on triple combination of vanzacaftor studies.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.997845"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.157549,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.207868",
        "ticker_sentiment_score": "0.170279",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KOD",
        "relevance_score": "0.207868",
        "ticker_sentiment_score": "0.021676",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PBYI",
        "relevance_score": "0.173832",
        "ticker_sentiment_score": "0.128676",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals' Triple Combo Treatment For Lung Disorder Meets Primary Goal In Adult And Pediatric Patients - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/general/biotech/24/02/36957190/vertex-pharmaceuticals-triple-combo-treatment-for-lung-disorder-meets-primary-goal-in-adult-and-p",
    "time_published": "20240206T145712",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Vertex Pharmaceuticals Incorporated VRTX released results from its once-daily vanzacaftor/tezacaftor/deutivacaftor ( vanza triple ) program for cystic fibrosis ( CF ) , a progressive, multi-organ disease caused by dysfunction of the CFTR protein.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/VRTX_0.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.025745,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.443626",
        "ticker_sentiment_score": "0.014816",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals Has a $10 Billion Opportunity on the Table. Here's How You Can Invest",
    "url": "https://www.fool.com/investing/2024/02/06/vertex-pharmaceuticals-has-10-billion-opportunity/",
    "time_published": "20240206T145300",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Its foray into developing analgesics seems to be going swimmingly.",
    "banner_image": "https://g.foolcdn.com/editorial/images/762884/vertex-sign.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.169194,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.103109",
        "ticker_sentiment_score": "0.114407",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Futures Dip; Palantir Soars On Surging AI Demand",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-fall-palantir-soars-on-surging-ai-demand/",
    "time_published": "20240206T131700",
    "authors": [
      "SCOTT LEHTONEN",
      "Investor's Business Daily"
    ],
    "summary": "Dow Jones Futures Fall As Tesla Slides On Downgrade. Palantir Soars On Surging AI Demand Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2021/09/Stock-wallstreetflag-01-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.795202"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.142857"
      }
    ],
    "overall_sentiment_score": 0.205444,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.157741",
        "ticker_sentiment_score": "0.110092",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.196451",
        "ticker_sentiment_score": "0.134443",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.118647",
        "ticker_sentiment_score": "0.130868",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXPE",
        "relevance_score": "0.157741",
        "ticker_sentiment_score": "0.107195",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.079261",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDB",
        "relevance_score": "0.157741",
        "ticker_sentiment_score": "0.015246",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.039679",
        "ticker_sentiment_score": "0.117525",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.118647",
        "ticker_sentiment_score": "0.081445",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.196451",
        "ticker_sentiment_score": "0.077388",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LEN",
        "relevance_score": "0.157741",
        "ticker_sentiment_score": "0.059783",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.118647",
        "ticker_sentiment_score": "0.130868",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PLTR",
        "relevance_score": "0.079261",
        "ticker_sentiment_score": "-0.054554",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.157741",
        "ticker_sentiment_score": "0.008044",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Uber To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday - Church & Dwight Co  ( NYSE:CHD ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",
    "url": "https://www.benzinga.com/news/24/02/36952827/uber-to-rally-around-15-here-are-10-top-analyst-forecasts-for-tuesday",
    "time_published": "20240206T125409",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Keybanc boosted the price target for Uber Technologies, Inc. UBER from $70 to $79.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/02/06/uber_-logo.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.752319"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.148997,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "SAIA",
        "relevance_score": "0.159569",
        "ticker_sentiment_score": "0.050807",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COST",
        "relevance_score": "0.237358",
        "ticker_sentiment_score": "0.216759",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.159569",
        "ticker_sentiment_score": "0.068369",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.237358",
        "ticker_sentiment_score": "0.294014",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.237358",
        "ticker_sentiment_score": "0.190605",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CHGG",
        "relevance_score": "0.237358",
        "ticker_sentiment_score": "-0.113226",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LI",
        "relevance_score": "0.237358",
        "ticker_sentiment_score": "0.011337",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.237358",
        "ticker_sentiment_score": "0.207157",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.237358",
        "ticker_sentiment_score": "-0.118868",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PLTR",
        "relevance_score": "0.237358",
        "ticker_sentiment_score": "0.179235",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "This High-Flying Stock Just Got Some Bad News: Should You Sell?",
    "url": "https://www.fool.com/investing/2024/02/06/this-high-flying-stock-got-some-bad-news-should/",
    "time_published": "20240206T101500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "It's just a minor setback for this leading biotech.",
    "banner_image": "https://g.foolcdn.com/editorial/images/763539/patient-taking-medicine.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.193532,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.306198",
        "ticker_sentiment_score": "0.254214",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( VRTX )  Q4 2023 Earnings Call Transcript",
    "url": "https://www.fool.com/earnings/call-transcripts/2024/02/05/vertex-pharmaceuticals-vrtx-q4-2023-earnings-call/",
    "time_published": "20240206T043022",
    "authors": [
      "Motley Fool Transcribing"
    ],
    "summary": "VRTX earnings call for the period ending December 31, 2023.",
    "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.986714"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.22875,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.004136",
        "ticker_sentiment_score": "0.146739",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.004136",
        "ticker_sentiment_score": "0.129189",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.004136",
        "ticker_sentiment_score": "0.099232",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.008272",
        "ticker_sentiment_score": "0.095199",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.004136",
        "ticker_sentiment_score": "0.129189",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/insights/news/24/02/36984914/100-invested-in-this-stock-5-years-ago-would-be-worth-200-today",
    "time_published": "20240207T160027",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Vertex Pharmaceuticals VRTX has outperformed the market over the past 5 years by 5.51% on an annualized basis producing an average annual return of 18.17%. Currently, Vertex Pharmaceuticals has a market capitalization of $109.27 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_4.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.160819,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.980595",
        "ticker_sentiment_score": "0.386944",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals Stock Is Approaching a Huge Catalyst, But Is It a Buy?",
    "url": "https://www.fool.com/investing/2024/02/08/vertex-pharmaceuticals-stock-is-approaching-a-huge/",
    "time_published": "20240208T145300",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Its pain medicine isn't precisely what it hoped for, but it could still sell.",
    "banner_image": "https://g.foolcdn.com/editorial/images/764024/vertex.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.188249,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.153145",
        "ticker_sentiment_score": "0.172069",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Healthcare Stocks to Buy Hand Over Fist in February",
    "url": "https://www.fool.com/investing/2024/02/08/2-healthcare-stocks-to-buy-hand-over-fist-february/",
    "time_published": "20240208T075900",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "Both companies are proven innovators.",
    "banner_image": "https://g.foolcdn.com/editorial/images/763505/doctor-and-patient-in-a-hospital-room.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      }
    ],
    "overall_sentiment_score": 0.284787,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.050359",
        "ticker_sentiment_score": "0.153555",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.386626",
        "ticker_sentiment_score": "0.37483",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "3 Growth Stocks With More Potential Than Any Cryptocurrency",
    "url": "https://www.fool.com/investing/2024/02/09/3-growth-stocks-with-more-potential-than-any-crypt/",
    "time_published": "20240209T130000",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "The stock market is full of opportunities for investors of all risk appetites and trading styles.",
    "banner_image": "https://g.foolcdn.com/editorial/images/764143/woman-finance-calculator-laptop-notebook.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.225818,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CHWY",
        "relevance_score": "0.193001",
        "ticker_sentiment_score": "0.130956",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.077845",
        "ticker_sentiment_score": "0.119384",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABNB",
        "relevance_score": "0.116536",
        "ticker_sentiment_score": "0.063703",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stock Market Hits Highs As AI Plays Skyrocket: Weekly Review",
    "url": "https://www.investors.com/news/stock-market-hits-highs-as-arm-palantir-cloudflare-skyrocket/",
    "time_published": "20240209T001300",
    "authors": [
      "IBD STAFF",
      "Investor's Business Daily"
    ],
    "summary": "The stock market rally generally advanced with the S&P 500 hitting 5,000 for the first time and the Nasdaq at its best levels in over two years. The Dow Jones held just below its all-time highs while the Russell 2000 rebounded back above key levels.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/01/Stock-colorfullightbulb-generatedai-01-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.088082,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MDNDF",
        "relevance_score": "0.017902",
        "ticker_sentiment_score": "-0.147329",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEX",
        "relevance_score": "0.053669",
        "ticker_sentiment_score": "0.066999",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NBIX",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.051683",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RPD",
        "relevance_score": "0.053669",
        "ticker_sentiment_score": "-0.012012",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXPE",
        "relevance_score": "0.053669",
        "ticker_sentiment_score": "0.049042",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVGI",
        "relevance_score": "0.017902",
        "ticker_sentiment_score": "0.067321",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.071517",
        "ticker_sentiment_score": "0.053795",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARCB",
        "relevance_score": "0.071517",
        "ticker_sentiment_score": "0.054344",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DT",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "-0.078802",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.069261",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QLYS",
        "relevance_score": "0.053669",
        "ticker_sentiment_score": "-0.004005",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HLT",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.048215",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRUS",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.09861",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ORLY",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "-0.129876",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.089328",
        "ticker_sentiment_score": "0.118465",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AOSL",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.09861",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CYBR",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "-0.101404",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RBLX",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PINS",
        "relevance_score": "0.053669",
        "ticker_sentiment_score": "-0.224249",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "-0.158803",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "-0.016619",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HMC",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.072035",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BABA",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "-0.07722",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PYPL",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.037818",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GM",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.072035",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NXPI",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.09861",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.051683",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RMBS",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.09861",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INTA",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "-0.151575",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "YUM",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "-0.158803",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "FTNT",
        "relevance_score": "0.053669",
        "ticker_sentiment_score": "-0.074739",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PI",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.09861",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DIOD",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.09861",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.051683",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARM",
        "relevance_score": "0.071517",
        "ticker_sentiment_score": "0.07345",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NET",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.018656",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AFRM",
        "relevance_score": "0.035794",
        "ticker_sentiment_score": "0.037818",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Vertex Pharmaceuticals Stock a Buy Now?",
    "url": "https://www.fool.com/investing/2024/02/10/is-vertex-pharmaceuticals-stock-a-buy-now/",
    "time_published": "20240210T173700",
    "authors": [
      "David Jagielski"
    ],
    "summary": "The company just released its latest earnings report, and growth investors may be a little disappointed.",
    "banner_image": "https://g.foolcdn.com/editorial/images/764147/doctor-discussing-results-with-a-family.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.972476"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.277891,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.174167",
        "ticker_sentiment_score": "0.317279",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Healthcare Stocks You Can Buy and Hold for the Next Decade",
    "url": "https://www.fool.com/investing/2024/02/10/2-healthcare-stocks-you-can-buy-and-hold-for-the/",
    "time_published": "20240210T144500",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "These businesses are built to last.",
    "banner_image": "https://g.foolcdn.com/editorial/images/764139/getty-happy-person-sign-language-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.972756"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.186521,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.097062",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TDOC",
        "relevance_score": "0.097062",
        "ticker_sentiment_score": "0.063214",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 No-Brainer Healthcare Stocks to Buy Right Now",
    "url": "https://www.fool.com/investing/2024/02/10/2-no-brainer-healthcare-stocks-to-buy-right-now/",
    "time_published": "20240210T133000",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "Companies in the healthcare industry tend to generate returns in a wide range of market environments.",
    "banner_image": "https://g.foolcdn.com/editorial/images/764140/getty-happy-with-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.858979"
      }
    ],
    "overall_sentiment_score": 0.235427,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.095707",
        "ticker_sentiment_score": "0.186655",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.452295",
        "ticker_sentiment_score": "0.208152",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Stocks That Could Trounce the Market in 2024",
    "url": "https://www.fool.com/investing/2024/02/10/3-stocks-that-could-trounce-the-market-in-2024/",
    "time_published": "20240210T114900",
    "authors": [
      "David Jagielski",
      "and Prosper Junior Bakiny",
      "Keith Speights"
    ],
    "summary": "These stocks appear to have what it takes to beat the market this year.",
    "banner_image": "https://g.foolcdn.com/editorial/images/764580/person-smiling-and-looking-at-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.998932"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.285154,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.196132",
        "ticker_sentiment_score": "0.143278",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.157483",
        "ticker_sentiment_score": "0.154214",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.039614",
        "ticker_sentiment_score": "0.153045",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.039614",
        "ticker_sentiment_score": "0.096768",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.234307",
        "ticker_sentiment_score": "0.179938",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Could Vertex Pharmaceuticals Reach $500 in 2024?",
    "url": "https://www.fool.com/investing/2024/02/10/could-vertex-pharmaceuticals-reach-500-in-2024/",
    "time_published": "20240210T100400",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Vertex shares have several catalysts on the horizon...",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F764714%2Fgettyimages-906798262.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.980716"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.254636,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.109206",
        "ticker_sentiment_score": "0.187464",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Healthcare Stocks That Could Help Set You Up for Life",
    "url": "https://www.fool.com/investing/2024/02/12/2-healthcare-stocks-that-could-help-set-you-up-for/",
    "time_published": "20240212T144500",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "These rock-solid businesses can add meaningful returns to a long-term portfolio.",
    "banner_image": "https://g.foolcdn.com/editorial/images/764511/getty-woman-reading-book.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.334431,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MRNA",
        "relevance_score": "0.05387",
        "ticker_sentiment_score": "0.129741",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.107495",
        "ticker_sentiment_score": "0.304128",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.31482",
        "ticker_sentiment_score": "0.323059",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should You Invest in the VanEck Biotech ETF  ( BBH ) ?",
    "url": "https://www.zacks.com/stock/news/2224468/should-you-invest-in-the-vaneck-biotech-etf-bbh",
    "time_published": "20240212T112005",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default115.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.138412,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.133841",
        "ticker_sentiment_score": "0.071297",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.133841",
        "ticker_sentiment_score": "0.071297",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.133841",
        "ticker_sentiment_score": "0.071297",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "If You Invested $10,000 in Vertex Pharmaceuticals in 2014, This Is How Much You Would Have Today",
    "url": "https://www.fool.com/investing/2024/02/13/if-you-invested-10000-in-vertex-pharmaceuticals-in/",
    "time_published": "20240213T144500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "You can't go back in the past, but it's not too late to invest in this top stock.",
    "banner_image": "https://media.ycharts.com/charts/52f89a400a4da82e6a4287387a6d9bc7.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.327505,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.194242",
        "ticker_sentiment_score": "0.200822",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY\u2122  ( exagamglogene autotemcel ) , for the Treatment of Sickle Cell Disease  ( SCD )  and Transfusion-Dependent Beta Thalassemia  ( TDT ) ",
    "url": "https://www.globenewswire.com/news-release/2024/02/13/2827965/0/en/European-Commission-Approves-First-CRISPR-Cas9-Gene-Edited-Therapy-CASGEVY-exagamglogene-autotemcel-for-the-Treatment-of-Sickle-Cell-Disease-SCD-and-Transfusion-Dependent-Beta-Thal.html",
    "time_published": "20240213T073000",
    "authors": [
      "CRISPR Therapeutics AG"
    ],
    "summary": "-Over 8,000 patients 12 years of age and older with severe SCD or TDT may be eligible for ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/5dac7d0d-131d-4047-bab7-db8e0719bf58",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.126555,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.046498",
        "ticker_sentiment_score": "0.10958",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRSP",
        "relevance_score": "0.069697",
        "ticker_sentiment_score": "0.08956",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Check Out What Whales Are Doing With CRSP - CRISPR Therapeutics  ( NASDAQ:CRSP ) ",
    "url": "https://www.benzinga.com/insights/options/24/02/37134842/check-out-what-whales-are-doing-with-crsp",
    "time_published": "20240214T183123",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Deep-pocketed investors have adopted a bearish approach towards CRISPR Therapeutics CRSP, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.246116,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.083541",
        "ticker_sentiment_score": "0.156827",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Prodigy Education Levels-Up Leadership Team with Appointment of Jeff Cassidy as Chief Financial Officer",
    "url": "https://www.newswire.ca/news-releases/prodigy-education-levels-up-leadership-team-with-appointment-of-jeff-cassidy-as-chief-financial-officer-890472622.html",
    "time_published": "20240214T140600",
    "authors": [
      "Prodigy Education Inc."
    ],
    "summary": "TORONTO, Feb. 14, 2024 /CNW/ - Game-based learning leader ( 'Prodigy' ) has made another key addition to its leadership team by appointing experienced EdTech executive Jeff Cassidy as Chief Financial Officer.",
    "banner_image": "https://mma.prnewswire.com/media/2338002/Prodigy_Education_Inc__Prodigy_Education_Levels_Up_Leadership_Te.jpg?p=facebook",
    "source": "Canada Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.newswire.ca",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.525523,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.074692",
        "ticker_sentiment_score": "0.062516",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "CRISPR  ( CRSP )  to Report Q4 Earnings: What's in the Cards?",
    "url": "https://www.zacks.com/stock/news/2225999/crispr-crsp-to-report-q4-earnings-whats-in-the-cards",
    "time_published": "20240214T131500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "On CRISPR's (CRSP) fourth-quarter 2023 earnings call, investors' focus is likely to be on the company's progress with the launch activities of the newly approved gene therapy, Casgevy (exa-cel).",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/86/1981.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999756"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.200197,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.125789",
        "ticker_sentiment_score": "0.189046",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRSP",
        "relevance_score": "0.24847",
        "ticker_sentiment_score": "0.078887",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALKS",
        "relevance_score": "0.365166",
        "ticker_sentiment_score": "0.089784",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NTLA",
        "relevance_score": "0.307731",
        "ticker_sentiment_score": "-0.13139",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex  ( VRTX ) , CRSP's Casgevy Gets EU Nod for Two Blood Disorders",
    "url": "https://www.zacks.com/stock/news/2225957/vertex-vrtx-crsps-casgevy-gets-eu-nod-for-two-blood-disorders",
    "time_published": "20240214T123200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Following the approval of Vertex (VRTX) and CRISPR Therapeutics' (CRSP) Casgevy, approximately 8,000 patients, 12 years of age and older, with SCD or TDT in Europe, become potentially eligible for treatment.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/96/702.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.21237,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BEAM",
        "relevance_score": "0.15347",
        "ticker_sentiment_score": "0.095083",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.15347",
        "ticker_sentiment_score": "0.050459",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EDIT",
        "relevance_score": "0.301315",
        "ticker_sentiment_score": "0.158477",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BLUE",
        "relevance_score": "0.15347",
        "ticker_sentiment_score": "0.100248",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stock-Split Watch: Is Vertex Pharmaceuticals Next?",
    "url": "https://www.fool.com/investing/2024/02/14/stock-split-watch-is-vertex-pharmaceuticals-next/",
    "time_published": "20240214T100500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "It's on track to launch more blockbuster drugs.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F765133%2Fgettyimages-1203044156.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.692272"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.857896"
      }
    ],
    "overall_sentiment_score": 0.33268,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.096671",
        "ticker_sentiment_score": "0.069401",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.048425",
        "ticker_sentiment_score": "0.054795",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.048425",
        "ticker_sentiment_score": "0.054795",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Giving Uber Its Due",
    "url": "https://www.fool.com/investing/2024/02/15/giving-uber-its-due/",
    "time_published": "20240215T193600",
    "authors": [
      "Motley Fool Staff"
    ],
    "summary": "We've also got a look at good news from Chipotle and Roblox, and we put some stocks on a dating show.",
    "banner_image": "https://g.foolcdn.com/editorial/images/764987/mfm_07.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999954"
      }
    ],
    "overall_sentiment_score": 0.208592,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSTR",
        "relevance_score": "0.031089",
        "ticker_sentiment_score": "0.11266",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.015547",
        "ticker_sentiment_score": "0.081851",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.007774",
        "ticker_sentiment_score": "0.153075",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NOW",
        "relevance_score": "0.069878",
        "ticker_sentiment_score": "0.10196",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.015547",
        "ticker_sentiment_score": "0.136076",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RBLX",
        "relevance_score": "0.123884",
        "ticker_sentiment_score": "0.1709",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.069878",
        "ticker_sentiment_score": "0.087659",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.131558",
        "ticker_sentiment_score": "0.08799",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.023319",
        "ticker_sentiment_score": "0.047126",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.085352",
        "ticker_sentiment_score": "0.08747",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit",
    "url": "https://www.globenewswire.com/news-release/2024/02/15/2829970/0/en/CRISPR-Therapeutics-to-Present-at-the-Citi-2024-Virtual-Oncology-Leadership-Summit.html",
    "time_published": "20240215T133000",
    "authors": [
      "CRISPR Therapeutics AG"
    ],
    "summary": "ZUG, Switzerland and BOSTON, Feb. 15, 2024 ( GLOBE NEWSWIRE ) -- CRISPR Therapeutics ( Nasdaq: CRSP ) , a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the Citi ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/5dac7d0d-131d-4047-bab7-db8e0719bf58",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.220158,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.159569",
        "ticker_sentiment_score": "0.163634",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "C",
        "relevance_score": "0.159569",
        "ticker_sentiment_score": "0.0842",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRSP",
        "relevance_score": "0.31282",
        "ticker_sentiment_score": "0.235512",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Biotech Stock Roundup: BIIB's Q4 Results, CBAY Up on GILD's Acquisition & Other Updates",
    "url": "https://www.zacks.com/stock/news/2226672/biotech-stock-roundup-biibs-q4-results-cbay-up-on-gilds-acquisition-other-updates",
    "time_published": "20240215T132800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Earnings from Biogen (BIIB) and CymaBay (CBAY) are in focus in the biotech sector.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ba/1149.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.993781"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.085969,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CBAY",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "0.210031",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.153797",
        "ticker_sentiment_score": "0.118139",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.153797",
        "ticker_sentiment_score": "0.115914",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.051551",
        "ticker_sentiment_score": "0.038922",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "-0.079966",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Want $1 Million in Retirement? Invest $250,000 in These 3 Stocks and Wait a Decade.",
    "url": "https://www.fool.com/investing/2024/02/15/want-1-million-in-retirement-invest-250000-in/",
    "time_published": "20240215T121500",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "These stocks have what it takes to drive superior returns in the years to come.",
    "banner_image": "https://g.foolcdn.com/editorial/images/764698/father-and-daughter-doing-homework-at-dinner-table.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      }
    ],
    "overall_sentiment_score": 0.223118,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.174587",
        "ticker_sentiment_score": "0.196102",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.07031",
        "ticker_sentiment_score": "0.165981",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABNB",
        "relevance_score": "0.208764",
        "ticker_sentiment_score": "0.034596",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Vertex Pharmaceuticals Stock Too Expensive With a Price-to-Sales Ratio of 11x?",
    "url": "https://www.fool.com/investing/2024/02/15/is-vertex-pharmaceuticals-stock-too-expensive-with/",
    "time_published": "20240215T105000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "There's more to consider with Vertex's valuation than one number.",
    "banner_image": "https://media.ycharts.com/charts/2fecaf2b17edb7bea7e642aaf78529a1.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.140562,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.054732",
        "ticker_sentiment_score": "0.078016",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.109206",
        "ticker_sentiment_score": "0.181943",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Wall Street Thinks These 3 Stocks Are Hidden Gems That Could Soar 43% to 59% Over the Next 12 Months",
    "url": "https://www.fool.com/investing/2024/02/16/wall-street-thinks-these-3-stocks-are-hidden-gems/",
    "time_published": "20240216T105000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "Analysts are quite bullish about these beaten-down stocks.",
    "banner_image": "https://g.foolcdn.com/editorial/images/765200/oil-rig-workers-talking.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.234969,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BABA",
        "relevance_score": "0.421485",
        "ticker_sentiment_score": "0.231642",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SLB",
        "relevance_score": "0.366061",
        "ticker_sentiment_score": "0.140709",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.063258",
        "ticker_sentiment_score": "0.042253",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RPRX",
        "relevance_score": "0.366061",
        "ticker_sentiment_score": "0.015773",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.063258",
        "ticker_sentiment_score": "0.042253",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.063258",
        "ticker_sentiment_score": "0.042253",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals Will Use $100 Million to Tank Its Own Market Share. Here's Why That's a Smart Move.",
    "url": "https://www.fool.com/investing/2024/02/17/vertex-pharmaceuticals-will-use-100-million-to-tan/",
    "time_published": "20240217T192500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Sometimes, the winning move doesn't look right at first.",
    "banner_image": "https://media.ycharts.com/charts/f3001cf27c95a481dd50fac0e9b0f2ff.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.229022,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.101367",
        "ticker_sentiment_score": "0.137845",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Healthcare Growth Stocks That Are No-Brainer Buys Right Now",
    "url": "https://www.fool.com/investing/2024/02/17/2-healthcare-growth-stocks-that-are-no-brainer-buy/",
    "time_published": "20240217T150000",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "The healthcare industry often remains resilient amid macro headwinds, and these two stocks are prime examples.",
    "banner_image": "https://g.foolcdn.com/editorial/images/765083/dna-sequencing-genome-science-lab.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.980922"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.251685,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MRNA",
        "relevance_score": "0.04406",
        "ticker_sentiment_score": "0.140759",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.087985",
        "ticker_sentiment_score": "0.080195",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.301052",
        "ticker_sentiment_score": "0.109152",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Could This News Upset Vertex Pharmaceuticals' Prospects in the Billion-Dollar Pain Management Market?",
    "url": "https://www.fool.com/investing/2024/02/18/could-this-news-upset-vertex-pain-drug-prospects/",
    "time_published": "20240218T141000",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "The pain market is in great need of new options.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F765678%2Fgettyimages-1254423087.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.120293,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.108958",
        "ticker_sentiment_score": "0.044581",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Top Growth Stocks to Buy With $1,000 Right Now",
    "url": "https://www.fool.com/investing/2024/02/18/2-top-growth-stocks-to-buy-with-1000-right-now/",
    "time_published": "20240218T054500",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "Even a modest starting investment in the right stocks could pay off in the years ahead.",
    "banner_image": "https://g.foolcdn.com/editorial/images/765086/happy-pregnant-mother.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.177817,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EVR",
        "relevance_score": "0.046543",
        "ticker_sentiment_score": "0.015863",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.092927",
        "ticker_sentiment_score": "0.204593",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.092927",
        "ticker_sentiment_score": "0.176915",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.092927",
        "ticker_sentiment_score": "0.058566",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Magnificent Growth Stocks to Buy Right Now",
    "url": "https://www.fool.com/investing/2024/02/19/3-magnificent-growth-stocks-to-buy-right-now/",
    "time_published": "20240219T151500",
    "authors": [
      "Keith Speights",
      "and Prosper Junior Bakiny",
      "David Jagielski"
    ],
    "summary": "These stocks share at least two common denominators: a biopharmaceutical focus and great long-term prospects.",
    "banner_image": "https://g.foolcdn.com/editorial/images/765520/happy-stock-investor-holding-smartphone.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.947132"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999365"
      }
    ],
    "overall_sentiment_score": 0.264978,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.27676",
        "ticker_sentiment_score": "0.342352",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.160365",
        "ticker_sentiment_score": "0.311688",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CERE",
        "relevance_score": "0.040348",
        "ticker_sentiment_score": "0.044696",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.387075",
        "ticker_sentiment_score": "0.271117",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "If You Invested $10,000 in CRISPR Therapeutics in 2019, This Is How Much You Would Have Today",
    "url": "https://www.fool.com/investing/2024/02/19/if-you-invested-10000-in-crispr-therapeutics-in/",
    "time_published": "20240219T064500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "It would have been a great move.",
    "banner_image": "https://media.ycharts.com/charts/d43e75e5e2208c5ce019d6f466020f37.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.276186,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.11894",
        "ticker_sentiment_score": "0.136129",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BLUE",
        "relevance_score": "0.059636",
        "ticker_sentiment_score": "-0.029027",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "New treatments are emerging for type-1 diabetes",
    "url": "https://www.economist.com/science-and-technology/2024/02/20/new-treatments-are-emerging-for-type-1-diabetes",
    "time_published": "20240220T161623",
    "authors": [
      "The Economist"
    ],
    "summary": "\"W the islets of Langerhans?\" is a trick question that pops up from time to time in quizzes. The answer is to be found not in atlases of geography, but rather in those of anatomy, for the so-called islets are in fact clusters of cells scattered through the pancreas.",
    "banner_image": "https://www.economist.com/img/b/1280/720/90/media-assets/image/20240224_STP501.jpg",
    "source": "The Economist",
    "category_within_source": "BusinessGoogleRSS",
    "source_domain": "www.economist.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.040811,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.045396",
        "ticker_sentiment_score": "0.009972",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SANA",
        "relevance_score": "0.045396",
        "ticker_sentiment_score": "-0.025966",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Top 20 global biopharmaceutical companies report 1.6% market capitalization growth to $3.67 trillion in 2023, reveals GlobalData",
    "url": "https://www.investorideas.com/news/2024/biotech/02201Global-Biopharmaceutical.asp",
    "time_published": "20240220T150551",
    "authors": [],
    "summary": "Top 20 global biopharmaceutical companies report 1.6% market capitalization growth to $3.67 trillion in 2023, reveals ... ...",
    "banner_image": null,
    "source": "Investor Ideas",
    "category_within_source": "n/a",
    "source_domain": "www.investorideas.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.152626,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVO",
        "relevance_score": "0.159922",
        "ticker_sentiment_score": "0.108103",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.159922",
        "ticker_sentiment_score": "-0.036799",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GLDAF",
        "relevance_score": "0.159922",
        "ticker_sentiment_score": "0.010941",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.053629",
        "ticker_sentiment_score": "0.260895",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SKXJF",
        "relevance_score": "0.053629",
        "ticker_sentiment_score": "-0.175762",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "DSKYF",
        "relevance_score": "0.053629",
        "ticker_sentiment_score": "-0.175762",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.107016",
        "ticker_sentiment_score": "-0.208134",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.053629",
        "ticker_sentiment_score": "0.260895",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.107016",
        "ticker_sentiment_score": "-0.208134",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.159922",
        "ticker_sentiment_score": "-0.069573",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals Is About to Extend Its Leadership in This Billion-Dollar Market",
    "url": "https://www.fool.com/investing/2024/02/20/vertex-is-about-to-extend-its-lead-in-key-market/",
    "time_published": "20240220T103500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Vertex's main business may be heading for a new era of growth...",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F765901%2Fgettyimages-968838136.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.235736,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.122581",
        "ticker_sentiment_score": "0.092658",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cathie Wood Is Betting on This Top Technology: 2 Stocks She Just Bought",
    "url": "https://www.fool.com/investing/2024/02/20/cathie-wood-is-betting-on-this-top-technology/",
    "time_published": "20240220T100200",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "These exciting players could deliver explosive growth over time.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F765827%2Fgettyimages-1197547531.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.329597,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.056011",
        "ticker_sentiment_score": "0.153929",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NTLA",
        "relevance_score": "0.274628",
        "ticker_sentiment_score": "0.248828",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Smart Money Is Betting Big In CRSP Options - CRISPR Therapeutics  ( NASDAQ:CRSP ) ",
    "url": "https://www.benzinga.com/insights/options/24/02/37268158/smart-money-is-betting-big-in-crsp-options",
    "time_published": "20240222T181554",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bearish stance on CRISPR Therapeutics CRSP. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.188975,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.092927",
        "ticker_sentiment_score": "0.160057",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Moderna  ( MRNA )  Beats on Q4 Earnings & Sales, Reiterates View",
    "url": "https://www.zacks.com/stock/news/2230442/moderna-mrna-beats-on-q4-earnings-sales-reiterates-view",
    "time_published": "20240222T180800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Moderna (MRNA) beats expectations for earnings and sales. Management reiterates guidance to record around $4 billion from product sales in 2024.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/db/3160.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.99998"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.021532,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.041039",
        "ticker_sentiment_score": "0.113058",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.428632",
        "ticker_sentiment_score": "-0.103052",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ACET",
        "relevance_score": "0.163078",
        "ticker_sentiment_score": "0.042951",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PBYI",
        "relevance_score": "0.203045",
        "ticker_sentiment_score": "0.131053",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.041039",
        "ticker_sentiment_score": "0.012894",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "EBay, Salesforce.com And Inflation Data; Investing Action Plan",
    "url": "https://www.investors.com/research/investing-action-plan/ebay-salesforce-com-and-inflation-data-investing-action-plan/",
    "time_published": "20240223T225500",
    "authors": [
      "ALAN R. ELLIOTT",
      "Investor's Business Daily"
    ],
    "summary": "EBay, Salesforce.com And Inflation Data. Investing Action Plan Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2019/11/stock-NYSE-exterior-04-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.890401"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999997"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.142857"
      }
    ],
    "overall_sentiment_score": 0.106924,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "PPC",
        "relevance_score": "0.153666",
        "ticker_sentiment_score": "-0.092556",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CSCO",
        "relevance_score": "0.092569",
        "ticker_sentiment_score": "-0.038873",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SRPT",
        "relevance_score": "0.06179",
        "ticker_sentiment_score": "-0.068325",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HPQ",
        "relevance_score": "0.092569",
        "ticker_sentiment_score": "0.106367",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VEEV",
        "relevance_score": "0.06179",
        "ticker_sentiment_score": "0.138048",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "URBN",
        "relevance_score": "0.092569",
        "ticker_sentiment_score": "0.140993",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DPZ",
        "relevance_score": "0.06179",
        "ticker_sentiment_score": "0.135045",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BBY",
        "relevance_score": "0.06179",
        "ticker_sentiment_score": "0.135045",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DELL",
        "relevance_score": "0.06179",
        "ticker_sentiment_score": "0.102019",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADSK",
        "relevance_score": "0.06179",
        "ticker_sentiment_score": "0.101018",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.092569",
        "ticker_sentiment_score": "0.017017",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MANH",
        "relevance_score": "0.092569",
        "ticker_sentiment_score": "0.017017",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAP",
        "relevance_score": "0.06179",
        "ticker_sentiment_score": "0.135045",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DMPZF",
        "relevance_score": "0.030918",
        "ticker_sentiment_score": "0.127236",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LEN",
        "relevance_score": "0.092569",
        "ticker_sentiment_score": "0.017017",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EBAY",
        "relevance_score": "0.123209",
        "ticker_sentiment_score": "0.119647",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZO",
        "relevance_score": "0.092569",
        "ticker_sentiment_score": "0.140993",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.06179",
        "ticker_sentiment_score": "0.010095",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.06179",
        "ticker_sentiment_score": "0.010095",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ROST",
        "relevance_score": "0.06179",
        "ticker_sentiment_score": "0.135045",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.06179",
        "ticker_sentiment_score": "0.010095",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FTI",
        "relevance_score": "0.092569",
        "ticker_sentiment_score": "0.017017",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RCL",
        "relevance_score": "0.092569",
        "ticker_sentiment_score": "0.017017",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPLK",
        "relevance_score": "0.092569",
        "ticker_sentiment_score": "-0.038873",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HPE",
        "relevance_score": "0.092569",
        "ticker_sentiment_score": "0.106367",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.030918",
        "ticker_sentiment_score": "0.145166",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's Why IBD Stock Of The Day Vertex Is Now Actionable",
    "url": "https://www.investors.com/research/ibd-stock-of-the-day/vrtx-stock-ibd-stock-of-the-day-is-now-actionable-here-is-why/",
    "time_published": "20240223T184200",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "Vertex Pharmaceuticals ( VRTX ) is the IBD Stock Of The Day. After pulling back, VRTX stock has bounced off its 50-day line as investors watch for the first sales of its gene-editing drug. That drug, dubbed Casgevy, is now approved in multiple countries, including the U.S.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/02/sotd-for-02-23-2024-desktop.png",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99977"
      }
    ],
    "overall_sentiment_score": 0.139818,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.496915",
        "ticker_sentiment_score": "0.181393",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "New sickle cell gene therapies are a breakthrough, but solving how to pay their high prices is a struggle",
    "url": "https://www.cnbc.com/2024/02/23/sickle-cell-disease-gene-therapies-casgevy-lyfgenia-insurance-cost-issues.html",
    "time_published": "20240223T160110",
    "authors": [
      "Bertha Coombs"
    ],
    "summary": "Breakthrough sickle cell treatments are available in the U.S., but their high cost is forcing insurers to get creative.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107377453-1708696168205-gettyimages-1824452072-sicklecell.jpeg?v=1708696229&w=1920&h=1080",
    "source": "CNBC",
    "category_within_source": "Business",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.121649,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.03453",
        "ticker_sentiment_score": "-0.10769",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BLUE",
        "relevance_score": "0.068995",
        "ticker_sentiment_score": "0.121733",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nasdaq Closes In On All-Time High; Carvana Spikes On Earnings While Nvidia Vaults Above 800",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-nasdaq-sp500-carvana-nvda-stock/",
    "time_published": "20240223T153400",
    "authors": [
      "KEN SHREVE",
      "Investor's Business Daily"
    ],
    "summary": "Nasdaq Closes In On All-Time High. Carvana Spikes On Earnings While Nvidia Vaults Above 800 Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2021/02/Stock-MarketBoard-Blue42-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      }
    ],
    "overall_sentiment_score": 0.217737,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.279015",
        "ticker_sentiment_score": "0.296559",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNOW",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "0.080743",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "-0.130875",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "-0.138692",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NKE",
        "relevance_score": "0.169676",
        "ticker_sentiment_score": "0.05745",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.169676",
        "ticker_sentiment_score": "0.05745",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.169676",
        "ticker_sentiment_score": "0.105594",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WDAY",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "0.080743",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COLL",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "0.339019",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NTNX",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "0.080743",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVNA",
        "relevance_score": "0.169676",
        "ticker_sentiment_score": "0.142178",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ZS",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "0.039715",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BKNG",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "-0.286498",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "SQ",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "0.158811",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PANW",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "0.039715",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "There's A Problem With Today's Obesity Drugs - How These Companies Are Solving It",
    "url": "https://www.investors.com/news/technology/weight-loss-drugs-how-outliers-like-biohaven-regeneron-are-trying-to-squeeze-into-the-obesity-space/",
    "time_published": "20240223T133000",
    "authors": [
      "ALLISON GATLIN",
      "Investor's Business Daily"
    ],
    "summary": "Weight-Loss Drugs: How Outliers Like Biohaven, Regeneron Are Taking On The Muscle Dilemma In The Obesity Space Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/02/A1MAIN_weightloss_022324.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.905476"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": -0.012175,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "EVR",
        "relevance_score": "0.031992",
        "ticker_sentiment_score": "-0.027602",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BHVN",
        "relevance_score": "0.063933",
        "ticker_sentiment_score": "-0.03917",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARWR",
        "relevance_score": "0.031992",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CYTK",
        "relevance_score": "0.015999",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALUR",
        "relevance_score": "0.031992",
        "ticker_sentiment_score": "0.05222",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.031992",
        "ticker_sentiment_score": "-0.09668",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALNY",
        "relevance_score": "0.031992",
        "ticker_sentiment_score": "-0.061293",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.158938",
        "ticker_sentiment_score": "0.096962",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.031992",
        "ticker_sentiment_score": "0.092157",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.031992",
        "ticker_sentiment_score": "-0.025591",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.031992",
        "ticker_sentiment_score": "0.092157",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Best Stocks to Invest $5,000 in Right Now",
    "url": "https://www.fool.com/investing/2024/02/23/the-best-stocks-to-invest-5000-in-right-now/",
    "time_published": "20240223T105000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "These stocks could be huge winners for long-term investors.",
    "banner_image": "https://g.foolcdn.com/editorial/images/766024/woman-in-it-data-center.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.795202"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.309195,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PYPL",
        "relevance_score": "0.177584",
        "ticker_sentiment_score": "0.016666",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.11894",
        "ticker_sentiment_score": "0.094363",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.11894",
        "ticker_sentiment_score": "0.093897",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Three S&P 500 Giants Lead This List Of Stocks Near Buy Points",
    "url": "https://www.investors.com/news/sp-500-giants-lead-this-list-of-stocks-near-buy-points/",
    "time_published": "20240224T130000",
    "authors": [
      "Investor's Business Daily",
      "KIT NORTON"
    ],
    "summary": "After Nvidia ( NVDA ) electrified the market, S&P 500 stocks Lennar ( LEN ) , Royal Caribbean ( RCL ) and Vertex Pharmaceuticals ( VRTX ) along with TechnipFMC ( FTI ) and Manhattan Associates ( MANH ) are in focus this week.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2023/07/Stock-royalcaribbean-cruiseship-02-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.211039,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.129168",
        "ticker_sentiment_score": "0.112359",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HAL",
        "relevance_score": "0.064797",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LEN",
        "relevance_score": "0.224013",
        "ticker_sentiment_score": "0.259338",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMD",
        "relevance_score": "0.097062",
        "ticker_sentiment_score": "0.16814",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BKR",
        "relevance_score": "0.064797",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.161062",
        "ticker_sentiment_score": "0.086034",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FTI",
        "relevance_score": "0.254973",
        "ticker_sentiment_score": "0.044625",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RCL",
        "relevance_score": "0.192694",
        "ticker_sentiment_score": "0.147207",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MANH",
        "relevance_score": "0.254973",
        "ticker_sentiment_score": "0.128234",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Stocks That Could Crush the Market in 2024",
    "url": "https://www.fool.com/investing/2024/02/25/2-stocks-that-could-crush-the-market-in-2024/",
    "time_published": "20240225T120900",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "These companies aren't slowing down, and their addressable markets are widening.",
    "banner_image": "https://g.foolcdn.com/editorial/images/766122/getty-consulting-financial-advisor-adviser-advice-professional.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999822"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.251722,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.085324",
        "ticker_sentiment_score": "0.287829",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.29234",
        "ticker_sentiment_score": "0.205285",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Top Stock Reports for JPMorgan Chase, Salesforce & Vertex Pharmaceuticals",
    "url": "https://www.zacks.com/research-daily/2231762/top-stock-reports-for-jpmorgan-chase-salesforce-vertex-pharmaceuticals",
    "time_published": "20240226T190600",
    "authors": [
      "Mark Vickery"
    ],
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Salesforce, Inc. (CRM) and Vertex Pharmaceuticals Incorporated (VRTX).",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/18/753.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.317704,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.107495",
        "ticker_sentiment_score": "0.273923",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.107495",
        "ticker_sentiment_score": "0.136",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Median Drug Prices For Rare Diseases Hit $300K In 2023, Report Highlights Lack of Clear Rationale Behind Escalating Drug Prices - CRISPR Therapeutics  ( NASDAQ:CRSP ) , Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ",
    "url": "https://www.benzinga.com/general/biotech/24/02/37316706/median-drug-prices-for-rare-diseases-hit-300k-in-2023-report-highlights-lack-of-clear-rationale-b",
    "time_published": "20240226T171435",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "In a significant trend, pharmaceutical companies in the U.S. introduced new drugs last year at prices 35% higher than in 2022, notably attributed to the industry's focus on costly therapies for rare diseases such as muscular dystrophy.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Ozempic-weight-loss-pill.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.065302,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.172713",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRSP",
        "relevance_score": "0.172713",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.172713",
        "ticker_sentiment_score": "-0.056321",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SRPT",
        "relevance_score": "0.172713",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Biotech Stocks In A Tizzy As New Weight-Loss Rival Enters The Arena",
    "url": "https://www.investors.com/news/technology/biotech-stocks-diverge-on-new-results-for-weight-loss-drug-in-mash-patients/",
    "time_published": "20240226T155200",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "Biotech Stocks Diverge On New Results For Weight-Loss Drug In MASH Patients Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/02/Stock-Altimmune-01-shutt.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.170267,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VKTX",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.472711",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.057767",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "-0.059975",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.282886",
        "ticker_sentiment_score": "0.059661",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDGL",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.057767",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AKRO",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "-0.013949",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALT",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "-0.030348",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Biotech Stocks to Buy and Hold for the Next 10 Years",
    "url": "https://www.fool.com/investing/2024/02/26/3-biotech-stocks-you-can-buy-and-hold-for-the-next/",
    "time_published": "20240226T135000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "There's a lot to like about these three drugmakers right now, and that shouldn't stop anytime soon.",
    "banner_image": "https://g.foolcdn.com/editorial/images/766287/doctor-with-patient-talking.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.236594,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.054359",
        "ticker_sentiment_score": "0.162818",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.054359",
        "ticker_sentiment_score": "-0.089059",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.414559",
        "ticker_sentiment_score": "0.252334",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JAZZ",
        "relevance_score": "0.054359",
        "ticker_sentiment_score": "0.090108",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXSM",
        "relevance_score": "0.214937",
        "ticker_sentiment_score": "0.2195",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer",
    "url": "https://www.globenewswire.com/news-release/2024/02/26/2835130/0/en/Disc-Medicine-Expands-Leadership-Team-with-Appointment-of-Industry-Veteran-Pamela-Stephenson-MPH-as-Chief-Commercial-Officer.html",
    "time_published": "20240226T133000",
    "authors": [
      "Disc Medicine Inc"
    ],
    "summary": "Pamela Stephenson is an accomplished industry executive with over 25 years of global commercial leadership experience and a track record of numerous successful launches Pamela Stephenson is an accomplished industry executive with over 25 years of global commercial leadership experience and a ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/ca38ccab-c7d0-43bf-af35-e67b5bc64683",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.997902"
      }
    ],
    "overall_sentiment_score": 0.208657,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.034381",
        "ticker_sentiment_score": "0.045561",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IRON",
        "relevance_score": "0.068698",
        "ticker_sentiment_score": "0.084917",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ZYNE",
        "relevance_score": "0.034381",
        "ticker_sentiment_score": "0.045561",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.034381",
        "ticker_sentiment_score": "0.045561",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HRMY",
        "relevance_score": "0.034381",
        "ticker_sentiment_score": "0.045561",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Ultimate Growth Stock to Buy With $1,000 Right Now",
    "url": "https://www.fool.com/investing/2024/02/26/the-ultimate-growth-stock-to-buy-with-1000-right-n/",
    "time_published": "20240226T105200",
    "authors": [
      "Keith Speights"
    ],
    "summary": "The positives are many and the negatives are few with this high-flying stock.",
    "banner_image": "https://g.foolcdn.com/editorial/images/766590/scientists-happy.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.343448,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.055881",
        "ticker_sentiment_score": "0.092884",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.166551",
        "ticker_sentiment_score": "0.247836",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "$100 Invested In This Stock 15 Years Ago Would Be Worth $1,500 Today - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/insights/news/24/02/37346429/100-invested-in-this-stock-15-years-ago-would-be-worth-1-500-today",
    "time_published": "20240227T203025",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Vertex Pharmaceuticals VRTX has outperformed the market over the past 15 years by 6.1% on an annualized basis producing an average annual return of 20.02%. Currently, Vertex Pharmaceuticals has a market capitalization of $112.02 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_4.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.160819,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.980595",
        "ticker_sentiment_score": "0.386944",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "How Beam, Up 28% Today, Is Planning To Take On Crispr",
    "url": "https://www.investors.com/news/technology/beam-stock-rockets-to-year-high-as-efforts-to-take-on-crispr-deepen/",
    "time_published": "20240227T192800",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "Beam Stock Rockets To Year High As Efforts To Take On Crispr Deepen Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2022/10/Stock-beamtherapeutics-01-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999186"
      }
    ],
    "overall_sentiment_score": 0.12433,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BEAM",
        "relevance_score": "0.177584",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.177584",
        "ticker_sentiment_score": "0.06926",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.11894",
        "ticker_sentiment_score": "0.38104",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VERV",
        "relevance_score": "0.11894",
        "ticker_sentiment_score": "0.055094",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BLUE",
        "relevance_score": "0.11894",
        "ticker_sentiment_score": "0.38104",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights JPMorgan Chase, Salesforce, Vertex Pharmaceuticals, Palo Alto Networks and The Williams Companies",
    "url": "https://www.zacks.com/stock/news/2232350/the-zacks-analyst-blog-highlights-jpmorgan-chase-salesforce-vertex-pharmaceuticals-palo-alto-networks-and-the-williams-companies",
    "time_published": "20240227T142100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "JPMorgan Chase, Salesforce, Vertex Pharmaceuticals, Palo Alto Networks and The Williams Companies are part of the Zacks top Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/583.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.25014,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.251645",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.290607",
        "ticker_sentiment_score": "0.116678",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PANW",
        "relevance_score": "0.147818",
        "ticker_sentiment_score": "0.0363",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results",
    "url": "https://www.globenewswire.com/news-release/2024/02/27/2835894/0/en/Verve-Therapeutics-Provides-Pipeline-Progress-and-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html",
    "time_published": "20240227T123000",
    "authors": [
      "Verve Therapeutics"
    ],
    "summary": "Three Clinical Stage Programs Targeting PCSK9 and ANGPTL3 Expected in ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/2a4edc4b-98df-4e32-ade8-159b39872434",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.917436"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.997335"
      }
    ],
    "overall_sentiment_score": 0.13346,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BEAM",
        "relevance_score": "0.016939",
        "ticker_sentiment_score": "0.096093",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.016939",
        "ticker_sentiment_score": "0.068454",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VERV",
        "relevance_score": "0.06768",
        "ticker_sentiment_score": "0.103367",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow",
    "url": "https://www.fool.com/investing/2024/02/27/3-reasons-to-buy-vertex-pharmaceuticals-stock/",
    "time_published": "20240227T100300",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Vertex shares have climbed almost 50% over the past year.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F766684%2Fgettyimages-1335027284.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.995015"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.297898,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.114956",
        "ticker_sentiment_score": "0.189887",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TRMNF",
        "relevance_score": "0.057628",
        "ticker_sentiment_score": "0.166995",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "This biotech ETF sees 'breakout' while U.S. small-cap technology stocks lag",
    "url": "https://www.marketwatch.com/story/this-biotech-etf-sees-breakout-while-u-s-small-cap-technology-stocks-lag-69a87d4a",
    "time_published": "20240229T234600",
    "authors": [
      "Christine Idzelis"
    ],
    "summary": "This week's ETF Wrap digs into the jump in biotech funds, as well as an \"unusual\" trend in U.S. small-cap stocks versus small-cap tech equities.",
    "banner_image": "https://images.mktw.net/im-341402/social",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.184554,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VKTX",
        "relevance_score": "0.100588",
        "ticker_sentiment_score": "-0.005415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CYTK",
        "relevance_score": "0.067158",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STT",
        "relevance_score": "0.033609",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IOVA",
        "relevance_score": "0.067158",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.067158",
        "ticker_sentiment_score": "0.044071",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.100588",
        "ticker_sentiment_score": "0.004297",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.067158",
        "ticker_sentiment_score": "0.044071",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.067158",
        "ticker_sentiment_score": "0.044071",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.033609",
        "ticker_sentiment_score": "0.097256",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Elanco Animal Health is Executing on Plan to Deliver for Shareholders",
    "url": "https://www.prnewswire.com/news-releases/elanco-animal-health-is-executing-on-plan-to-deliver-for-shareholders-302076221.html",
    "time_published": "20240229T180800",
    "authors": [
      "Elanco Animal Health"
    ],
    "summary": "Ancora Nominates Director Candidates Despite Elanco's Meaningful Operational Progress and Good Faith Engagement with the Investor",
    "banner_image": "https://mma.prnewswire.com/media/2309278/Elanco_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.209925,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "A",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ZBH",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STE",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ENDPQ",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PRGO",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EW",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HOLX",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ELAN",
        "relevance_score": "0.211601",
        "ticker_sentiment_score": "0.230182",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JAZZ",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ZTS",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAX",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IDXX",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INCY",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XRAY",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRL",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Could These 3 Companies Headline a \"Magnificent Seven\" of Biotech Stocks?",
    "url": "https://www.fool.com/investing/2024/02/29/could-these-3-companies-headline-magnificent-seven/",
    "time_published": "20240229T140000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "These stocks meet many of the criteria long-term investors look for.",
    "banner_image": "https://media.ycharts.com/charts/a0139fd0df9b9ac5ba1cc3d6745e3b8b.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.303241,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.442767",
        "ticker_sentiment_score": "0.443683",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.205807",
        "ticker_sentiment_score": "0.163124",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.442767",
        "ticker_sentiment_score": "0.372147",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "CRISPR Therapeutics Stock Has 32% Upside, According to 1 Wall Street Analyst",
    "url": "https://www.fool.com/investing/2024/02/29/crispr-therapeutics-stock-has-32-upside-analyst/",
    "time_published": "20240229T113100",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "This company's fortunes are likely to improve, and soon.",
    "banner_image": "https://g.foolcdn.com/editorial/images/766837/lab-research-scientists-women-in-stem.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.217752,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.127456",
        "ticker_sentiment_score": "0.059127",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Apple Sinks After Wall Street Titan Pulls Magnificent 7 Stock From Conviction List Apple Sinks After Wall Street Titan Pulls Magnificent 7 Stock From Conviction List Post-iPhone 15, Vision Pro Launches - Apple  ( NASDAQ:AAPL ) , Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37423877/apple-sinks-after-wall-street-titan-pulls-magnificent-7-stock-from-conviction-list",
    "time_published": "20240301T153958",
    "authors": [
      "Chris Katje"
    ],
    "summary": "A leading financial analyst company has removed technology giant Apple Inc AAPL from its \"Conviction List\" one month after first-quarter earnings were reported. What Happened: Apple has had several eventful months with the release of the iPhone 15 in September and the Vision Pro mixed reality ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/apple-cupertino-chart.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.947132"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.222975,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.124486",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSTK",
        "relevance_score": "0.062434",
        "ticker_sentiment_score": "0.286517",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.727186",
        "ticker_sentiment_score": "0.212187",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.566543",
        "ticker_sentiment_score": "0.371248",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.185781",
        "ticker_sentiment_score": "0.077418",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VMC",
        "relevance_score": "0.185781",
        "ticker_sentiment_score": "0.302804",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "These 4 Stocks Are the \"Magnificent Seven\" of Healthcare",
    "url": "https://www.fool.com/investing/2024/03/01/these-stocks-are-magnificent-seven-of-healthcare/",
    "time_published": "20240301T065900",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Their growth trajectories aren't as meteoric, but they're still notable.",
    "banner_image": "https://media.ycharts.com/charts/13eb85c054da9d0aa6615994f237628d.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.27987,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.155786",
        "ticker_sentiment_score": "0.028625",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.052226",
        "ticker_sentiment_score": "0.154565",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.104228",
        "ticker_sentiment_score": "0.188971",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.052226",
        "ticker_sentiment_score": "0.154565",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.104228",
        "ticker_sentiment_score": "0.083806",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.155786",
        "ticker_sentiment_score": "0.137514",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Magnificent Growth Stocks to Buy in March",
    "url": "https://www.fool.com/investing/2024/03/02/3-magnificent-growth-stocks-to-buy-in-march/",
    "time_published": "20240302T143000",
    "authors": [
      "and Prosper Junior Bakiny",
      "David Jagielski",
      "Keith Speights"
    ],
    "summary": "These three stocks have two important common denominators: the same industry and tremendous growth prospects.",
    "banner_image": "https://g.foolcdn.com/editorial/images/767491/happy-woman-because-the-stock-market-went-up.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.211721,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.262052",
        "ticker_sentiment_score": "0.24374",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.262052",
        "ticker_sentiment_score": "0.240059",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.344473",
        "ticker_sentiment_score": "0.130278",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.044469",
        "ticker_sentiment_score": "0.153986",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.044469",
        "ticker_sentiment_score": "0.060995",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Editas Medicine Stock Soared as Much as 42% Higher This Week",
    "url": "https://www.fool.com/investing/2024/03/02/why-editas-medicine-stock-soared-as-much-as-42-hig/",
    "time_published": "20240303T024955",
    "authors": [
      "Danny Vena"
    ],
    "summary": "The clinical-stage genome editing company dropped a couple of important announcements for shareholders.",
    "banner_image": "https://g.foolcdn.com/editorial/images/767772/scientist-injecting-samples-into-test-tubes.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.189365,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.105604",
        "ticker_sentiment_score": "0.134125",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.105604",
        "ticker_sentiment_score": "0.041673",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EDIT",
        "relevance_score": "0.404563",
        "ticker_sentiment_score": "0.17954",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.105604",
        "ticker_sentiment_score": "0.074399",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.105604",
        "ticker_sentiment_score": "0.074399",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Smart Money Is Betting Big In CRSP Options - CRISPR Therapeutics  ( NASDAQ:CRSP ) ",
    "url": "https://www.benzinga.com/insights/options/24/03/37462391/smart-money-is-betting-big-in-crsp-options",
    "time_published": "20240304T171716",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Financial giants have made a conspicuous bearish move on CRISPR Therapeutics. Our analysis of options history for CRISPR Therapeutics CRSP revealed 11 unusual trades. Delving into the details, we found 9% of traders were bullish, while 90% showed bearish tendencies.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.196999,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.098659",
        "ticker_sentiment_score": "0.162448",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "1 Beaten-Down Stock With 55% Upside, According to Wall Street",
    "url": "https://www.fool.com/investing/2024/03/04/1-beaten-down-stock-with-55-upside-according-to/",
    "time_published": "20240304T153000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The biotech has bounced back some in the past year.",
    "banner_image": "https://media.ycharts.com/charts/a254569c9daf335c7ab69c0e0d8d2cc7.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.250661,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.057079",
        "ticker_sentiment_score": "0.16198",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "EDIT",
        "relevance_score": "0.717171",
        "ticker_sentiment_score": "0.345005",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "GSK vs. VRTX: Which Stock Is the Better Value Option?",
    "url": "https://www.zacks.com/stock/news/2236145/gsk-vs-vrtx-which-stock-is-the-better-value-option",
    "time_published": "20240305T164006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with GSK ( GSK Quick QuoteGSK - ) and Vertex Pharmaceuticals ( VRTX Quick QuoteVRTX - ) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default124.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.516804,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.757528",
        "ticker_sentiment_score": "0.629398",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "3 Biopharma Stocks You Don't Want to Miss in the New Bull Market",
    "url": "https://www.fool.com/investing/2024/03/05/3-biopharma-stocks-you-dont-want-to-miss-in-the/",
    "time_published": "20240305T143000",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "All three have exciting programs on the way.",
    "banner_image": "https://g.foolcdn.com/editorial/images/767685/investor-inspects-papers-on-a-couch.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.310743,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.100518",
        "ticker_sentiment_score": "0.134296",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRMNF",
        "relevance_score": "0.050359",
        "ticker_sentiment_score": "0.271888",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CMPS",
        "relevance_score": "0.100518",
        "ticker_sentiment_score": "0.22573",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CPRX",
        "relevance_score": "0.100518",
        "ticker_sentiment_score": "0.071891",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Invesco Biotechnology & Genome ETF  ( PBE )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2235766/is-invesco-biotechnology-genome-etf-pbe-a-strong-etf-right-now",
    "time_published": "20240305T112006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default303.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999998"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.260125,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.119532",
        "ticker_sentiment_score": "0.067655",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.178459",
        "ticker_sentiment_score": "0.252738",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ILMN",
        "relevance_score": "0.119532",
        "ticker_sentiment_score": "0.067655",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NBIX",
        "relevance_score": "0.119532",
        "ticker_sentiment_score": "0.067655",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex  ( VRTX )  Down 0.2% Since Last Earnings Report: Can It Rebound?",
    "url": "https://www.zacks.com/stock/news/2236814/vertex-vrtx-down-02-since-last-earnings-report-can-it-rebound",
    "time_published": "20240306T163016",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default165.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999938"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.135492,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.048327",
        "ticker_sentiment_score": "-0.003996",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( NASDAQ:VRTX )  Lifted to Strong-Buy at StockNews.com",
    "url": "https://www.defenseworld.net/2024/03/06/vertex-pharmaceuticals-nasdaqvrtx-lifted-to-strong-buy-at-stocknews-com.html",
    "time_published": "20240306T092841",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "StockNews.com upgraded shares of Vertex Pharmaceuticals ( NASDAQ:VRTX - Free Report ) from a buy rating to a strong-buy rating in a research note issued to investors on Tuesday morning.",
    "banner_image": "https://www.marketbeat.com/logos/vertex-pharmaceuticals-incorporated-logo.png?v=20231228113929",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.261396,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EVR",
        "relevance_score": "0.043108",
        "ticker_sentiment_score": "0.049179",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MCQEF",
        "relevance_score": "0.08609",
        "ticker_sentiment_score": "0.179318",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GTLB",
        "relevance_score": "0.043108",
        "ticker_sentiment_score": "0.112696",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.043108",
        "ticker_sentiment_score": "0.049179",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.043108",
        "ticker_sentiment_score": "0.049179",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.743681",
        "ticker_sentiment_score": "0.389757",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CCORF",
        "relevance_score": "0.043108",
        "ticker_sentiment_score": "0.049179",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.043108",
        "ticker_sentiment_score": "0.112696",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "After the Miracle Drug",
    "url": "https://www.theatlantic.com/magazine/archive/2024/04/cystic-fibrosis-trikafta-breakthrough-treatment/677471/",
    "time_published": "20240307T120000",
    "authors": [
      "Sarah Zhang"
    ],
    "summary": "The Cystic Fibrosis Breakthrough That Changed Everything The Atlantic ...",
    "banner_image": "https://cdn.theatlantic.com/thumbor/Im7TPiWpnPA1kGGYIGspBqfFmTQ=/0x0:2450x3185/655x852/media/img/posts/2024/03/Zhang_3/original.png",
    "source": "The Atlantic",
    "category_within_source": "n/a",
    "source_domain": "www.theatlantic.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": -0.065121,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NYT",
        "relevance_score": "0.005541",
        "ticker_sentiment_score": "-0.060078",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.005541",
        "ticker_sentiment_score": "0.050286",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 15 Years - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/insights/news/24/03/37558661/heres-how-much-you-would-have-made-owning-vertex-pharmaceuticals-stock-in-the-last-15-years",
    "time_published": "20240308T140016",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Vertex Pharmaceuticals VRTX has outperformed the market over the past 15 years by 6.13% on an annualized basis producing an average annual return of 19.77%. Currently, Vertex Pharmaceuticals has a market capitalization of $106.16 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_3.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.160819,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.980595",
        "ticker_sentiment_score": "0.386944",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Missed Out on Eli Lilly? 3 Healthcare Stocks With Big Catalysts on the Horizon.",
    "url": "https://www.fool.com/investing/2024/03/09/missed-out-on-eli-lilly-3-healthcare-stocks-with-b/",
    "time_published": "20240309T105200",
    "authors": [
      "Keith Speights"
    ],
    "summary": "Good news could be in store for all three of these drugmakers.",
    "banner_image": "https://g.foolcdn.com/editorial/images/768349/scientists-looking-at-screen-with-icons.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.203035,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MDGL",
        "relevance_score": "0.088635",
        "ticker_sentiment_score": "-0.023012",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.088635",
        "ticker_sentiment_score": "0.216933",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.088635",
        "ticker_sentiment_score": "-0.025548",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.044386",
        "ticker_sentiment_score": "0.037547",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Biotech ETFs to Watch",
    "url": "https://investingnews.com/daily/life-science-investing/biotech-investing/small-biotech-etfs/",
    "time_published": "20240311T211500",
    "authors": [
      "Melissa Pistilli"
    ],
    "summary": "The life science sector can certainly be risky, and ETFs are a good way to enter more safely than by investing in standalone stocks. A key advantage is that even if one company in the ETF takes a hit, the impact will be less direct.",
    "banner_image": "https://investingnews.com/media-library/double-helix-molecule-with-word-etf.jpg?id=34930357&width=1200&height=800&quality=85&coordinates=0%2C0%2C0%2C1",
    "source": "Investing News Network",
    "category_within_source": "n/a",
    "source_domain": "investingnews.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.976671"
      }
    ],
    "overall_sentiment_score": 0.112426,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MGNX",
        "relevance_score": "0.075635",
        "ticker_sentiment_score": "0.038335",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.075635",
        "ticker_sentiment_score": "-0.004057",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JANX",
        "relevance_score": "0.075635",
        "ticker_sentiment_score": "0.038335",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRSN",
        "relevance_score": "0.075635",
        "ticker_sentiment_score": "0.038335",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RARE",
        "relevance_score": "0.075635",
        "ticker_sentiment_score": "0.042374",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXAS",
        "relevance_score": "0.075635",
        "ticker_sentiment_score": "0.053488",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SRPT",
        "relevance_score": "0.075635",
        "ticker_sentiment_score": "0.053488",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KRTX",
        "relevance_score": "0.075635",
        "ticker_sentiment_score": "0.053488",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.150592",
        "ticker_sentiment_score": "0.024391",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.075635",
        "ticker_sentiment_score": "0.052477",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( VRTX )  Stock Sinks As Market Gains: What You Should Know",
    "url": "https://www.zacks.com/stock/news/2239563/vertex-pharmaceuticals-vrtx-stock-sinks-as-market-gains-what-you-should-know",
    "time_published": "20240312T215019",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $412.45, moving -0.49% from the previous trading session.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default247.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.995921"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.242152,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.52949",
        "ticker_sentiment_score": "0.336918",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance",
    "url": "https://www.globenewswire.com/news-release/2024/03/12/2845000/0/en/MaxCyte-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Reiterates-2024-Guidance.html",
    "time_published": "20240312T200500",
    "authors": [
      "Inc.",
      "MaxCyte"
    ],
    "summary": "MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance ROCKVILLE, MD, March 12, 2024 - MaxCyte, Inc., ( NASDAQ: MXCT.",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/ca8c6b64-4f99-4a88-86a6-5c0b5f3d49fe",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.94762"
      }
    ],
    "overall_sentiment_score": 0.113427,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MXCT",
        "relevance_score": "0.214937",
        "ticker_sentiment_score": "0.186631",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.01978",
        "ticker_sentiment_score": "0.179386",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "CRISPR Therapeutics Proposes New Appointment to the Board of Directors - CRISPR Therapeutics  ( NASDAQ:CRSP ) ",
    "url": "https://www.benzinga.com/pressreleases/24/03/g37656751/crispr-therapeutics-proposes-new-appointment-to-the-board-of-directors",
    "time_published": "20240313T123000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "ZUG, Switzerland and BOSTON, March 13, 2024 ( GLOBE NEWSWIRE ) -- CRISPR Therapeutics CRSP, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Christian Rommel, Ph.D., to its Board of Directors at the ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.085897,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.034381",
        "ticker_sentiment_score": "0.116366",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ONPH",
        "relevance_score": "0.034381",
        "ticker_sentiment_score": "-0.043846",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRSP",
        "relevance_score": "0.102888",
        "ticker_sentiment_score": "0.112824",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Bluebird Bio Stock a Buy Now?",
    "url": "https://www.fool.com/investing/2024/03/13/is-bluebird-bio-stock-a-buy-now/",
    "time_published": "20240313T115000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "Are you feeling brave?",
    "banner_image": "https://g.foolcdn.com/editorial/images/768626/patient-sitting-on-hospital-bed.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.240001,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.063763",
        "ticker_sentiment_score": "0.025167",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BLUE",
        "relevance_score": "0.528475",
        "ticker_sentiment_score": "0.302516",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results",
    "url": "https://www.globenewswire.com/news-release/2024/03/13/2845281/0/en/Entrada-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html",
    "time_published": "20240313T110000",
    "authors": [
      "Inc.",
      "Entrada Therapeutics"
    ],
    "summary": "- Cash runway extended through the second quarter of ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/77a7db51-bcfe-41a6-b2b5-9b281921f81c",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.147018,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "TRDA",
        "relevance_score": "0.127321",
        "ticker_sentiment_score": "0.090328",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.025569",
        "ticker_sentiment_score": "0.061422",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the Invesco Biotechnology & Genome ETF  ( PBE ) ?",
    "url": "https://www.zacks.com/stock/news/2239702/should-you-invest-in-the-invesco-biotechnology-genome-etf-pbe",
    "time_published": "20240313T102006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default261.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.175438,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.129168",
        "ticker_sentiment_score": "0.070052",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.254973",
        "ticker_sentiment_score": "0.089233",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ILMN",
        "relevance_score": "0.129168",
        "ticker_sentiment_score": "0.070052",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NBIX",
        "relevance_score": "0.129168",
        "ticker_sentiment_score": "0.070052",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( NASDAQ:VRTX )  Downgraded by StockNews.com to Buy",
    "url": "https://www.americanbankingnews.com/2024/03/13/vertex-pharmaceuticals-nasdaqvrtx-downgraded-by-stocknews-com-to-buy.html",
    "time_published": "20240313T062332",
    "authors": [
      "ABMN Staff"
    ],
    "summary": "Vertex Pharmaceuticals ( NASDAQ:VRTX - Get Free Report ) was downgraded by equities research analysts at StockNews.com from a \"strong-buy\" rating to a \"buy\" rating in a report released on Wednesday. A number of other equities analysts have also recently commented on VRTX. Sanford C.",
    "banner_image": "https://www.marketbeat.com/logos/vertex-pharmaceuticals-incorporated-logo-1200x675.png?v=20231228113929",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.americanbankingnews.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.779048"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.231407,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TFC",
        "relevance_score": "0.047465",
        "ticker_sentiment_score": "0.020856",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.829016",
        "ticker_sentiment_score": "0.384904",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CCORF",
        "relevance_score": "0.047465",
        "ticker_sentiment_score": "0.020856",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.047465",
        "ticker_sentiment_score": "0.020856",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GME",
        "relevance_score": "0.047465",
        "ticker_sentiment_score": "0.075007",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( NASDAQ:VRTX )  Downgraded by StockNews.com to Buy",
    "url": "https://www.defenseworld.net/2024/03/13/vertex-pharmaceuticals-nasdaqvrtx-downgraded-by-stocknews-com-to-buy.html",
    "time_published": "20240313T062248",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Vertex Pharmaceuticals ( NASDAQ:VRTX - Get Free Report ) was downgraded by research analysts at StockNews.com from a \"strong-buy\" rating to a \"buy\" rating in a note issued to investors on Wednesday. Several other equities research analysts have also issued reports on the stock. Robert W.",
    "banner_image": "https://www.marketbeat.com/logos/vertex-pharmaceuticals-incorporated-logo-1200x675.png?v=20231228113929",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.917436"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.25691,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TFC",
        "relevance_score": "0.045569",
        "ticker_sentiment_score": "0.045308",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.722395",
        "ticker_sentiment_score": "0.404262",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.045569",
        "ticker_sentiment_score": "0.045308",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GME",
        "relevance_score": "0.045569",
        "ticker_sentiment_score": "0.099793",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Charles River  ( CRL )  Extends Gene Therapy Offering With New Pact",
    "url": "https://www.zacks.com/stock/news/2241549/charles-river-crl-extends-gene-therapy-offering-with-new-pact",
    "time_published": "20240315T143000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Charles River's (CRL) partnership with Navega Therapeutics will enable it to leverage its strong AAV portfolio and leading gene therapy CDMO capabilities.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/41/899.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.988787"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.012078,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.058188",
        "ticker_sentiment_score": "0.039024",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.229691",
        "ticker_sentiment_score": "0.117544",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRL",
        "relevance_score": "0.116067",
        "ticker_sentiment_score": "0.059026",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.229691",
        "ticker_sentiment_score": "0.040261",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COR",
        "relevance_score": "0.229691",
        "ticker_sentiment_score": "-0.05677",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is It Too Late to Buy CRISPR Therapeutics Stock?",
    "url": "https://www.fool.com/investing/2024/03/16/is-it-too-late-to-buy-crispr-therapeutics-stock/",
    "time_published": "20240316T124500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The biotech has been making a lot of noise since late last year.",
    "banner_image": "https://media.ycharts.com/charts/71e8749f1b9511598dbd335d1e295d7e.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.226968,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.059935",
        "ticker_sentiment_score": "0.116191",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BLUE",
        "relevance_score": "0.119532",
        "ticker_sentiment_score": "-0.041501",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now",
    "url": "https://www.fool.com/investing/2024/03/17/2-no-brainer-healthcare-stocks-to-buy-with-1000/",
    "time_published": "20240317T135000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "It's always a good time to buy great stocks with excellent prospects.",
    "banner_image": "https://media.ycharts.com/charts/fe06bc0dc476eae3fd92df3402c8957d.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.284288,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MFCSF",
        "relevance_score": "0.061159",
        "ticker_sentiment_score": "-0.047108",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.241085",
        "ticker_sentiment_score": "0.228278",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LTRCF",
        "relevance_score": "0.061159",
        "ticker_sentiment_score": "0.208122",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HCA",
        "relevance_score": "0.557075",
        "ticker_sentiment_score": "0.23588",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Unstoppable Stocks You Can Buy Now Without Any Hesitation",
    "url": "https://www.fool.com/investing/2024/03/17/3-unstoppable-stocks-you-can-buy-now-without-any/",
    "time_published": "20240317T130000",
    "authors": [
      "Keith Speights",
      "and Prosper Junior Bakiny",
      "David Jagielski"
    ],
    "summary": "There's no need for delays in buying these great stocks.",
    "banner_image": "https://g.foolcdn.com/editorial/images/769331/young-woman-smiling-hands-behind-head.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.127458,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.2256",
        "ticker_sentiment_score": "-0.115588",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.151539",
        "ticker_sentiment_score": "-0.165219",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.367141",
        "ticker_sentiment_score": "0.252288",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Forget Tesla, Buy This Magnificent Healthcare Stock Instead",
    "url": "https://www.fool.com/investing/2024/03/17/forget-tesla-buy-this-magnificent-stock/",
    "time_published": "20240317T125400",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Vertex Pharmaceuticals already has a fantastic business, and it could get much bigger in the future.",
    "banner_image": "https://g.foolcdn.com/editorial/images/768805/advisor-reviewing-data-on-a-laptop-with-a-family.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.995921"
      }
    ],
    "overall_sentiment_score": 0.360975,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.190167",
        "ticker_sentiment_score": "0.370656",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.25168",
        "ticker_sentiment_score": "0.141414",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( VRTX )  Beats Stock Market Upswing: What Investors Need to Know",
    "url": "https://www.zacks.com/stock/news/2242471/vertex-pharmaceuticals-vrtx-beats-stock-market-upswing-what-investors-need-to-know",
    "time_published": "20240318T215018",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $411.38, denoting a +0.91% change from the preceding trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default30.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.976913"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.180991,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.521961",
        "ticker_sentiment_score": "0.252459",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "New Non-Opioid Pain Meds Hold Promise, But Face Clinical Development And Insurer Challenges",
    "url": "https://www.forbes.com/sites/joshuacohen/2024/03/18/new-non-opioid-pain-meds-hold-promise-but-face-clinical-development-and-insurer-challenges/",
    "time_published": "20240318T213945",
    "authors": [
      "Joshua Cohen"
    ],
    "summary": "Vertex Pharmaceuticals recently released late-stage trial results for an investigational non-opioid pain medication showing it was safe and efficacious while offering modest pain relief. Pain impacts tens of millions of Americans on a daily basis.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65f858addc550e3f9d2bf671/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.123339,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.045918",
        "ticker_sentiment_score": "0.043234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.091684",
        "ticker_sentiment_score": "-0.102477",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "bluebird  ( BLUE )  Gets $175 Million Loan From Hercules, Shares Up",
    "url": "https://www.zacks.com/stock/news/2242650/bluebird-blue-gets-175-million-loan-from-hercules-shares-up",
    "time_published": "20240319T114400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "bluebird (BLUE) obtains a $175 million five-year, term loan facility from Hercules that stretches its cash runaway by two years. The company's shares rise on the news.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ab/2180.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      }
    ],
    "overall_sentiment_score": 0.18201,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.128478",
        "ticker_sentiment_score": "0.072212",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BLUE",
        "relevance_score": "0.314017",
        "ticker_sentiment_score": "0.234771",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Smart Money Is Betting Big In CRSP Options - CRISPR Therapeutics  ( NASDAQ:CRSP ) ",
    "url": "https://www.benzinga.com/insights/options/24/03/37875309/smart-money-is-betting-big-in-crsp-options",
    "time_published": "20240321T161710",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "High-rolling investors have positioned themselves bullish on CRISPR Therapeutics CRSP, and it's important for retail traders to take note. \\This activity came to our attention today through Benzinga's tracking of publicly available options data.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.222695,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.066414",
        "ticker_sentiment_score": "0.153392",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.066414",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.066414",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex  ( VRTX )  Kidney Disease Drug to Enter Clinical Development",
    "url": "https://www.zacks.com/stock/news/2245081/vertex-vrtx-kidney-disease-drug-to-enter-clinical-development",
    "time_published": "20240322T160900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex Pharmaceuticals (VRTX) plans to begin a phase I study on VX-407 in autosomal dominant polycystic kidney disease later this month.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.127277,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.288044",
        "ticker_sentiment_score": "0.04965",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADMA",
        "relevance_score": "0.420316",
        "ticker_sentiment_score": "0.328265",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Buying These Dirt-Cheap Stocks Could Be a Brilliant Move",
    "url": "https://www.fool.com/investing/2024/03/23/buying-these-dirt-cheap-stocks-could-be-a-brillian/",
    "time_published": "20240323T104500",
    "authors": [
      "Keith Speights",
      "and Prosper Junior Bakiny",
      "David Jagielski"
    ],
    "summary": "The price could be right for these three biopharma stocks.",
    "banner_image": "https://g.foolcdn.com/editorial/images/770146/stock-chart-on-tablet-young-woman.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.918141"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.214586,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.048621",
        "ticker_sentiment_score": "0.190904",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BHVN",
        "relevance_score": "0.048621",
        "ticker_sentiment_score": "0.052355",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.457977",
        "ticker_sentiment_score": "0.459533",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AXSM",
        "relevance_score": "0.416844",
        "ticker_sentiment_score": "0.081841",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( VRTX )  Rises As Market Takes a Dip: Key Facts",
    "url": "https://www.zacks.com/stock/news/2245680/vertex-pharmaceuticals-vrtx-rises-as-market-takes-a-dip-key-facts",
    "time_published": "20240325T215020",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $416.03, indicating a +0.09% shift from the previous trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default198.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.160989,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.520477",
        "ticker_sentiment_score": "0.192507",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "If You Invested $100 In This Stock 20 Years Ago, You Would Have $4,400 Today - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/insights/news/24/03/37924426/if-you-invested-100-in-this-stock-20-years-ago-you-would-have-4-400-today",
    "time_published": "20240325T213028",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Vertex Pharmaceuticals VRTX has outperformed the market over the past 20 years by 12.82% on an annualized basis producing an average annual return of 20.71%. Currently, Vertex Pharmaceuticals has a market capitalization of $107.71 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_3.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.238974,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.9545",
        "ticker_sentiment_score": "0.384186",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Vertex  ( VRTX )  Continues to Diversify Beyond CF Franchise",
    "url": "https://www.zacks.com/stock/news/2245348/vertex-vrtx-continues-to-diversify-beyond-cf-franchise",
    "time_published": "20240325T131000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "While CF remains the main area of focus for Vertex Pharmaceuticals (VRTX), it is seeing success in the development of its non-CF pipeline candidates.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/cc/389.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.072863,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MRNA",
        "relevance_score": "0.150278",
        "ticker_sentiment_score": "-0.167923",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.150278",
        "ticker_sentiment_score": "0.142135",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "bluebird  ( BLUE )  Misses on Q4 Revenues, Provides Portfolio Updates",
    "url": "https://www.zacks.com/stock/news/2246818/bluebird-blue-misses-on-q4-revenues-provides-portfolio-updates",
    "time_published": "20240327T153700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "bluebird bio (BLUE) revenues miss the Zacks Consensus Estimate in the fourth quarter. The company progresses with the launch of its three approved gene therapies.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default200.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.175449,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.098456",
        "ticker_sentiment_score": "0.065485",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BLUE",
        "relevance_score": "0.463792",
        "ticker_sentiment_score": "0.121057",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 No-Brainer Healthcare Stocks to Buy Right Now for Less Than $1,000",
    "url": "https://www.fool.com/investing/2024/03/27/3-no-brainer-healthcare-stocks-to-buy-right-now/",
    "time_published": "20240327T085000",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Each of these three companies are entering a new era of growth.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F770674%2Finvestors-look-at-tablet-outside.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999346"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.330564,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MDT",
        "relevance_score": "0.305058",
        "ticker_sentiment_score": "0.485723",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.052112",
        "ticker_sentiment_score": "0.049686",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.206245",
        "ticker_sentiment_score": "0.11208",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Cathie Wood's Darling Crispr Has Tumbled For Five Weeks Straight",
    "url": "https://www.investors.com/news/technology/crispr-stock-cathie-wood-ark-innovation-etf-gene-editing/",
    "time_published": "20240328T165825",
    "authors": [
      "ALLISON GATLIN",
      "Investor's Business Daily"
    ],
    "summary": "Crispr Stock, A Cathie Wood's Holding, Dives For The Fifth Straight Week - Here's Why Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2023/11/Stock-crispr-dna-03-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998962"
      }
    ],
    "overall_sentiment_score": 0.15584,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.155954",
        "ticker_sentiment_score": "0.193025",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BLUE",
        "relevance_score": "0.155954",
        "ticker_sentiment_score": "0.193025",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SLDB",
        "relevance_score": "0.078354",
        "ticker_sentiment_score": "0.240337",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Brokers Suggest Investing in Vertex  ( VRTX ) : Read This Before Placing a Bet",
    "url": "https://www.zacks.com/stock/news/2247293/brokers-suggest-investing-in-vertex-vrtx-read-this-before-placing-a-bet",
    "time_published": "20240328T133011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "According to the average brokerage recommendation (ABR), one should invest in Vertex (VRTX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default131.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.890401"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      }
    ],
    "overall_sentiment_score": 0.281543,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.05387",
        "ticker_sentiment_score": "0.120737",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the iShares Biotechnology ETF  ( IBB ) ?",
    "url": "https://www.zacks.com/stock/news/2247086/should-you-invest-in-the-ishares-biotechnology-etf-ibb",
    "time_published": "20240328T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default38.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      }
    ],
    "overall_sentiment_score": 0.20999,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.068502",
        "ticker_sentiment_score": "0.034077",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.136499",
        "ticker_sentiment_score": "0.072027",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.136499",
        "ticker_sentiment_score": "0.072027",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.136499",
        "ticker_sentiment_score": "0.072027",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Bluebird Bio Stock Has 138% Upside, According to 1 Wall Street Analyst",
    "url": "https://www.fool.com/investing/2024/03/29/bluebird-bio-stock-upside-wall-street-analyst/",
    "time_published": "20240329T092000",
    "authors": [
      "Eric Volkman"
    ],
    "summary": "Biotech stocks are famously volatile. One analyst feels this one could be volatile enough to produce an outsized gain.",
    "banner_image": "https://g.foolcdn.com/editorial/images/770960/two-people-seated-at-a-lab-desk-featuring-a-pc-screen-and-microscope.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.875462"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.078955,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.112008",
        "ticker_sentiment_score": "0.061383",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BLUE",
        "relevance_score": "0.426824",
        "ticker_sentiment_score": "0.16588",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Unstoppable Stocks to Buy Hand Over Fist in April",
    "url": "https://www.fool.com/investing/2024/03/30/unstoppable-stocks-to-buy-hand-over-fist-in-april/",
    "time_published": "20240330T105000",
    "authors": [
      "and Prosper Junior Bakiny",
      "David Jagielski",
      "Keith Speights"
    ],
    "summary": "These stocks have exceptionally bright prospects.",
    "banner_image": "https://g.foolcdn.com/editorial/images/771014/happy-woman-because-the-stock-market-went-up.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.166515,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.293339",
        "ticker_sentiment_score": "0.024678",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.21193",
        "ticker_sentiment_score": "0.117682",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( NASDAQ:VRTX )  Downgraded by StockNews.com to \"Buy\"",
    "url": "https://www.defenseworld.net/2024/03/30/vertex-pharmaceuticals-nasdaqvrtx-downgraded-by-stocknews-com-to-buy-2.html",
    "time_published": "20240330T062642",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Vertex Pharmaceuticals ( NASDAQ:VRTX - Get Free Report ) was downgraded by equities research analysts at StockNews.com from a \"strong-buy\" rating to a \"buy\" rating in a research note issued on Saturday. VRTX has been the topic of several other reports.",
    "banner_image": "https://www.marketbeat.com/logos/vertex-pharmaceuticals-incorporated-logo-1200x675.png?v=20231228113929",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.82617"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.976913"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.231321,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TFC",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "-0.016806",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.807885",
        "ticker_sentiment_score": "0.381491",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "-0.016806",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FL",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "0.112731",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "1 Top Growth Stock to Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/03/31/1-top-growth-stock-to-buy-and-hold-forever/",
    "time_published": "20240331T131500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "This drugmaker looks unstoppable.",
    "banner_image": "https://media.ycharts.com/charts/ec3a35b56e25408cdbc05258d7f23c36.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.331706,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.444734",
        "ticker_sentiment_score": "0.460788",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "KRYS",
        "relevance_score": "0.133841",
        "ticker_sentiment_score": "0.119276",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Rock-Solid Growth Stocks to Buy Right Now and Hold for at Least 5 Years",
    "url": "https://www.fool.com/investing/2024/03/31/2-rock-solid-growth-stocks-to-buy-right-now-and/",
    "time_published": "20240331T103000",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "Great businesses are here to stay. These are two excellent examples.",
    "banner_image": "https://g.foolcdn.com/editorial/images/770984/senior-woman-learning-to-use-tablet-computer-with-the-help-of-her-adult-daughter.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.295989,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SHOP",
        "relevance_score": "0.483888",
        "ticker_sentiment_score": "0.40387",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.068995",
        "ticker_sentiment_score": "0.312296",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.03453",
        "ticker_sentiment_score": "0.048089",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EBAY",
        "relevance_score": "0.03453",
        "ticker_sentiment_score": "0.113516",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.03453",
        "ticker_sentiment_score": "0.113516",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( VRTX )  Increases Despite Market Slip: Here's What You Need to Know",
    "url": "https://www.zacks.com/stock/news/2248705/vertex-pharmaceuticals-vrtx-increases-despite-market-slip-heres-what-you-need-to-know",
    "time_published": "20240401T215020",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $420.48, denoting a +0.59% change from the preceding trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default28.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.95493"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.179155,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.588876",
        "ticker_sentiment_score": "0.277452",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Vertex Announces New Drug Submission for Exagamglogene Autotemcel  ( exa-cel )  Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia",
    "url": "https://www.newswire.ca/news-releases/vertex-announces-new-drug-submission-for-exagamglogene-autotemcel-exa-cel-has-been-accepted-for-priority-review-by-health-canada-for-the-treatment-of-sickle-cell-disease-and-transfusion-dependent-beta-thalassemia-840383125.html",
    "time_published": "20240401T150000",
    "authors": [
      "Vertex Pharmaceuticals (Canada) Inc."
    ],
    "summary": "Vertex Announces New Drug Submission for Exagamglogene Autotemcel ( exa-cel ) Has Been Accepted for Priority ... Canada ...",
    "banner_image": "https://mma.prnewswire.com/media/2376280/Vertex_Pharmaceuticals__Canada__Inc__Vertex_Announces_New_Drug_S.jpg?p=facebook",
    "source": "Canada Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.newswire.ca",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.109092,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.116489",
        "ticker_sentiment_score": "0.083775",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.02922",
        "ticker_sentiment_score": "0.149438",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Missed the \"Magnificent Seven\"? Try Buying These 3 Forever Stocks Instead",
    "url": "https://www.fool.com/investing/2024/04/01/missed-the-magnificent-seven-try-buying-these-3/",
    "time_published": "20240401T130000",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "All three companies have very long runways for growth ahead.",
    "banner_image": "https://g.foolcdn.com/editorial/images/768661/two-investors-consider-a-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.918141"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.297572,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.166935",
        "ticker_sentiment_score": "0.06688",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.056011",
        "ticker_sentiment_score": "0.177046",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.111747",
        "ticker_sentiment_score": "0.206816",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.056011",
        "ticker_sentiment_score": "0.177046",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "COST",
        "relevance_score": "0.221313",
        "ticker_sentiment_score": "0.128312",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates",
    "url": "https://www.globenewswire.com/news-release/2024/04/01/2855119/0/en/CervoMed-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Corporate-Updates.html",
    "time_published": "20240401T120000",
    "authors": [
      "CervoMed Inc."
    ],
    "summary": "- Announced private placement of up to $149.4 million led by RA Capital Management with participation from Armistice Capital, Special Situations Funds and Soleus Capital. pro forma cash and cash equivalents from upfront proceeds expected to provide runway through the end of ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/60efdcfe-9817-4072-ad55-0132b9c6452f",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.993856"
      }
    ],
    "overall_sentiment_score": 0.100857,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.041358",
        "ticker_sentiment_score": "0.06926",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRVO",
        "relevance_score": "0.123632",
        "ticker_sentiment_score": "0.073823",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy  ( ASGCT )  2024 Annual Meeting - CRISPR Therapeutics  ( NASDAQ:CRSP ) ",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38020125/crispr-therapeutics-to-present-at-the-american-society-of-gene-cell-therapy-asgct-2024-annual-meet",
    "time_published": "20240401T120000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "ZUG, Switzerland and BOSTON, April 01, 2024 ( GLOBE NEWSWIRE ) -- CRISPR Therapeutics CRSP, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced an oral presentation at the American Society of Gene & Cell Therapy ( ASGCT ) 2024 ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.207137,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.110973",
        "ticker_sentiment_score": "0.134183",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRSP",
        "relevance_score": "0.219809",
        "ticker_sentiment_score": "0.171898",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Meet The \"Magnificent Seven\" of Healthcare Stocks",
    "url": "https://www.fool.com/investing/2024/04/01/meet-the-magnificent-seven-of-healthcare-stocks/",
    "time_published": "20240401T083000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The tech sector doesn't have a monopoly on magnificent corporations.",
    "banner_image": "https://g.foolcdn.com/editorial/images/770839/person-sitting-and-working-at-a-desk.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.24052,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.042048",
        "ticker_sentiment_score": "0.180009",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.125679",
        "ticker_sentiment_score": "0.255601",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HCA",
        "relevance_score": "0.248259",
        "ticker_sentiment_score": "0.115038",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.207928",
        "ticker_sentiment_score": "0.28535",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.167032",
        "ticker_sentiment_score": "0.306284",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.167032",
        "ticker_sentiment_score": "0.286408",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.207928",
        "ticker_sentiment_score": "0.134207",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.207928",
        "ticker_sentiment_score": "0.100054",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex  ( VRTX )  Moves Kidney Disease Drug to Phase 3 Development",
    "url": "https://www.zacks.com/stock/news/2249335/vertex-vrtx-moves-kidney-disease-drug-to-phase-3-development",
    "time_published": "20240402T152600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex (VRTX) advances inaxaplin to late-stage development. It will evaluate the drug in lower age groups and will enroll patients aged 10 years and older with APOL1-mediated kidney disease.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/29/1920.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.976913"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.174909,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.18856",
        "ticker_sentiment_score": "-0.096055",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADMA",
        "relevance_score": "0.279547",
        "ticker_sentiment_score": "0.18126",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ANIP",
        "relevance_score": "0.234458",
        "ticker_sentiment_score": "0.147016",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Got $1,000? 2 Bulletproof Stocks to Buy in 2024 and Hold for the Long Haul",
    "url": "https://www.fool.com/investing/2024/04/05/got-1000-2-bulletproof-stocks-to-buy-in-2024-and/",
    "time_published": "20240405T133000",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "These businesses are booming.",
    "banner_image": "https://g.foolcdn.com/editorial/images/771624/dna-sequencing-genome-science-lab.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.938793"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.302699,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "0.33025",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HCSG",
        "relevance_score": "0.107255",
        "ticker_sentiment_score": "0.132616",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.263942",
        "ticker_sentiment_score": "0.176594",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is iShares Biotechnology ETF  ( IBB )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2250861/is-ishares-biotechnology-etf-ibb-a-strong-etf-right-now",
    "time_published": "20240405T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default81.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999892"
      }
    ],
    "overall_sentiment_score": 0.256572,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.061949",
        "ticker_sentiment_score": "0.11403",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.123526",
        "ticker_sentiment_score": "0.06173",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.123526",
        "ticker_sentiment_score": "0.06173",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.123526",
        "ticker_sentiment_score": "0.06173",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "This Growth Stock Is One Step Closer to Launching a New Blockbuster: Time to Buy?",
    "url": "https://www.fool.com/investing/2024/04/09/this-growth-stock-is-one-step-closer-to-launching/",
    "time_published": "20240409T140700",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "This innovative machine rolls on.",
    "banner_image": "https://g.foolcdn.com/editorial/images/771663/physician-giving-medicine-to-elderly-patient.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.795202"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.238483,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.607406",
        "ticker_sentiment_score": "0.402416",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Better Buy: CRISPR Therapeutics Vs. Viking Therapeutics",
    "url": "https://www.fool.com/investing/2024/04/09/better-buy-crispr-therapeutics-viking-therapeutics/",
    "time_published": "20240409T140000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "These rising drugmakers have serious arguments in their favor.",
    "banner_image": "https://media.ycharts.com/charts/2f608acbdbb878f8afcf1739cda7cee5.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.356724,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.183895",
        "ticker_sentiment_score": "0.293276",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.514619",
        "ticker_sentiment_score": "0.48879",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Jim Cramer Was Upset At This Hostile Takeover, But 'They Fixed The Situation. Stock's Been A Horse' - Abbott Laboratories  ( NYSE:ABT ) , Emerson Electric  ( NYSE:EMR ) ",
    "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/04/38155367/jim-cramer-was-upset-at-this-hostile-takeover-but-they-fixed-the-situation-stocks-been-a",
    "time_published": "20240409T131029",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "On CNBC's \"Mad Money Lightning Round,\" Jim Cramer said he prefers Abbott Laboratories ABT over Penumbra, Inc. PEN. \"I still fear it after the environmental damage. I am concerned that you can't really put a price on it,\" Cramer said when asked about Hawaiian Electric Industries, Inc.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/09/shutterstock_2246181693.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.083032,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "EE",
        "relevance_score": "0.205807",
        "ticker_sentiment_score": "-0.019508",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HAWEL",
        "relevance_score": "0.205807",
        "ticker_sentiment_score": "0.012065",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.205807",
        "ticker_sentiment_score": "-0.106949",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SBSW",
        "relevance_score": "0.304428",
        "ticker_sentiment_score": "0.120339",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "F",
        "relevance_score": "0.205807",
        "ticker_sentiment_score": "-0.09122",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GM",
        "relevance_score": "0.205807",
        "ticker_sentiment_score": "-0.09122",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PEN",
        "relevance_score": "0.304428",
        "ticker_sentiment_score": "-0.154852",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.304428",
        "ticker_sentiment_score": "0.466411",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "EMR",
        "relevance_score": "0.304428",
        "ticker_sentiment_score": "-0.207998",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "HE",
        "relevance_score": "0.103778",
        "ticker_sentiment_score": "-0.092462",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 High-Growth Biotech Stocks Investors Shouldn't Sleep On in April",
    "url": "https://markets.businessinsider.com/news/stocks/3-high-growth-biotech-stocks-investors-shouldnt-sleep-on-in-april-1033232893",
    "time_published": "20240409T110000",
    "authors": [
      "Chris MacDonald"
    ],
    "summary": "It's been a volatile start to the second quarter for many sectors. However, investors continue to seek out undervalued biotech stocks for robust returns over the long term. Plenty of options exist in various niches within the biotech sector.",
    "banner_image": "https://investorplace.com/wp-content/uploads/2023/03/eli-lilly-lly-stock-sign-1600-300x169.jpg",
    "source": "Business Insider",
    "category_within_source": "GoogleRSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.281774,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.048327",
        "ticker_sentiment_score": "0.092033",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.144275",
        "ticker_sentiment_score": "0.216645",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.328611",
        "ticker_sentiment_score": "0.335479",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.",
    "url": "https://www.fool.com/investing/2024/04/09/missed-out-on-eli-lilly-2-stocks-with-catalysts/",
    "time_published": "20240409T103500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "These companies are close to launching new products that could supercharge revenue.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F772200%2Fscientists-high-five-smile.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.268179,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.11894",
        "ticker_sentiment_score": "0.079945",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.11894",
        "ticker_sentiment_score": "0.070731",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.499254",
        "ticker_sentiment_score": "0.217058",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.11894",
        "ticker_sentiment_score": "0.054324",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( VRTX )  Registers a Bigger Fall Than the Market: Important Facts to Note",
    "url": "https://www.zacks.com/stock/news/2253681/vertex-pharmaceuticals-vrtx-registers-a-bigger-fall-than-the-market-important-facts-to-note",
    "time_published": "20240410T220020",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex Pharmaceuticals (VRTX) reachead $397.58 at the closing of the latest trading day, reflecting a -1.71% change compared to its last close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default203.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.115566,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.5341",
        "ticker_sentiment_score": "0.169787",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Vertex Pharma Nabs Alpine Immune Sciences In $4.9 Billion Deal",
    "url": "https://www.investors.com/news/technology/vertex-pharmaceuticals-alpine-stock-takeover/",
    "time_published": "20240410T204500",
    "authors": [
      "ALLISON GATLIN",
      "Investor's Business Daily"
    ],
    "summary": "Vertex Pharmaceuticals ( VRTX ) will pay $4.9 billion to acquire immunological-focused biotech Alpine Immune Sciences ( ALPN ) , the companies said late Wednesday. Alpine stock rocketed after-hours after soaring on rumors of the deal.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2020/04/Stock-Vertex-04-shutt.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.012001,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.395012",
        "ticker_sentiment_score": "-0.31994",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ALPN",
        "relevance_score": "0.395012",
        "ticker_sentiment_score": "-0.31994",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact",
    "url": "https://markets.businessinsider.com/news/stocks/vertex-s-alpine-acquisition-unpacking-analyst-predictions-on-povetacicept-s-potential-impact-1033242338",
    "time_published": "20240411T191243",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Wednesday, Vertex Pharmaceuticals Incorporated ( NASDAQ:VRTX ) agreed to acquire Alpine Immune Sciences Inc ( NASDAQ:ALPN ) for $65 per share or approximately $4.9 billion in cash.",
    "banner_image": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2024/Genetic-Research-And-Biotech-Science-Con_7.jpeg",
    "source": "Business Insider",
    "category_within_source": "GoogleRSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.249038,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.245339",
        "ticker_sentiment_score": "0.335759",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VERA",
        "relevance_score": "0.124164",
        "ticker_sentiment_score": "0.08491",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALPN",
        "relevance_score": "0.245339",
        "ticker_sentiment_score": "0.245512",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38209569/vertexs-alpine-acquisition-unpacking-analyst-predictions-on-povetacicepts-potential",
    "time_published": "20240411T184733",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Wednesday, Vertex Pharmaceuticals Incorporated VRTX agreed to acquire Alpine Immune Sciences Inc ALPN for $65 per share or approximately $4.9 billion in cash.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Genetic-Research-And-Biotech-Science-Con_7.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.262839,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.325924",
        "ticker_sentiment_score": "0.392182",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VERA",
        "relevance_score": "0.220809",
        "ticker_sentiment_score": "0.10847",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALPN",
        "relevance_score": "0.325924",
        "ticker_sentiment_score": "0.270473",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Biotech Stocks Heat Up, Driven By A Spate Of Billion-Dollar Deals",
    "url": "https://www.investors.com/news/technology/biotech-stocks-arvinas-novartis-licensing-deal-janux-takeover-interest/",
    "time_published": "20240411T131700",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "Biotech Stocks Heat Up As Arvinas Scores Licensing Deal And Janux Reportedly Explores Options Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2020/06/Stock-biotech-06-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      }
    ],
    "overall_sentiment_score": -0.065165,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.268294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JANX",
        "relevance_score": "0.268294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VERA",
        "relevance_score": "0.268294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALPN",
        "relevance_score": "0.268294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARVN",
        "relevance_score": "0.769861",
        "ticker_sentiment_score": "-0.300102",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals: Buy, Sell, or Hold?",
    "url": "https://www.fool.com/investing/2024/04/11/vertex-pharmaceuticals-buy-sell-or-hold/",
    "time_published": "20240411T131500",
    "authors": [
      "David Jagielski"
    ],
    "summary": "The stock hasn't made for a great buy this year, but is Vertex worth investing in for the long run?",
    "banner_image": "https://g.foolcdn.com/editorial/images/772095/doctor-giving-a-patient-medication.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99977"
      }
    ],
    "overall_sentiment_score": 0.330248,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.235252",
        "ticker_sentiment_score": "0.248911",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals Moves Beyond $10B Cystic Fibrosis Franchise, Pays Around $5B For Kidney Disease Player Alpine Immune Why Alpine Immune Sciences Stock Is Trading Higher Today? - Alpine Immune Sciences  ( NASDAQ:ALPN ) , Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/general/biotech/24/04/38201798/vertex-pharmaceuticals-move-beyond-its-10b-cystic-fibrosis-franchise-pays-around-5b-for-kidney-di",
    "time_published": "20240411T130111",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Wednesday, Vertex Pharmaceuticals Incorporated VRTX agreed to acquire Alpine Immune Sciences Inc ALPN for $65 per share or approximately $4.9 billion in cash. Alpine's lead molecule, povetacicept ( ALPN-303 ) , is a highly potent and effective dual antagonist of BAFF ( B cell activating factor ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/ALPN_0.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.188415,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.270773",
        "ticker_sentiment_score": "0.337598",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALPN",
        "relevance_score": "0.355588",
        "ticker_sentiment_score": "0.2381",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Futures Fall Before Another Key Inflation Report",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaq-ppi-inflation-jobs-data-nvidia-microsoft/",
    "time_published": "20240411T121800",
    "authors": [
      "ED CARSON",
      "Investor's Business Daily"
    ],
    "summary": "Stock Market Today: Dow Jones Futures Fall Ahead Of Inflation, Jobs Data. Nvidia, Microsoft Price Targets Raised Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/02/stock-wallStreet-1-shutter.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": -0.051128,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "EVR",
        "relevance_score": "0.03878",
        "ticker_sentiment_score": "-0.013941",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.077468",
        "ticker_sentiment_score": "0.188886",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.077468",
        "ticker_sentiment_score": "0.188886",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.266412",
        "ticker_sentiment_score": "-0.045052",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.03878",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.115974",
        "ticker_sentiment_score": "-0.05969",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.302708",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALPN",
        "relevance_score": "0.115974",
        "ticker_sentiment_score": "-0.05969",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMX",
        "relevance_score": "0.077468",
        "ticker_sentiment_score": "-0.105361",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STZ",
        "relevance_score": "0.077468",
        "ticker_sentiment_score": "-0.105361",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARM",
        "relevance_score": "0.077468",
        "ticker_sentiment_score": "0.188886",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FAST",
        "relevance_score": "0.077468",
        "ticker_sentiment_score": "-0.105361",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.115974",
        "ticker_sentiment_score": "-0.152994",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.115974",
        "ticker_sentiment_score": "0.016664",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "S&P 500, Nasdaq Set For Lower Open While Bitcoin Holds Above $70K: What's Moving Stock Futures? - Alpine Immune Sciences  ( NASDAQ:ALPN ) ",
    "url": "https://www.benzinga.com/markets/equities/24/04/38199244/wall-street-braces-for-another-red-day-ahead-of-more-inflation-data-while-bitcoin-holds-above-70",
    "time_published": "20240411T112742",
    "authors": [
      "Shanthi Rexaline"
    ],
    "summary": "The negative mood on Wall Street may persist as investors await the release of another inflation report, which will have significant implications for the near-term trend in consumer prices. Wholesale price inflation typically flows down the supply chain and manifests as higher retail prices in ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Wall-Street_8.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.99489"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": -0.014678,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LOVE",
        "relevance_score": "0.095138",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSTK",
        "relevance_score": "0.047654",
        "ticker_sentiment_score": "0.284962",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALPN",
        "relevance_score": "0.095138",
        "ticker_sentiment_score": "0.175777",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KMX",
        "relevance_score": "0.095138",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STZ",
        "relevance_score": "0.095138",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.095138",
        "ticker_sentiment_score": "0.175777",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FAST",
        "relevance_score": "0.095138",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HOOD",
        "relevance_score": "0.095138",
        "ticker_sentiment_score": "-0.423407",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.095138",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Market Signals Mixed; Nvidia, Inflation, Iran In Focus: Weekly Review",
    "url": "https://www.investors.com/news/stock-market-sends-mixed-nvidia-inflation-mideast-fears/",
    "time_published": "20240412T163800",
    "authors": [
      "Investor's Business Daily",
      "IBD STAFF"
    ],
    "summary": "Market Signals Mixed. Nvidia, Inflation, Iran In Focus: Weekly Review Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2021/08/Stock-BullPaintedRushing-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.918141"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.955357"
      }
    ],
    "overall_sentiment_score": 0.034413,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.13409",
        "ticker_sentiment_score": "0.053436",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.264419",
        "ticker_sentiment_score": "0.04425",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.089629",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.306416",
        "ticker_sentiment_score": "0.105313",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.089629",
        "ticker_sentiment_score": "0.131392",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.221616",
        "ticker_sentiment_score": "0.083091",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.089629",
        "ticker_sentiment_score": "0.041697",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.044885",
        "ticker_sentiment_score": "0.053987",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DAL",
        "relevance_score": "0.17813",
        "ticker_sentiment_score": "0.04203",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PSMT",
        "relevance_score": "0.089629",
        "ticker_sentiment_score": "0.05814",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSM",
        "relevance_score": "0.13409",
        "ticker_sentiment_score": "0.108339",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.089629",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STT",
        "relevance_score": "0.13409",
        "ticker_sentiment_score": "0.053436",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SGH",
        "relevance_score": "0.089629",
        "ticker_sentiment_score": "-0.238004",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.221616",
        "ticker_sentiment_score": "0.083091",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALPN",
        "relevance_score": "0.13409",
        "ticker_sentiment_score": "0.049171",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARM",
        "relevance_score": "0.089629",
        "ticker_sentiment_score": "-0.005236",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.089629",
        "ticker_sentiment_score": "-0.062768",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PANW",
        "relevance_score": "0.089629",
        "ticker_sentiment_score": "-0.005236",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alpine  ( ALPN )  Surges 37% on $4.9B Buyout Offer From Vertex",
    "url": "https://www.zacks.com/stock/news/2254800/alpine-alpn-surges-37-on-49b-buyout-offer-from-vertex",
    "time_published": "20240412T163600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex (VRTX) is set to acquire Alpine Immune Sciences (ALPN) for $65 per share in cash. The transaction is likely to close by second-quarter 2024.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.184498,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.231773",
        "ticker_sentiment_score": "0.044053",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TVTX",
        "relevance_score": "0.046999",
        "ticker_sentiment_score": "0.034996",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.046999",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VERA",
        "relevance_score": "0.093836",
        "ticker_sentiment_score": "0.187882",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALPN",
        "relevance_score": "0.320081",
        "ticker_sentiment_score": "0.210238",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Magnificent Stocks That Could Double or More by 2030",
    "url": "https://www.fool.com/investing/2024/04/13/magnificent-stocks-could-double-or-more-by-2030/",
    "time_published": "20240413T124700",
    "authors": [
      "David Jagielski",
      "and Prosper Junior Bakiny",
      "Keith Speights"
    ],
    "summary": "There's no guarantee these stocks will double by 2030, but their growth prospects look great.",
    "banner_image": "https://g.foolcdn.com/editorial/images/772646/african-american-young-couple-dancing.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.317862,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.298113",
        "ticker_sentiment_score": "0.219395",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.038162",
        "ticker_sentiment_score": "0.120138",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.151778",
        "ticker_sentiment_score": "-0.107742",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.038162",
        "ticker_sentiment_score": "0.134657",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Could This Stock Be the Next Biotech Buyout?",
    "url": "https://www.fool.com/investing/2024/04/13/could-this-stock-be-the-next-biotech-buyout/",
    "time_published": "20240413T092900",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "Vertex Pharmaceuticals' $4.9 billion purchase of Alpine Immune Sciences probably won't be the last acquisition of a company focused on kidney disease.",
    "banner_image": "https://g.foolcdn.com/editorial/images/772593/investor-individual-stock-charts-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.099346,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.162802",
        "ticker_sentiment_score": "0.092021",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VERA",
        "relevance_score": "0.318897",
        "ticker_sentiment_score": "0.194567",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALPN",
        "relevance_score": "0.215894",
        "ticker_sentiment_score": "0.163899",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( NASDAQ:VRTX )  Rating Increased to Strong-Buy at StockNews.com",
    "url": "https://www.defenseworld.net/2024/04/14/vertex-pharmaceuticals-nasdaqvrtx-rating-increased-to-strong-buy-at-stocknews-com.html",
    "time_published": "20240414T054443",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Vertex Pharmaceuticals ( NASDAQ:VRTX - Get Free Report ) was upgraded by research analysts at StockNews.com from a \"buy\" rating to a \"strong-buy\" rating in a research report issued on Friday. A number of other brokerages have also weighed in on VRTX. Sanford C.",
    "banner_image": "https://www.marketbeat.com/logos/vertex-pharmaceuticals-incorporated-logo-1200x675.png?v=20231228113929",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999998"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.247512,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TFC",
        "relevance_score": "0.046907",
        "ticker_sentiment_score": "0.047622",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.736282",
        "ticker_sentiment_score": "0.358638",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.046907",
        "ticker_sentiment_score": "0.047622",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CCORF",
        "relevance_score": "0.046907",
        "ticker_sentiment_score": "0.047622",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.046907",
        "ticker_sentiment_score": "0.047622",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharma scientist talks about the long road to developing non-addictive painkillers",
    "url": "https://apnews.com/article/vertex-pharmaceuticals-pain-drug-opioid-medication-study-5ec38713f486ccbab827b7dd04aa8484",
    "time_published": "20240415T212300",
    "authors": [
      "MATTHEW PERRONE"
    ],
    "summary": "WASHINGTON ( AP ) - For decades, patients seeking medication for pain have had two choices: over-the-counter drugs like aspirin or powerful prescription opioids like oxycodone.",
    "banner_image": "https://dims.apnews.com/dims4/default/4b56d40/2147483647/strip/true/crop/3115x2075+0+1/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F86%2F77%2F3100f57dab55cab3caa13a590d42%2F89b687e9243d4bb582a6bcf8ad524a0f",
    "source": "Associated Press",
    "category_within_source": "Markets",
    "source_domain": "apnews.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.012383,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.066414",
        "ticker_sentiment_score": "0.048782",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "CRVO: $150 Million Financing Strengthens Balance Sheet; Topline Data for Phase 2b Trial in 4Q24 - CervoMed  ( NASDAQ:CRVO ) ",
    "url": "https://www.benzinga.com/news/24/04/38244483/crvo-150-million-financing-strengthens-balance-sheet-topline-data-for-phase-2b-trial-in-4q24",
    "time_published": "20240415T164938",
    "authors": [
      "Zacks Small Cap Research"
    ],
    "summary": "On March 5, 2024, CervoMed Inc. CRVO announced the presentation of biomarker data from the AscenD-LB Phase 2a trial of neflamapimod in patients with dementia with Lewy bodies ( DLB ) was featured in a poster presentation at the 18th International Conference on Alzheimer's and Parkinson's Disease ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/15/clay-banks-cezmop5ftv4-unsplash.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.98396"
      }
    ],
    "overall_sentiment_score": 0.163355,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.028524",
        "ticker_sentiment_score": "0.034634",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRVO",
        "relevance_score": "0.197643",
        "ticker_sentiment_score": "0.124463",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's  ( at Least )  1 new Reason to Buy Vertex Pharmaceuticals Stock",
    "url": "https://www.fool.com/investing/2024/04/15/heres-at-least-1-new-reason-to-buy-vertex-pharma/",
    "time_published": "20240415T131500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Vertex just laid claim to an asset that might be very valuable.",
    "banner_image": "https://g.foolcdn.com/editorial/images/772774/two-investors-meet-and-discuss.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.231663,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "0.177833",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALPN",
        "relevance_score": "0.331765",
        "ticker_sentiment_score": "0.227415",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Investors Heavily Search Vertex Pharmaceuticals Incorporated  ( VRTX ) : Here is What You Need to Know",
    "url": "https://www.zacks.com/stock/news/2255115/investors-heavily-search-vertex-pharmaceuticals-incorporated-vrtx-here-is-what-you-need-to-know",
    "time_published": "20240415T130410",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default303.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.212961,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.104228",
        "ticker_sentiment_score": "0.040727",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Bluebird Bio Stock a Buy?",
    "url": "https://www.fool.com/investing/2024/04/15/is-bluebird-bio-stock-a-buy/",
    "time_published": "20240415T121500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "This small biotech is struggling to fly -- and investors should probably steer clear.",
    "banner_image": "https://g.foolcdn.com/editorial/images/771828/one-investor-explains-something-to-another-at-a-cafe.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.106928,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.054607",
        "ticker_sentiment_score": "0.046",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BLUE",
        "relevance_score": "0.41627",
        "ticker_sentiment_score": "0.209977",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( VRTX )  Stock Falls Amid Market Uptick: What Investors Need to Know",
    "url": "https://www.zacks.com/stock/news/2256422/vertex-pharmaceuticals-vrtx-stock-falls-amid-market-uptick-what-investors-need-to-know",
    "time_published": "20240416T220018",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex Pharmaceuticals (VRTX) closed at $394.17 in the latest trading session, marking a -0.8% move from the prior day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default92.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.983783"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.179494,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.592095",
        "ticker_sentiment_score": "0.319518",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "bluebird  ( BLUE )  Underperforms Industry YTD Amid Challenges",
    "url": "https://www.zacks.com/stock/news/2256355/bluebird-blue-underperforms-industry-ytd-amid-challenges",
    "time_published": "20240416T180500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "bluebird (BLUE) plunges 25% year to date as it struggles to fuel the growth of its complex and expensive gene therapies.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/01/1887.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.10221,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.145145",
        "ticker_sentiment_score": "0.129501",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADMA",
        "relevance_score": "0.352557",
        "ticker_sentiment_score": "0.306955",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "If You Invested $1000 In This Stock 10 Years Ago, You Would Have $6,000 Today - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/insights/news/24/04/38275378/if-you-invested-1000-in-this-stock-10-years-ago-you-would-have-6-000-today",
    "time_published": "20240416T160035",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 8.81% on an annualized basis producing an average annual return of 19.19%. Currently, Vertex Pharmaceuticals has a market capitalization of $102.14 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_4.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.238974,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.9545",
        "ticker_sentiment_score": "0.384186",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Is Vertex  ( VRTX )  a Buy as Wall Street Analysts Look Optimistic?",
    "url": "https://www.zacks.com/stock/news/2255964/is-vertex-vrtx-a-buy-as-wall-street-analysts-look-optimistic",
    "time_published": "20240416T133010",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "According to the average brokerage recommendation (ABR), one should invest in Vertex (VRTX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default355.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.938238"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      }
    ],
    "overall_sentiment_score": 0.28794,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.054732",
        "ticker_sentiment_score": "0.14283",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MGRC, ALPN, NXPL - Alpine Immune Sciences  ( NASDAQ:ALPN ) , McGrath RentCorp  ( NASDAQ:MGRC ) ",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38267927/shareholder-investigation-halper-sadeh-llc-investigates-mgrc-alpn-nxpl",
    "time_published": "20240416T121109",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, April 16, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.178652,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.119235",
        "ticker_sentiment_score": "0.094776",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NXPL",
        "relevance_score": "0.235823",
        "ticker_sentiment_score": "0.342559",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WSC",
        "relevance_score": "0.119235",
        "ticker_sentiment_score": "0.126585",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALPN",
        "relevance_score": "0.119235",
        "ticker_sentiment_score": "0.094776",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MGRC",
        "relevance_score": "0.119235",
        "ticker_sentiment_score": "0.126585",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "CRISPR Therapeutics's Options Frenzy: What You Need to Know - CRISPR Therapeutics  ( NASDAQ:CRSP ) ",
    "url": "https://www.benzinga.com/insights/options/24/04/38298821/crispr-therapeuticss-options-frenzy-what-you-need-to-know",
    "time_published": "20240417T173157",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Financial giants have made a conspicuous bearish move on CRISPR Therapeutics. Our analysis of options history for CRISPR Therapeutics CRSP revealed 11 unusual trades. Delving into the details, we found 45% of traders were bullish, while 54% showed bearish tendencies.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.247085,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.08687",
        "ticker_sentiment_score": "0.158908",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Tesla To $123? Here Are 10 Top Analyst Forecasts For Thursday - Tesla  ( NASDAQ:TSLA ) ",
    "url": "https://www.benzinga.com/news/24/04/38313029/tesla-to-123-here-are-10-top-analyst-forecasts-for-thursday",
    "time_published": "20240418T124642",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Morgan Stanley raised the price target for United Airlines Holdings, Inc. UAL from $75 to $80.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/18/tesla_-_logo.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99999"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.142857"
      }
    ],
    "overall_sentiment_score": 0.108217,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CNK",
        "relevance_score": "0.22421",
        "ticker_sentiment_score": "0.334872",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UAL",
        "relevance_score": "0.22421",
        "ticker_sentiment_score": "0.09685",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "B",
        "relevance_score": "0.364987",
        "ticker_sentiment_score": "0.104601",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.22421",
        "ticker_sentiment_score": "-0.106635",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KNX",
        "relevance_score": "0.22421",
        "ticker_sentiment_score": "0.056292",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.150592",
        "ticker_sentiment_score": "0.072628",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BJ",
        "relevance_score": "0.22421",
        "ticker_sentiment_score": "-0.101241",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CCI",
        "relevance_score": "0.22421",
        "ticker_sentiment_score": "-0.092659",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.22421",
        "ticker_sentiment_score": "-0.036841",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CDNS",
        "relevance_score": "0.150592",
        "ticker_sentiment_score": "0.146633",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Does This Acquisition Make Vertex Pharmaceuticals Stock a Buy?",
    "url": "https://www.fool.com/investing/2024/04/18/does-this-acquisition-make-vertex-pharmaceuticals/",
    "time_published": "20240418T123000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The biotech just added another potential growth driver to its pipeline.",
    "banner_image": "https://g.foolcdn.com/editorial/images/772621/physician-shaking-patients-hand.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.197811,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.185306",
        "ticker_sentiment_score": "0.258956",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALPN",
        "relevance_score": "0.185306",
        "ticker_sentiment_score": "0.092627",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( VRTX )  Gains As Market Dips: What You Should Know",
    "url": "https://www.zacks.com/stock/news/2258789/vertex-pharmaceuticals-vrtx-gains-as-market-dips-what-you-should-know",
    "time_published": "20240419T215018",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $394.28, indicating a +0.2% shift from the previous trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default118.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.972476"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.147602,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.580956",
        "ticker_sentiment_score": "0.240011",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Vertex  ( VRTX )  Begins Rolling NDA Filing for Acute Pain Drug",
    "url": "https://www.zacks.com/stock/news/2258650/vertex-vrtx-begins-rolling-nda-filing-for-acute-pain-drug",
    "time_published": "20240419T155700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex (VRTX) begins rolling NDA submission for its investigational non-opioid candidate, suzetrigine, for acute pain management. The submission is expected to be completed in second-quarter 2024.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/29/1920.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.947132"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.063068,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.200688",
        "ticker_sentiment_score": "-0.147616",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADMA",
        "relevance_score": "0.239698",
        "ticker_sentiment_score": "0.119408",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FGEN",
        "relevance_score": "0.200688",
        "ticker_sentiment_score": "0.012958",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ANVS",
        "relevance_score": "0.200688",
        "ticker_sentiment_score": "-0.024456",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Vertex Pharmaceuticals Stock a Millionaire Maker?",
    "url": "https://www.fool.com/investing/2024/04/19/vertex-pharmaceuticals-stock-millionaire-maker/",
    "time_published": "20240419T083000",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Does this pharma stock have the potential to turn a $25,000 investment into seven figures or more?",
    "banner_image": "https://g.foolcdn.com/editorial/images/772811/a-group-of-scientists-looking-at-a-report.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.967645"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999998"
      }
    ],
    "overall_sentiment_score": 0.246512,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.149346",
        "ticker_sentiment_score": "0.160462",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALPN",
        "relevance_score": "0.050044",
        "ticker_sentiment_score": "0.057748",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Everlasting Big Pharma Stocks to Buy Today and Hold Forever",
    "url": "https://www.fool.com/investing/2024/04/20/2-everlasting-big-pharma-stocks-to-buy-today-and/",
    "time_published": "20240420T134500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "These stocks probably won't be getting much cheaper.",
    "banner_image": "https://g.foolcdn.com/editorial/images/773219/investor-holds-glasses-while-considering-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      }
    ],
    "overall_sentiment_score": 0.229299,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.098255",
        "ticker_sentiment_score": "0.265057",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.098255",
        "ticker_sentiment_score": "-0.111101",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Relatively Safe Growth Stocks You Can Buy and Hold",
    "url": "https://www.fool.com/investing/2024/04/20/relatively-safe-growth-stocks-you-can-buy-and-hold/",
    "time_published": "20240420T104800",
    "authors": [
      "David Jagielski",
      "and Prosper Junior Bakiny",
      "Keith Speights"
    ],
    "summary": "Low risk and high-reward potential? These stocks could offer both.",
    "banner_image": "https://g.foolcdn.com/editorial/images/773405/hands-behind-head-young-woman.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.875462"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99393"
      }
    ],
    "overall_sentiment_score": 0.300536,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.356154",
        "ticker_sentiment_score": "0.337205",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.162802",
        "ticker_sentiment_score": "0.020054",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.280846",
        "ticker_sentiment_score": "0.1808",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALPN",
        "relevance_score": "0.040969",
        "ticker_sentiment_score": "0.100232",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( NASDAQ:VRTX )  Downgraded by StockNews.com",
    "url": "https://www.defenseworld.net/2024/04/20/vertex-pharmaceuticals-nasdaqvrtx-downgraded-by-stocknews-com.html",
    "time_published": "20240420T062241",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Vertex Pharmaceuticals ( NASDAQ:VRTX - Get Free Report ) was downgraded by investment analysts at StockNews.com from a \"strong-buy\" rating to a \"buy\" rating in a research note issued on Saturday. VRTX has been the subject of a number of other research reports.",
    "banner_image": "https://www.marketbeat.com/logos/vertex-pharmaceuticals-incorporated-logo-1200x675.png?v=20231228113929",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.82617"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.947132"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.262699,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EVR",
        "relevance_score": "0.046184",
        "ticker_sentiment_score": "0.063091",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MCQEF",
        "relevance_score": "0.092213",
        "ticker_sentiment_score": "0.186081",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.046184",
        "ticker_sentiment_score": "0.063091",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.092213",
        "ticker_sentiment_score": "0.186081",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.753259",
        "ticker_sentiment_score": "0.390532",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CCORF",
        "relevance_score": "0.046184",
        "ticker_sentiment_score": "0.063091",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.046184",
        "ticker_sentiment_score": "0.100983",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "CRISPR Therapeutics Stock  ( NASDAQ:CRSP )  Pushes Lower, But Fundamentals Are Intact",
    "url": "https://markets.businessinsider.com/news/stocks/crispr-therapeutics-stock-nasdaq-crsp-pushes-lower-but-fundamentals-are-intact-1033267516",
    "time_published": "20240420T031231",
    "authors": [
      "Tipranks"
    ],
    "summary": "CRISPR Therapeutics Stock (NASDAQ:CRSP) Pushes Lower, But Fundamentals Are Intact - Markets Insider ...",
    "banner_image": "https://blog.tipranks.com/wp-content/uploads/2024/04/image-728.png?utm_source=markets.businessinsider.com&utm_medium=referral",
    "source": "Business Insider",
    "category_within_source": "GoogleRSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      }
    ],
    "overall_sentiment_score": 0.196879,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.046452",
        "ticker_sentiment_score": "0.147414",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger - ALPN, LABP, SWAV, FUSN",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38366584/take-action-the-m-a-class-action-firm-launches-legal-inquiry-for-the-merger-alpn-labp-swav-fusn",
    "time_published": "20240422T213316",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, April 22, 2024 ( GLOBE NEWSWIRE ) -- Monteverde & Associates PC ( the \"M&A Class Action Firm\" ) , has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      }
    ],
    "overall_sentiment_score": 0.270721,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LABP",
        "relevance_score": "0.334008",
        "ticker_sentiment_score": "0.312006",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALPN",
        "relevance_score": "0.334008",
        "ticker_sentiment_score": "0.281733",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.085936",
        "ticker_sentiment_score": "0.124976",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.085936",
        "ticker_sentiment_score": "0.124976",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.085936",
        "ticker_sentiment_score": "0.139374",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FUSN",
        "relevance_score": "0.334008",
        "ticker_sentiment_score": "0.312006",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.334008",
        "ticker_sentiment_score": "0.281733",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy  ( ASGCT )  2024 Annual Meeting",
    "url": "https://www.globenewswire.com/news-release/2024/04/22/2867236/0/en/CRISPR-Therapeutics-to-Present-Oral-Presentation-at-the-American-Society-of-Gene-Cell-Therapy-ASGCT-2024-Annual-Meeting.html",
    "time_published": "20240422T203000",
    "authors": [
      "CRISPR Therapeutics AG"
    ],
    "summary": "ZUG, Switzerland and BOSTON, April 22, 2024 ( GLOBE NEWSWIRE ) -- CRISPR Therapeutics ( Nasdaq: CRSP ) , a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced an oral presentation highlighting the Company's lipid nanoparticle ( ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/5dac7d0d-131d-4047-bab7-db8e0719bf58",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.111374,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.03878",
        "ticker_sentiment_score": "0.145768",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRSP",
        "relevance_score": "0.077468",
        "ticker_sentiment_score": "0.125811",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates INRD, AIRC, ELYM, ALPN - Apartment Income REIT  ( NYSE:AIRC ) , Alpine Immune Sciences  ( NASDAQ:ALPN ) ",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38359836/shareholder-investigation-halper-sadeh-llc-investigates-inrd-airc-elym-alpn",
    "time_published": "20240422T151241",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, April 22, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Inrad Optics, Inc.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.161909,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.112008",
        "ticker_sentiment_score": "0.092492",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ELYM",
        "relevance_score": "0.112008",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INRD",
        "relevance_score": "0.112008",
        "ticker_sentiment_score": "0.143525",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BX",
        "relevance_score": "0.112008",
        "ticker_sentiment_score": "0.164659",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AIRC",
        "relevance_score": "0.112008",
        "ticker_sentiment_score": "0.164659",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALPN",
        "relevance_score": "0.112008",
        "ticker_sentiment_score": "0.092492",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Kuehn Law Encourages INRD, AIRC, ELYM, and ALPN Investors to Contact Law Firm - Apartment Income REIT  ( NYSE:AIRC ) , Alpine Immune Sciences  ( NASDAQ:ALPN ) ",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38357480/kuehn-law-encourages-inrd-airc-elym-and-alpn-investors-to-contact-law-firm",
    "time_published": "20240422T134807",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, April 22, 2024 ( GLOBE NEWSWIRE ) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.317621,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.110973",
        "ticker_sentiment_score": "0.22297",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ELYM",
        "relevance_score": "0.110973",
        "ticker_sentiment_score": "0.172983",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "INRD",
        "relevance_score": "0.110973",
        "ticker_sentiment_score": "0.37382",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BX",
        "relevance_score": "0.110973",
        "ticker_sentiment_score": "0.255206",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AIRC",
        "relevance_score": "0.219809",
        "ticker_sentiment_score": "0.376775",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ALPN",
        "relevance_score": "0.110973",
        "ticker_sentiment_score": "0.22297",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Making Sense of Amazon CEO Andy Jassy's Latest Letter",
    "url": "https://www.fool.com/investing/2024/04/22/making-sense-of-amazon-ceo-andy-jassys-latest-lett/",
    "time_published": "20240422T130300",
    "authors": [
      "Motley Fool Staff"
    ],
    "summary": "And that's just part of the interesting news for investors to dig into.",
    "banner_image": "https://g.foolcdn.com/editorial/images/773014/mfm_12.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.999682"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      }
    ],
    "overall_sentiment_score": 0.024188,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.011198",
        "ticker_sentiment_score": "-0.003361",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.083833",
        "ticker_sentiment_score": "0.066078",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COST",
        "relevance_score": "0.06153",
        "ticker_sentiment_score": "0.100202",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SBUX",
        "relevance_score": "0.011198",
        "ticker_sentiment_score": "0.01883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALPN",
        "relevance_score": "0.005599",
        "ticker_sentiment_score": "-0.023649",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.011198",
        "ticker_sentiment_score": "0.005923",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CPNG",
        "relevance_score": "0.02799",
        "ticker_sentiment_score": "0.071209",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.083833",
        "ticker_sentiment_score": "0.082705",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HSY",
        "relevance_score": "0.02799",
        "ticker_sentiment_score": "0.035879",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.005599",
        "ticker_sentiment_score": "0.163714",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "If You'd Invested $10,000 in Vertex Pharmaceuticals 5 Years Ago, Here's How Much You'd Have Today",
    "url": "https://www.fool.com/investing/2024/04/22/if-youd-invested-10000-in-vertex-pharmaceuticals-5/",
    "time_published": "20240422T111655",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Could Vertex's growth story continue?",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F773088%2Fgettyimages-1316445673.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.301217,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.245339",
        "ticker_sentiment_score": "0.030775",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Looking for Once-in-a-Generation Investment Opportunities? Here Are 3 Magnificent Stocks to Buy Right Now",
    "url": "https://www.fool.com/investing/2024/04/22/once-in-a-generation-investment-stocks-buy-now/",
    "time_published": "20240422T095200",
    "authors": [
      "Keith Speights"
    ],
    "summary": "These stocks could be near major inflection points.",
    "banner_image": "https://g.foolcdn.com/editorial/images/773509/woman-smiling-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.918141"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.195707,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PATH",
        "relevance_score": "0.3527",
        "ticker_sentiment_score": "0.29633",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.104002",
        "ticker_sentiment_score": "0.095623",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OXY",
        "relevance_score": "0.104002",
        "ticker_sentiment_score": "-0.048341",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALPN",
        "relevance_score": "0.052112",
        "ticker_sentiment_score": "0.025953",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.052112",
        "ticker_sentiment_score": "0.088004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.052112",
        "ticker_sentiment_score": "0.06463",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex  ( VRTX ) , TreeFrog Sign Deal for Diabetes Cell Therapies",
    "url": "https://www.zacks.com/stock/news/2259918/vertex-vrtx-treefrog-sign-deal-for-diabetes-cell-therapies",
    "time_published": "20240423T120900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex (VRTX) signs a collaboration agreement with TreeFrog to utilize the latter's C-Stem technology in order to optimize the production of its T1D cell therapies.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c8/39674.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.947132"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.142413,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.326643",
        "ticker_sentiment_score": "0.224018",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ADMA",
        "relevance_score": "0.326643",
        "ticker_sentiment_score": "0.152989",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FGEN",
        "relevance_score": "0.274628",
        "ticker_sentiment_score": "0.016626",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ANVS",
        "relevance_score": "0.274628",
        "ticker_sentiment_score": "-0.031365",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals Just Made 2 Big Moves. Is the Stock a Buy?",
    "url": "https://www.fool.com/investing/2024/04/23/vertex-just-made-2-big-moves-time-to-buy/",
    "time_published": "20240423T100500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Vertex is broadening its portfolio.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F773697%2Fbiotech-pharma-researchers-talk-lab.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.169141,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.169279",
        "ticker_sentiment_score": "0.283305",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALPN",
        "relevance_score": "0.113329",
        "ticker_sentiment_score": "0.247078",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES",
    "url": "https://www.newswire.ca/news-releases/vertex-and-treefrog-therapeutics-announce-licensing-agreement-and-collaboration-to-optimize-production-of-vertex-s-cell-therapies-for-type-1-diabetes-816234418.html",
    "time_published": "20240423T044500",
    "authors": [
      "TreeFrog Therapeutics"
    ],
    "summary": "VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO ... Canada ...",
    "banner_image": "https://mma.prnewswire.com/media/2394272/TreeFrog_Release.pdf?p=pdfthumbnail",
    "source": "Canada Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.newswire.ca",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.858979"
      }
    ],
    "overall_sentiment_score": 0.177475,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.197816",
        "ticker_sentiment_score": "0.220191",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES",
    "url": "https://www.prnewswire.com/news-releases/vertex-and-treefrog-therapeutics-announce-licensing-agreement-and-collaboration-to-optimize-production-of-vertexs-cell-therapies-for-type-1-diabetes-302123856.html",
    "time_published": "20240423T044500",
    "authors": [
      "TreeFrog Therapeutics"
    ],
    "summary": "VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/2394272/TreeFrog_Release.pdf?p=pdfthumbnail",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.858979"
      }
    ],
    "overall_sentiment_score": 0.16838,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.154785",
        "ticker_sentiment_score": "0.181251",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.051886",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.051886",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/pressreleases/24/04/n38369311/vertex-and-treefrog-therapeutics-announce-licensing-agreement-and-collaboration-to-optimize-produc",
    "time_published": "20240423T044500",
    "authors": [
      "PRNewswire"
    ],
    "summary": "Vertex obtains an exclusive license to TreeFrog's C-StemTM manufacturing technology in type 1 diabetes TreeFrog and Vertex to collaborate on scale-up of fully differentiated, insulin-producing pancreatic islet cells",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.918141"
      }
    ],
    "overall_sentiment_score": 0.180014,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.148121",
        "ticker_sentiment_score": "0.173985",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.049629",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.049629",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/pressreleases/24/04/n38369317/vertex-and-treefrog-therapeutics-announce-licensing-agreement-and-collaboration-to-optimize-produc",
    "time_published": "20240423T044500",
    "authors": [
      "PRNewswire"
    ],
    "summary": "Vertex obtains an exclusive license to TreeFrog's C-StemTM manufacturing technology in type 1 diabetes TreeFrog and Vertex to collaborate on scale-up of fully differentiated, insulin-producing pancreatic islet cells",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.918141"
      }
    ],
    "overall_sentiment_score": 0.180014,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.148121",
        "ticker_sentiment_score": "0.173985",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.049629",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.049629",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Op-ed: Here are 6 health-care stocks to watch now, amid a bumpy recovery",
    "url": "https://www.cnbc.com/2024/04/24/op-ed-here-are-health-care-stocks-to-watch-now-amid-a-bumpy-recovery.html",
    "time_published": "20240424T123001",
    "authors": [
      "Dave Sheaff Gilreath",
      "a certified financial planner and partner/founder and chief investment officer of Sheaff Brock Investment Advisors and Innovative Portfolio"
    ],
    "summary": "Health care, long an ailing stock market sector, has recovered over the past six months, with currently robust vital signs and strong growth projections.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/106408902-1582655595706gettyimages-936365986.jpg?v=1690462881&w=600&h=300&vtcrop=y",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.248998,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MEDP",
        "relevance_score": "0.113062",
        "ticker_sentiment_score": "0.107262",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.075516",
        "ticker_sentiment_score": "0.072695",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.075516",
        "ticker_sentiment_score": "-0.040715",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.113062",
        "ticker_sentiment_score": "-0.024999",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COR",
        "relevance_score": "0.075516",
        "ticker_sentiment_score": "0.092718",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IQV",
        "relevance_score": "0.075516",
        "ticker_sentiment_score": "0.134491",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.",
    "url": "https://www.fool.com/investing/2024/04/24/missed-out-on-novo-nordisk-2-healthcare-stocks-wit/",
    "time_published": "20240424T095000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "Good news could be just around the corner for two drugmakers not named Novo Nordisk.",
    "banner_image": "https://g.foolcdn.com/editorial/images/773900/young-woman-frustrated-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.21905,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.137671",
        "ticker_sentiment_score": "0.170819",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.137671",
        "ticker_sentiment_score": "0.298323",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.271274",
        "ticker_sentiment_score": "0.358237",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( VRTX )  Falls More Steeply Than Broader Market: What Investors Need to Know",
    "url": "https://www.zacks.com/stock/news/2262756/vertex-pharmaceuticals-vrtx-falls-more-steeply-than-broader-market-what-investors-need-to-know",
    "time_published": "20240425T215019",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $397.70, moving -0.76% from the previous trading session.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default39.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.983783"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.165762,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.63188",
        "ticker_sentiment_score": "0.296855",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": " ( VRTX )  - Analyzing Vertex Pharmaceuticals's Short Interest - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/insights/short-sellers/24/04/38441248/vrtx-analyzing-vertex-pharmaceuticalss-short-interest",
    "time_published": "20240425T183018",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Vertex Pharmaceuticals's VRTX short percent of float has fallen 3.75% since its last report. The company recently reported that it has 3.98 million shares sold short, which is 1.54% of all regular shares that are available for trading.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.262256,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.209365",
        "ticker_sentiment_score": "0.079385",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX",
    "url": "https://www.zacks.com/stock/news/2262685/biotech-stock-roundup-biib-bmys-q1-earnings-incys-acquisition-updates-from-vrtx",
    "time_published": "20240425T182800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Biogen (BIIB) and Bristol Myers (BMY) are in focus following Q1 earnings announcement.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/58/608.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.99915"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.09579,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.137671",
        "ticker_sentiment_score": "0.091651",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INCY",
        "relevance_score": "0.182851",
        "ticker_sentiment_score": "0.202489",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.271274",
        "ticker_sentiment_score": "0.039009",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.137671",
        "ticker_sentiment_score": "0.027938",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Fantastic Growth Stocks to Buy Right Now",
    "url": "https://www.fool.com/investing/2024/04/25/2-fantastic-growth-stocks-to-buy-right-now/",
    "time_published": "20240425T134500",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "Don't overlook these high-growth businesses.",
    "banner_image": "https://g.foolcdn.com/editorial/images/773906/man-20s-30s-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.955357"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.215907,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.084572",
        "ticker_sentiment_score": "0.123402",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PINS",
        "relevance_score": "0.28987",
        "ticker_sentiment_score": "0.21647",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals",
    "url": "https://www.zacks.com/stock/news/2263174/the-zacks-analyst-blog-highlights-biogen-bristol-myers-squibb-incyte-and-vertex-pharmaceuticals",
    "time_published": "20240426T122500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/29/1920.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.99915"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.105017,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.166455",
        "ticker_sentiment_score": "0.062668",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INCY",
        "relevance_score": "0.207216",
        "ticker_sentiment_score": "0.114321",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.28696",
        "ticker_sentiment_score": "0.029806",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.166455",
        "ticker_sentiment_score": "0.021049",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Its blockbuster cystic fibrosis treatment costs $300,000 a year. Now Vertex wants to solve the opioid crisis",
    "url": "https://www.ft.com/content/39ed9ca1-e49b-48cd-ac6d-acb4b9744432",
    "time_published": "20240426T090005",
    "authors": [
      "Oliver Barnes"
    ],
    "summary": "With revenues having more than doubled since 2019, to $10bn, US pharma group targets painkillers ...",
    "banner_image": "https://www.ft.com/__origami/service/image/v2/images/raw/https%3A%2F%2Fwww.ft.com%2F__origami%2Fservice%2Fimage%2Fv2%2Fimages%2Fraw%2Fhttps%253A%252F%252Fd1e00ek4ebabms.cloudfront.net%252Fproduction%252F6fe29dd5-29b2-4955-b741-c1f4b9ced8e9.jpg%3Fsource%3Dnext-article%26fit%3Dscale-down%26quality%3Dhighest%26width%3D700%26dpr%3D1?source=next&fit=scale-down&dpr=2&width=240",
    "source": "Financial Times",
    "category_within_source": "Companies",
    "source_domain": "www.ft.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.079686,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JHG",
        "relevance_score": "0.03804",
        "ticker_sentiment_score": "0.0197",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.03804",
        "ticker_sentiment_score": "0.127454",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.03804",
        "ticker_sentiment_score": "0.129687",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALPN",
        "relevance_score": "0.03804",
        "ticker_sentiment_score": "0.121825",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLC Investigates MODN, AIRC, INRD, ALPN - Apartment Income REIT  ( NYSE:AIRC ) , Alpine Immune Sciences  ( NASDAQ:ALPN ) ",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38476366/shareholder-investigation-notice-halper-sadeh-llc-investigates-modn-airc-inrd-alpn",
    "time_published": "20240427T124724",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, April 27, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Model N, Inc.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.17125,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MODN",
        "relevance_score": "0.218817",
        "ticker_sentiment_score": "0.129245",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.110462",
        "ticker_sentiment_score": "0.092032",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INRD",
        "relevance_score": "0.110462",
        "ticker_sentiment_score": "0.142808",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BX",
        "relevance_score": "0.110462",
        "ticker_sentiment_score": "0.163837",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AIRC",
        "relevance_score": "0.110462",
        "ticker_sentiment_score": "0.163837",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALPN",
        "relevance_score": "0.110462",
        "ticker_sentiment_score": "0.092032",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Want $1 Million in Retirement? 3 Stocks to Buy Now And Hold for Decades.",
    "url": "https://www.fool.com/investing/2024/04/27/want-1-million-in-retirement-3-stocks-to-buy-now-a/",
    "time_published": "20240427T095000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "These three should have a lot of room to run.",
    "banner_image": "https://g.foolcdn.com/editorial/images/774142/young-woman-smiling-hands-behind-head.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      }
    ],
    "overall_sentiment_score": 0.24664,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MELI",
        "relevance_score": "0.288214",
        "ticker_sentiment_score": "0.105032",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.395012",
        "ticker_sentiment_score": "0.314561",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Top Growth Stocks to Buy Right Now and Hold Forever",
    "url": "https://www.fool.com/investing/2024/04/28/2-top-growth-stocks-to-buy-now-and-hold-forever/",
    "time_published": "20240428T124500",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "These healthcare stocks can provide enviable long-term portfolio growth.",
    "banner_image": "https://g.foolcdn.com/editorial/images/773907/getty-couple-happy-in-kitchen.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.989041"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.318166,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.043738",
        "ticker_sentiment_score": "0.142649",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.087344",
        "ticker_sentiment_score": "0.23405",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.043738",
        "ticker_sentiment_score": "0.195492",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.043738",
        "ticker_sentiment_score": "0.184503",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALPN",
        "relevance_score": "0.043738",
        "ticker_sentiment_score": "0.077297",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.216087",
        "ticker_sentiment_score": "0.249471",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( VRTX )  Earnings Expected to Grow: Should You Buy?",
    "url": "https://www.zacks.com/stock/news/2264206/vertex-pharmaceuticals-vrtx-earnings-expected-to-grow-should-you-buy",
    "time_published": "20240429T140031",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default272.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.130996,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.087663",
        "ticker_sentiment_score": "0.1249",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex  ( VRTX )  to Report Q1 Earnings: What's in the Cards?",
    "url": "https://www.zacks.com/stock/news/2264633/vertex-vrtx-to-report-q1-earnings-whats-in-the-cards",
    "time_published": "20240430T093600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex's (VRTX) revenues in the first quarter of 2024 are likely to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/29/1920.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.997845"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.078146,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ALNY",
        "relevance_score": "0.123104",
        "ticker_sentiment_score": "-0.019889",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.320453",
        "ticker_sentiment_score": "0.036627",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALPN",
        "relevance_score": "0.123104",
        "ticker_sentiment_score": "0.067103",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Will Arcus Biosciences, Inc.  ( RCUS )  Report Negative Earnings Next Week? What You Should Know",
    "url": "https://www.zacks.com/stock/news/2266039/will-arcus-biosciences-inc-rcus-report-negative-earnings-next-week-what-you-should-know",
    "time_published": "20240501T140133",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Arcus Biosciences (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default23.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.121821,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.087663",
        "ticker_sentiment_score": "0.039084",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RCUS",
        "relevance_score": "0.258808",
        "ticker_sentiment_score": "0.009978",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Unveiling Vertex  ( VRTX )  Q1 Outlook: Wall Street Estimates for Key Metrics",
    "url": "https://www.zacks.com/stock/news/2265824/unveiling-vertex-vrtx-q1-outlook-wall-street-estimates-for-key-metrics",
    "time_published": "20240501T131519",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Besides Wall Street's top -and-bottom-line estimates for Vertex (VRTX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default274.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.947132"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.176713,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.209365",
        "ticker_sentiment_score": "0.156853",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals Incorporated  ( VRTX )  Is a Trending Stock: Facts to Know Before Betting on It",
    "url": "https://www.zacks.com/stock/news/2265779/vertex-pharmaceuticals-incorporated-vrtx-is-a-trending-stock-facts-to-know-before-betting-on-it",
    "time_published": "20240501T130012",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default301.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.228679,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.103331",
        "ticker_sentiment_score": "0.036336",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( VRTX )  Stock Falls Amid Market Uptick: What Investors Need to Know",
    "url": "https://www.zacks.com/stock/news/2267448/vertex-pharmaceuticals-vrtx-stock-falls-amid-market-uptick-what-investors-need-to-know",
    "time_published": "20240502T215009",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $400.16, representing a -0.49% change from its previous close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default152.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.176238,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.571686",
        "ticker_sentiment_score": "0.299555",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 10 Years - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/insights/news/24/05/38590361/heres-how-much-you-would-have-made-owning-vertex-pharmaceuticals-stock-in-the-last-10-years",
    "time_published": "20240502T160022",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 9.66% on an annualized basis producing an average annual return of 19.99%. Currently, Vertex Pharmaceuticals has a market capitalization of $105.03 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.238974,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.9545",
        "ticker_sentiment_score": "0.384186",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Moderna  ( MRNA )  Q1 Earnings Beat Estimates, Revenues Down Y/Y",
    "url": "https://www.zacks.com/stock/news/2267310/moderna-mrna-q1-earnings-beat-estimates-revenues-down-yy",
    "time_published": "20240502T151400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Moderna (MRNA) beats expectations for both earnings and sales. Management reiterates guidance to record around $4 billion from product sales in 2024.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/db/3160.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.9996"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": -0.021493,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.041251",
        "ticker_sentiment_score": "-0.00098",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ANIP",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "0.128692",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LGND",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "0.177286",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.49868",
        "ticker_sentiment_score": "-0.076448",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.041251",
        "ticker_sentiment_score": "0.011917",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Biotech Stocks to Buy and Hold Through 2030 and Beyond",
    "url": "https://www.fool.com/investing/2024/05/02/3-biotech-stocks-to-buy-and-hold-through-2030-and/",
    "time_published": "20240502T111500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "It pays to develop novel medicines for life-threatening illnesses.",
    "banner_image": "https://media.ycharts.com/charts/f4c4dd8f935eb3a2754dff70e48b97f7.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.291164,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "REGN",
        "relevance_score": "0.105836",
        "ticker_sentiment_score": "0.079944",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.053035",
        "ticker_sentiment_score": "0.050961",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.260559",
        "ticker_sentiment_score": "0.253054",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Disney, Ferrari Highlight A Week Of Fast-Moving Stocks",
    "url": "https://www.investors.com/news/week-of-fast-moving-stocks-ahead/",
    "time_published": "20240503T215800",
    "authors": [
      "ALAN R. ELLIOTT",
      "Investor's Business Daily"
    ],
    "summary": "Stock Market: Ferrari Leads Fast-Moving Stocks Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/11/stock-Ferrari-01-company.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.142857"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999995"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.142857"
      }
    ],
    "overall_sentiment_score": 0.206765,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ARES",
        "relevance_score": "0.067536",
        "ticker_sentiment_score": "0.066511",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.101154",
        "ticker_sentiment_score": "0.071731",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ANET",
        "relevance_score": "0.067536",
        "ticker_sentiment_score": "0.095366",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ATKR",
        "relevance_score": "0.067536",
        "ticker_sentiment_score": "0.103268",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CEG",
        "relevance_score": "0.13459",
        "ticker_sentiment_score": "0.125758",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TTD",
        "relevance_score": "0.067536",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.033799",
        "ticker_sentiment_score": "0.095779",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.033799",
        "ticker_sentiment_score": "0.098134",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CROX",
        "relevance_score": "0.067536",
        "ticker_sentiment_score": "-0.058209",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NBIX",
        "relevance_score": "0.067536",
        "ticker_sentiment_score": "0.066511",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.067536",
        "ticker_sentiment_score": "0.135414",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ACM",
        "relevance_score": "0.067536",
        "ticker_sentiment_score": "0.103268",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SHOP",
        "relevance_score": "0.101154",
        "ticker_sentiment_score": "0.118429",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OXY",
        "relevance_score": "0.13459",
        "ticker_sentiment_score": "0.12413",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FANG",
        "relevance_score": "0.067536",
        "ticker_sentiment_score": "0.1026",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PHM",
        "relevance_score": "0.101154",
        "ticker_sentiment_score": "0.071731",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ANF",
        "relevance_score": "0.067536",
        "ticker_sentiment_score": "0.066511",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARM",
        "relevance_score": "0.067536",
        "ticker_sentiment_score": "0.064133",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HUBS",
        "relevance_score": "0.101154",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HMC",
        "relevance_score": "0.033799",
        "ticker_sentiment_score": "0.178727",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Shhh! 3 Secret Pharma Stocks Flying Below Wall Street's Radar",
    "url": "https://markets.businessinsider.com/news/stocks/shhh-3-secret-pharma-stocks-flying-below-wall-streets-radar-1033325813",
    "time_published": "20240503T101500",
    "authors": [
      "Matthew Farley"
    ],
    "summary": "Pharma stocks and massive potential go hand in hand. With devastating diseases like cancer, diabetes and heart disease still far from finding a cure, drugs that treat these conditions often command exorbitant prices.",
    "banner_image": "https://investorplace.com/wp-content/uploads/2020/03/regeneron_regn1600-300x169.jpg",
    "source": "Business Insider",
    "category_within_source": "GoogleRSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.2077,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MRNA",
        "relevance_score": "0.290952",
        "ticker_sentiment_score": "0.045164",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.234684",
        "ticker_sentiment_score": "0.104411",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.17715",
        "ticker_sentiment_score": "0.168325",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 No-Brainer Stocks to Buy in May",
    "url": "https://www.fool.com/investing/2024/05/05/3-no-brainer-stocks-to-buy-in-may/",
    "time_published": "20240505T105500",
    "authors": [
      "Keith Speights",
      "David Jagielski",
      "and Prosper Junior Bakiny"
    ],
    "summary": "These great stocks are great picks for investors as spring winds down.",
    "banner_image": "https://g.foolcdn.com/editorial/images/775632/person-pleasantly-surprised-with-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999976"
      }
    ],
    "overall_sentiment_score": 0.30299,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.271489",
        "ticker_sentiment_score": "0.364937",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.157227",
        "ticker_sentiment_score": "0.036643",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.195814",
        "ticker_sentiment_score": "0.039621",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALPN",
        "relevance_score": "0.039548",
        "ticker_sentiment_score": "-0.014494",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNXYF",
        "relevance_score": "0.039548",
        "ticker_sentiment_score": "0.020745",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( NASDAQ:VRTX )  Stock Rating Upgraded by StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/05/vertex-pharmaceuticals-nasdaqvrtx-stock-rating-upgraded-by-stocknews-com.html",
    "time_published": "20240505T094659",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Vertex Pharmaceuticals ( NASDAQ:VRTX - Get Free Report ) was upgraded by equities researchers at StockNews.com from a \"buy\" rating to a \"strong-buy\" rating in a research report issued to clients and investors on Friday.",
    "banner_image": "https://www.marketbeat.com/logos/vertex-pharmaceuticals-incorporated-logo-1200x675.png?v=20231228113929",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99999"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.947132"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.305556,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EVR",
        "relevance_score": "0.046816",
        "ticker_sentiment_score": "0.041491",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.857817",
        "ticker_sentiment_score": "0.500624",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CCORF",
        "relevance_score": "0.046816",
        "ticker_sentiment_score": "0.041491",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.046816",
        "ticker_sentiment_score": "0.041491",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals Shines in the First Quarter",
    "url": "https://www.fool.com/data-news/2024/05/06/vertex-shines-in-q1-earnings/",
    "time_published": "20240506T221913",
    "authors": [
      "JesterAI"
    ],
    "summary": "The cystic fibrosis leader reported higher-than-expected earnings and revenue.",
    "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.98396"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.125898,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.199859",
        "ticker_sentiment_score": "-0.053739",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALPN",
        "relevance_score": "0.100729",
        "ticker_sentiment_score": "-0.022594",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( VRTX )  Q1 Earnings and Revenues Top Estimates",
    "url": "https://www.zacks.com/stock/news/2269069/vertex-pharmaceuticals-vrtx-q1-earnings-and-revenues-top-estimates",
    "time_published": "20240506T211004",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex (VRTX) delivered earnings and revenue surprises of 16.10% and 5.15%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default95.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999992"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.148433,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.139265",
        "ticker_sentiment_score": "0.096077",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TELA",
        "relevance_score": "0.207571",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Stock Flat On Reiterated Outlook Despite First-Quarter Beat",
    "url": "https://www.investors.com/news/technology/vertex-stock-vertex-pharmaceuticals-earnings-q1-2024/",
    "time_published": "20240506T201500",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "Late Monday, Vertex stock was flat after the company reported adjusted earnings of $4.76 per share on $2.69 billion in first-quarter sales. On average, analysts polled by FactSet expected Vertex Pharmaceuticals ( VRTX ) to earn $4.08 per share and report $2.58 billion in sales.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/11/Stock-vertex-01-company.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.875462"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.291443,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.358152",
        "ticker_sentiment_score": "0.264215",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.183895",
        "ticker_sentiment_score": "0.464557",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BNTX",
        "relevance_score": "0.183895",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "NEW ENGLAND PATRIOTS QUARTERBACK DRAKE MAYE NAMED HONORARY CHAIR OF 25TH ANNIVERSARY BEST BUDDIES CHALLENGE: HYANNIS PORT PRESENTED BY JERSEY MIKE'S SUBS, SHAW'S AND STAR MARKET FOUNDATION AND THE TJX COMPANIES, INC.",
    "url": "https://www.prnewswire.com/news-releases/new-england-patriots-quarterback-drake-maye-named-honorary-chair-of-25th-anniversary-best-buddies-challenge-hyannis-port-presented-by-jersey-mikes-subs-shaws-and-star-market-foundation-and-the-tjx-companies-inc-302136982.html",
    "time_published": "20240506T165000",
    "authors": [
      "Best Buddies International"
    ],
    "summary": "NEW ENGLAND PATRIOTS QUARTERBACK DRAKE MAYE NAMED HONORARY CHAIR OF 25TH ANNIVERSARY ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/90018/best_buddies_international_logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.568194,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.04583",
        "ticker_sentiment_score": "0.132303",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TJX",
        "relevance_score": "0.091509",
        "ticker_sentiment_score": "0.233123",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.04583",
        "ticker_sentiment_score": "0.132303",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.04583",
        "ticker_sentiment_score": "0.132303",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.04583",
        "ticker_sentiment_score": "0.132303",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NOW",
        "relevance_score": "0.04583",
        "ticker_sentiment_score": "0.132303",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "NEW ENGLAND PATRIOTS QUARTERBACK DRAKE MAYE NAMED HONORARY CHAIR OF 25TH ANNIVERSARY BEST BUDDIES CHALLENGE: HYANNIS PORT PRESENTED BY JERSEY MIKE'S SUBS, SHAW'S AND STAR MARKET FOUNDATION AND THE TJX COMPANIES, INC.",
    "url": "https://www.benzinga.com/pressreleases/24/05/n38649098/new-england-patriots-quarterback-drake-maye-named-honorary-chair-of-25th-anniversary-best-buddies-",
    "time_published": "20240506T165000",
    "authors": [
      "PRNewswire"
    ],
    "summary": "BOSTON, May 6, 2024 /PRNewswire/ -- Best Buddies International, a nonprofit dedicated to creating opportunities for one-to-one friendships, integrated employment, leadership development, inclusive living, and family support for people with intellectual and developmental disabilities ( IDD ) , is ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.560305,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.043738",
        "ticker_sentiment_score": "0.130725",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TJX",
        "relevance_score": "0.087344",
        "ticker_sentiment_score": "0.22779",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.043738",
        "ticker_sentiment_score": "0.130725",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.043738",
        "ticker_sentiment_score": "0.130725",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.043738",
        "ticker_sentiment_score": "0.130725",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NOW",
        "relevance_score": "0.043738",
        "ticker_sentiment_score": "0.130725",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "CRISPR  ( CRSP )  to Report Q1 Earnings: What's in the Cards?",
    "url": "https://www.zacks.com/stock/news/2268986/crispr-crsp-to-report-q1-earnings-whats-in-the-cards",
    "time_published": "20240506T164300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "On CRISPR Therapeutics' (CRSP) first-quarter 2024 earnings call, investors' focus is likely to be on the updates related to the first sales numbers of its newly approved gene therapy, Casgevy.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/612.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999855"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.205165,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.122581",
        "ticker_sentiment_score": "0.18688",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ANIP",
        "relevance_score": "0.30021",
        "ticker_sentiment_score": "0.256224",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSVT",
        "relevance_score": "0.30021",
        "ticker_sentiment_score": "0.166481",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Smart Money Is Betting Big In VRTX Options - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/insights/options/24/05/38648258/smart-money-is-betting-big-in-vrtx-options",
    "time_published": "20240506T161550",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bullish stance on Vertex Pharmaceuticals VRTX. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.129526,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CCORF",
        "relevance_score": "0.068502",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EVR",
        "relevance_score": "0.068502",
        "ticker_sentiment_score": "0.143562",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.771193",
        "ticker_sentiment_score": "0.164186",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "5 Biotech Stocks Worth Adding to Your Portfolio in 2024",
    "url": "https://www.zacks.com/commentary/2268804/5-biotech-stocks-worth-adding-to-your-portfolio-in-2024",
    "time_published": "20240506T135000",
    "authors": [
      "Ekta Bagri"
    ],
    "summary": "New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position BMRN, BPMC, IMVT, KYMR and LGND well amid volatility.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default304.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.200397,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "IMVT",
        "relevance_score": "0.122394",
        "ticker_sentiment_score": "0.133011",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KYMR",
        "relevance_score": "0.04912",
        "ticker_sentiment_score": "0.100637",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LGND",
        "relevance_score": "0.098054",
        "ticker_sentiment_score": "0.122431",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMRN",
        "relevance_score": "0.04912",
        "ticker_sentiment_score": "0.100637",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.024572",
        "ticker_sentiment_score": "0.059273",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BPMC",
        "relevance_score": "0.073622",
        "ticker_sentiment_score": "0.115727",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.024572",
        "ticker_sentiment_score": "0.059273",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.024572",
        "ticker_sentiment_score": "0.109979",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Apple, Berkshire Hathaway, Perficient, Vistra, Li Auto, Micron, Palantir, and More Stock Market Movers",
    "url": "https://www.barrons.com/amp/articles/stock-market-movers-6056c5fd",
    "time_published": "20240506T082100",
    "authors": [
      "Joe Woelfel"
    ],
    "summary": "Apple, Berkshire Hathaway, Perficient, Vistra, Luminar, Palantir, and More Market Movers ...",
    "banner_image": "https://images.barrons.com/im-770273/social",
    "source": "Barrons",
    "category_within_source": "n/a",
    "source_domain": "www.barrons.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999186"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.219892,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ANET",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GETY",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DDOG",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IFF",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABNB",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPG",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LAZR",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "-0.10162",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNTX",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SHOP",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OXY",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DOCN",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RBLX",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EA",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PLTR",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NWSAL",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "0.134502",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSN",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LCID",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VST",
        "relevance_score": "0.156461",
        "ticker_sentiment_score": "0.126302",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "0.098412",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ENB",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARM",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LI",
        "relevance_score": "0.156461",
        "ticker_sentiment_score": "0.096232",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AFRM",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex's  ( VRTX )  Q1 Earnings Beat, Trikafta Drives Sales",
    "url": "https://www.zacks.com/stock/news/2269625/vertexs-vrtx-q1-earnings-beat-trikafta-drives-sales",
    "time_published": "20240507T134400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex's (VRTX) first-quarter earnings and revenues surpass estimates. Higher sales of Trikafta/Kaftrio in U.S. and ex-U.S. markets drive the top line.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/2633.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.994953"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.15819,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.130041",
        "ticker_sentiment_score": "-0.002446",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LGND",
        "relevance_score": "0.193982",
        "ticker_sentiment_score": "0.278238",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALPN",
        "relevance_score": "0.065238",
        "ticker_sentiment_score": "0.079177",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update",
    "url": "https://www.globenewswire.com/news-release/2024/05/07/2876568/0/en/Prelude-Therapeutics-Reports-First-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html",
    "time_published": "20240507T110100",
    "authors": [
      "Prelude Therapeutics",
      "Inc."
    ],
    "summary": "First-in-class IV SMARCA2 degrader, PRT3789 and potentially best-in-class CDK9 inhibitor, PRT2527 remain on track to generate initial proof-of-concept data in ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/cab62748-b61a-42cb-b552-b0c6c91c4e83",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.0857,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.023079",
        "ticker_sentiment_score": "0.031681",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PRDS",
        "relevance_score": "0.023079",
        "ticker_sentiment_score": "0.031681",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ACRS",
        "relevance_score": "0.046139",
        "ticker_sentiment_score": "0.017897",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.023079",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PRLD",
        "relevance_score": "0.092124",
        "ticker_sentiment_score": "-0.056148",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand",
    "url": "https://www.zacks.com/stock/news/2269243/zacks-industry-outlook-highlights-biomarin-blueprint-medicines-immunovant-kymera-and-ligand",
    "time_published": "20240507T104000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand have been highlighted in this Industry Outlook article.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/37/2337.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.996023"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.202635,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "IMVT",
        "relevance_score": "0.157631",
        "ticker_sentiment_score": "0.066854",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KYMR",
        "relevance_score": "0.067919",
        "ticker_sentiment_score": "0.046236",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LGND",
        "relevance_score": "0.112956",
        "ticker_sentiment_score": "0.047676",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALPN",
        "relevance_score": "0.022664",
        "ticker_sentiment_score": "0.046768",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMRN",
        "relevance_score": "0.067919",
        "ticker_sentiment_score": "0.046236",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.022664",
        "ticker_sentiment_score": "0.046768",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BPMC",
        "relevance_score": "0.090474",
        "ticker_sentiment_score": "0.127463",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.022664",
        "ticker_sentiment_score": "0.046768",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.022664",
        "ticker_sentiment_score": "0.010574",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( VRTX )  Q1 2024 Earnings Call Transcript",
    "url": "https://www.fool.com/earnings/call-transcripts/2024/05/06/vertex-pharmaceuticals-vrtx-q1-2024-earnings-call/",
    "time_published": "20240507T004515",
    "authors": [
      "Motley Fool Transcribing"
    ],
    "summary": "VRTX earnings call for the period ending March 31, 2024.",
    "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.213119,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EVR",
        "relevance_score": "0.004698",
        "ticker_sentiment_score": "0.161696",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.004698",
        "ticker_sentiment_score": "0.062529",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.004698",
        "ticker_sentiment_score": "0.129792",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALPN",
        "relevance_score": "0.028182",
        "ticker_sentiment_score": "0.116481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.004698",
        "ticker_sentiment_score": "0.139438",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.004698",
        "ticker_sentiment_score": "0.129792",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.004698",
        "ticker_sentiment_score": "-0.003021",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Futures: Robinhood, Arm Lead Earnings Movers Late",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-sp-500-toast-robinhood-arm-earnings-movers-late/",
    "time_published": "20240508T210800",
    "authors": [
      "ED CARSON",
      "Investor's Business Daily"
    ],
    "summary": "Dow Jones Futures: S&P 500 Holds, Toast Leads 5 New Buys. Robinhood, Arm Are Earnings Movers Late Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2020/09/Stock-BullHead-91-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999858"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.104959,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "APP",
        "relevance_score": "0.214665",
        "ticker_sentiment_score": "0.038085",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.273807",
        "ticker_sentiment_score": "0.072545",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ANET",
        "relevance_score": "0.092927",
        "ticker_sentiment_score": "0.128116",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CEG",
        "relevance_score": "0.031038",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TTD",
        "relevance_score": "0.184598",
        "ticker_sentiment_score": "0.106175",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.092927",
        "ticker_sentiment_score": "0.029209",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABNB",
        "relevance_score": "0.154257",
        "ticker_sentiment_score": "-0.089552",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DUOL",
        "relevance_score": "0.184598",
        "ticker_sentiment_score": "0.023099",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NTAP",
        "relevance_score": "0.123685",
        "ticker_sentiment_score": "0.078996",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NTNX",
        "relevance_score": "0.154257",
        "ticker_sentiment_score": "-0.059255",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TOST",
        "relevance_score": "0.244415",
        "ticker_sentiment_score": "-0.016906",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARM",
        "relevance_score": "0.092927",
        "ticker_sentiment_score": "0.012852",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HOOD",
        "relevance_score": "0.154257",
        "ticker_sentiment_score": "0.062716",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CART",
        "relevance_score": "0.092927",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "A Closer Look at Vertex Pharmaceuticals's Options Market Dynamics - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/insights/options/24/05/38710625/a-closer-look-at-vertex-pharmaceuticalss-options-market-dynamics",
    "time_published": "20240508T184546",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Financial giants have made a conspicuous bullish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex Pharmaceuticals VRTX revealed 8 unusual trades. Delving into the details, we found 50% of traders were bullish, while 0% showed bearish tendencies.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.163208,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CCORF",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EVR",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.268407",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.648497",
        "ticker_sentiment_score": "0.117582",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "5 Reasons Vertex Pharmaceuticals Is a Screaming Buy on the Dip",
    "url": "https://www.fool.com/investing/2024/05/08/5-reasons-vertex-pharmaceuticals-is-a-screaming-bu/",
    "time_published": "20240508T094300",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "New drugs in development and a lack of significant patent cliffs ahead make this a great pharma stock to buy now and hold over the long run.",
    "banner_image": "https://g.foolcdn.com/editorial/images/776190/investment-advisor-with-client-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.157722,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.134339",
        "ticker_sentiment_score": "0.175194",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALPN",
        "relevance_score": "0.04497",
        "ticker_sentiment_score": "0.115179",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Editas  ( EDIT )  Q1 Earnings & Revenues Lag Estimates, Stock Down",
    "url": "https://www.zacks.com/stock/news/2271695/editas-edit-q1-earnings-revenues-lag-estimates-stock-down",
    "time_published": "20240509T164000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Editas (EDIT) reports weaker-than-expected first-quarter 2024 results as both earnings and revenues fall shy of estimates. Shares fall.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.857896"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.096735,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.105372",
        "ticker_sentiment_score": "0.033768",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EDIT",
        "relevance_score": "0.308891",
        "ticker_sentiment_score": "0.079911",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LGND",
        "relevance_score": "0.208914",
        "ticker_sentiment_score": "0.205866",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ENTX",
        "relevance_score": "0.157483",
        "ticker_sentiment_score": "0.083769",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "CRISPR's  ( CRSP )  Q1 Loss Narrower-Than-Expected, Sales Miss",
    "url": "https://www.zacks.com/stock/news/2271625/crisprs-crsp-q1-loss-narrower-than-expected-sales-miss",
    "time_published": "20240509T145800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "CRISPR Therapeutics (CRSP) reports mixed earnings results for first-quarter 2024. Management claims that the commercial launch for the first ever CRISPR-based gene therapy is progressing well.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.997874"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.147016,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.095707",
        "ticker_sentiment_score": "0.04355",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LGND",
        "relevance_score": "0.236281",
        "ticker_sentiment_score": "0.158454",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRSP",
        "relevance_score": "0.143131",
        "ticker_sentiment_score": "-0.005163",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.326129",
        "ticker_sentiment_score": "0.17536",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference - CRISPR Therapeutics  ( NASDAQ:CRSP ) ",
    "url": "https://www.benzinga.com/pressreleases/24/05/g38729788/crispr-therapeutics-to-present-at-the-bank-of-america-securities-health-care-conference",
    "time_published": "20240509T123000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "ZUG, Switzerland and BOSTON, May 09, 2024 ( GLOBE NEWSWIRE ) -- CRISPR Therapeutics CRSP, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the Bank of America ... ET.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.304501,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BAC",
        "relevance_score": "0.109455",
        "ticker_sentiment_score": "0.165031",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.109455",
        "ticker_sentiment_score": "0.159999",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRSP",
        "relevance_score": "0.21686",
        "ticker_sentiment_score": "0.241708",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Stock Market Moves Toward Highs: Weekly Review",
    "url": "https://www.investors.com/news/stock-market-moves-toward-highs-arista-toast-palantir-earnings/",
    "time_published": "20240510T142200",
    "authors": [
      "IBD STAFF",
      "Investor's Business Daily"
    ],
    "summary": "Stock Market Moves Toward Highs. Arista, Toast, Palantir Key Earnings Movers: Weekly Review Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2020/02/Stock-ClimbingUptrend-04-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.104196,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "APP",
        "relevance_score": "0.087824",
        "ticker_sentiment_score": "0.090412",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CELH",
        "relevance_score": "0.035189",
        "ticker_sentiment_score": "-0.055008",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.087824",
        "ticker_sentiment_score": "-0.040679",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ANET",
        "relevance_score": "0.07031",
        "ticker_sentiment_score": "0.089565",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ATKR",
        "relevance_score": "0.035189",
        "ticker_sentiment_score": "-0.050849",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FROG",
        "relevance_score": "0.035189",
        "ticker_sentiment_score": "0.069301",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TTD",
        "relevance_score": "0.035189",
        "ticker_sentiment_score": "-0.083749",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BLDR",
        "relevance_score": "0.07031",
        "ticker_sentiment_score": "0.015512",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CROX",
        "relevance_score": "0.052763",
        "ticker_sentiment_score": "-0.02111",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DDOG",
        "relevance_score": "0.035189",
        "ticker_sentiment_score": "-0.068927",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXON",
        "relevance_score": "0.035189",
        "ticker_sentiment_score": "0.027233",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RIVN",
        "relevance_score": "0.035189",
        "ticker_sentiment_score": "-0.12648",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.017599",
        "ticker_sentiment_score": "0.067401",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DUOL",
        "relevance_score": "0.07031",
        "ticker_sentiment_score": "0.112305",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MKSI",
        "relevance_score": "0.035189",
        "ticker_sentiment_score": "0.263266",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SHOP",
        "relevance_score": "0.035189",
        "ticker_sentiment_score": "-0.113179",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALAB",
        "relevance_score": "0.035189",
        "ticker_sentiment_score": "-0.001968",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRUS",
        "relevance_score": "0.035189",
        "ticker_sentiment_score": "0.263266",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.035189",
        "ticker_sentiment_score": "-0.3053",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "GFS",
        "relevance_score": "0.035189",
        "ticker_sentiment_score": "0.263266",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IBP",
        "relevance_score": "0.035189",
        "ticker_sentiment_score": "-0.050849",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TDG",
        "relevance_score": "0.035189",
        "ticker_sentiment_score": "0.157851",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AOSL",
        "relevance_score": "0.035189",
        "ticker_sentiment_score": "0.263266",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SN",
        "relevance_score": "0.035189",
        "ticker_sentiment_score": "0.153917",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.052763",
        "ticker_sentiment_score": "0.030152",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CLSK",
        "relevance_score": "0.035189",
        "ticker_sentiment_score": "0.060124",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HMC",
        "relevance_score": "0.052763",
        "ticker_sentiment_score": "0.108055",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PLTR",
        "relevance_score": "0.07031",
        "ticker_sentiment_score": "0.042564",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BABA",
        "relevance_score": "0.035189",
        "ticker_sentiment_score": "0.030338",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MARA",
        "relevance_score": "0.052763",
        "ticker_sentiment_score": "0.06199",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.017599",
        "ticker_sentiment_score": "0.08014",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.035189",
        "ticker_sentiment_score": "0.002956",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CEG",
        "relevance_score": "0.052763",
        "ticker_sentiment_score": "0.003004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.035189",
        "ticker_sentiment_score": "0.002956",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.035189",
        "ticker_sentiment_score": "0.098259",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SITM",
        "relevance_score": "0.035189",
        "ticker_sentiment_score": "0.263266",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LCID",
        "relevance_score": "0.052763",
        "ticker_sentiment_score": "-0.13162",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VECO",
        "relevance_score": "0.035189",
        "ticker_sentiment_score": "0.263266",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "POWI",
        "relevance_score": "0.035189",
        "ticker_sentiment_score": "0.263266",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VST",
        "relevance_score": "0.052763",
        "ticker_sentiment_score": "0.003004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CPNG",
        "relevance_score": "0.052763",
        "ticker_sentiment_score": "0.031006",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GCT",
        "relevance_score": "0.035189",
        "ticker_sentiment_score": "0.038705",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TM",
        "relevance_score": "0.035189",
        "ticker_sentiment_score": "0.106263",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BLD",
        "relevance_score": "0.035189",
        "ticker_sentiment_score": "-0.050849",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TOST",
        "relevance_score": "0.087824",
        "ticker_sentiment_score": "0.061544",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARM",
        "relevance_score": "0.035189",
        "ticker_sentiment_score": "-0.001968",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HUBS",
        "relevance_score": "0.052763",
        "ticker_sentiment_score": "0.089",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:JPY",
        "relevance_score": "0.017599",
        "ticker_sentiment_score": "0.09934",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.017599",
        "ticker_sentiment_score": "0.055156",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( NASDAQ:VRTX )  Cut to \"Buy\" at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/11/vertex-pharmaceuticals-nasdaqvrtx-cut-to-buy-at-stocknews-com.html",
    "time_published": "20240511T072446",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Vertex Pharmaceuticals ( NASDAQ:VRTX - Get Free Report ) was downgraded by investment analysts at StockNews.com from a \"strong-buy\" rating to a \"buy\" rating in a research report issued to clients and investors on Saturday. Other research analysts also recently issued reports about the stock.",
    "banner_image": "https://www.marketbeat.com/logos/vertex-pharmaceuticals-incorporated-logo-1200x675.png?v=20231228113929",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.988787"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.272949,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.659096",
        "ticker_sentiment_score": "0.39944",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.042196",
        "ticker_sentiment_score": "0.028411",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RBCPF",
        "relevance_score": "0.042196",
        "ticker_sentiment_score": "0.028411",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CCORF",
        "relevance_score": "0.042196",
        "ticker_sentiment_score": "0.028411",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FROG",
        "relevance_score": "0.042196",
        "ticker_sentiment_score": "0.112724",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals Is Racing Towards a New Blockbuster: Why the Stock Is a Smart Buy",
    "url": "https://www.fool.com/investing/2024/05/12/vertex-pharmaceuticals-is-racing-towards-new-block/",
    "time_published": "20240512T184700",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The biotech's shares dropped following its latest quarterly update, but that shouldn't matter to long-term investors.",
    "banner_image": "https://g.foolcdn.com/editorial/images/776494/patient-taking-medicine.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.242658,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.612343",
        "ticker_sentiment_score": "0.392423",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "2 Unbelievable Growth Stocks You Can Buy and Hold for the Next Decade",
    "url": "https://www.fool.com/investing/2024/05/12/2-unbelievable-growth-stocks-you-can-buy-and-hold/",
    "time_published": "20240512T162000",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "These companies are raking in profits at astonishing clips.",
    "banner_image": "https://g.foolcdn.com/editorial/images/776335/getty-finger-on-lips-quiet-secret.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.905476"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.317788,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.083833",
        "ticker_sentiment_score": "0.212692",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ULTA",
        "relevance_score": "0.041975",
        "ticker_sentiment_score": "0.180845",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALPN",
        "relevance_score": "0.041975",
        "ticker_sentiment_score": "0.081767",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.041975",
        "ticker_sentiment_score": "0.180845",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Catalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating",
    "url": "https://www.investors.com/news/catalyst-pharmaceuticals-stock-clears-technical-benchmark-with-rs-rating/",
    "time_published": "20240514T191000",
    "authors": [
      "JULIE MAK",
      "Investor's Business Daily",
      "INVESTOR'S BUSINESS DAILY"
    ],
    "summary": "On Tuesday, Catalyst Pharmaceuticals ( CPRX ) stock hit an important technical milestone, with its Relative Strength ( RS ) Rating climbing into the 80-plus percentile with an improvement to 83, up from 79 the day before.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/05/IRU6.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      }
    ],
    "overall_sentiment_score": 0.292876,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.340915",
        "ticker_sentiment_score": "0.13703",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.174587",
        "ticker_sentiment_score": "0.191885",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CPRX",
        "relevance_score": "0.622414",
        "ticker_sentiment_score": "0.349357",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.340915",
        "ticker_sentiment_score": "0.13703",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.340915",
        "ticker_sentiment_score": "0.13703",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Is Writing A New Playbook For Pharma R&D. And It's Working.",
    "url": "https://www.forbes.com/sites/chasefeiger/2024/05/14/vertex-is-writing-a-new-playbook-for-pharma-rd-and-its-working/",
    "time_published": "20240514T152207",
    "authors": [
      "Chase Feiger",
      "M.D."
    ],
    "summary": "Vertex Pharmaceuticals ( NDAQ: VRTX ) stands today as a top 20 pharma company with over a $100 billion market cap. But this biotech beacon has ridden a bumpy path to its current perch and, along the way, just may have authored a new playbook for life sciences R&D.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/66325f3276cdd5e83f3fb6b3/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.257765,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.066722",
        "ticker_sentiment_score": "0.043156",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.04451",
        "ticker_sentiment_score": "0.138607",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Healthcare Stocks to Buy and Hold for Great Long-Term Potential",
    "url": "https://www.fool.com/investing/2024/05/14/2-healthcare-stocks-to-buy-and-hold-for-great-long/",
    "time_published": "20240514T140700",
    "authors": [
      "Ryan Downie"
    ],
    "summary": "These healthcare stocks offer completely different approaches to long-term investment gains.",
    "banner_image": "https://media.ycharts.com/charts/41fe7f8757dd942e0f256a54810d6229.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.990893"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.230964,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.213936",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.270373",
        "ticker_sentiment_score": "0.150748",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 10 Years - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/insights/news/24/05/38818068/heres-how-much-you-would-have-made-owning-vertex-pharmaceuticals-stock-in-the-last-10-years",
    "time_published": "20240514T140041",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 9.86% on an annualized basis producing an average annual return of 20.63%. Currently, Vertex Pharmaceuticals has a market capitalization of $110.28 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.238974,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.9545",
        "ticker_sentiment_score": "0.384186",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Here's Why Vertex Pharmaceuticals  ( VRTX )  is a Strong Growth Stock",
    "url": "https://www.zacks.com/stock/news/2273506/heres-why-vertex-pharmaceuticals-vrtx-is-a-strong-growth-stock",
    "time_published": "20240514T134508",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default297.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.361406,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.62523",
        "ticker_sentiment_score": "0.43077",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Innoviva Shows Rising Relative Price Performance; Still Shy Of Key Benchmark",
    "url": "https://www.investors.com/ibd-data-stories/innoviva-shows-rising-relative-price-performance-still-shy-of-key-benchmark/",
    "time_published": "20240514T070000",
    "authors": [
      "Investor's Business Daily",
      "INVESTOR'S BUSINESS DAILY"
    ],
    "summary": "Innoviva Shows Rising Relative Price Performance. Still Shy Of Key Benchmark Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.287796,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.355588",
        "ticker_sentiment_score": "0.141497",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INVA",
        "relevance_score": "0.644033",
        "ticker_sentiment_score": "0.38355",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.355588",
        "ticker_sentiment_score": "0.141497",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.355588",
        "ticker_sentiment_score": "0.141497",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stocks With Rising Relative Price Strength: Catalyst Pharmaceuticals",
    "url": "https://www.investors.com/ibd-data-stories/stocks-with-rising-relative-price-strength-catalyst-pharmaceuticals/",
    "time_published": "20240514T070000",
    "authors": [
      "Investor's Business Daily",
      "INVESTOR'S BUSINESS DAILY"
    ],
    "summary": "On Tuesday, Catalyst Pharmaceuticals ( CPRX ) hit an important technical milestone, with its Relative Strength ( RS ) Rating climbing into the 80-plus percentile with an improvement to 83, up from 79 the day before.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      }
    ],
    "overall_sentiment_score": 0.329589,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.343279",
        "ticker_sentiment_score": "0.137758",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.175859",
        "ticker_sentiment_score": "0.187219",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CPRX",
        "relevance_score": "0.495015",
        "ticker_sentiment_score": "0.392375",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.343279",
        "ticker_sentiment_score": "0.137758",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.343279",
        "ticker_sentiment_score": "0.137758",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stocks To Watch: Moderna Sees Relative Strength Rating Rise To 92",
    "url": "https://www.investors.com/ibd-data-stories/stocks-to-watch-moderna-sees-relative-strength-rating-rise-to-92/",
    "time_published": "20240514T070000",
    "authors": [
      "Investor's Business Daily",
      "INVESTOR'S BUSINESS DAILY"
    ],
    "summary": "On Tuesday, Moderna ( MRNA ) cleared a noteworthy performance benchmark, with its Relative Strength ( RS ) Rating climbing into the 90-plus percentile with an upgrade to 92, a rise from 89 the day before.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      }
    ],
    "overall_sentiment_score": 0.316459,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.331765",
        "ticker_sentiment_score": "0.138781",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.608634",
        "ticker_sentiment_score": "0.40665",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.331765",
        "ticker_sentiment_score": "0.138781",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.331765",
        "ticker_sentiment_score": "0.138781",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Stock Hit All-Time High, Paused, And Is Rising Again",
    "url": "https://www.investors.com/news/technology/stocks-with-rising-relative-strength-vertex-pharmaceuticals-3/",
    "time_published": "20240514T070000",
    "authors": [
      "JAMES DETAR",
      "Investor's Business Daily",
      "INVESTOR'S BUSINESS DAILY"
    ],
    "summary": "Vertex Stock Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2020/08/Stock-medicaloffice-01-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999365"
      }
    ],
    "overall_sentiment_score": 0.357576,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.228431",
        "ticker_sentiment_score": "0.310257",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.15347",
        "ticker_sentiment_score": "0.208804",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals's Options Frenzy: What You Need to Know - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/insights/options/24/05/38857935/vertex-pharmaceuticalss-options-frenzy-what-you-need-to-know",
    "time_published": "20240515T203123",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Whales with a lot of money to spend have taken a noticeably bearish stance on Vertex Pharmaceuticals. Looking at options history for Vertex Pharmaceuticals VRTX we detected 15 trades.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.104829,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.664882",
        "ticker_sentiment_score": "0.01871",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is CRISPR Stock Going to $95? 1 Wall Street Analyst Thinks So.",
    "url": "https://www.fool.com/investing/2024/05/15/wall-street-analyst-says-crispr-stock-going-to-95/",
    "time_published": "20240515T151100",
    "authors": [
      "Rich Smith"
    ],
    "summary": "How much would you pay for a stock that might earn $25 a year in six years?",
    "banner_image": "https://g.foolcdn.com/editorial/images/777237/dna.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.065229,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.213988",
        "ticker_sentiment_score": "-0.015059",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pfizer, Freeport-McMoRan, Vertex Pharmaceuticals And A Major Tech Stock On CNBC's 'Final Trades' - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/news/24/05/38843826/pfizer-freeport-mcmoran-vertex-pharmaceuticals-and-a-major-tech-stock-on-cnbcs-final-trades",
    "time_published": "20240515T130722",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "On CNBC's \"Halftime Report Final Trades,\" Joshua Brown of Ritholtz Wealth Management said under $30, Pfizer Inc. PFE is a gift. Pfizer is looking to build on the success of its COVID-19 vaccine rollout by introducing a direct-to-consumer medicines platform under the brand \"Pfizer for All.\"",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/15/Pfizer-shutterstock2.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.212647,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.573213",
        "ticker_sentiment_score": "0.462329",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "FCX",
        "relevance_score": "0.448842",
        "ticker_sentiment_score": "0.273108",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "QCOM",
        "relevance_score": "0.573213",
        "ticker_sentiment_score": "0.19728",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.679474",
        "ticker_sentiment_score": "0.481826",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update",
    "url": "https://www.globenewswire.com/news-release/2024/05/15/2882409/0/en/Third-Harmonic-Bio-Announces-First-Quarter-2024-Financial-Results-and-Provides-Business-Update.html",
    "time_published": "20240515T120500",
    "authors": [
      "Third Harmonic Bio"
    ],
    "summary": "U.S. FDA clears Investigational New Drug application for ...",
    "banner_image": "",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.136379,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GBIO",
        "relevance_score": "0.045482",
        "ticker_sentiment_score": "0.003954",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.045482",
        "ticker_sentiment_score": "0.037532",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "THRD",
        "relevance_score": "0.267804",
        "ticker_sentiment_score": "0.098403",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BLUE",
        "relevance_score": "0.02275",
        "ticker_sentiment_score": "0.003588",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KRON",
        "relevance_score": "0.02275",
        "ticker_sentiment_score": "0.061087",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vaxcyte Scores Relative Strength Rating Upgrade; Hits Key Benchmark",
    "url": "https://www.investors.com/ibd-data-stories/vaxcyte-scores-relative-strength-rating-upgrade-hits-key-benchmark/",
    "time_published": "20240515T070000",
    "authors": [
      "Investor's Business Daily",
      "INVESTOR'S BUSINESS DAILY"
    ],
    "summary": "Vaxcyte Scores Relative Strength Rating Upgrade. Hits Key Benchmark Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.29693,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PCVX",
        "relevance_score": "0.686739",
        "ticker_sentiment_score": "0.249705",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.38588",
        "ticker_sentiment_score": "0.155456",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.38588",
        "ticker_sentiment_score": "0.155456",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.38588",
        "ticker_sentiment_score": "0.155456",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "IBD Rating Upgrades: BridgeBio Pharma Flashes Improved Technical Strength",
    "url": "https://www.investors.com/ibd-data-stories/ibd-rating-upgrades-bridgebio-pharma-flashes-improved-technical-strength/",
    "time_published": "20240515T070000",
    "authors": [
      "Investor's Business Daily",
      "INVESTOR'S BUSINESS DAILY"
    ],
    "summary": "The Relative Strength ( RS ) Rating for BridgeBio Pharma ( BBIO ) moved into a higher percentile Wednesday, as it got a lift from 61 to 74. X IBD's proprietary RS Rating identifies technical performance by showing how a stock's price action over the last 52 weeks compares to that of the other ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.23413,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.358152",
        "ticker_sentiment_score": "0.142265",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BBIO",
        "relevance_score": "0.647749",
        "ticker_sentiment_score": "0.512723",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.358152",
        "ticker_sentiment_score": "0.142265",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.358152",
        "ticker_sentiment_score": "0.142265",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Biohaven Joins Rank Of Stocks With RS Ratings Over 90",
    "url": "https://www.investors.com/ibd-data-stories/biohaven-joins-rank-of-stocks-with-rs-ratings-over-90/",
    "time_published": "20240515T070000",
    "authors": [
      "Investor's Business Daily",
      "INVESTOR'S BUSINESS DAILY"
    ],
    "summary": "Biohaven ( BHVN ) saw a positive improvement to its Relative Strength ( RS ) Rating on Wednesday, rising from 90 to 93. X IBD's unique rating identifies market leadership with a 1 ( worst ) to 99 ( best ) score.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      }
    ],
    "overall_sentiment_score": 0.39648,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.345674",
        "ticker_sentiment_score": "0.143233",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BHVN",
        "relevance_score": "0.629492",
        "ticker_sentiment_score": "0.595034",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.345674",
        "ticker_sentiment_score": "0.143233",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.345674",
        "ticker_sentiment_score": "0.143233",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stocks With Rising Relative Strength: Syndax Pharmaceuticals",
    "url": "https://www.investors.com/ibd-data-stories/stocks-with-rising-relative-strength-syndax-pharmaceuticals-3/",
    "time_published": "20240515T070000",
    "authors": [
      "Investor's Business Daily",
      "INVESTOR'S BUSINESS DAILY"
    ],
    "summary": "In a welcome move, Syndax Pharmaceuticals ( SNDX ) saw its Relative Strength Rating improve from 61 to 72 on Wednesday. X IBD's proprietary rating tracks share price action with a 1 ( worst ) to 99 ( best ) score.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.41093,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.343279",
        "ticker_sentiment_score": "0.137758",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNDX",
        "relevance_score": "0.625937",
        "ticker_sentiment_score": "0.598442",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.175859",
        "ticker_sentiment_score": "0.155671",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.343279",
        "ticker_sentiment_score": "0.137758",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.343279",
        "ticker_sentiment_score": "0.137758",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Day One Biopharm Hits 80-Plus Relative Strength Rating Benchmark",
    "url": "https://www.investors.com/ibd-data-stories/day-one-biopharm-hits-80-plus-relative-strength-rating-benchmark/",
    "time_published": "20240515T070000",
    "authors": [
      "Investor's Business Daily",
      "INVESTOR'S BUSINESS DAILY"
    ],
    "summary": "Day One Biopharm ( DAWN ) had its Relative Strength ( RS ) Rating upgraded from 78 to 85 Wednesday. X IBD's proprietary rating measures market leadership with a 1 ( worst ) to 99 ( best ) score. The score shows how a stock's price performance over the trailing 52 weeks holds up against all ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      }
    ],
    "overall_sentiment_score": 0.257635,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.340915",
        "ticker_sentiment_score": "0.134682",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.340915",
        "ticker_sentiment_score": "0.134682",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.340915",
        "ticker_sentiment_score": "0.134682",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stocks With Rising Relative Strength: Immunovant",
    "url": "https://www.investors.com/ibd-data-stories/stocks-with-rising-relative-strength-immunovant/",
    "time_published": "20240515T070000",
    "authors": [
      "INVESTOR'S BUSINESS DAILY",
      "Investor's Business Daily"
    ],
    "summary": "The Relative Strength ( RS ) Rating for Immunovant ( IMVT ) moved up into a new percentile Wednesday, as it got a lift from 67 to 72. X This exclusive rating from Investor's Business Daily measures price action with a 1 ( worst ) to 99 ( best ) score.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.360453,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "IMVT",
        "relevance_score": "0.585687",
        "ticker_sentiment_score": "0.539856",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.316846",
        "ticker_sentiment_score": "0.129444",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.16171",
        "ticker_sentiment_score": "0.17304",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.316846",
        "ticker_sentiment_score": "0.129444",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.316846",
        "ticker_sentiment_score": "0.129444",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Halozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS Rating",
    "url": "https://www.investors.com/news/technology/halozyme-therapeutics-stock-earns-ibd-stock-rating-upgrade-hitting-80-plus-rs-rating-2/",
    "time_published": "20240516T185500",
    "authors": [
      "INVESTOR'S BUSINESS DAILY",
      "Investor's Business Daily",
      "JULIE MAK"
    ],
    "summary": "Halozyme Therapeutics ( HALO ) stock had its Relative Strength ( RS ) Rating upgraded from 80 to 84 Thursday. IBD's unique RS Rating identifies market leadership by using a 1 ( worst ) to 99 ( best ) score that identifies how a stock's price action over the trailing 52 weeks matches up ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/05/IRU4.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      }
    ],
    "overall_sentiment_score": 0.290279,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.360752",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.651499",
        "ticker_sentiment_score": "0.404059",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.360752",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Bluebird Bio Stock a Buy?",
    "url": "https://www.fool.com/investing/2024/05/16/is-bluebird-bio-stock-a-buy/",
    "time_published": "20240516T132200",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "It won't be easy for the company to bounce back.",
    "banner_image": "https://g.foolcdn.com/editorial/images/777204/patient-sitting-on-hospital-bed.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.122141,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.058903",
        "ticker_sentiment_score": "0.063095",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BLUE",
        "relevance_score": "0.583672",
        "ticker_sentiment_score": "0.207006",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "How Gene Editing Therapies Could Go Beyond Rare Diseases",
    "url": "https://www.forbes.com/sites/juergeneckhardt/2024/05/16/how-gene-editing-therapies-could-go-beyond-rare-diseases/",
    "time_published": "20240516T130000",
    "authors": [
      "Juergen Eckhardt"
    ],
    "summary": "Earlier this year, a group of scientists in the Netherlands used the gene editing tool CRISPR to eliminate HIV from immune cells in the lab, an eye-catching approach that is forming the basis of potentially curative therapies for the disease.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/663e6e2a27434ffbd3e5ee6b/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.134674,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.031907",
        "ticker_sentiment_score": "0.02874",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VERV",
        "relevance_score": "0.031907",
        "ticker_sentiment_score": "0.090207",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MGX",
        "relevance_score": "0.127119",
        "ticker_sentiment_score": "0.100998",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NTLA",
        "relevance_score": "0.031907",
        "ticker_sentiment_score": "0.090207",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stocks To Watch: Amgen Sees RS Rating Jump To 81",
    "url": "https://www.investors.com/ibd-data-stories/stocks-to-watch-amgen-sees-rs-rating-jump-to-81/",
    "time_published": "20240516T070000",
    "authors": [
      "INVESTOR'S BUSINESS DAILY",
      "Investor's Business Daily"
    ],
    "summary": "The Relative Strength ( RS ) Rating for Amgen ( AMGN ) climbed into a new percentile Thursday, with an increase from 77 to 81. X This exclusive rating from Investor's Business Daily tracks share price action with a 1 ( worst ) to 99 ( best ) score.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      }
    ],
    "overall_sentiment_score": 0.294968,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.358152",
        "ticker_sentiment_score": "0.142265",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.183895",
        "ticker_sentiment_score": "0.255143",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.514619",
        "ticker_sentiment_score": "0.225806",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.358152",
        "ticker_sentiment_score": "0.142265",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.358152",
        "ticker_sentiment_score": "0.142265",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Halozyme Therapeutics Clears Key Benchmark, Hitting 80-Plus RS Rating",
    "url": "https://www.investors.com/ibd-data-stories/halozyme-therapeutics-clears-key-benchmark-hitting-80-plus-rs-rating-2/",
    "time_published": "20240516T070000",
    "authors": [
      "Investor's Business Daily",
      "INVESTOR'S BUSINESS DAILY"
    ],
    "summary": "Halozyme Therapeutics ( HALO ) had its Relative Strength ( RS ) Rating upgraded from 80 to 84 Thursday. X IBD's unique RS Rating identifies market leadership by using a 1 ( worst ) to 99 ( best ) score that identifies how a stock's price action over the trailing 52 weeks matches up against ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      }
    ],
    "overall_sentiment_score": 0.327213,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.355588",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.644033",
        "ticker_sentiment_score": "0.41416",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.355588",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is CRISPR Therapeutics Stock a Buy?",
    "url": "https://www.fool.com/investing/2024/05/17/is-crispr-therapeutics-stock-a-buy/",
    "time_published": "20240517T133000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The gene-editing therapy specialist is rising in prominence.",
    "banner_image": "https://g.foolcdn.com/editorial/images/777339/physician-giving-a-high-five-to-a-young-patient.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.219378,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.169676",
        "ticker_sentiment_score": "0.086075",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BLUE",
        "relevance_score": "0.056943",
        "ticker_sentiment_score": "0.051999",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( NASDAQ:VRTX )  Stock Rating Upgraded by StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/19/vertex-pharmaceuticals-nasdaqvrtx-stock-rating-upgraded-by-stocknews-com-2.html",
    "time_published": "20240519T075044",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Vertex Pharmaceuticals ( NASDAQ:VRTX - Get Free Report ) was upgraded by analysts at StockNews.com from a \"buy\" rating to a \"strong-buy\" rating in a report released on Sunday. Other equities analysts have also recently issued research reports about the company.",
    "banner_image": "https://www.marketbeat.com/logos/vertex-pharmaceuticals-incorporated-logo-1200x675.png?v=20231228113929",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.980509"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999998"
      }
    ],
    "overall_sentiment_score": 0.285209,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CCORF",
        "relevance_score": "0.099271",
        "ticker_sentiment_score": "0.038364",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.78775",
        "ticker_sentiment_score": "0.458997",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Vertex  ( VRTX )  Outperforms Industry on Rapid Pipeline Progress",
    "url": "https://www.zacks.com/stock/news/2276762/vertex-vrtx-outperforms-industry-on-rapid-pipeline-progress",
    "time_published": "20240521T154700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "While CF remains the main area of focus, Vertex (VRTX) has seen rapid success in its non-CF pipeline candidates' development in the past year.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/cc/389.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.795202"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.176699,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.209365",
        "ticker_sentiment_score": "0.19549",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LGND",
        "relevance_score": "0.126561",
        "ticker_sentiment_score": "0.201278",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALPN",
        "relevance_score": "0.042346",
        "ticker_sentiment_score": "0.095408",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick",
    "url": "https://www.zacks.com/stock/news/2276655/are-you-a-momentum-investor-this-1-stock-could-be-the-perfect-pick",
    "time_published": "20240521T135011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default184.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.890401"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.339229,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.422897",
        "ticker_sentiment_score": "0.182125",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Corcept Therapeutics Shows Improved Relative Price Performance; Still Shy Of Benchmark",
    "url": "https://www.investors.com/ibd-data-stories/corcept-therapeutics-shows-improved-relative-price-performance-still-shy-of-benchmark/",
    "time_published": "20240521T070000",
    "authors": [
      "INVESTOR'S BUSINESS DAILY",
      "Investor's Business Daily"
    ],
    "summary": "Corcept Therapeutics Shows Improved Relative Price Performance. Still Shy Of Benchmark Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.221627,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.348103",
        "ticker_sentiment_score": "0.139234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CORT",
        "relevance_score": "0.501398",
        "ticker_sentiment_score": "0.280376",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.348103",
        "ticker_sentiment_score": "0.139234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.348103",
        "ticker_sentiment_score": "0.139234",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stocks Flashing Renewed Technical Strength: PTC Therapeutics",
    "url": "https://www.investors.com/ibd-data-stories/stocks-flashing-renewed-technical-strength-ptc-therapeutics-4/",
    "time_published": "20240521T070000",
    "authors": [
      "Investor's Business Daily",
      "INVESTOR'S BUSINESS DAILY"
    ],
    "summary": "One important metric to look for in a stock is an 80 or higher Relative Strength Rating. PTC Therapeutics ( PTCT ) cleared that benchmark Tuesday, with a jump from 67 to 89 Tuesday.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.858979"
      }
    ],
    "overall_sentiment_score": 0.297176,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PTCT",
        "relevance_score": "0.705799",
        "ticker_sentiment_score": "0.478565",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.325208",
        "ticker_sentiment_score": "0.136644",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.325208",
        "ticker_sentiment_score": "0.136644",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.325208",
        "ticker_sentiment_score": "0.136644",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Scholar Rock Holding Shows Rising Price Performance With Jump To 83 RS Rating",
    "url": "https://www.investors.com/ibd-data-stories/scholar-rock-holding-shows-rising-price-performance-with-jump-to-83-rs-rating/",
    "time_published": "20240521T070000",
    "authors": [
      "INVESTOR'S BUSINESS DAILY",
      "Investor's Business Daily"
    ],
    "summary": "On Tuesday, Scholar Rock Holding ( SRRK ) got a positive adjustment to its Relative Strength ( RS ) Rating, from 80 to 83. X IBD's unique RS Rating measures technical performance by using a 1 ( worst ) to 99 ( best ) score that identifies how a stock's price performance over the trailing 52 ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      }
    ],
    "overall_sentiment_score": 0.335429,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.325208",
        "ticker_sentiment_score": "0.136644",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.325208",
        "ticker_sentiment_score": "0.136644",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SRRK",
        "relevance_score": "0.598621",
        "ticker_sentiment_score": "0.479848",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.325208",
        "ticker_sentiment_score": "0.136644",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "TG Therapeutics Shows Rising Price Performance With Jump To 81 RS Rating",
    "url": "https://www.investors.com/ibd-data-stories/tg-therapeutics-shows-rising-price-performance-with-jump-to-81-rs-rating-2/",
    "time_published": "20240522T070000",
    "authors": [
      "Investor's Business Daily",
      "INVESTOR'S BUSINESS DAILY"
    ],
    "summary": "On Wednesday, TG Therapeutics ( TGTX ) got an upgrade to its Relative Strength ( RS ) Rating, from 76 to 81. X IBD's unique rating tracks price movement with a 1 ( worst ) to 99 ( best ) score. The score shows how a stock's price movement over the last 52 weeks compares to all the other ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.399125,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TGTX",
        "relevance_score": "0.758753",
        "ticker_sentiment_score": "0.482236",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.360752",
        "ticker_sentiment_score": "0.147931",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.185306",
        "ticker_sentiment_score": "0.160679",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.360752",
        "ticker_sentiment_score": "0.147931",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.360752",
        "ticker_sentiment_score": "0.147931",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stocks To Watch: Avadel Pharmaceuticals Sees Relative Strength Rating Rise To 85",
    "url": "https://www.investors.com/ibd-data-stories/stocks-to-watch-avadel-pharmaceuticals-sees-relative-strength-rating-rise-to-85/",
    "time_published": "20240522T070000",
    "authors": [
      "INVESTOR'S BUSINESS DAILY",
      "Investor's Business Daily"
    ],
    "summary": "On Wednesday, Avadel Pharmaceuticals ( AVDL ) reached an important technical milestone, seeing its Relative Strength ( RS ) Rating jump into the 80-plus percentile with an improvement to 85, up from 79 the day before.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.346621,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.340915",
        "ticker_sentiment_score": "0.13703",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVDL",
        "relevance_score": "0.340915",
        "ticker_sentiment_score": "0.570619",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.340915",
        "ticker_sentiment_score": "0.13703",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.340915",
        "ticker_sentiment_score": "0.13703",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Spotlight on Vertex Pharmaceuticals: Analyzing the Surge in Options Activity - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/insights/options/24/05/38993706/spotlight-on-vertex-pharmaceuticals-analyzing-the-surge-in-options-activity",
    "time_published": "20240523T194609",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Financial giants have made a conspicuous bullish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex Pharmaceuticals VRTX revealed 16 unusual trades. Delving into the details, we found 56% of traders were bullish, while 25% showed bearish tendencies.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.19269,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.620415",
        "ticker_sentiment_score": "0.065191",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "SLB, First Solar And 2 Other Stocks Insiders Are Selling - Schlumberger  ( NYSE:SLB ) ",
    "url": "https://www.benzinga.com/news/24/05/38984382/slb-first-solar-and-2-other-stocks-insiders-are-selling",
    "time_published": "20240523T123141",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "The Nasdaq 100 closed slightly lower on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/23/SLB---logo.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.16318,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SLB",
        "relevance_score": "0.17715",
        "ticker_sentiment_score": "0.204024",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.424317",
        "ticker_sentiment_score": "0.057048",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FSLR",
        "relevance_score": "0.345674",
        "ticker_sentiment_score": "0.117115",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LSCC",
        "relevance_score": "0.424317",
        "ticker_sentiment_score": "0.165715",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Walmart, Vertex Pharmaceuticals And More On CNBC's 'Final Trades' - Walmart  ( NYSE:WMT ) ",
    "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/05/38984355/walmart-vertex-pharmaceuticals-and-more-on-cnbcs-final-trades",
    "time_published": "20240523T123031",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "Joseph M. Terranova of Virtus Investment Partners named VanEck Semiconductor ETF SMH on CNBC's \"Halftime Report Final Trades.\" If NVIDIA Corporation NVDA goes above the $1,000 level, Terranova recommends buying puts on the SMH. Jason Snipe of Odyssey Capital Advisors said he likes Walmart Inc.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/23/walmart-store-exterior-at-night-site-.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.818451"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.220791,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.524949",
        "ticker_sentiment_score": "0.256148",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.279015",
        "ticker_sentiment_score": "0.102547",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTS",
        "relevance_score": "0.141726",
        "ticker_sentiment_score": "-0.232804",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.524949",
        "ticker_sentiment_score": "0.719319",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Stocks To Watch: Arvinas Sees RS Rating Rise To 83",
    "url": "https://www.investors.com/ibd-data-stories/stocks-to-watch-arvinas-sees-rs-rating-rise-to-83/",
    "time_published": "20240523T070000",
    "authors": [
      "INVESTOR'S BUSINESS DAILY",
      "Investor's Business Daily"
    ],
    "summary": "Arvinas ( ARVN ) had its Relative Strength ( RS ) Rating upgraded from 75 to 83 Thursday. X This unique rating identifies market leadership by using a 1 ( worst ) to 99 ( best ) score that indicates how a stock's price action over the last 52 weeks matches up against that of all other stocks.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.388848,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.380012",
        "ticker_sentiment_score": "0.153733",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.380012",
        "ticker_sentiment_score": "0.153733",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.380012",
        "ticker_sentiment_score": "0.153733",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ARVN",
        "relevance_score": "0.678673",
        "ticker_sentiment_score": "0.554168",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Stocks To Watch: Ascendis Pharma ADR Sees Relative Strength Rating Rise To 81",
    "url": "https://www.investors.com/ibd-data-stories/stocks-to-watch-ascendis-pharma-adr-sees-relative-strength-rating-rise-to-81/",
    "time_published": "20240523T070000",
    "authors": [
      "Investor's Business Daily",
      "INVESTOR'S BUSINESS DAILY"
    ],
    "summary": "Ascendis Pharma ADR ( ASND ) had its Relative Strength ( RS ) Rating upgraded from 64 to 81 Thursday. X IBD's proprietary RS Rating identifies technical performance by using a 1 ( worst ) to 99 ( best ) score that indicates how a stock's price performance over the last 52 weeks matches up ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.280539,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.363388",
        "ticker_sentiment_score": "0.141361",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.363388",
        "ticker_sentiment_score": "0.141361",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.363388",
        "ticker_sentiment_score": "0.141361",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Keros Therapeutics Shows Improved Relative Strength; Still Shy Of Benchmark",
    "url": "https://www.investors.com/ibd-data-stories/keros-therapeutics-shows-improved-relative-strength-still-shy-of-benchmark/",
    "time_published": "20240523T070000",
    "authors": [
      "INVESTOR'S BUSINESS DAILY",
      "Investor's Business Daily"
    ],
    "summary": "Keros Therapeutics Shows Improved Relative Strength. Still Shy Of Benchmark Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.331985,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KROS",
        "relevance_score": "0.48268",
        "ticker_sentiment_score": "0.443399",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.334008",
        "ticker_sentiment_score": "0.134885",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.170878",
        "ticker_sentiment_score": "0.179444",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.334008",
        "ticker_sentiment_score": "0.134885",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.334008",
        "ticker_sentiment_score": "0.134885",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "New Pain Drug Could Be Big For Vertex Stock As Shares Score Breakout",
    "url": "https://www.investors.com/stock-lists/stock-spotlight/vertex-vrtx-stock-breakout/",
    "time_published": "20240524T202800",
    "authors": [
      "RACHEL FOX",
      "Investor's Business Daily"
    ],
    "summary": "Cystic fibrosis treatment leader Vertex Pharmaceuticals ( VRTX ) scored a breakout from a cup base the past week. The breakout came a few weeks after the stock took out an early entry on May 7. That day, shares simultaneously moved above the 407 entry and the 50-day moving average.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2020/04/Stock-Vertex-04-shutt.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.115725,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.200688",
        "ticker_sentiment_score": "0.07273",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Biotech Stocks to Buy in May",
    "url": "https://www.fool.com/investing/2024/05/25/2-biotech-stocks-to-buy-in-may/",
    "time_published": "20240525T140000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "You could buy these in any month, really.",
    "banner_image": "https://g.foolcdn.com/editorial/images/778167/physician-giving-medicine-to-elderly-patient.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.839681"
      }
    ],
    "overall_sentiment_score": 0.292194,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "REGN",
        "relevance_score": "0.151222",
        "ticker_sentiment_score": "0.1006",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.200688",
        "ticker_sentiment_score": "0.253925",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.101154",
        "ticker_sentiment_score": "0.011965",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 High-Flying Stocks That Could Soar Even More",
    "url": "https://www.fool.com/investing/2024/05/25/3-high-flying-stocks-that-could-soar-even-more/",
    "time_published": "20240525T104700",
    "authors": [
      "David Jagielski",
      "Keith Speights",
      "and Prosper Junior Bakiny"
    ],
    "summary": "The momentum should continue for Eli Lilly, Novo Nordisk, and Vertex Pharmaceuticals.",
    "banner_image": "https://g.foolcdn.com/editorial/images/778486/stock-chart-rocket.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.203016,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.410505",
        "ticker_sentiment_score": "0.21727",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.334008",
        "ticker_sentiment_score": "0.116918",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CURN",
        "relevance_score": "0.04303",
        "ticker_sentiment_score": "0.062785",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.212674",
        "ticker_sentiment_score": "0.062603",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Got $500? 3 Pharma Stocks to Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/05/26/got-500-3-pharma-stocks-to-buy-and-hold-forever/",
    "time_published": "20240526T141500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "These players might even beat the market when the conditions are right.",
    "banner_image": "https://g.foolcdn.com/editorial/images/778164/investor-thinks-while-looking-out-a-window.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.265035,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.164656",
        "ticker_sentiment_score": "0.244994",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.110209",
        "ticker_sentiment_score": "0.239132",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.110209",
        "ticker_sentiment_score": "0.18474",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is It Too Late to Buy Vertex Pharmaceuticals Stock?",
    "url": "https://www.fool.com/investing/2024/05/26/is-it-too-late-to-buy-vertex-pharmaceuticals-stock/",
    "time_published": "20240526T134500",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Shares of the growing biotech company have doubled in three years.",
    "banner_image": "https://media.ycharts.com/charts/0832aba37d1888c8f1fe5824d4e5a109.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      }
    ],
    "overall_sentiment_score": 0.320543,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.144708",
        "ticker_sentiment_score": "0.237969",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALPN",
        "relevance_score": "0.072655",
        "ticker_sentiment_score": "0.126951",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.072655",
        "ticker_sentiment_score": "0.11382",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Reasons to Buy CRISPR Therapeutics Stock Like There's No Tomorrow",
    "url": "https://www.fool.com/investing/2024/05/26/3-reasons-to-buy-crispr-therapeutics-stock-like-th/",
    "time_published": "20240526T131500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "There are a handful of different factors that could buoy its stock.",
    "banner_image": "https://g.foolcdn.com/editorial/images/777423/lab-scientist-beaker.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.297259,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.062761",
        "ticker_sentiment_score": "0.063013",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( NASDAQ:VRTX )  Lowered to Buy at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/27/vertex-pharmaceuticals-nasdaqvrtx-lowered-to-buy-at-stocknews-com.html",
    "time_published": "20240527T052246",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Vertex Pharmaceuticals ( NASDAQ:VRTX - Get Free Report ) was downgraded by stock analysts at StockNews.com from a \"strong-buy\" rating to a \"buy\" rating in a report issued on Monday.",
    "banner_image": "https://www.marketbeat.com/logos/vertex-pharmaceuticals-incorporated-logo-1200x675.png?v=20231228113929",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999967"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.938793"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.261145,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.82927",
        "ticker_sentiment_score": "0.404354",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CCORF",
        "relevance_score": "0.054607",
        "ticker_sentiment_score": "0.052969",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWDBY",
        "relevance_score": "0.054607",
        "ticker_sentiment_score": "0.173983",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AROW",
        "relevance_score": "0.108958",
        "ticker_sentiment_score": "0.192261",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why Is Arcturus Therapeutics Stock Trading Higher On Tuesday? - Arcturus Therapeutics  ( NASDAQ:ARCT ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/05/39045542/arcturus-therapeutics-early-cystic-fibrosis-trial-results-encouraging-analyst-cauti",
    "time_published": "20240528T185543",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Tuesday, Arcturus Therapeutics Holdings Inc. ARCT announced that it will present Phase 1 results in healthy volunteers and new Phase 1b interim data in cystic fibrosis ( CF ) for ARCT-032 at the European Cystic Fibrosis Conference.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/28/ARCT.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.338248,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ARCT",
        "relevance_score": "0.63878",
        "ticker_sentiment_score": "0.406405",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.205807",
        "ticker_sentiment_score": "-0.096314",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stocks To Watch: Avalo Therapeutics Sees RS Rating Rise To 93",
    "url": "https://www.investors.com/ibd-data-stories/stocks-to-watch-avalo-therapeutics-sees-rs-rating-rise-to-93/",
    "time_published": "20240528T070000",
    "authors": [
      "INVESTOR'S BUSINESS DAILY",
      "Investor's Business Daily"
    ],
    "summary": "Avalo Therapeutics ( AVTX ) had its Relative Strength ( RS ) Rating upgraded from 85 to 93 Tuesday. X IBD's proprietary RS Rating tracks market leadership by using a 1 ( worst ) to 99 ( best ) score that identifies how a stock's price performance over the trailing 52 weeks matches up against ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      }
    ],
    "overall_sentiment_score": 0.350288,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.331765",
        "ticker_sentiment_score": "0.138781",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.331765",
        "ticker_sentiment_score": "0.138781",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.331765",
        "ticker_sentiment_score": "0.138781",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVTX",
        "relevance_score": "0.716023",
        "ticker_sentiment_score": "0.526966",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Why Vertex Pharmaceuticals  ( VRTX )  is a Top Growth Stock for the Long-Term",
    "url": "https://www.zacks.com/stock/news/2281284/why-vertex-pharmaceuticals-vrtx-is-a-top-growth-stock-for-the-long-term",
    "time_published": "20240530T134511",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default278.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      }
    ],
    "overall_sentiment_score": 0.495478,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.551295",
        "ticker_sentiment_score": "0.40879",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals Incorporated  ( VRTX )  is Attracting Investor Attention: Here is What You Should Know",
    "url": "https://www.zacks.com/stock/news/2281193/vertex-pharmaceuticals-incorporated-vrtx-is-attracting-investor-attention-here-is-what-you-should-know",
    "time_published": "20240530T130011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default288.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.235155,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.105372",
        "ticker_sentiment_score": "0.036553",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should Abbott and DexCom Investors Be Worried About Vertex Pharmaceuticals?",
    "url": "https://www.fool.com/investing/2024/05/30/should-abbott-and-dexcom-investors-worry-vertex/",
    "time_published": "20240530T095000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "Vertex might not present a clear and present danger to Abbott and DexCom but could present a clear future threat.",
    "banner_image": "https://g.foolcdn.com/editorial/images/778863/diabetes-type-1.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.0916,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.132855",
        "ticker_sentiment_score": "0.062626",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.344473",
        "ticker_sentiment_score": "0.007584",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Analyst Expectations For Vertex Pharmaceuticals's Future",
    "url": "https://markets.businessinsider.com/news/stocks/analyst-expectations-for-vertex-pharmaceuticals-s-future-1033441748",
    "time_published": "20240531T152304",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "During the last three months, 10 analysts shared their evaluations of Vertex Pharmaceuticals ( NASDAQ:VRTX ) , revealing diverse outlooks from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing ...",
    "banner_image": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2023/analyst_ratings_image_2.jpeg",
    "source": "Business Insider",
    "category_within_source": "GoogleRSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.215915,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.295867",
        "ticker_sentiment_score": "0.076644",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nvidia CEO, CrowdStrike, Jobs Report Headline Action Plan",
    "url": "https://www.investors.com/research/investing-action-plan/nvidia-ceo-crowdstrike-jobs-report/",
    "time_published": "20240531T142300",
    "authors": [
      "ED CARSON",
      "Investor's Business Daily"
    ],
    "summary": "Here is this week's Investing Action Plan, what you need to know for the week ahead. Economic data dominates the week, capped by the May jobs report on Friday. As for earnings, cybersecurity leader CrowdStrike ( CRWD ) headlines a small lineup of earnings reports.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/09/econ01-jobs-090117-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.918141"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999975"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.125102,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.090304",
        "ticker_sentiment_score": "0.064197",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRWD",
        "relevance_score": "0.179454",
        "ticker_sentiment_score": "0.071209",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.135094",
        "ticker_sentiment_score": "0.0738",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.090304",
        "ticker_sentiment_score": "0.064197",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HPQ",
        "relevance_score": "0.045224",
        "ticker_sentiment_score": "-0.069689",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.090304",
        "ticker_sentiment_score": "0.126669",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.045224",
        "ticker_sentiment_score": "0.057548",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IOT",
        "relevance_score": "0.135094",
        "ticker_sentiment_score": "0.071161",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LULU",
        "relevance_score": "0.090304",
        "ticker_sentiment_score": "0.12349",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FIVE",
        "relevance_score": "0.135094",
        "ticker_sentiment_score": "0.105249",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QCOM",
        "relevance_score": "0.090304",
        "ticker_sentiment_score": "0.064197",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.090304",
        "ticker_sentiment_score": "0.064197",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.135094",
        "ticker_sentiment_score": "0.0738",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARM",
        "relevance_score": "0.090304",
        "ticker_sentiment_score": "0.064197",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HPE",
        "relevance_score": "0.090304",
        "ticker_sentiment_score": "-0.073547",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.135094",
        "ticker_sentiment_score": "0.0738",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OLLI",
        "relevance_score": "0.090304",
        "ticker_sentiment_score": "0.089852",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "S&P 500 Giants Lead Five Healthy Stocks Near Buy Points",
    "url": "https://www.investors.com/news/sp-500-giants-stocks-near-buy-points/",
    "time_published": "20240601T120000",
    "authors": [
      "Investor's Business Daily",
      "HARRISON MILLER"
    ],
    "summary": "With many leading stocks in need of some repair, investors may want to seek medical attention. Eli Lilly ( LLY ) , Novo Nordisk ( NVO ) , Vertex Pharmaceuticals ( VRTX ) , Intuitive Surgical ( ISRG ) and Universal Health ( UHS ) are all trading in or near buy zones.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2018/05/Stock-HealthCloud-01-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.94762"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.124906,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CTLT",
        "relevance_score": "0.064018",
        "ticker_sentiment_score": "-0.132137",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.312026",
        "ticker_sentiment_score": "0.139665",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HCA",
        "relevance_score": "0.064018",
        "ticker_sentiment_score": "-0.408769",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.064018",
        "ticker_sentiment_score": "0.094068",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.252006",
        "ticker_sentiment_score": "0.092848",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.159148",
        "ticker_sentiment_score": "0.132957",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.064018",
        "ticker_sentiment_score": "0.094068",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.312026",
        "ticker_sentiment_score": "0.136597",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.032035",
        "ticker_sentiment_score": "-0.073241",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 No-Brainer Stocks to Buy in June",
    "url": "https://www.fool.com/investing/2024/06/02/3-no-brainer-stocks-to-buy-in-june/",
    "time_published": "20240602T100000",
    "authors": [
      "Keith Speights",
      "and Prosper Junior Bakiny",
      "David Jagielski"
    ],
    "summary": "Now is the time to invest in these great stocks.",
    "banner_image": "https://g.foolcdn.com/editorial/images/779075/light-bulbs-with-dollar-sign-person-looking-up.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.947132"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999612"
      }
    ],
    "overall_sentiment_score": 0.401751,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.29234",
        "ticker_sentiment_score": "0.408509",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.382925",
        "ticker_sentiment_score": "0.371254",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.382925",
        "ticker_sentiment_score": "0.369735",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "5 Top Stocks to Buy in June",
    "url": "https://www.fool.com/investing/2024/06/02/5-top-stocks-to-buy-in-june/",
    "time_published": "20240602T094700",
    "authors": [
      "Daniel Foelber",
      "and Neha Chamaria",
      "Keith Speights",
      "Demitri Kalogeropoulos",
      "Anders Bylund"
    ],
    "summary": "This medley of growth, value, and income stocks is poised to thrive long-term, even if the stock market sells off this summer.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F779157%2Fgettyimages-1652005987-1200x800-5b2df79.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999763"
      }
    ],
    "overall_sentiment_score": 0.267287,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.019683",
        "ticker_sentiment_score": "0.195604",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.059",
        "ticker_sentiment_score": "0.143342",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SOUN",
        "relevance_score": "0.117678",
        "ticker_sentiment_score": "0.098055",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIPC",
        "relevance_score": "0.137111",
        "ticker_sentiment_score": "0.200965",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ADBE",
        "relevance_score": "0.23281",
        "ticker_sentiment_score": "0.157881",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "0.010468",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEAM",
        "relevance_score": "0.019683",
        "ticker_sentiment_score": "-0.134721",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.019683",
        "ticker_sentiment_score": "0.068014",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HD",
        "relevance_score": "0.098174",
        "ticker_sentiment_score": "0.061952",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Market Closes Strong, Nvidia Jumps; 7 Stocks Near Buy Points",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-nvidia-meta-buy-points/",
    "time_published": "20240603T210200",
    "authors": [
      "ED CARSON",
      "Investor's Business Daily"
    ],
    "summary": "Market Closes Strong, Nvidia Jumps. 7 Stocks Near Buy Points Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2020/06/Stock-bullbearweight-02-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": -0.019407,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "HQY",
        "relevance_score": "0.103778",
        "ticker_sentiment_score": "0.215896",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.138066",
        "ticker_sentiment_score": "0.023294",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.304428",
        "ticker_sentiment_score": "-0.121194",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.138066",
        "ticker_sentiment_score": "0.139374",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.256705",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ARM",
        "relevance_score": "0.138066",
        "ticker_sentiment_score": "0.107296",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.03468",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "This Is What Whales Are Betting On Vertex Pharmaceuticals - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/insights/options/24/06/39144897/this-is-what-whales-are-betting-on-vertex-pharmaceuticals",
    "time_published": "20240603T191600",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Whales with a lot of money to spend have taken a noticeably bullish stance on Vertex Pharmaceuticals. Looking at options history for Vertex Pharmaceuticals VRTX we detected 16 trades.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      }
    ],
    "overall_sentiment_score": 0.127909,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.70655",
        "ticker_sentiment_score": "0.166487",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Sarepta Therapeutics Trying To Close In On Key Technical Measure",
    "url": "https://www.investors.com/ibd-data-stories/sarepta-therapeutics-trying-to-close-in-on-key-technical-measure/",
    "time_published": "20240603T070000",
    "authors": [
      "INVESTOR'S BUSINESS DAILY",
      "Investor's Business Daily"
    ],
    "summary": "In a welcome move, Sarepta Therapeutics ( SRPT ) saw its Relative Strength Rating improve from 70 to 78 on Monday. X This proprietary rating measures technical performance by using a 1 ( worst ) to 99 ( best ) score that shows how a stock's price action over the last 52 weeks stacks up against ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.377662,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.348103",
        "ticker_sentiment_score": "0.143999",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CORT",
        "relevance_score": "0.348103",
        "ticker_sentiment_score": "0.143999",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SRPT",
        "relevance_score": "0.740604",
        "ticker_sentiment_score": "0.710753",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.348103",
        "ticker_sentiment_score": "0.143999",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Health Care Stocks Show Relative Strength as S&P 500 Stalls",
    "url": "https://www.zacks.com/commentary/2283580/health-care-stocks-show-relative-strength-as-sp-500-stalls",
    "time_published": "20240604T184400",
    "authors": [
      "Bryan Hayes"
    ],
    "summary": "Several stocks are breaking out and trading near all-time highs.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/charts/ad/67851.jpg?v=390850030",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.22387,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "REGN",
        "relevance_score": "0.106778",
        "ticker_sentiment_score": "0.124182",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.106778",
        "ticker_sentiment_score": "0.113939",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cathie Wood Is Buying the Dip on These 2 Biotech Stocks. Should You?",
    "url": "https://www.fool.com/investing/2024/06/04/cathie-wood-is-buying-the-dip-on-these-2-biotech/",
    "time_published": "20240604T104500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "In keeping with Cathie Wood's style, these picks are riskier than average.",
    "banner_image": "https://g.foolcdn.com/editorial/images/778437/investors-considers-papers-on-a-table-while-holding-a-tablet.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.875462"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      }
    ],
    "overall_sentiment_score": 0.199389,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GLDAF",
        "relevance_score": "0.054483",
        "ticker_sentiment_score": "0.173009",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.054483",
        "ticker_sentiment_score": "0.133801",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NTLA",
        "relevance_score": "0.108712",
        "ticker_sentiment_score": "0.105771",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "BridgeBio Pharma Shows Rising Relative Price Performance; Still Shy Of Key Threshold",
    "url": "https://www.investors.com/ibd-data-stories/bridgebio-pharma-shows-rising-relative-price-performance-still-shy-of-key-threshold/",
    "time_published": "20240604T070000",
    "authors": [
      "Investor's Business Daily",
      "INVESTOR'S BUSINESS DAILY"
    ],
    "summary": "BridgeBio Pharma Shows Rising Relative Price Performance. Still Shy Of Key Threshold Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.413174,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.377142",
        "ticker_sentiment_score": "0.147833",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BBIO",
        "relevance_score": "0.674691",
        "ticker_sentiment_score": "0.600551",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.194242",
        "ticker_sentiment_score": "0.161784",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.377142",
        "ticker_sentiment_score": "0.147833",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.377142",
        "ticker_sentiment_score": "0.147833",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cytokinetics Trying To Close In On Key Technical Benchmark",
    "url": "https://www.investors.com/ibd-data-stories/cytokinetics-trying-to-close-in-on-key-technical-benchmark/",
    "time_published": "20240604T070000",
    "authors": [
      "INVESTOR'S BUSINESS DAILY",
      "Investor's Business Daily"
    ],
    "summary": "Cytokinetics ( CYTK ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Tuesday, with an upgrade from 63 to 77. X This exclusive rating from Investor's Business Daily identifies market leadership with a 1 ( worst ) to 99 ( best ) score.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.374817,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.343279",
        "ticker_sentiment_score": "0.142475",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CYTK",
        "relevance_score": "0.733479",
        "ticker_sentiment_score": "0.672049",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.343279",
        "ticker_sentiment_score": "0.142475",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.343279",
        "ticker_sentiment_score": "0.142475",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nuvalent Earns Relative Strength Rating Upgrade; Hits Key Threshold",
    "url": "https://www.investors.com/ibd-data-stories/nuvalent-earns-relative-strength-rating-upgrade-hits-key-threshold/",
    "time_published": "20240604T070000",
    "authors": [
      "Investor's Business Daily",
      "INVESTOR'S BUSINESS DAILY"
    ],
    "summary": "Nuvalent Earns Relative Strength Rating Upgrade. Hits Key Threshold Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.419144,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.340915",
        "ticker_sentiment_score": "0.141723",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NUVL",
        "relevance_score": "0.729947",
        "ticker_sentiment_score": "0.646826",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.174587",
        "ticker_sentiment_score": "0.186287",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.340915",
        "ticker_sentiment_score": "0.141723",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.340915",
        "ticker_sentiment_score": "0.141723",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stocks With Rising Relative Price Strength: Arcturus Therapeutics",
    "url": "https://www.investors.com/ibd-data-stories/stocks-with-rising-relative-price-strength-arcturus-therapeutics-3/",
    "time_published": "20240604T070000",
    "authors": [
      "Investor's Business Daily",
      "INVESTOR'S BUSINESS DAILY"
    ],
    "summary": "On Tuesday, Arcturus Therapeutics ( ARCT ) reached an important technical milestone, seeing its Relative Strength ( RS ) Rating jump into the 90-plus percentile with an improvement to 92, up from 88 the day before. X IBD's proprietary rating identifies market leadership with a 1 ( worst ) to ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.366715,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.338582",
        "ticker_sentiment_score": "0.140977",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARCT",
        "relevance_score": "0.726435",
        "ticker_sentiment_score": "0.504045",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.338582",
        "ticker_sentiment_score": "0.140977",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.338582",
        "ticker_sentiment_score": "0.140977",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stocks Flashing Renewed Technical Strength: IDEAYA Biosciences",
    "url": "https://www.investors.com/ibd-data-stories/stocks-flashing-renewed-technical-strength-ideaya-biosciences-2/",
    "time_published": "20240604T070000",
    "authors": [
      "INVESTOR'S BUSINESS DAILY",
      "Investor's Business Daily"
    ],
    "summary": "IDEAYA Biosciences ( IDYA ) saw a positive improvement to its Relative Strength ( RS ) Rating on Tuesday, rising from 69 to 81. X IBD's proprietary rating measures market leadership with a 1 ( worst ) to 99 ( best ) score.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.377596,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.33628",
        "ticker_sentiment_score": "0.135594",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IDYA",
        "relevance_score": "0.485711",
        "ticker_sentiment_score": "0.634911",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.33628",
        "ticker_sentiment_score": "0.135594",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.33628",
        "ticker_sentiment_score": "0.135594",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "$1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/insights/news/24/06/39191241/1000-invested-in-vertex-pharmaceuticals-5-years-ago-would-be-worth-this-much-today",
    "time_published": "20240605T180032",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Vertex Pharmaceuticals VRTX has outperformed the market over the past 5 years by 9.91% on an annualized basis producing an average annual return of 22.94%. Currently, Vertex Pharmaceuticals has a market capitalization of $124.66 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.238974,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.9545",
        "ticker_sentiment_score": "0.384186",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Why Is Vertex  ( VRTX )  Up 15.8% Since Last Earnings Report?",
    "url": "https://www.zacks.com/stock/news/2284123/why-is-vertex-vrtx-up-158-since-last-earnings-report",
    "time_published": "20240605T153035",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default253.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.997335"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.158753,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.041755",
        "ticker_sentiment_score": "0.17478",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GERN",
        "relevance_score": "0.165883",
        "ticker_sentiment_score": "0.025852",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nuvalent Earns Relative Strength Rating Upgrade; Hits Key Benchmark",
    "url": "https://www.investors.com/ibd-data-stories/nuvalent-earns-relative-strength-rating-upgrade-hits-key-benchmark/",
    "time_published": "20240605T070000",
    "authors": [
      "INVESTOR'S BUSINESS DAILY",
      "Investor's Business Daily"
    ],
    "summary": "Nuvalent Earns Relative Strength Rating Upgrade. Hits Key Benchmark Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.391024,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.388879",
        "ticker_sentiment_score": "0.151169",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ADMA",
        "relevance_score": "0.388879",
        "ticker_sentiment_score": "0.151169",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NUVL",
        "relevance_score": "0.690822",
        "ticker_sentiment_score": "0.668686",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.388879",
        "ticker_sentiment_score": "0.151169",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Stocks To Watch: Olema Pharmaceuticals Sees RS Rating Rise To 90",
    "url": "https://www.investors.com/ibd-data-stories/stocks-to-watch-olema-pharmaceuticals-sees-rs-rating-rise-to-90/",
    "time_published": "20240605T070000",
    "authors": [
      "INVESTOR'S BUSINESS DAILY",
      "Investor's Business Daily"
    ],
    "summary": "On Wednesday, Olema Pharmaceuticals ( OLMA ) got a positive adjustment to its Relative Strength ( RS ) Rating, from 72 to 90. X IBD's unique rating measures price action with a 1 ( worst ) to 99 ( best ) score.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      }
    ],
    "overall_sentiment_score": 0.430991,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.33628",
        "ticker_sentiment_score": "0.140239",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADMA",
        "relevance_score": "0.33628",
        "ticker_sentiment_score": "0.140239",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "0.152535",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "OLMA",
        "relevance_score": "0.722944",
        "ticker_sentiment_score": "0.592328",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.33628",
        "ticker_sentiment_score": "0.140239",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stocks To Watch: Catalyst Pharmaceuticals Sees RS Rating Rise To 83",
    "url": "https://www.investors.com/ibd-data-stories/stocks-to-watch-catalyst-pharmaceuticals-sees-rs-rating-rise-to-83/",
    "time_published": "20240606T070000",
    "authors": [
      "INVESTOR'S BUSINESS DAILY",
      "Investor's Business Daily"
    ],
    "summary": "One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Catalyst Pharmaceuticals ( CPRX ) cleared that benchmark Thursday, with a jump from 79 to 83 Thursday. X IBD's unique rating tracks market leadership with a 1 ( worst ) to 99 ( best ) score.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.339907,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.358152",
        "ticker_sentiment_score": "0.14713",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADMA",
        "relevance_score": "0.358152",
        "ticker_sentiment_score": "0.14713",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CPRX",
        "relevance_score": "0.755086",
        "ticker_sentiment_score": "0.408722",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.358152",
        "ticker_sentiment_score": "0.14713",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cytokinetics Meets 80-Plus Relative Strength Rating Benchmark",
    "url": "https://www.investors.com/ibd-data-stories/cytokinetics-meets-80-plus-relative-strength-rating-benchmark/",
    "time_published": "20240606T070000",
    "authors": [
      "INVESTOR'S BUSINESS DAILY",
      "Investor's Business Daily"
    ],
    "summary": "The Relative Strength ( RS ) Rating for Cytokinetics ( CYTK ) entered a new percentile Thursday, with a rise from 77 to 88. X IBD's proprietary RS Rating measures market leadership by using a 1 ( worst ) to 99 ( best ) score that identifies how a stock's price action over the trailing 52 ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.292034,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.33628",
        "ticker_sentiment_score": "0.140239",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADMA",
        "relevance_score": "0.33628",
        "ticker_sentiment_score": "0.140239",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CYTK",
        "relevance_score": "0.722944",
        "ticker_sentiment_score": "0.446661",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.33628",
        "ticker_sentiment_score": "0.140239",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "SpringWorks Therapeutics Hits 80-Plus Relative Strength Rating Benchmark",
    "url": "https://www.investors.com/ibd-data-stories/springworks-therapeutics-hits-80-plus-relative-strength-rating-benchmark-2/",
    "time_published": "20240606T070000",
    "authors": [
      "INVESTOR'S BUSINESS DAILY",
      "Investor's Business Daily"
    ],
    "summary": "On Thursday, SpringWorks Therapeutics ( SWTX ) reached a key technical benchmark, with its Relative Strength ( RS ) Rating climbing into the 80-plus percentile with an improvement to 84, an increase from 80 the day before.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      }
    ],
    "overall_sentiment_score": 0.328109,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.33628",
        "ticker_sentiment_score": "0.135594",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADMA",
        "relevance_score": "0.33628",
        "ticker_sentiment_score": "0.135594",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.33628",
        "ticker_sentiment_score": "0.135594",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWTX",
        "relevance_score": "0.485711",
        "ticker_sentiment_score": "0.462323",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "What's Going On With Arcturus Therapeutics Stock On Friday? - Arcturus Therapeutics  ( NASDAQ:ARCT ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39234193/arcturus-inhaled-mrna-therapeutic-in-cystic-fibrosis-study-highlights-potential-ami",
    "time_published": "20240607T184444",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Friday, Arcturus Therapeutics Holdings Inc ARCT presented Phase 1 results in healthy volunteers and Phase 1b interim data in people with cystic fibrosis for ARCT-032, an inhaled investigational mRNA therapeutic, at the European Cystic Fibrosis Conference.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/07/Doctor-Examining-A-Lung-Radiography.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.260156,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ARCT",
        "relevance_score": "0.485711",
        "ticker_sentiment_score": "0.507189",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSTK",
        "relevance_score": "0.086556",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "VRTX: 3 Popular Biotech Stocks Offering Solid June Returns",
    "url": "https://stocknews.com/news/vrtx-jazz-exel-3-popular-biotech-stocks-offering-solid-june-returns/",
    "time_published": "20240607T123106",
    "authors": [
      "StockNews.com Staff"
    ],
    "summary": "The increasing demand for personalized medicine, numerous advancements in genetic engineering, and the rapid integration of AI in the biopharmaceutical market are some of the major factors propelling growth in the biotech industry.",
    "banner_image": "https://stocknews.com/wp-content/uploads/2023/03/Nidhi-Agarwal_Headshot-3.jpg",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "stocknews.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.321376,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.331765",
        "ticker_sentiment_score": "0.346696",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JAZZ",
        "relevance_score": "0.154455",
        "ticker_sentiment_score": "0.325191",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "EXEL",
        "relevance_score": "0.331765",
        "ticker_sentiment_score": "0.34821",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Cathie Wood Goes Bargain Hunting: 2 Stocks She Just Bought",
    "url": "https://www.fool.com/investing/2024/06/09/cathie-wood-bargain-hunts-2-stocks-she-bought/",
    "time_published": "20240609T102000",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "These companies could generate explosive growth over time.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F779964%2Fgettyimages-998452928.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.263597,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.057907",
        "ticker_sentiment_score": "0.244016",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NTLA",
        "relevance_score": "0.22861",
        "ticker_sentiment_score": "0.07594",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer",
    "url": "https://www.globenewswire.com/news-release/2024/06/10/2895873/0/en/Centessa-Pharmaceuticals-Strengthens-Executive-Leadership-with-Appointment-of-John-Crowley-CPA-as-Chief-Financial-Officer-and-Gregory-Weinhoff-MD-MBA-as-Chief-Business-Officer.html",
    "time_published": "20240610T110000",
    "authors": [
      "Centessa Pharmaceuticals plc"
    ],
    "summary": "BOSTON and LONDON, June 10, 2024 ( GLOBE NEWSWIRE ) -- Centessa Pharmaceuticals plc ( Nasdaq: CNTA ) , a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that John Crowley CPA, has been appointed Chief ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/533cd07d-9cb0-4de6-8ce1-6b1327f27625",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.136684,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "FOLD",
        "relevance_score": "0.033282",
        "ticker_sentiment_score": "0.050652",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IRWD",
        "relevance_score": "0.033282",
        "ticker_sentiment_score": "-0.033267",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.033282",
        "ticker_sentiment_score": "-0.033267",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.033282",
        "ticker_sentiment_score": "0.050652",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CNTA",
        "relevance_score": "0.099614",
        "ticker_sentiment_score": "0.086977",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.033282",
        "ticker_sentiment_score": "-0.033267",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FUSN",
        "relevance_score": "0.033282",
        "ticker_sentiment_score": "-0.033267",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRL",
        "relevance_score": "0.033282",
        "ticker_sentiment_score": "-0.033267",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer - Centessa Pharmaceuticals  ( NASDAQ:CNTA ) ",
    "url": "https://www.benzinga.com/pressreleases/24/06/g39246879/centessa-pharmaceuticals-strengthens-executive-leadership-with-appointment-of-john-crowley-cpa-as-",
    "time_published": "20240610T110000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "BOSTON and LONDON, June 10, 2024 ( GLOBE NEWSWIRE ) -- Centessa Pharmaceuticals plc CNTA, a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that John Crowley CPA, has been appointed Chief Financial Officer, ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.143651,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "FOLD",
        "relevance_score": "0.031446",
        "ticker_sentiment_score": "0.050196",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IRWD",
        "relevance_score": "0.031446",
        "ticker_sentiment_score": "-0.032995",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.031446",
        "ticker_sentiment_score": "-0.032995",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.031446",
        "ticker_sentiment_score": "0.050196",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CNTA",
        "relevance_score": "0.094143",
        "ticker_sentiment_score": "0.084702",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.031446",
        "ticker_sentiment_score": "-0.032995",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FUSN",
        "relevance_score": "0.031446",
        "ticker_sentiment_score": "-0.032995",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRL",
        "relevance_score": "0.031446",
        "ticker_sentiment_score": "-0.032995",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alphabet To Rally Over 28%? Here Are 10 Top Analyst Forecasts For Tuesday - Alphabet  ( NASDAQ:GOOGL ) ",
    "url": "https://www.benzinga.com/news/24/06/39269848/alphabet-to-rally-over-28-here-are-10-top-analyst-forecasts-for-tuesday",
    "time_published": "20240611T125307",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. JP Morgan slashed the price target for Nucor Corporation NUE from $190 to $180.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/11/Google-Parent-Alphabet.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.259219,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PAR",
        "relevance_score": "0.236588",
        "ticker_sentiment_score": "0.29498",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TRGP",
        "relevance_score": "0.236588",
        "ticker_sentiment_score": "0.219675",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FRPT",
        "relevance_score": "0.236588",
        "ticker_sentiment_score": "0.308442",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.079921",
        "ticker_sentiment_score": "0.179379",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FSLR",
        "relevance_score": "0.236588",
        "ticker_sentiment_score": "0.226597",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WDC",
        "relevance_score": "0.236588",
        "ticker_sentiment_score": "0.202313",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.236588",
        "ticker_sentiment_score": "0.005469",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DRI",
        "relevance_score": "0.159043",
        "ticker_sentiment_score": "0.011344",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OCS",
        "relevance_score": "0.159043",
        "ticker_sentiment_score": "0.066907",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NUE",
        "relevance_score": "0.236588",
        "ticker_sentiment_score": "0.096616",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( VRTX )  Stock Declines While Market Improves: Some Information for Investors",
    "url": "https://www.zacks.com/stock/news/2287551/vertex-pharmaceuticals-vrtx-stock-declines-while-market-improves-some-information-for-investors",
    "time_published": "20240612T215009",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $475.79, signifying a -1.19% move from its prior day's close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default145.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.208688,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.537213",
        "ticker_sentiment_score": "0.214097",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Investors Heavily Search Vertex Pharmaceuticals Incorporated  ( VRTX ) : Here is What You Need to Know",
    "url": "https://www.zacks.com/stock/news/2287129/investors-heavily-search-vertex-pharmaceuticals-incorporated-vrtx-here-is-what-you-need-to-know",
    "time_published": "20240612T130011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default191.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.235407,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.104002",
        "ticker_sentiment_score": "0.036407",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Healthcare Stocks to Buy Hand Over Fist in June",
    "url": "https://www.fool.com/investing/2024/06/12/2-healthcare-stocks-to-buy-hand-over-fist-in-june/",
    "time_published": "20240612T114500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "They both have pretty impressive pasts, and their prospects look just as bright.",
    "banner_image": "https://media.ycharts.com/charts/19bc1a080c6f69546fc44ee4ad147602.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.341233,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.217346",
        "ticker_sentiment_score": "0.360761",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.217346",
        "ticker_sentiment_score": "0.338294",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Small IndianAmerican community making grand contributions in US Report",
    "url": "https://www.business-standard.com/india-news/small-indianamerican-community-making-grand-contributions-in-us-report-124061500440_1.html",
    "time_published": "20240615T124109",
    "authors": [
      "Press Trust of India"
    ],
    "summary": "Small Indian-American community making grand contributions in US: Report Business Standard ...",
    "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2024-06/15/full/1718455219-8468.jpg?im=FeatureCrop,size=(826,465)",
    "source": "Business Standard",
    "category_within_source": "GoogleRSS",
    "source_domain": "www.business-standard.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.301672,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JWN",
        "relevance_score": "0.03792",
        "ticker_sentiment_score": "0.068503",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.03792",
        "ticker_sentiment_score": "0.08463",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.03792",
        "ticker_sentiment_score": "0.08463",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSTK",
        "relevance_score": "0.03792",
        "ticker_sentiment_score": "0.002958",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NHPEF",
        "relevance_score": "0.03792",
        "ticker_sentiment_score": "-0.116872",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Growth Stocks You Can Buy Right Now Without Any Hesitation",
    "url": "https://www.fool.com/investing/2024/06/15/3-growth-stocks-you-can-buy-right-now-without-any/",
    "time_published": "20240615T105000",
    "authors": [
      "Keith Speights",
      "and Prosper Junior Bakiny",
      "David Jagielski"
    ],
    "summary": "Want peace of mind about your investments? Consider these great stocks.",
    "banner_image": "https://g.foolcdn.com/editorial/images/780514/happy-stock-investor-holding-smartphone.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.230394,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.308407",
        "ticker_sentiment_score": "0.342258",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.157227",
        "ticker_sentiment_score": "0.127925",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.039548",
        "ticker_sentiment_score": "0.003901",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.414559",
        "ticker_sentiment_score": "0.241327",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( NASDAQ:VRTX )  Upgraded to Strong-Buy by StockNews.com",
    "url": "https://www.defenseworld.net/2024/06/15/vertex-pharmaceuticals-nasdaqvrtx-upgraded-to-strong-buy-by-stocknews-com.html",
    "time_published": "20240615T095311",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "StockNews.com upgraded shares of Vertex Pharmaceuticals ( NASDAQ:VRTX - Free Report ) from a buy rating to a strong-buy rating in a report issued on Friday morning.",
    "banner_image": "https://www.marketbeat.com/logos/vertex-pharmaceuticals-incorporated-logo.png?v=20231228113929",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.972476"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.300223,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.797383",
        "ticker_sentiment_score": "0.482525",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "RBCPF",
        "relevance_score": "0.046184",
        "ticker_sentiment_score": "0.094863",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nvidia, AbbVie, Vertex Pharmaceuticals And An Oil Giant: CNBC's 'Final Trades' - NVIDIA  ( NASDAQ:NVDA ) ",
    "url": "https://www.benzinga.com/news/24/06/39355721/nvidia-abbvie-vertex-pharmaceuticals-and-an-oil-giant-cnbcs-final-trades",
    "time_published": "20240617T124719",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "On CNBC's \"Halftime Report Final Trades,\" Bryn Talkington of Requisite Capital Management named NVIDIA Corporation NVDA as her final trade. NVIDIA recently announced a 10-for-1 stock split. The semiconductor giant revealed this decision during its recent quarterly earnings report.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/17/trader-ai2.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.266102,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.357293",
        "ticker_sentiment_score": "0.22137",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.463792",
        "ticker_sentiment_score": "0.137818",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.463792",
        "ticker_sentiment_score": "0.355944",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "MRO",
        "relevance_score": "0.24289",
        "ticker_sentiment_score": "0.25761",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "COP",
        "relevance_score": "0.463792",
        "ticker_sentiment_score": "0.239412",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should You Invest in the VanEck Biotech ETF  ( BBH ) ?",
    "url": "https://www.zacks.com/stock/news/2288898/should-you-invest-in-the-vaneck-biotech-etf-bbh",
    "time_published": "20240617T102005",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default1.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.168003,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.134214",
        "ticker_sentiment_score": "0.071398",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.134214",
        "ticker_sentiment_score": "0.071398",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.134214",
        "ticker_sentiment_score": "0.071398",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( VRTX )  Stock Dips While Market Gains: Key Facts",
    "url": "https://www.zacks.com/stock/news/2290112/vertex-pharmaceuticals-vrtx-stock-dips-while-market-gains-key-facts",
    "time_published": "20240618T220022",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $467.28, indicating a -1.35% shift from the previous trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default243.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.2031,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.52949",
        "ticker_sentiment_score": "0.260998",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/insights/news/24/06/39388207/heres-how-much-you-would-have-made-owning-vertex-pharmaceuticals-stock-in-the-last-20-years",
    "time_published": "20240618T193029",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Vertex Pharmaceuticals VRTX has outperformed the market over the past 20 years by 12.7% on an annualized basis producing an average annual return of 20.87%. Currently, Vertex Pharmaceuticals has a market capitalization of $120.90 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_3.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.238974,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.9545",
        "ticker_sentiment_score": "0.384186",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "3 Top Stocks I'd Buy Today and Hold Forever Without Any Hesitation",
    "url": "https://www.fool.com/investing/2024/06/18/3-top-stocks-id-buy-today-and-hold-forever-without/",
    "time_published": "20240618T105000",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Evergreen business models make it easier to hold for the long run.",
    "banner_image": "https://media.ycharts.com/charts/5517de7c5bd4114a9a07acfb5f892c44.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.875462"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.311955,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.103778",
        "ticker_sentiment_score": "0.165915",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.255641",
        "ticker_sentiment_score": "0.233684",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "COST",
        "relevance_score": "0.304428",
        "ticker_sentiment_score": "0.239447",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Reshma Kewalramani Is Guiding Vertex Pharmaceuticals to Its Next Big Thing",
    "url": "https://www.barrons.com/amp/articles/vertex-pharmaceuticals-reshma-kewalramani-top-ceo-stock-price-54b64a0d",
    "time_published": "20240621T160000",
    "authors": [
      "Josh Nathan-Kazis"
    ],
    "summary": "Vertex Pharmaceuticals CEO Reshma Kewalramani | Barron's Top ...",
    "banner_image": "https://images.barrons.com/im-63958140/social",
    "source": "Barrons",
    "category_within_source": "n/a",
    "source_domain": "www.barrons.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.240493,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.207571",
        "ticker_sentiment_score": "0.198556",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Forget Eli Lilly, Buy This Magnificent Biotech Stock Instead",
    "url": "https://www.fool.com/investing/2024/06/21/forget-eli-lilly-buy-magnificent-biotech-stock/",
    "time_published": "20240621T095100",
    "authors": [
      "Keith Speights"
    ],
    "summary": "Lilly is a good pick...but this one is better.",
    "banner_image": "https://g.foolcdn.com/editorial/images/780926/scientist-in-lab-young-african-american-female.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.310445,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.583672",
        "ticker_sentiment_score": "0.52003",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.175433",
        "ticker_sentiment_score": "0.298239",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( VRTX )  Ascends While Market Falls: Some Facts to Note",
    "url": "https://www.zacks.com/stock/news/2292534/vertex-pharmaceuticals-vrtx-ascends-while-market-falls-some-facts-to-note",
    "time_published": "20240624T220017",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $474.95, signifying a +1.33% move from its prior day's close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default25.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.226746,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.541943",
        "ticker_sentiment_score": "0.317216",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Here's Why Vertex Pharmaceuticals  ( VRTX )  is a Strong Growth Stock",
    "url": "https://www.zacks.com/stock/news/2292215/heres-why-vertex-pharmaceuticals-vrtx-is-a-strong-growth-stock",
    "time_published": "20240624T134513",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default298.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.46661,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.555911",
        "ticker_sentiment_score": "0.40759",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Everyone's Talking About Vertex Pharmaceuticals. Is It Time to Buy?",
    "url": "https://www.fool.com/investing/2024/06/25/everyones-talking-about-vertex-pharmaceuticals-is/",
    "time_published": "20240625T081200",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "It looks like Vertex's experimental new therapy could become a functional cure for lots of people with diabetes.",
    "banner_image": "https://g.foolcdn.com/editorial/images/781490/individual-investor-devices-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.117306,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.240965",
        "ticker_sentiment_score": "0.258162",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.048919",
        "ticker_sentiment_score": "0.090922",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( NASDAQ:VRTX )  Downgraded to \"Buy\" at StockNews.com",
    "url": "https://www.defenseworld.net/2024/06/25/vertex-pharmaceuticals-nasdaqvrtx-downgraded-to-buy-at-stocknews-com.html",
    "time_published": "20240625T065048",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "StockNews.com downgraded shares of Vertex Pharmaceuticals ( NASDAQ:VRTX - Free Report ) from a strong-buy rating to a buy rating in a research report sent to investors on Monday morning.",
    "banner_image": "https://www.marketbeat.com/logos/vertex-pharmaceuticals-incorporated-logo.png?v=20231228113929",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.977154"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.264192,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.785083",
        "ticker_sentiment_score": "0.373968",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "RBCPF",
        "relevance_score": "0.047092",
        "ticker_sentiment_score": "0.04753",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Peering Into Vertex Pharmaceuticals's Recent Short Interest - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/insights/short-sellers/24/06/39512710/peering-into-vertex-pharmaceuticalss-recent-short-interest",
    "time_published": "20240626T203019",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Vertex Pharmaceuticals's VRTX short percent of float has risen 15.75% since its last report. The company recently reported that it has 4.35 million shares sold short, which is 1.69% of all regular shares that are available for trading.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.287757,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.209365",
        "ticker_sentiment_score": "0.148634",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals Incorporated  ( VRTX )  Is a Trending Stock: Facts to Know Before Betting on It",
    "url": "https://www.zacks.com/stock/news/2293517/vertex-pharmaceuticals-incorporated-vrtx-is-a-trending-stock-facts-to-know-before-betting-on-it",
    "time_published": "20240626T130010",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default86.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.239638,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.104455",
        "ticker_sentiment_score": "0.036454",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "You've Been Warned! 3 Biotech Stocks to Buy Now or Regret Forever.",
    "url": "https://markets.businessinsider.com/news/stocks/youve-been-warned-3-biotech-stocks-to-buy-now-or-regret-forever-1033512850",
    "time_published": "20240627T182143",
    "authors": [
      "Muslim Farooque"
    ],
    "summary": "Biotech stocks to buy now reflect a more dynamic shift in investor focus of late. Over the past few years, the biotech space attracted plenty of investor interest, driven by the Covid-19 pandemic. Global vaccine sales for the crippling virus were upwards of $142 billion from 2020 to 2023.",
    "banner_image": "https://investorplace.com/wp-content/uploads/2020/10/tmo-stock-1-300x169.jpg",
    "source": "Business Insider",
    "category_within_source": "GoogleRSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.27897,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.051111",
        "ticker_sentiment_score": "0.041906",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NHPEF",
        "relevance_score": "0.051111",
        "ticker_sentiment_score": "0.041906",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.25142",
        "ticker_sentiment_score": "0.277253",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Vertex  ( VRTX )  Rises 16.5% YTD: Time to Bet On the Stock?",
    "url": "https://www.zacks.com/stock/news/2294363/vertex-vrtx-rises-165-ytd-time-to-bet-on-the-stock",
    "time_published": "20240627T135400",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "While CF remains the main area of focus, Vertex (VRTX) has seen rapid success in its non-CF pipeline candidates' development in the past year.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/2633.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.623304"
      }
    ],
    "overall_sentiment_score": 0.223039,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MRNA",
        "relevance_score": "0.081691",
        "ticker_sentiment_score": "0.00924",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.122269",
        "ticker_sentiment_score": "0.166274",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "This Vertex Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/news/24/06/39523582/this-vertex-pharmaceuticals-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for",
    "time_published": "20240627T124140",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. BMO Capital analyst Keith Tapper initiated coverage on ACADIA Pharmaceuticals Inc.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/27/xrdDAFzgn8dVBs2-j9120197723021318877-t23.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.18446,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.397098",
        "ticker_sentiment_score": "0.127197",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KD",
        "relevance_score": "0.397098",
        "ticker_sentiment_score": "0.142929",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HOLX",
        "relevance_score": "0.397098",
        "ticker_sentiment_score": "0.144661",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ACAD",
        "relevance_score": "0.397098",
        "ticker_sentiment_score": "0.140089",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GRAB",
        "relevance_score": "0.271274",
        "ticker_sentiment_score": "0.014796",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is CRISPR Therapeutics Stock a Buy? One Analyst Thinks the Biotech Is \"Very Undervalued.\"",
    "url": "https://www.fool.com/investing/2024/06/27/is-crispr-therapeutics-stock-a-buy/",
    "time_published": "20240627T120000",
    "authors": [
      "George Budwell"
    ],
    "summary": "The biotech's shares have traded sideways for over a year, but better days could be on the near-term horizon.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F781749%2Fbuy-dice.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.2163,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.20997",
        "ticker_sentiment_score": "-0.137126",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MORN",
        "relevance_score": "0.070725",
        "ticker_sentiment_score": "0.08138",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Superior Growth Stocks to Buy if You Have $1,000 Right Now",
    "url": "https://www.fool.com/investing/2024/06/28/2-superior-growth-stocks-to-buy-if-you-have-1000-/",
    "time_published": "20240628T114500",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "Growth stocks with wide moats and strong financials can compound investor returns with time.",
    "banner_image": "https://g.foolcdn.com/editorial/images/781464/getty-happy-person-indoors-smiling.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.972756"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.918141"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.218615,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SPOT",
        "relevance_score": "0.324139",
        "ticker_sentiment_score": "0.140603",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.083251",
        "ticker_sentiment_score": "0.18767",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors",
    "url": "https://www.globenewswire.com/news-release/2024/06/28/2905765/0/en/Verve-Therapeutics-Announces-Appointment-of-Nia-Tatsis-Ph-D-and-Jodie-Morrison-to-its-Board-of-Directors.html",
    "time_published": "20240628T110000",
    "authors": [
      "Verve Therapeutics"
    ],
    "summary": "BOSTON, June 28, 2024 ( GLOBE NEWSWIRE ) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its board ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/2a4edc4b-98df-4e32-ade8-159b39872434",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.15042,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.061394",
        "ticker_sentiment_score": "-0.028005",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VERV",
        "relevance_score": "0.122425",
        "ticker_sentiment_score": "0.086818",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.03072",
        "ticker_sentiment_score": "-0.041589",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AKBA",
        "relevance_score": "0.03072",
        "ticker_sentiment_score": "0.050946",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.061394",
        "ticker_sentiment_score": "-0.045",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors - Verve Therapeutics  ( NASDAQ:VERV ) ",
    "url": "https://www.benzinga.com/pressreleases/24/06/g39544851/verve-therapeutics-announces-appointment-of-nia-tatsis-ph-d-and-jodie-morrison-to-its-board-of-dir",
    "time_published": "20240628T110000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "BOSTON, June 28, 2024 ( GLOBE NEWSWIRE ) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its board ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      }
    ],
    "overall_sentiment_score": 0.157344,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.058759",
        "ticker_sentiment_score": "-0.026999",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VERV",
        "relevance_score": "0.175009",
        "ticker_sentiment_score": "0.101257",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.029399",
        "ticker_sentiment_score": "-0.041291",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AKBA",
        "relevance_score": "0.029399",
        "ticker_sentiment_score": "0.048726",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.058759",
        "ticker_sentiment_score": "-0.044982",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030",
    "url": "https://www.fool.com/investing/2024/06/28/prediction-best-performing-healthcare-stocks/",
    "time_published": "20240628T095000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "These healthcare stocks have clear paths to growth over the next few years.",
    "banner_image": "https://g.foolcdn.com/editorial/images/781869/health-monitoring-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.226026,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.113866",
        "ticker_sentiment_score": "0.180233",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.113866",
        "ticker_sentiment_score": "0.034567",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMDX",
        "relevance_score": "0.383765",
        "ticker_sentiment_score": "0.18974",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Healthcare Stocks That Are Screaming Buys in June",
    "url": "https://www.fool.com/investing/2024/06/28/healthcare-stocks-screaming-buys-june-vrtx-pfe/",
    "time_published": "20240628T073100",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "These top healthcare stocks are no-brainer buys in 2024 and beyond.",
    "banner_image": "https://g.foolcdn.com/editorial/images/781627/businesswoman-working-finances-1.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999822"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.172731,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.069394",
        "ticker_sentiment_score": "0.112996",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BHVN",
        "relevance_score": "0.03473",
        "ticker_sentiment_score": "0.00291",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HLN",
        "relevance_score": "0.069394",
        "ticker_sentiment_score": "-0.041313",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.304847",
        "ticker_sentiment_score": "0.029693",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNTX",
        "relevance_score": "0.03473",
        "ticker_sentiment_score": "0.059308",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "$1000 Invested In This Stock 15 Years Ago Would Be Worth $14,000 Today - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/insights/news/24/07/39581745/1000-invested-in-this-stock-15-years-ago-would-be-worth-14-000-today",
    "time_published": "20240701T183022",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Vertex Pharmaceuticals VRTX has outperformed the market over the past 15 years by 6.43% on an annualized basis producing an average annual return of 19.36%. Currently, Vertex Pharmaceuticals has a market capitalization of $120.86 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.238974,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.9545",
        "ticker_sentiment_score": "0.384186",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Bull Market Buys: 2 Growth Stocks to Own for the Long Run",
    "url": "https://www.fool.com/investing/2024/07/01/bull-market-buys-2-growth-stocks-to-own-for-the/",
    "time_published": "20240701T133000",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "The latest bull market has plenty of intriguing buying opportunities.",
    "banner_image": "https://g.foolcdn.com/editorial/images/782020/drinking-coffee-using-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.998682"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.858979"
      }
    ],
    "overall_sentiment_score": 0.263001,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MRNA",
        "relevance_score": "0.03453",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.068995",
        "ticker_sentiment_score": "0.165779",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( NASDAQ:VRTX )  Upgraded to \"Strong-Buy\" by StockNews.com",
    "url": "https://www.defenseworld.net/2024/07/02/vertex-pharmaceuticals-nasdaqvrtx-upgraded-to-strong-buy-by-stocknews-com-2.html",
    "time_published": "20240702T052043",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Vertex Pharmaceuticals ( NASDAQ:VRTX - Get Free Report ) was upgraded by equities research analysts at StockNews.com from a \"buy\" rating to a \"strong-buy\" rating in a research note issued to investors on Tuesday. VRTX has been the subject of a number of other reports.",
    "banner_image": "https://www.marketbeat.com/logos/vertex-pharmaceuticals-incorporated-logo-1200x675.png?v=20231228113929",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.95493"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.290155,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.75892",
        "ticker_sentiment_score": "0.459905",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.042496",
        "ticker_sentiment_score": "0.07233",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex  ( VRTX )  NDA for Vanza Triple Therapy Accepted by FDA",
    "url": "https://www.zacks.com/stock/news/2296538/vertex-vrtx-nda-for-vanza-triple-therapy-accepted-by-fda",
    "time_published": "20240703T131300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The FDA accepts Vertex's (VRTX) new drug application for vanza triple therapy for people living with cystic fibrosis aged six years and above. A decision is due on Jan 2, 2025.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/49/1007.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.928139"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.133028,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ACRV",
        "relevance_score": "0.257668",
        "ticker_sentiment_score": "0.095407",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.257668",
        "ticker_sentiment_score": "0.160458",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALGS",
        "relevance_score": "0.257668",
        "ticker_sentiment_score": "0.035587",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RAPT",
        "relevance_score": "0.257668",
        "ticker_sentiment_score": "0.037646",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Forget Eli Lilly: 3 Biotech Stocks to Buy Instead",
    "url": "https://www.fool.com/investing/2024/07/04/forget-eli-lilly-3-biotech-stocks-to-buy-instead/",
    "time_published": "20240704T095000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "Eli Lilly is a good stock to buy, but these should be even better.",
    "banner_image": "https://g.foolcdn.com/editorial/images/782405/scientists-in-a-lab-smiling.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.795202"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.331406,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.574608",
        "ticker_sentiment_score": "0.507325",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.140216",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "-0.049168",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.43789",
        "ticker_sentiment_score": "0.424724",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "1 Stock That Increased 10,000% in 33 Years to Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/07/05/1-stock-that-increased-12000-in-30-years-to-buy/",
    "time_published": "20240705T114500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "It's not too late to get in on the act.",
    "banner_image": "https://media.ycharts.com/charts/9201b7f998a785abd71ad5a996e12333.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.28856,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.299478",
        "ticker_sentiment_score": "0.411082",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Did Vertex Pharmaceuticals Just Invent the Next Ozempic?",
    "url": "https://www.fool.com/investing/2024/07/05/did-vertex-pharmaceuticals-just-invent-the-next-oz/",
    "time_published": "20240705T094500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Vertex Pharmaceuticals likely has a breakthrough medicine on its hands.",
    "banner_image": "https://g.foolcdn.com/editorial/images/782327/healthcare-lab-treatment-research-scientist.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.217825,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.221819",
        "ticker_sentiment_score": "0.327502",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.20416",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Prediction: This Will Be Vertex Pharmaceuticals' New Billion-Dollar Growth Driver  ( and It's Coming Soon ) .",
    "url": "https://www.fool.com/investing/2024/07/06/prediction-vertex-pharmas-new-growth-driver/",
    "time_published": "20240706T081500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Vertex shares have advanced by triple digits over the past few years.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F782488%2Fgettyimages-1357572936.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.194393,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.104683",
        "ticker_sentiment_score": "0.051546",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 No-Brainer Stocks to Buy in July",
    "url": "https://www.fool.com/investing/2024/07/08/3-no-brainer-stocks-to-buy-in-july/",
    "time_published": "20240708T120000",
    "authors": [
      "and Prosper Junior Bakiny",
      "Keith Speights",
      "David Jagielski"
    ],
    "summary": "Investors shouldn't have to think too hard about these great stocks.",
    "banner_image": "https://g.foolcdn.com/editorial/images/782643/scientists-in-a-lab-monitor-microscope.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      }
    ],
    "overall_sentiment_score": 0.340429,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.266828",
        "ticker_sentiment_score": "0.355812",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.154455",
        "ticker_sentiment_score": "0.140868",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.154455",
        "ticker_sentiment_score": "0.120086",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.038843",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( VRTX )  Outpaces Stock Market Gains: What You Should Know",
    "url": "https://www.zacks.com/stock/news/2298807/vertex-pharmaceuticals-vrtx-outpaces-stock-market-gains-what-you-should-know",
    "time_published": "20240709T220020",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $485.99, indicating a +0.85% shift from the previous trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default268.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.231446,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.532556",
        "ticker_sentiment_score": "0.388726",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Attovia Therapeutics Announces Election of Mitchell Gold and Angie You to Board of Directors -  ( ALPN ) , ORIC Pharmaceuticals  ( NASDAQ:ORIC ) ",
    "url": "https://www.benzinga.com/pressreleases/24/07/g39684095/attovia-therapeutics-announces-election-of-mitchell-gold-and-angie-you-to-board-of-directors",
    "time_published": "20240709T113000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "FREMONT, Calif., July 09, 2024 ( GLOBE NEWSWIRE ) -- Attovia Therapeutics today announced the election of Mitchell H. Gold, M.D., and Angie You, Ph.D., as independent members of its Board of Directors. Drs.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.317633,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ORIC",
        "relevance_score": "0.10607",
        "ticker_sentiment_score": "0.061499",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.053153",
        "ticker_sentiment_score": "0.074039",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.053153",
        "ticker_sentiment_score": "0.056736",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.053153",
        "ticker_sentiment_score": "0.056736",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.053153",
        "ticker_sentiment_score": "0.056736",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Check Out What Whales Are Doing With VRTX - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/insights/options/24/07/39714698/check-out-what-whales-are-doing-with-vrtx",
    "time_published": "20240710T170722",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "High-rolling investors have positioned themselves bullish on Vertex Pharmaceuticals VRTX, and it's important for retail traders to take note. \\This activity came to our attention today through Benzinga's tracking of publicly available options data.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.111764,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.757058",
        "ticker_sentiment_score": "0.209259",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.07157",
        "ticker_sentiment_score": "-0.106634",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Investors Need to Take Advantage of These 2 Medical Stocks Now",
    "url": "https://www.zacks.com/stock/news/2299063/why-investors-need-to-take-advantage-of-these-2-medical-stocks-now",
    "time_published": "20240710T125011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default232.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999953"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.364166,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.378094",
        "ticker_sentiment_score": "0.352644",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "THC",
        "relevance_score": "0.378094",
        "ticker_sentiment_score": "0.354949",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "1 Biotech Stock to Buy Hand Over Fist and 1 to Avoid",
    "url": "https://www.fool.com/investing/2024/07/11/1-biotech-stock-to-buy-hand-over-fist-and-1-to/",
    "time_published": "20240711T124500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "These two stocks could have vastly different long-term performances.",
    "banner_image": "https://media.ycharts.com/charts/2f54c8a47f8ef5a58f413dc9bfdcce42.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.905476"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.197842,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.052112",
        "ticker_sentiment_score": "0.212636",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BLUE",
        "relevance_score": "0.052112",
        "ticker_sentiment_score": "0.14154",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OCGN",
        "relevance_score": "0.398939",
        "ticker_sentiment_score": "0.153869",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Got $1,000? 2 Incredible Growth Stocks to Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/07/14/got-1000-2-incredible-growth-stocks-to-buy-and/",
    "time_published": "20240714T131500",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "These companies have what it takes to stand the test of time in a portfolio.",
    "banner_image": "https://g.foolcdn.com/editorial/images/783036/getty-happy-tattooed.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.209414,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.093653",
        "ticker_sentiment_score": "0.181456",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.046907",
        "ticker_sentiment_score": "0.083841",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HCSG",
        "relevance_score": "0.046907",
        "ticker_sentiment_score": "0.038993",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HCA",
        "relevance_score": "0.275867",
        "ticker_sentiment_score": "0.223948",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( VRTX )  Exceeds Market Returns: Some Facts to Consider",
    "url": "https://www.zacks.com/stock/news/2302097/vertex-pharmaceuticals-vrtx-exceeds-market-returns-some-facts-to-consider",
    "time_published": "20240715T220021",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $490.85, signifying a +0.43% move from its prior day's close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default183.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.246981,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.590482",
        "ticker_sentiment_score": "0.345067",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "J&J  ( JNJ )  Stock Before Q2 Earnings: To Buy or Not to Buy?",
    "url": "https://www.zacks.com/stock/news/2301766/jj-jnj-stock-before-q2-earnings-to-buy-or-not-to-buy",
    "time_published": "20240715T144700",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e3/1178.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.983605"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999365"
      }
    ],
    "overall_sentiment_score": 0.217562,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.084275",
        "ticker_sentiment_score": "0.161176",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.084275",
        "ticker_sentiment_score": "0.059295",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.126119",
        "ticker_sentiment_score": "0.163775",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Health Canada Grants Marketing Authorization for TRIKAFTA\u00ae  ( elexacaftor/tezacaftor/ivacaftor and ivacaftor )  for People With Cystic Fibrosis Aged 2 Years and Older With Certain Rare Mutations",
    "url": "https://www.newswire.ca/news-releases/health-canada-grants-marketing-authorization-for-trikafta-r-elexacaftor-tezacaftor-ivacaftor-and-ivacaftor-for-people-with-cystic-fibrosis-aged-2-years-and-older-with-certain-rare-mutations-836460288.html",
    "time_published": "20240715T130000",
    "authors": [
      "Vertex Pharmaceuticals (Canada) Inc."
    ],
    "summary": "-Approximately 200 people with certain rare CF mutations are now eligible for TRIKAFTA\u00ae-",
    "banner_image": "https://mma.prnewswire.com/media/2454860/Vertex_Pharmaceuticals__Canada__Inc__Health_Canada_Grants_Market.jpg?p=facebook",
    "source": "Canada Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.newswire.ca",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.172663,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.096542",
        "ticker_sentiment_score": "0.179611",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.032251",
        "ticker_sentiment_score": "0.151308",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Bull Market and Beyond: 2 Stocks Just Waiting to Soar",
    "url": "https://www.fool.com/investing/2024/07/15/bull-market-and-beyond-2-stocks-waiting-to-soar/",
    "time_published": "20240715T111500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "These innovative drugmakers are hard to ignore.",
    "banner_image": "https://g.foolcdn.com/editorial/images/782917/physician-talking-to-patient.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.281626,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.22595",
        "ticker_sentiment_score": "0.344555",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AXSM",
        "relevance_score": "0.280294",
        "ticker_sentiment_score": "0.331595",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split",
    "url": "https://www.fool.com/investing/2024/07/15/stock-split-watch-2-stocks-that-could-split/",
    "time_published": "20240715T081500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Revenue is climbing at these two drug companies -- and the trend should continue.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F783050%2Fgettyimages-investor-uses-tablet-and-phone.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999998"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999355"
      }
    ],
    "overall_sentiment_score": 0.266356,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.045482",
        "ticker_sentiment_score": "0.205092",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.090816",
        "ticker_sentiment_score": "-0.056158",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.310283",
        "ticker_sentiment_score": "0.203449",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.090816",
        "ticker_sentiment_score": "0.37177",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.045482",
        "ticker_sentiment_score": "0.205092",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.045482",
        "ticker_sentiment_score": "0.059207",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.045482",
        "ticker_sentiment_score": "0.059207",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.045482",
        "ticker_sentiment_score": "0.059207",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.045482",
        "ticker_sentiment_score": "0.205092",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog ASML, SAP, Nvidia, Vertex and EssilorLuxxottica",
    "url": "https://www.zacks.com/stock/news/2302210/the-zacks-analyst-blog-asml-sap-nvidia-vertex-and-essilorluxxottica",
    "time_published": "20240716T104300",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "ASML, SAP, Nvidia, Vertex and EssilorLuxxottica are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ab/1753.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.9545"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.043253,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.060312",
        "ticker_sentiment_score": "-0.04001",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.09036",
        "ticker_sentiment_score": "0.015709",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ESLOF",
        "relevance_score": "0.060312",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?",
    "url": "https://www.fool.com/investing/2024/07/16/could-crispr-therapeutics-become-the-next-vertex/",
    "time_published": "20240716T081500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "CRISPR Therapeutics could start reporting product revenue soon.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F783246%2Fscientists-high-five-smile.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.967645"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.237675,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.141726",
        "ticker_sentiment_score": "0.205648",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is Viking Therapeutics the Best Biotech Stock for You?",
    "url": "https://www.fool.com/investing/2024/07/17/is-viking-therapeutics-the-best-biotech-stock-for/",
    "time_published": "20240717T112500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "Let's look beyond the hype the company is generating this year.",
    "banner_image": "https://g.foolcdn.com/editorial/images/783175/elderly-person-sitting-on-a-bed.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.918141"
      }
    ],
    "overall_sentiment_score": 0.225591,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.061003",
        "ticker_sentiment_score": "0.029069",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.298023",
        "ticker_sentiment_score": "0.164757",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.12165",
        "ticker_sentiment_score": "0.261023",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "CRISPR Therapeutics  ( CRSP )  Moves 9.2% Higher: Will This Strength Last?",
    "url": "https://www.zacks.com/stock/news/2303120/crispr-therapeutics-crsp-moves-92-higher-will-this-strength-last",
    "time_published": "20240717T100800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default9.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.222533,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.10607",
        "ticker_sentiment_score": "0.139746",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXSM",
        "relevance_score": "0.310843",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRSP",
        "relevance_score": "0.310843",
        "ticker_sentiment_score": "0.196917",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "How to Find Strong Medical Stocks Slated for Positive Earnings Surprises",
    "url": "https://www.zacks.com/stock/news/2305062/how-to-find-strong-medical-stocks-slated-for-positive-earnings-surprises",
    "time_published": "20240719T125011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default295.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999855"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.412657,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.373378",
        "ticker_sentiment_score": "0.347513",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Monster Stocks in the Making to Buy Right Now",
    "url": "https://www.fool.com/investing/2024/07/20/3-monster-stocks-in-the-making-to-buy-right-now/",
    "time_published": "20240720T100000",
    "authors": [
      "Keith Speights",
      "David Jagielski",
      "and Prosper Junior Bakiny"
    ],
    "summary": "They're small now, but these stocks could grow much larger.",
    "banner_image": "https://g.foolcdn.com/editorial/images/783811/person-smiling-and-looking-at-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.232826,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.044304",
        "ticker_sentiment_score": "0.188697",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.175859",
        "ticker_sentiment_score": "0.01489",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.044304",
        "ticker_sentiment_score": "0.060949",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Historically Flawless Metrics Suggest the Stock Market Can Plunge: Here Are 3 Stocks I've Sold Ahead of What May Be a Big Move for Wall Street",
    "url": "https://www.fool.com/investing/2024/07/21/2-flawless-metrics-suggest-stock-market-can-plunge/",
    "time_published": "20240721T090600",
    "authors": [
      "Sean Williams"
    ],
    "summary": "Neither of these predictive indicators has ever been wrong when back-tested for more than 150 years!",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F783871%2Fstock-market-plunge-crash-newspaper-bear-market-getty.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999981"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.972193"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.065294,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.07793",
        "ticker_sentiment_score": "0.06424",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.180557",
        "ticker_sentiment_score": "0.101322",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.155118",
        "ticker_sentiment_score": "-0.055047",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's Why Vertex Pharmaceuticals  ( VRTX )  Gained But Lagged the Market Today",
    "url": "https://www.zacks.com/stock/news/2306420/heres-why-vertex-pharmaceuticals-vrtx-gained-but-lagged-the-market-today",
    "time_published": "20240722T220046",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $495.91, indicating a +0.88% shift from the previous trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default122.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.252189,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.532556",
        "ticker_sentiment_score": "0.337088",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Here's How Much $100 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth Today - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/insights/news/24/07/39908908/heres-how-much-100-invested-in-vertex-pharmaceuticals-5-years-ago-would-be-worth-today",
    "time_published": "20240723T143033",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Vertex Pharmaceuticals VRTX has outperformed the market over the past 5 years by 11.09% on an annualized basis producing an average annual return of 24.11%. Currently, Vertex Pharmaceuticals has a market capitalization of $126.33 billion.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1721745030_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.238974,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.9545",
        "ticker_sentiment_score": "0.384186",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Is a Beat in the Cards for CRISPR  ( CRSP )  in Q2 Earnings?",
    "url": "https://www.zacks.com/stock/news/2307037/is-a-beat-in-the-cards-for-crispr-crsp-in-q2-earnings",
    "time_published": "20240723T134800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "On CRISPR Therapeutics' (CRSP) second-quarter 2024 earnings call, investors' focus is likely to be on the sales numbers of its newly approved gene therapy, Casgevy, and other pipeline updates.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999992"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.167396,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.116631",
        "ticker_sentiment_score": "0.201145",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRSP",
        "relevance_score": "0.340134",
        "ticker_sentiment_score": "0.024504",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADVM",
        "relevance_score": "0.286193",
        "ticker_sentiment_score": "0.030376",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.340134",
        "ticker_sentiment_score": "0.1555",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( VRTX )  Rises As Market Takes a Dip: Key Facts",
    "url": "https://www.zacks.com/stock/news/2308319/vertex-pharmaceuticals-vrtx-rises-as-market-takes-a-dip-key-facts",
    "time_published": "20240724T215019",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $490.80, denoting a +0.1% change from the preceding trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default9.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.201264,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.546745",
        "ticker_sentiment_score": "0.259427",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated  ( VRTX )  is a Trending Stock",
    "url": "https://www.zacks.com/stock/news/2307638/here-is-what-to-know-beyond-why-vertex-pharmaceuticals-incorporated-vrtx-is-a-trending-stock",
    "time_published": "20240724T130010",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default202.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.226052,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.104911",
        "ticker_sentiment_score": "0.036503",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Vertex Pharmaceuticals' Monopoly in Danger?",
    "url": "https://www.fool.com/investing/2024/07/25/is-vertex-pharmaceuticals-monopoly-in-danger/",
    "time_published": "20240725T121500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "As a shareholder, I am nowhere close to panic mode.",
    "banner_image": "https://media.ycharts.com/charts/d86ffbfc3171c7981a379c09d37dbd75.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.209677,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.236972",
        "ticker_sentiment_score": "0.125575",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow",
    "url": "https://www.fool.com/investing/2024/07/25/3-reasons-to-buy-vertex-pharmaceuticals-stock-like/",
    "time_published": "20240725T081000",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Vertex shares have soared by triple-digit percentages over the past three years.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F784254%2Fgettyimages-research-team-smiles-in-lab.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.875462"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.329083,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "0.137123",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Twist Bioscience  ( TWST )  Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release",
    "url": "https://www.zacks.com/stock/news/2310056/twist-bioscience-twst-expected-to-beat-earnings-estimates-what-to-know-ahead-of-q3-release",
    "time_published": "20240726T140031",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Twist Bioscience (TWST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default119.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.154159,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.087185",
        "ticker_sentiment_score": "0.039047",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TWST",
        "relevance_score": "0.257442",
        "ticker_sentiment_score": "0.171386",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 No-Brainer Growth Stocks to Buy With $1,000 Right Now",
    "url": "https://www.fool.com/investing/2024/07/28/2-no-brainer-growth-stocks-to-buy-with-1000-right/",
    "time_published": "20240728T084100",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "These companies are paving the way to future growth and market share in their respective industries.",
    "banner_image": "https://g.foolcdn.com/editorial/images/784338/middle-aged-woman-with-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.905476"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.988915"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.183881,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SG",
        "relevance_score": "0.277433",
        "ticker_sentiment_score": "0.228093",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.105914",
        "ticker_sentiment_score": "0.238084",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Vertex  ( VRTX )  Stock Before Q2 Earnings: To Buy or Not to Buy?",
    "url": "https://www.zacks.com/stock/news/2311058/vertex-vrtx-stock-before-q2-earnings-to-buy-or-not-to-buy",
    "time_published": "20240729T144400",
    "authors": [
      "Ahan Chakraborty"
    ],
    "summary": "Vertex's (VRTX) second-quarter revenues are expected to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/29/1920.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.996675"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.246688,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MRNA",
        "relevance_score": "0.069798",
        "ticker_sentiment_score": "-0.064232",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.173333",
        "ticker_sentiment_score": "0.155082",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "5 Biotech Stocks to Bet On Bright Industry Prospects",
    "url": "https://www.zacks.com/commentary/2310685/5-biotech-stocks-to-bet-on-bright-industry-prospects",
    "time_published": "20240729T134100",
    "authors": [
      "Ekta Bagri"
    ],
    "summary": "New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position MRNA, SRPT, HALO, KRYS and AXSM well in this volatile sector.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/37/2337.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.23638,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KRYS",
        "relevance_score": "0.072802",
        "ticker_sentiment_score": "0.132917",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SRPT",
        "relevance_score": "0.048572",
        "ticker_sentiment_score": "0.061778",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.024297",
        "ticker_sentiment_score": "0.053269",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.024297",
        "ticker_sentiment_score": "0.053269",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.048572",
        "ticker_sentiment_score": "0.061778",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.121037",
        "ticker_sentiment_score": "0.152304",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AXSM",
        "relevance_score": "0.048572",
        "ticker_sentiment_score": "0.061778",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Curious about Vertex  ( VRTX )  Q2 Performance? Explore Wall Street Estimates for Key Metrics",
    "url": "https://www.zacks.com/stock/news/2310694/curious-about-vertex-vrtx-q2-performance-explore-wall-street-estimates-for-key-metrics",
    "time_published": "20240729T131613",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Vertex (VRTX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default131.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.947132"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.190807,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.18967",
        "ticker_sentiment_score": "0.167875",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings - SPDR S&P 500  ( ARCA:SPY ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/07/40006542/apple-amazon-microsoft-meta-lead-the-charge-as-investors-bank-on-tech-cheer-for-ral",
    "time_published": "20240729T102511",
    "authors": [
      "Shanthi Rexaline"
    ],
    "summary": "The earnings reports of last week were a mixed bag, with some Tesla, Inc. TSLA, Alphabet, Inc. GOOGL GOOG and STMicroelectronics N.V. STM, among companies disappointing to the downside.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/29/The-Magnificent-Seven--7-Of-Largest-Us-T.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.983605"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.142857"
      }
    ],
    "overall_sentiment_score": 0.113434,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "DD",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "-0.087364",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSTR",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.104835",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ANET",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LSCC",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.190156",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MDNDF",
        "relevance_score": "0.035035",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LOGI",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KHC",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "-0.087364",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADM",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RNG",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ITW",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STM",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "-0.089376",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COIN",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DV",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "-0.089376",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SBUX",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMD",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TLRY",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.190156",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "EA",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AIG",
        "relevance_score": "0.104835",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DKNG",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MO",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "-0.087364",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HST",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BLCO",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "-0.087364",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SANM",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.190156",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SIRI",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AEP",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FSLR",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SOFI",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CZR",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARM",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BHC",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MAR",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "-0.087364",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CNK",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOLD",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "-0.087364",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDLZ",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "D",
        "relevance_score": "0.035035",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MBLY",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.035035",
        "ticker_sentiment_score": "0.05845",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FLR",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HTZ",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BUD",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.104835",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IBM",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.153656",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NCLH",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "-0.087364",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QCOM",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LRCX",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "X",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PINS",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BKNG",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WU",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ON",
        "relevance_score": "0.035035",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PYPL",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.104835",
        "ticker_sentiment_score": "-0.045353",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JBLU",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TDOC",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MGA",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OSK",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "-0.087364",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LYV",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWKS",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MCD",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OPEN",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMUS",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "-0.087364",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BZH",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QSR",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MGM",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALB",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LGIH",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "-0.087364",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NET",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?",
    "url": "https://www.zacks.com/stock/news/2312313/watch-these-5-biotech-stocks-for-q2-earnings-beat-or-miss",
    "time_published": "20240730T173100",
    "authors": [
      "Ekta Bagri"
    ],
    "summary": "Let's focus on biotech stocks like GSK, VRTX, BIIB, MRNA and REGN, which are scheduled to report this week.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c2/53795.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.148346,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.040416",
        "ticker_sentiment_score": "0.084018",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.200024",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.040416",
        "ticker_sentiment_score": "0.084018",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.238913",
        "ticker_sentiment_score": "0.050762",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.200024",
        "ticker_sentiment_score": "0.027721",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GSK",
        "relevance_score": "0.31482",
        "ticker_sentiment_score": "0.05152",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.200024",
        "ticker_sentiment_score": "0.029263",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "BMY vs. VRTX: Which Stock Should Value Investors Buy Now?",
    "url": "https://www.zacks.com/stock/news/2312160/bmy-vs-vrtx-which-stock-should-value-investors-buy-now",
    "time_published": "20240730T154011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "BMY vs. VRTX: Which Stock Is the Better Value Option?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default93.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.476284,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.626443",
        "ticker_sentiment_score": "0.496281",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.747404",
        "ticker_sentiment_score": "0.566064",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "DexCom Stock Plunged Over 40% Last Week. Are Eli Lilly's and Novo Nordisk's Drugs to Blame?",
    "url": "https://www.fool.com/investing/2024/07/30/dexcom-stock-plunged-eli-lilly-novo-nordisk/",
    "time_published": "20240730T094800",
    "authors": [
      "Keith Speights"
    ],
    "summary": "DexCom faces several challenges, but GLP-1 drugs aren't big problems for the company right now.",
    "banner_image": "https://g.foolcdn.com/editorial/images/785036/diabetes-cgm-man-in-wheelchair.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.009701,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "-0.056535",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "-0.091966",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.524949",
        "ticker_sentiment_score": "0.019978",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "-0.056535",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Zacks Industry Outlook Highlights Moderna, Sarepta Therapeutics, Halozyme Therapeutics, Krystal Biotech and Axsome Therapeutics",
    "url": "https://www.zacks.com/stock/news/2311476/zacks-industry-outlook-highlights-moderna-sarepta-therapeutics-halozyme-therapeutics-krystal-biotech-and-axsome-therapeutics",
    "time_published": "20240730T090600",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Moderna, Sarepta Therapeutics, Halozyme Therapeutics, Krystal Biotech and Axsome Therapeutics have been highlighted in this Industry Outlook article.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6f/3484.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.247578,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KRYS",
        "relevance_score": "0.114354",
        "ticker_sentiment_score": "0.199593",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SRPT",
        "relevance_score": "0.068764",
        "ticker_sentiment_score": "0.046273",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.022947",
        "ticker_sentiment_score": "0.086924",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.022947",
        "ticker_sentiment_score": "0.086924",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.114354",
        "ticker_sentiment_score": "0.068355",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.137018",
        "ticker_sentiment_score": "0.147957",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXSM",
        "relevance_score": "0.068764",
        "ticker_sentiment_score": "0.046273",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the iShares Biotechnology ETF? - First Trust Amex Biotech Index Fund  ( ARCA:FBT ) , Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/general/biotech/24/07/40064786/should-you-invest-in-the-ishares-biotechnology-etf",
    "time_published": "20240731T174834",
    "authors": [
      "Zacks"
    ],
    "summary": "Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the iShares Biotechnology ETF IBB is a passively managed exchange traded fund launched on 02/05/2001.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/31/louis-reed-pwckf7l4-no-unsplash.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999994"
      }
    ],
    "overall_sentiment_score": 0.264116,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.072435",
        "ticker_sentiment_score": "0.034181",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.144275",
        "ticker_sentiment_score": "0.117832",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.144275",
        "ticker_sentiment_score": "0.117832",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.144275",
        "ticker_sentiment_score": "0.117832",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the iShares Biotechnology ETF  ( IBB ) ?",
    "url": "https://www.zacks.com/stock/news/2312595/should-you-invest-in-the-ishares-biotechnology-etf-ibb",
    "time_published": "20240731T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default110.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.236543,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.070105",
        "ticker_sentiment_score": "0.034114",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.139669",
        "ticker_sentiment_score": "0.072917",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.139669",
        "ticker_sentiment_score": "0.072917",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.139669",
        "ticker_sentiment_score": "0.072917",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( VRTX )  Reports Q2 Loss, Misses Revenue Estimates",
    "url": "https://www.zacks.com/stock/news/2314628/vertex-pharmaceuticals-vrtx-reports-q2-loss-misses-revenue-estimates",
    "time_published": "20240801T211511",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex (VRTX) delivered earnings and revenue surprises of -11.57% and 0.08%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default79.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999981"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.146317,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.139669",
        "ticker_sentiment_score": "-0.005123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADCT",
        "relevance_score": "0.208166",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Moderna  ( MRNA )  Q2 Earnings Beat, Stock Down on Guidance Slash",
    "url": "https://www.zacks.com/stock/news/2314559/moderna-mrna-q2-earnings-beat-stock-down-on-guidance-slash",
    "time_published": "20240801T155400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Moderna (MRNA) beats expectations for earnings and sales. Management cuts sales guidance by $0.5-$1.0 billion on concerns about competition for its marketed products and low sales in the EU.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/a1/7439.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.967321"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.021531,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.044141",
        "ticker_sentiment_score": "0.09318",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.493442",
        "ticker_sentiment_score": "-0.063147",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRDA",
        "relevance_score": "0.21803",
        "ticker_sentiment_score": "0.136836",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.175221",
        "ticker_sentiment_score": "0.126292",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.044141",
        "ticker_sentiment_score": "0.011963",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Got $500? 2 Compelling Growth Stocks to Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/08/01/got-500-2-compelling-growth-stocks-to-buy-and-hold/",
    "time_published": "20240801T141500",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "These businesses are looking like increasingly attractive buys.",
    "banner_image": "https://g.foolcdn.com/editorial/images/784949/businesswoman-celebrating-1.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.997405"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.20625,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.115787",
        "ticker_sentiment_score": "0.089548",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TOST",
        "relevance_score": "0.337811",
        "ticker_sentiment_score": "0.165436",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Wall Street Poised To Start Higher: What's Driving Action In Futures Market - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ",
    "url": "https://www.benzinga.com/news/earnings/24/08/40096676/wall-street-looks-to-ride-on-earnings-cheer-as-meta-q2-impresses-investors-analyst-says-economic-da",
    "time_published": "20240801T113552",
    "authors": [
      "Shanthi Rexaline"
    ],
    "summary": "After Wednesday's tech-led rebound amid the Federal Reserve's rate decision, the stock market could be in for further gains. The major index futures point to a higher opening, although suggesting a slowdown in the upward momentum is in the cards.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/01/Nyc-ny---usa-may-27-2019-Nasdaq-Sign-In-.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999499"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.142857"
      }
    ],
    "overall_sentiment_score": 0.06455,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSTR",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ROKU",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.099202",
        "ticker_sentiment_score": "0.100725",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "D",
        "relevance_score": "0.033144",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MBLY",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RNG",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.033144",
        "ticker_sentiment_score": "0.143026",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CLX",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COIN",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HTZ",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BUD",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "W",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "X",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.033144",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LPLA",
        "relevance_score": "0.033144",
        "ticker_sentiment_score": "-0.043423",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BKNG",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SQ",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DKNG",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.185533",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TDOC",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COP",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.033144",
        "ticker_sentiment_score": "0.025364",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SIRI",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HSY",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OPEN",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BZH",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.132004",
        "ticker_sentiment_score": "0.112372",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVNA",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EVGO",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARM",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "-0.200619",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "BHC",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NET",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.099202",
        "ticker_sentiment_score": "0.100725",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.077399",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Raises Guidance Despite Q2's Bottom-Line Losses",
    "url": "https://www.fool.com/data-news/2024/08/02/vertex-raises-guidance-despite-q2-s-bottom-line-losses/",
    "time_published": "20240802T184843",
    "authors": [
      "JesterAI"
    ],
    "summary": "Revenues rose, but the drugmaker experienced a significant net income loss due to acquisition expenses.",
    "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999499"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.201699,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.21258",
        "ticker_sentiment_score": "0.129265",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals Lifts Annual Guidance, Positive Growth For Its Cystic Fibrosis Franchise And Pain Management Pipeline - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40138336/vertex-pharmaceuticals-lifts-annual-guidance-positive-growth-for-its-cystic-fibrosi",
    "time_published": "20240802T174819",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Thursday, Vertex Pharmaceuticals Incorporated VTRX reported second-quarter revenues of $2.65 billion, almost in line with the consensus of estimate of $2.66 billion. Vertex Pharmaceuticals reported an adjusted EPS loss of $ ( 12.83 ) , compared to $3.89 a year ago, missing the consensus of $4.14.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/02/Genetic-Research-And-Biotech-Science-Con.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.216735,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.387374",
        "ticker_sentiment_score": "-0.237528",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Vertex  ( VRTX )  Q2 Loss Wider Than Expected, '24 Sales View Raised",
    "url": "https://www.zacks.com/stock/news/2315322/vertex-vrtx-q2-loss-wider-than-expected-24-sales-view-raised",
    "time_published": "20240802T140300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex (VRTX) incurs a wider-than-expected loss in the second quarter while sales come in line with estimates. Vertex raises its full-year product revenue guidance.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/62/5473.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999892"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.090358,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.10607",
        "ticker_sentiment_score": "0.021329",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADMA",
        "relevance_score": "0.132368",
        "ticker_sentiment_score": "0.138759",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.158519",
        "ticker_sentiment_score": "0.248387",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should You Invest in Vertex  ( VRTX )  Based on Bullish Wall Street Views?",
    "url": "https://www.zacks.com/stock/news/2315166/should-you-invest-in-vertex-vrtx-based-on-bullish-wall-street-views",
    "time_published": "20240802T133012",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "According to the average brokerage recommendation (ABR), one should invest in Vertex (VRTX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?",
    "banner_image": "https://staticx-tuner.zacks.com/images/yesopchart/brokerage_bar/VRTX_08022024.png",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.938238"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.278346,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.054114",
        "ticker_sentiment_score": "0.142774",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should Investors Worry About Vertex Pharmaceuticals $3.6 Billion Q2 Loss? Not Even for a Second.",
    "url": "https://www.fool.com/investing/2024/08/02/should-investors-worry-about-vertex-pharmaceutical/",
    "time_published": "20240802T095000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "Vertex's first loss in years is a big nothingburger.",
    "banner_image": "https://g.foolcdn.com/editorial/images/785623/woman-with-hands-over-face-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.144306,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "0.354881",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( VRTX )  Q2 2024 Earnings Call Transcript",
    "url": "https://www.fool.com/earnings/call-transcripts/2024/08/01/vertex-pharmaceuticals-vrtx-q2-2024-earnings-call/",
    "time_published": "20240802T013018",
    "authors": [
      "Motley Fool Transcribing"
    ],
    "summary": "VRTX earnings call for the period ending June 30, 2024.",
    "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.20845,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EVR",
        "relevance_score": "0.004964",
        "ticker_sentiment_score": "0.222965",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.004964",
        "ticker_sentiment_score": "0.130076",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.004964",
        "ticker_sentiment_score": "0.120508",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.004964",
        "ticker_sentiment_score": "0.178353",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.004964",
        "ticker_sentiment_score": "0.105905",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.004964",
        "ticker_sentiment_score": "0.046441",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.004964",
        "ticker_sentiment_score": "0.029654",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Unstoppable Stocks to Buy in August",
    "url": "https://www.fool.com/investing/2024/08/03/3-unstoppable-stocks-to-buy-in-august/",
    "time_published": "20240803T114500",
    "authors": [
      "and Prosper Junior Bakiny",
      "David Jagielski",
      "Keith Speights"
    ],
    "summary": "It's not hard to envision how all three of these stocks can deliver exceptional growth.",
    "banner_image": "https://g.foolcdn.com/editorial/images/785543/scientist-in-lab-young-african-american-female.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.918141"
      }
    ],
    "overall_sentiment_score": 0.166551,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.28008",
        "ticker_sentiment_score": "0.044135",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.234911",
        "ticker_sentiment_score": "-0.044925",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.28008",
        "ticker_sentiment_score": "-0.046718",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Prediction: 2 Stocks That Will Be Worth More Than Johnson & Johnson 10 Years From Now",
    "url": "https://www.fool.com/investing/2024/08/03/prediction-2-stocks-that-will-be-worth-more-than-j/",
    "time_published": "20240803T103800",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "These two healthcare companies have far more upside potential than Johnson & Johnson.",
    "banner_image": "https://media.ycharts.com/charts/24cfe84aece23f55456568fbd47c715d.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.918141"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.231837,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.232661",
        "ticker_sentiment_score": "0.127562",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.277433",
        "ticker_sentiment_score": "0.066605",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.364053",
        "ticker_sentiment_score": "0.214227",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Prediction: CRISPR Therapeutics Stock Could Be a Millionaire-Maker",
    "url": "https://www.fool.com/investing/2024/08/04/prediction-crispr-therapeutics-stock-could-be-a-mi/",
    "time_published": "20240804T102200",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The biotech recently became a commercial-stage company.",
    "banner_image": "https://g.foolcdn.com/editorial/images/785226/physician-giving-a-high-five-to-a-young-patient.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.258458,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.056275",
        "ticker_sentiment_score": "0.086",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BLUE",
        "relevance_score": "0.056275",
        "ticker_sentiment_score": "0.086",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Prediction: These Could Be the Best-Performing Growth Stocks Through 2030",
    "url": "https://www.fool.com/investing/2024/08/05/prediction-these-could-be-the-best-performing-grow/",
    "time_published": "20240805T105500",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "Great companies are found in every type of market landscape.",
    "banner_image": "https://g.foolcdn.com/editorial/images/785277/getty-happy-smiling-person-looking-at-phone.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.905476"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      }
    ],
    "overall_sentiment_score": 0.291371,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.09239",
        "ticker_sentiment_score": "0.313946",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CURN",
        "relevance_score": "0.046273",
        "ticker_sentiment_score": "0.055666",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MELI",
        "relevance_score": "0.272282",
        "ticker_sentiment_score": "0.193834",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "CRISPR Therapeutics  ( CRSP )  Q2 Loss Wider Than Expected",
    "url": "https://www.zacks.com/stock/news/2317138/crispr-therapeutics-crsp-q2-loss-wider-than-expected",
    "time_published": "20240806T143700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "CRISPR Therapeutics (CRSP) incurs a wider-than-expected loss in the second quarter of 2024. The commercial launch of CRISPR-based gene therapy, Casgevy, is progressing well.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.938238"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.106816,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.182506",
        "ticker_sentiment_score": "0.177713",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRSP",
        "relevance_score": "0.241684",
        "ticker_sentiment_score": "-0.01872",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RPTX",
        "relevance_score": "0.241684",
        "ticker_sentiment_score": "0.028448",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.182506",
        "ticker_sentiment_score": "0.240956",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Investors Heavily Search Vertex Pharmaceuticals Incorporated  ( VRTX ) : Here is What You Need to Know",
    "url": "https://www.zacks.com/stock/news/2316816/investors-heavily-search-vertex-pharmaceuticals-incorporated-vrtx-here-is-what-you-need-to-know",
    "time_published": "20240806T130012",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default315.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.254708,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.104228",
        "ticker_sentiment_score": "0.03643",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is It Too Late to Buy Vertex Pharmaceuticals Stock?",
    "url": "https://www.fool.com/investing/2024/08/06/is-it-too-late-to-buy-vertex-pharmaceuticals-stock/",
    "time_published": "20240806T083100",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "Shares of the rare disease drugmaker are already up more than 40% over the past year.",
    "banner_image": "https://g.foolcdn.com/editorial/images/785912/wall-street-analyst-with-laptop-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.151829,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.388018",
        "ticker_sentiment_score": "0.178819",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.057767",
        "ticker_sentiment_score": "0.042008",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is iShares Biotechnology ETF  ( IBB )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2317659/is-ishares-biotechnology-etf-ibb-a-strong-etf-right-now",
    "time_published": "20240807T102006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default69.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999998"
      }
    ],
    "overall_sentiment_score": 0.254443,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.060848",
        "ticker_sentiment_score": "0.109008",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.121343",
        "ticker_sentiment_score": "0.061251",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.121343",
        "ticker_sentiment_score": "0.061251",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.121343",
        "ticker_sentiment_score": "0.061251",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Top Research Reports for NVIDIA, Home Depot & Vertex Pharmaceuticals",
    "url": "https://www.zacks.com/research-daily/2318933/top-research-reports-for-nvidia-home-depot-vertex-pharmaceuticals",
    "time_published": "20240808T204900",
    "authors": [
      "Sheraz Mian"
    ],
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), The Home Depot, Inc. (HD) and Vertex Pharmaceuticals Incorporated (VRTX), as well as a micro-cap stock Moving iMage Technologies, Inc. (MITQ).",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default331.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.259078,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "HD",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.285811",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.071784",
        "ticker_sentiment_score": "0.196586",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.071784",
        "ticker_sentiment_score": "-0.021174",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Editas Q2 Earnings & Revenues Miss Estimates, Stock Down - Annovis Bio  ( NYSE:ANVS ) , Akero Therapeutics  ( NASDAQ:AKRO ) ",
    "url": "https://www.benzinga.com/general/biotech/24/08/40256886/editas-q2-earnings-revenues-miss-estimates-stock-down",
    "time_published": "20240808T195906",
    "authors": [
      "Zacks"
    ],
    "summary": "Editas Medicine, Inc. EDIT incurred a loss of 82 cents per share in the second quarter of 2024, wider than the Zacks Consensus Estimate of a loss of 69 cents. The company had reported a loss of 56 cents per share in the year-ago quarter.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/charts/06/73699.jpg?v=2014758018",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.064568,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.112008",
        "ticker_sentiment_score": "0.036782",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AKRO",
        "relevance_score": "0.221819",
        "ticker_sentiment_score": "0.110129",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EDIT",
        "relevance_score": "0.377958",
        "ticker_sentiment_score": "0.125126",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ANVS",
        "relevance_score": "0.221819",
        "ticker_sentiment_score": "-0.090417",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's How to Play Vertex  ( VRTX )  Stock After Q2 Loss, Price Dip",
    "url": "https://www.zacks.com/stock/news/2319355/heres-how-to-play-vertex-vrtx-stock-after-q2-loss-price-dip",
    "time_published": "20240808T150700",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Vertex (VRTX) is a great stock to have in one's portfolio based on its strong overall financial performance and robust pipeline progress.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.723405"
      }
    ],
    "overall_sentiment_score": 0.128847,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MRNA",
        "relevance_score": "0.06211",
        "ticker_sentiment_score": "0.00801",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.06211",
        "ticker_sentiment_score": "-0.012098",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Editas  ( EDIT )  Q2 Earnings & Revenues Miss Estimates, Stock Down",
    "url": "https://www.zacks.com/stock/news/2319312/editas-edit-q2-earnings-revenues-miss-estimates-stock-down",
    "time_published": "20240808T133300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Editas (EDIT) reports lower-than-expected second-quarter 2024 results as both earnings and revenues miss estimates. The stock falls 12.2%.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/98/2216.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.047761,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.112797",
        "ticker_sentiment_score": "0.034599",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AKRO",
        "relevance_score": "0.22335",
        "ticker_sentiment_score": "0.130333",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EDIT",
        "relevance_score": "0.380426",
        "ticker_sentiment_score": "0.123059",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ANVS",
        "relevance_score": "0.22335",
        "ticker_sentiment_score": "-0.03037",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Unpacking the Latest Options Trading Trends in Vertex Pharmaceuticals - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/insights/options/24/08/40293136/unpacking-the-latest-options-trading-trends-in-vertex-pharmaceuticals",
    "time_published": "20240809T184555",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with significant funds have taken a bearish position in Vertex Pharmaceuticals VRTX, a development that retail traders should be aware of. This was brought to our attention today through our monitoring of publicly accessible options data at Benzinga.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1723229152_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.05269,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CCORF",
        "relevance_score": "0.067919",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.693563",
        "ticker_sentiment_score": "0.030419",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.067919",
        "ticker_sentiment_score": "-0.111331",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "ProKidney Reports Business Updates and Second Quarter 2024 Financial Results",
    "url": "https://www.globenewswire.com/news-release/2024/08/09/2927692/0/en/ProKidney-Reports-Business-Updates-and-Second-Quarter-2024-Financial-Results.html",
    "time_published": "20240809T110000",
    "authors": [
      "ProKidney"
    ],
    "summary": "WINSTON-SALEM, N.C., Aug. 09, 2024 ( GLOBE NEWSWIRE ) -- ProKidney Corp. ( Nasdaq: PROK ) ( \"ProKidney\" or the \"Company\" ) , a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease ( CKD ) , today reported business updates and financial results for the ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/a96bc1a7-a4aa-478c-8794-2b186795cb47",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.116102,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MRSN",
        "relevance_score": "0.029292",
        "ticker_sentiment_score": "0.063259",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.029292",
        "ticker_sentiment_score": "0.063259",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PROK",
        "relevance_score": "0.174377",
        "ticker_sentiment_score": "0.105121",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Vertex Pharmaceuticals CRISPR and Moderna",
    "url": "https://www.zacks.com/stock/news/2319736/the-zacks-analyst-blog-vertex-pharmaceuticals-crispr-and-moderna",
    "time_published": "20240809T083000",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Vertex Pharmaceuticals CRISPR and Moderna are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/96/702.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.779048"
      }
    ],
    "overall_sentiment_score": 0.135687,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MRNA",
        "relevance_score": "0.08761",
        "ticker_sentiment_score": "0.004131",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.08761",
        "ticker_sentiment_score": "-0.006258",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cathie Wood's Ark Invest Continues Loads Up On $6.05M Worth Of Robinhood Shares Amid Bitcoin Rebound, Dumps Zoom Stock - Robinhood Markets  ( NASDAQ:HOOD ) ",
    "url": "https://www.benzinga.com/markets/cryptocurrency/24/08/40274766/cathie-woods-ark-invest-continues-loads-up-on-6-05m-worth-of-robinhood-shares-amid-bitcoin",
    "time_published": "20240809T023910",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "On Thursday, Cathie Wood-led Ark Invest made some significant trades, notably buying Robinhood Markets Inc HOOD and selling Zoom Video Communications Inc ZM. Ark Invest's decision to purchase Robinhood shares comes in the wake of the trading platform's impressive second-quarter revenue beat.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/08/Cathie-Wood-fa-shopping-durante-la-tempe_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.938793"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.310395,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.217834",
        "ticker_sentiment_score": "0.430032",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GH",
        "relevance_score": "0.217834",
        "ticker_sentiment_score": "0.430032",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ZM",
        "relevance_score": "0.419733",
        "ticker_sentiment_score": "0.277543",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HOOD",
        "relevance_score": "0.217834",
        "ticker_sentiment_score": "0.302622",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DCYHF",
        "relevance_score": "0.109956",
        "ticker_sentiment_score": "0.183484",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.217834",
        "ticker_sentiment_score": "-0.194579",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "2 Biotech Stocks to Buy Hand Over Fist in August",
    "url": "https://www.fool.com/investing/2024/08/12/2-biotech-stocks-to-buy-hand-over-fist-in-august/",
    "time_published": "20240812T133000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "Both of these biotechs are highly innovative companies.",
    "banner_image": "https://media.ycharts.com/charts/a7c39accb4a6befe9da412ad3d85bd4d.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.918141"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      }
    ],
    "overall_sentiment_score": 0.225813,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.22861",
        "ticker_sentiment_score": "0.136678",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SRPT",
        "relevance_score": "0.22861",
        "ticker_sentiment_score": "0.298965",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Biotech Stocks To Watch In August 2024",
    "url": "https://stockmarket.com/featured/2-biotech-stocks-to-watch-in-august-2024-2024-08-13",
    "time_published": "20240814T003656",
    "authors": [
      "Jonathan Phillip"
    ],
    "summary": "The biotech sector focuses on developing innovative medical treatments using biological processes. These companies research and create new drugs, therapies, and medical devices. Biotech stocks represent ownership in these cutting-edge firms.",
    "banner_image": "https://u3j7m9h7.rocketcdn.me/wp-content/uploads/2020/07/REGN-Stock.jpg",
    "source": "StockMarket.com",
    "category_within_source": "n/a",
    "source_domain": "stockmarket.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.962106"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99393"
      }
    ],
    "overall_sentiment_score": 0.101828,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "REGN",
        "relevance_score": "0.339978",
        "ticker_sentiment_score": "-0.02468",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.339978",
        "ticker_sentiment_score": "0.12511",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "BMY vs. VRTX: Which Stock Is the Better Value Option?",
    "url": "https://www.zacks.com/stock/news/2322713/bmy-vs-vrtx-which-stock-is-the-better-value-option",
    "time_published": "20240815T154009",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Bristol Myers Squibb ( BMY Quick QuoteBMY - ) or Vertex Pharmaceuticals ( VRTX Quick QuoteVRTX - ) . But which of these two stocks is more attractive to value investors?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default234.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.481956,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.624423",
        "ticker_sentiment_score": "0.445203",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.745397",
        "ticker_sentiment_score": "0.529996",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Vertex  ( VRTX )  Stock Outperforms Industry YTD: Here's Why",
    "url": "https://www.zacks.com/stock/news/2322412/vertex-vrtx-stock-outperforms-industry-ytd-heres-why",
    "time_published": "20240815T120200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex's (VRTX) CF sales are expected to remain strong despite a slight slowdown in the growth rate. Casgevy and suzetrigine (if approved) are set to provide the necessary diversification from the CF franchise.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.151556,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MRNA",
        "relevance_score": "0.084572",
        "ticker_sentiment_score": "0.008259",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.168197",
        "ticker_sentiment_score": "0.178918",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Prediction: These 4 Future Technologies Will Be Millionaire-Makers -- and Here Are the Top Stocks to Buy Now to Profit From Them",
    "url": "https://www.fool.com/investing/2024/08/15/prediction-these-4-future-technologies-will-be-mil/",
    "time_published": "20240815T094500",
    "authors": [
      "Keith Speights"
    ],
    "summary": "These technologies could be game-changers. And they could make forward-thinking investors a lot of money.",
    "banner_image": "https://g.foolcdn.com/editorial/images/787051/global-communications.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.348369,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.098255",
        "ticker_sentiment_score": "0.064391",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.195025",
        "ticker_sentiment_score": "0.106521",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.098255",
        "ticker_sentiment_score": "0.147482",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.146916",
        "ticker_sentiment_score": "0.267576",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BNXYF",
        "relevance_score": "0.049221",
        "ticker_sentiment_score": "0.233166",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Fantastic Growth Stocks to Buy in August",
    "url": "https://www.fool.com/investing/2024/08/17/3-fantastic-growth-stocks-to-buy-in-august/",
    "time_published": "20240817T113000",
    "authors": [
      "Keith Speights",
      "and Prosper Junior Bakiny",
      "David Jagielski"
    ],
    "summary": "These stocks should keep up their winning ways.",
    "banner_image": "https://g.foolcdn.com/editorial/images/787352/woman-smiling-looking-at-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      }
    ],
    "overall_sentiment_score": 0.361236,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.374",
        "ticker_sentiment_score": "0.277379",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.171485",
        "ticker_sentiment_score": "0.179105",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FMBRY",
        "relevance_score": "0.043186",
        "ticker_sentiment_score": "0.236572",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.374",
        "ticker_sentiment_score": "0.43317",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "These 2 Incredible Growth Stocks Are Set to Soar This Summer and Beyond",
    "url": "https://www.fool.com/investing/2024/08/18/these-2-incredible-growth-stocks-are-set-to-soar-t/",
    "time_published": "20240818T090000",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "It's always a good time to invest cash in quality businesses.",
    "banner_image": "https://g.foolcdn.com/editorial/images/787137/couple-at-home-budget-stocks.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.905476"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.980716"
      }
    ],
    "overall_sentiment_score": 0.256227,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.107016",
        "ticker_sentiment_score": "0.175171",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.246404",
        "ticker_sentiment_score": "0.148896",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "CRISPR  ( CRSP )  Loses 24% YTD: How Should You Play the Stock?",
    "url": "https://www.zacks.com/stock/news/2323980/crispr-crsp-loses-24-ytd-how-should-you-play-the-stock",
    "time_published": "20240819T154300",
    "authors": [
      "Sundeep Ganoria"
    ],
    "summary": "Despite gaining regulatory approvals in many countries for the first ever CRISPR-based gene therapy, investors should remain wary of investing in CRISPR Therapeutics' (CRSP) early-stage pipeline.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.997405"
      }
    ],
    "overall_sentiment_score": 0.175834,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BEAM",
        "relevance_score": "0.148731",
        "ticker_sentiment_score": "0.229035",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.099476",
        "ticker_sentiment_score": "0.057967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EDIT",
        "relevance_score": "0.148731",
        "ticker_sentiment_score": "0.229035",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should You Invest in the VanEck Biotech ETF  ( BBH ) ?",
    "url": "https://www.zacks.com/stock/news/2323511/should-you-invest-in-the-vaneck-biotech-etf-bbh",
    "time_published": "20240819T102006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default249.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.186436,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "REGN",
        "relevance_score": "0.135347",
        "ticker_sentiment_score": "0.071708",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.135347",
        "ticker_sentiment_score": "0.071708",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.135347",
        "ticker_sentiment_score": "0.071708",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Soviet Code Breaker Jim Simons' Hedge Fund Renaissance Technologies - Ozempic, Wegovy Maker Novo Nordisk Along With Nvidia, Palantir Among Top Holdings - Broadcom  ( NASDAQ:AVGO ) , Airbnb  ( NASDAQ:ABNB ) ",
    "url": "https://www.benzinga.com/markets/equities/24/08/40453485/soviet-code-breaker-jim-simons-hedge-fund-renaissance-technologies-ozempic-wegovy-maker-novo-nor",
    "time_published": "20240820T022541",
    "authors": [
      "Kaustubh Bagalkote"
    ],
    "summary": "Renaissance Technologies, the hedge fund founded by legendary mathematician and former National Security Agency code breaker Jim Simons, recently disclosed its latest stock holdings in a 13F filing with the U.S. Securities and Exchange Commission on Aug. 9.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/19/Premarket-Data.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.37625,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.158",
        "ticker_sentiment_score": "0.249193",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.235062",
        "ticker_sentiment_score": "0.388748",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.158",
        "ticker_sentiment_score": "0.196797",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.235062",
        "ticker_sentiment_score": "0.412523",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.235062",
        "ticker_sentiment_score": "0.349942",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.158",
        "ticker_sentiment_score": "0.333364",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABNB",
        "relevance_score": "0.158",
        "ticker_sentiment_score": "0.249193",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.158",
        "ticker_sentiment_score": "0.333364",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PLTR",
        "relevance_score": "0.235062",
        "ticker_sentiment_score": "0.222013",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "If You Invested $100 In This Stock 20 Years Ago, You Would Have $4,900 Today - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/insights/news/24/08/40490475/if-you-invested-100-in-this-stock-20-years-ago-you-would-have-4-900-today",
    "time_published": "20240821T163020",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Vertex Pharmaceuticals VRTX has outperformed the market over the past 20 years by 13.22% on an annualized basis producing an average annual return of 21.66%. Currently, Vertex Pharmaceuticals has a market capitalization of $125.87 billion.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1724257817_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.238974,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.9545",
        "ticker_sentiment_score": "0.384186",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals Incorporated  ( VRTX )  Is a Trending Stock: Facts to Know Before Betting on It",
    "url": "https://www.zacks.com/stock/news/2324864/vertex-pharmaceuticals-incorporated-vrtx-is-a-trending-stock-facts-to-know-before-betting-on-it",
    "time_published": "20240821T130011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default63.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.230589,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.104683",
        "ticker_sentiment_score": "0.036479",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Top Stock Reports for Texas Instruments, Union Pacific & Vertex Pharmaceuticals",
    "url": "https://www.zacks.com/research-daily/2325736/top-stock-reports-for-texas-instruments-union-pacific-vertex-pharmaceuticals",
    "time_published": "20240822T161000",
    "authors": [
      "Sheraz Mian"
    ],
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including Texas Instruments Incorporated (TXN), Union Pacific Corporation (UNP) and Vertex Pharmaceuticals Incorporated (VRTX), as well as two micro-cap stocks Tile Shop Holdings, Inc. (TTSH) and Gencor Industries, Inc. ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default39.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.084707,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.050894",
        "ticker_sentiment_score": "0.191405",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UNP",
        "relevance_score": "0.101582",
        "ticker_sentiment_score": "-0.09098",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TXN",
        "relevance_score": "0.101582",
        "ticker_sentiment_score": "0.123189",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Unpacking the Latest Options Trading Trends in Vertex Pharmaceuticals - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/insights/options/24/08/40533961/unpacking-the-latest-options-trading-trends-in-vertex-pharmaceuticals",
    "time_published": "20240823T180509",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "High-rolling investors have positioned themselves bearish on Vertex Pharmaceuticals VRTX, and it's important for retail traders to take note. \\This activity came to our attention today through Benzinga's tracking of publicly available options data.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1724436306_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.150268,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.643211",
        "ticker_sentiment_score": "0.102446",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Forget Novo Nordisk: Buy This Magnificent Pharma Stock Instead",
    "url": "https://www.fool.com/investing/2024/08/23/forget-novo-nordisk-buy-magnificent-pharma-stock/",
    "time_published": "20240823T094500",
    "authors": [
      "Keith Speights"
    ],
    "summary": "Vertex Pharmaceuticals has a lot going for it.",
    "banner_image": "https://g.foolcdn.com/editorial/images/788034/scientist-in-lab-young-african-american-female.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.219553,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.170878",
        "ticker_sentiment_score": "-0.070181",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.612033",
        "ticker_sentiment_score": "0.226399",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030",
    "url": "https://www.fool.com/investing/2024/08/26/prediction-these-could-be-best-performing-biotech/",
    "time_published": "20240826T113000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The companies are chasing major innovations.",
    "banner_image": "https://g.foolcdn.com/editorial/images/787348/doctor-and-patient-talking.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.297878,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.053153",
        "ticker_sentiment_score": "0.204754",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.451494",
        "ticker_sentiment_score": "0.299671",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.053153",
        "ticker_sentiment_score": "0.068851",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BLUE",
        "relevance_score": "0.053153",
        "ticker_sentiment_score": "0.056982",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.053153",
        "ticker_sentiment_score": "0.068851",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.053153",
        "ticker_sentiment_score": "0.068851",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Looking Into Vertex Pharmaceuticals's Recent Short Interest - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/insights/short-sellers/24/08/40582764/looking-into-vertex-pharmaceuticalss-recent-short-interest",
    "time_published": "20240827T164514",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Vertex Pharmaceuticals's VRTX short percent of float has risen 23.12% since its last report. The company recently reported that it has 5.08 million shares sold short, which is 1.97% of all regular shares that are available for trading.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1724777111_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.287757,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.209365",
        "ticker_sentiment_score": "0.148634",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals's Options Frenzy: What You Need to Know - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/insights/options/24/08/40636272/vertex-pharmaceuticalss-options-frenzy-what-you-need-to-know",
    "time_published": "20240829T191608",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Financial giants have made a conspicuous bullish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex Pharmaceuticals VRTX revealed 9 unusual trades. Delving into the details, we found 55% of traders were bullish, while 33% showed bearish tendencies.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1724958965_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.100724,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.642555",
        "ticker_sentiment_score": "0.07703",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.073321",
        "ticker_sentiment_score": "-0.180715",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "3 Rock-Solid Pharma Stocks to Buy Now and Hold Forever",
    "url": "https://www.fool.com/investing/2024/08/30/3-rock-solid-pharma-stocks-to-buy-now-and-hold-for/",
    "time_published": "20240830T104500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "These three have secure core businesses, plus multiple paths to grow.",
    "banner_image": "https://g.foolcdn.com/editorial/images/788607/doctor-and-nurse-talk-with-investor.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.94762"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.238076,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.089797",
        "ticker_sentiment_score": "-0.003168",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.134339",
        "ticker_sentiment_score": "0.043756",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.089797",
        "ticker_sentiment_score": "-0.004225",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow",
    "url": "https://www.fool.com/investing/2024/08/30/3-reasons-to-buy-vertex-pharmaceuticals-stock-like/",
    "time_published": "20240830T095000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "Vertex should have a future full of bright tomorrows.",
    "banner_image": "https://g.foolcdn.com/editorial/images/788821/scientists-happy.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.288279,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.195814",
        "ticker_sentiment_score": "0.257637",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 No-Brainer Stocks to Buy in September",
    "url": "https://www.fool.com/investing/2024/08/31/3-no-brainer-stocks-to-buy-in-september/",
    "time_published": "20240831T113000",
    "authors": [
      "and Prosper Junior Bakiny",
      "Keith Speights",
      "David Jagielski"
    ],
    "summary": "There's at least one key common denominator here: tremendous growth prospects.",
    "banner_image": "https://g.foolcdn.com/editorial/images/789084/man-with-arms-behind-head-looking-at-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.986714"
      }
    ],
    "overall_sentiment_score": 0.20788,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.277658",
        "ticker_sentiment_score": "0.142045",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.160901",
        "ticker_sentiment_score": "0.062054",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.315325",
        "ticker_sentiment_score": "0.205306",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals Incorporated  ( VRTX )  is Attracting Investor Attention: Here is What You Should Know",
    "url": "https://www.zacks.com/stock/news/2330153/vertex-pharmaceuticals-incorporated-vrtx-is-attracting-investor-attention-here-is-what-you-should-know",
    "time_published": "20240902T130012",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default201.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.248273,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.102449",
        "ticker_sentiment_score": "0.036245",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is DexCom a Millionaire-Maker Stock?",
    "url": "https://www.fool.com/investing/2024/09/02/is-dexcom-a-millionaire-maker-stock/",
    "time_published": "20240902T111200",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The stock has delivered superior returns in the past 19 years.",
    "banner_image": "https://g.foolcdn.com/editorial/images/788047/dexcom-g6-full-family.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      }
    ],
    "overall_sentiment_score": 0.273415,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.052455",
        "ticker_sentiment_score": "0.035922",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PODD",
        "relevance_score": "0.052455",
        "ticker_sentiment_score": "0.141586",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.104683",
        "ticker_sentiment_score": "0.121976",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TNDM",
        "relevance_score": "0.052455",
        "ticker_sentiment_score": "0.141586",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.642977",
        "ticker_sentiment_score": "0.493744",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Why Is Beam Therapeutics  ( BEAM )  Down 1.6% Since Last Earnings Report?",
    "url": "https://www.zacks.com/stock/news/2332278/why-is-beam-therapeutics-beam-down-16-since-last-earnings-report",
    "time_published": "20240905T153109",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default357.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.904684"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.028647,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BEAM",
        "relevance_score": "0.565003",
        "ticker_sentiment_score": "0.069173",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.088799",
        "ticker_sentiment_score": "0.061919",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Down Nearly 50% From Its 52-Week High, Is CRISPR Therapeutics a Steal of a Deal?",
    "url": "https://www.fool.com/investing/2024/09/05/down-nearly-50-from-its-52-week-high-is-crispr-the/",
    "time_published": "20240905T124500",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Is the potential upside for CRISPR Therapeutics too massive to ignore?",
    "banner_image": "https://g.foolcdn.com/editorial/images/789235/scientists-reviewing-dna.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.098321,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.072876",
        "ticker_sentiment_score": "0.138103",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "10th Annual Glow Ride for Cystic Fibrosis: Claire's Place Foundation Shines Brighter Than Ever",
    "url": "https://www.benzinga.com/pressreleases/24/09/g40728452/10th-annual-glow-ride-for-cystic-fibrosis-claires-place-foundation-shines-brighter-than-ever",
    "time_published": "20240905T121500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Los Angeles, CA, Sept. 05, 2024 ( GLOBE NEWSWIRE ) -- Claire's Place Foundation, a non-profit organization providing support to children and families affected by cystic fibrosis ( CF ) , is excited to announce its milestone 10th Annual Glow Ride for CF, set to light up Hermosa Beach on September ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.505799,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.053629",
        "ticker_sentiment_score": "0.138722",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HPNN",
        "relevance_score": "0.053629",
        "ticker_sentiment_score": "0.33902",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/insights/news/24/09/40754469/heres-how-much-you-would-have-made-owning-vertex-pharmaceuticals-stock-in-the-last-20-years",
    "time_published": "20240906T180031",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Vertex Pharmaceuticals VRTX has outperformed the market over the past 20 years by 13.03% on an annualized basis producing an average annual return of 21.14%. Currently, Vertex Pharmaceuticals has a market capitalization of $120.74 billion.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1725645628_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.238974,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.9545",
        "ticker_sentiment_score": "0.384186",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( VRTX )  Stock Sinks As Market Gains: What You Should Know",
    "url": "https://www.zacks.com/stock/news/2334275/vertex-pharmaceuticals-vrtx-stock-sinks-as-market-gains-what-you-should-know",
    "time_published": "20240910T215018",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $470.78, indicating a -0.07% shift from the previous trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default99.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.976913"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.221159,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.593715",
        "ticker_sentiment_score": "0.299821",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Vertex Stock Loses Around $3B in 3 Months: Buy the Dip or Steer Clear?",
    "url": "https://www.zacks.com/stock/news/2334770/vertex-stock-loses-around-3b-in-3-months-buy-the-dip-or-steer-clear",
    "time_published": "20240911T154400",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "VRTX is a good stock to have in one's portfolio based on its strong overall financial performance and robust pipeline progress.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/284.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.752319"
      }
    ],
    "overall_sentiment_score": 0.165938,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MRNA",
        "relevance_score": "0.063091",
        "ticker_sentiment_score": "0.008014",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.063091",
        "ticker_sentiment_score": "-0.048245",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "1 Biotech Stock Down 62% to Buy and Hold",
    "url": "https://www.fool.com/investing/2024/09/12/1-biotech-stock-down-62-to-buy-and-hold/",
    "time_published": "20240912T124500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "It's an excellent opportunity to buy shares of what could become a biotech giant on the dip.",
    "banner_image": "https://media.ycharts.com/charts/fdca1c99fbc977397f709d5f063f39ed.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.238073,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.056011",
        "ticker_sentiment_score": "0.071891",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BLUE",
        "relevance_score": "0.056011",
        "ticker_sentiment_score": "-0.112971",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cathie Wood's Ark Invest Continues To Sell Palantir - Offloads $6.4M Worth Of Shares, Loads Up On Coinbase Stock Amid Bitcoin Rebound - ARK Fintech Innovation ETF  ( ARCA:ARKF ) ",
    "url": "https://www.benzinga.com/markets/equities/24/09/40825098/cathie-woods-ark-invest-continues-to-sell-palantir-offloads-6-4m-worth-of-shares-loads-up-on-coi",
    "time_published": "20240912T034228",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "On Wednesday, the Cathie Wood-led Ark Invest made some significant trades, with Coinbase Global Inc COIN and Palantir Technologies Inc PLTR being the most prominent.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/11/8-Challenges-Cathie-Wood-Faced-And-Overc.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.986413"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.272989,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GH",
        "relevance_score": "0.219809",
        "ticker_sentiment_score": "0.296723",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.110973",
        "ticker_sentiment_score": "0.10543",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PSNL",
        "relevance_score": "0.219809",
        "ticker_sentiment_score": "0.296723",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "EXAS",
        "relevance_score": "0.219809",
        "ticker_sentiment_score": "0.296723",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.219809",
        "ticker_sentiment_score": "0.296723",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "COIN",
        "relevance_score": "0.514619",
        "ticker_sentiment_score": "0.531222",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "PLTR",
        "relevance_score": "0.423251",
        "ticker_sentiment_score": "0.319583",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.324495",
        "ticker_sentiment_score": "-0.168234",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Is Most-Watched Stock Vertex Pharmaceuticals Incorporated  ( VRTX )  Worth Betting on Now?",
    "url": "https://www.zacks.com/stock/news/2335740/is-most-watched-stock-vertex-pharmaceuticals-incorporated-vrtx-worth-betting-on-now",
    "time_published": "20240913T130012",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default306.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.223814,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.102013",
        "ticker_sentiment_score": "0.036201",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Stocks to Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/09/14/3-stocks-to-buy-and-hold-forever/",
    "time_published": "20240914T113000",
    "authors": [
      "Keith Speights",
      "David Jagielski",
      "and Prosper Junior Bakiny"
    ],
    "summary": "These stocks are built for the long run.",
    "banner_image": "https://g.foolcdn.com/editorial/images/790595/hands-behind-head-young-man.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.302576,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.420783",
        "ticker_sentiment_score": "0.432652",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.218423",
        "ticker_sentiment_score": "0.259411",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.260652",
        "ticker_sentiment_score": "0.074855",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.044222",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Prediction: These 3 Phenomenal Stocks Are Set to Soar",
    "url": "https://www.fool.com/investing/2024/09/14/prediction-these-3-phenomenal-stocks-set-to-soar/",
    "time_published": "20240914T094200",
    "authors": [
      "Keith Speights"
    ],
    "summary": "These stocks are already solid winners in 2024. They should be able to keep the momentum going.",
    "banner_image": "https://g.foolcdn.com/editorial/images/790469/smiling-man-holding-fist-up.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.208163,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.110462",
        "ticker_sentiment_score": "0.117393",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.165031",
        "ticker_sentiment_score": "0.072453",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "Z",
        "relevance_score": "0.055364",
        "ticker_sentiment_score": "-0.024049",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( VRTX )  Beats Stock Market Upswing: What Investors Need to Know",
    "url": "https://www.zacks.com/stock/news/2336824/vertex-pharmaceuticals-vrtx-beats-stock-market-upswing-what-investors-need-to-know",
    "time_published": "20240916T220022",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex Pharmaceuticals (VRTX) closed at $489.43 in the latest trading session, marking a +0.84% move from the prior day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default270.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.95493"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.269715,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.692465",
        "ticker_sentiment_score": "0.4073",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Looking Into Vertex Pharmaceuticals's Recent Short Interest - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/insights/short-sellers/24/09/40927626/looking-into-vertex-pharmaceuticalss-recent-short-interest",
    "time_published": "20240918T200055",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Vertex Pharmaceuticals's VRTX short percent of float has fallen 13.71% since its last report. The company recently reported that it has 4.38 million shares sold short, which is 1.7% of all regular shares that are available for trading.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1726689614_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.262256,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.209365",
        "ticker_sentiment_score": "0.079385",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030",
    "url": "https://www.fool.com/investing/2024/09/18/prediction-best-performing-biotech-stocks-2030/",
    "time_published": "20240918T094900",
    "authors": [
      "Keith Speights"
    ],
    "summary": "These biotech stocks have what it takes to be the biggest winners through the rest of the decade and beyond.",
    "banner_image": "https://g.foolcdn.com/editorial/images/790861/scientist-monitors-with-dna.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.15208,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MRNA",
        "relevance_score": "0.347058",
        "ticker_sentiment_score": "0.055229",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.152821",
        "ticker_sentiment_score": "0.126304",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.102231",
        "ticker_sentiment_score": "-0.076886",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Down 21% This Year, Is CRISPR Therapeutics Stock Still a Buy?",
    "url": "https://www.fool.com/investing/2024/09/19/down-21-this-year-is-crispr-therapeutics-still-buy/",
    "time_published": "20240919T083300",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "There's a lot of growth on the way, and soon.",
    "banner_image": "https://g.foolcdn.com/editorial/images/791051/lab-scientist-beaker.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.905476"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.996023"
      }
    ],
    "overall_sentiment_score": 0.188147,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.045139",
        "ticker_sentiment_score": "-0.058825",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Bull Market and Beyond: 2 Stocks Just Waiting to Soar",
    "url": "https://www.fool.com/investing/2024/09/21/bull-market-and-beyond-2-stocks-just-waiting-to/",
    "time_published": "20240921T141500",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "Great companies have persisted even in a tumultuous market.",
    "banner_image": "https://g.foolcdn.com/editorial/images/791088/confident-happy-businessman-taking-notes.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.99793"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.194301,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MRNA",
        "relevance_score": "0.03853",
        "ticker_sentiment_score": "0.167422",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.076971",
        "ticker_sentiment_score": "0.164279",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PINS",
        "relevance_score": "0.153226",
        "ticker_sentiment_score": "0.21957",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Dirt Cheap Stocks to Buy Right Now",
    "url": "https://www.fool.com/investing/2024/09/21/3-dirt-cheap-stocks-to-buy-right-now/",
    "time_published": "20240921T113600",
    "authors": [
      "Keith Speights",
      "and Prosper Junior Bakiny",
      "David Jagielski"
    ],
    "summary": "Bargain hunters should love these great stocks.",
    "banner_image": "https://g.foolcdn.com/editorial/images/791278/surprised-woman-looking-at-pc.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      }
    ],
    "overall_sentiment_score": 0.208961,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.090134",
        "ticker_sentiment_score": "0.070182",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.349329",
        "ticker_sentiment_score": "0.084178",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.265859",
        "ticker_sentiment_score": "0.202009",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "The Best Biotech Stock to Invest $1,000 in Right Now",
    "url": "https://www.fool.com/investing/2024/09/22/the-best-biotech-stock-to-invest-1000-in-right-now/",
    "time_published": "20240922T095000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "Vertex Pharmaceuticals isn't an ordinary biotech stock.",
    "banner_image": "https://g.foolcdn.com/editorial/images/791144/scientist-in-lab-young-african-american-female.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.858979"
      }
    ],
    "overall_sentiment_score": 0.183331,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.287537",
        "ticker_sentiment_score": "0.262285",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BNXYF",
        "relevance_score": "0.058759",
        "ticker_sentiment_score": "0.190007",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LDNXF",
        "relevance_score": "0.058759",
        "ticker_sentiment_score": "0.107994",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( VRTX )  Stock Declines While Market Improves: Some Information for Investors",
    "url": "https://www.zacks.com/stock/news/2340181/vertex-pharmaceuticals-vrtx-stock-declines-while-market-improves-some-information-for-investors",
    "time_published": "20240923T220022",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $460, moving -1.06% from the previous trading session.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default98.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.240314,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.465196",
        "ticker_sentiment_score": "0.30539",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Epigenetics Market to Witness 14.8% CAGR by 2031 | SkyQuest Technology",
    "url": "https://www.benzinga.com/pressreleases/24/09/g40999815/epigenetics-market-to-witness-14-8-cagr-by-2031-skyquest-technology",
    "time_published": "20240924T120000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Westford, USA, Sept. 24, 2024 ( GLOBE NEWSWIRE ) -- SkyQuest projects that Epigenetics Market will attain the value of USD 4.7 Billion by 2031, with a CAGR of 14.8% during the forecast period ( 2024-2031 ) . The prevalence of cancer across the globe is one of the major factors slowing the growth ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.18079,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.04583",
        "ticker_sentiment_score": "0.008003",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.04583",
        "ticker_sentiment_score": "0.008003",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.04583",
        "ticker_sentiment_score": "0.008003",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TAK",
        "relevance_score": "0.04583",
        "ticker_sentiment_score": "0.008003",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cathie Wood's Ark Invest Buys $4.5M Of PayPal And $3.5M Of Pinterest Shares, Sells Own Bitcoin ETF Amid Crypto Surge, And Continues Offloading Palantir - PayPal Holdings  ( NASDAQ:PYPL ) , ARK 21Shares Bitcoin ETF Common Shares of Beneficial Interests  ( BATS:ARKB ) , Pinterest  ( NYSE:PINS ) , Palantir Technologies  ( NYSE:PLTR ) ",
    "url": "https://www.benzinga.com/markets/equities/24/09/40994536/cathie-woods-ark-invest-buys-4-5m-of-paypal-and-3-5m-of-pinterest-shares-sells-own-bitcoin-etf-a",
    "time_published": "20240924T033707",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "On Monday, Cathie Wood-led Ark Invest made some significant trades. Notably, the firm bought shares of PayPal Holdings Inc PYPL and Pinterest Inc PINS, while selling its stake in ARK 21Shares Bitcoin ETF ARKB.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/23/Ark-Invest-acquista-azioni-Alphabet-e-Ro.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.795202"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.363641,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PYPL",
        "relevance_score": "0.354319",
        "ticker_sentiment_score": "0.364587",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ROKU",
        "relevance_score": "0.181819",
        "ticker_sentiment_score": "0.40582",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "DDD",
        "relevance_score": "0.181819",
        "ticker_sentiment_score": "0.40582",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "PACB",
        "relevance_score": "0.181819",
        "ticker_sentiment_score": "0.413869",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ADYYF",
        "relevance_score": "0.181819",
        "ticker_sentiment_score": "0.413869",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.181819",
        "ticker_sentiment_score": "0.413869",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "PINS",
        "relevance_score": "0.354319",
        "ticker_sentiment_score": "0.263288",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PLTR",
        "relevance_score": "0.181819",
        "ticker_sentiment_score": "0.450954",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.434514",
        "ticker_sentiment_score": "0.338504",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "If You Invested $100 In This Stock 15 Years Ago, You Would Have $1,200 Today - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/insights/news/24/09/41027417/if-you-invested-100-in-this-stock-15-years-ago-you-would-have-1-200-today",
    "time_published": "20240925T150016",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Vertex Pharmaceuticals VRTX has outperformed the market over the past 15 years by 6.9% on an annualized basis producing an average annual return of 18.94%. Currently, Vertex Pharmaceuticals has a market capitalization of $119.59 billion.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1727276412_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.238974,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.9545",
        "ticker_sentiment_score": "0.384186",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Is Trending Stock Vertex Pharmaceuticals Incorporated  ( VRTX )  a Buy Now?",
    "url": "https://www.zacks.com/stock/news/2341104/is-trending-stock-vertex-pharmaceuticals-incorporated-vrtx-a-buy-now",
    "time_published": "20240925T130012",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default341.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.219983,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.104002",
        "ticker_sentiment_score": "0.076203",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Wall Street Analysts See Vertex  ( VRTX )  as a Buy: Should You Invest?",
    "url": "https://www.zacks.com/stock/news/2341867/wall-street-analysts-see-vertex-vrtx-as-a-buy-should-you-invest",
    "time_published": "20240926T133011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The average brokerage recommendation (ABR) for Vertex (VRTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
    "banner_image": "https://staticx-tuner.zacks.com/images/yesopchart/brokerage_bar/VRTX_09262024.png",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.890401"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      }
    ],
    "overall_sentiment_score": 0.275317,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.053992",
        "ticker_sentiment_score": "0.142763",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( VRTX )  Surpasses Market Returns: Some Facts Worth Knowing",
    "url": "https://www.zacks.com/stock/news/2343709/vertex-pharmaceuticals-vrtx-surpasses-market-returns-some-facts-worth-knowing",
    "time_published": "20240930T220023",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $465.08, denoting a +0.48% change from the preceding trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default263.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.228333,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.548363",
        "ticker_sentiment_score": "0.384813",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Superluminal Medicines Announces Formation of Scientific Advisory Board",
    "url": "https://www.benzinga.com/pressreleases/24/09/g41089758/superluminal-medicines-announces-formation-of-scientific-advisory-board",
    "time_published": "20240930T120000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "BOSTON, Sept. 30, 2024 ( GLOBE NEWSWIRE ) -- Superluminal Medicines, Inc., \"The Membrane Company\" using generative biology, chemistry and machine learning approaches to revolutionize the speed and accuracy of how medicines are created, today announced the formation of its Scientific Advisory ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.15875,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ALNY",
        "relevance_score": "0.026098",
        "ticker_sentiment_score": "0.0705",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.052169",
        "ticker_sentiment_score": "0.088749",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HHH",
        "relevance_score": "0.026098",
        "ticker_sentiment_score": "0.009228",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.155619",
        "ticker_sentiment_score": "0.084572",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.026098",
        "ticker_sentiment_score": "0.0705",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions - AstraZeneca  ( NASDAQ:AZN ) , Johnson & Johnson  ( NYSE:JNJ ) ",
    "url": "https://www.benzinga.com/partner/biotech/24/10/41114297/the-rush-for-non-addictive-painkillers-to-counter-the-opioid-crisis-puts-two-companies-closer-to-",
    "time_published": "20241001T113000",
    "authors": [
      "Mangeet Kaur Bouns"
    ],
    "summary": "This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/01/Screenshot-2024-09-30-at-9-13-36PM.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": -0.201281,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.048621",
        "ticker_sentiment_score": "-0.09299",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.048621",
        "ticker_sentiment_score": "-0.107931",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.048621",
        "ticker_sentiment_score": "-0.09299",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TNXP",
        "relevance_score": "0.121159",
        "ticker_sentiment_score": "-0.019561",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.097062",
        "ticker_sentiment_score": "-0.101306",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.048621",
        "ticker_sentiment_score": "-0.09299",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "These 2 Healthcare Stocks With Big Catalysts on the Horizon Can Make You Richer",
    "url": "https://www.fool.com/investing/2024/10/02/2-healthcare-stocks-catalysts-make-you-richer/",
    "time_published": "20241002T085500",
    "authors": [
      "Justin Pope"
    ],
    "summary": "Market-beating returns could be on the way for patient investors in these two up-and-coming healthcare growth stocks.",
    "banner_image": "https://g.foolcdn.com/editorial/images/791469/light-bulb-idea.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.989041"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.118064,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.050148",
        "ticker_sentiment_score": "0.113864",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HIMS",
        "relevance_score": "0.100099",
        "ticker_sentiment_score": "-0.073733",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.100099",
        "ticker_sentiment_score": "0.129263",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust - Editas Medicine  ( NASDAQ:EDIT ) ",
    "url": "https://www.benzinga.com/pressreleases/24/10/g41176304/editas-medicine-announces-50-million-monetization-financing-with-dri-healthcare-trust",
    "time_published": "20241003T220059",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "CAMBRIDGE, Mass., Oct. 03, 2024 ( GLOBE NEWSWIRE ) -- Editas Medicine, Inc.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.235901,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DHTRF",
        "relevance_score": "0.130926",
        "ticker_sentiment_score": "0.135634",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.065685",
        "ticker_sentiment_score": "0.097142",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EDIT",
        "relevance_score": "0.838815",
        "ticker_sentiment_score": "0.38385",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust",
    "url": "https://www.globenewswire.com/news-release/2024/10/03/2958069/0/en/Editas-Medicine-Announces-50-Million-Monetization-Financing-with-DRI-Healthcare-Trust.html",
    "time_published": "20241003T220000",
    "authors": [
      "Editas Medicine",
      "Inc."
    ],
    "summary": "Strengthens balance sheet with non-dilutive capital to enable further pipeline development and related strategic priorities Strengthens balance sheet with non-dilutive capital to enable further pipeline development and related strategic priorities ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/03686b66-5cbc-40b5-9dfa-be0e7858ac97",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.576289"
      }
    ],
    "overall_sentiment_score": 0.180221,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DHTRF",
        "relevance_score": "0.091509",
        "ticker_sentiment_score": "0.124928",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.04583",
        "ticker_sentiment_score": "0.100494",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EDIT",
        "relevance_score": "0.642187",
        "ticker_sentiment_score": "0.352022",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Insider Trades: How to Find the Top Stocks",
    "url": "https://www.zacks.com/stock/news/2346302/insider-trades-how-to-find-the-top-stocks",
    "time_published": "20241004T172300",
    "authors": [
      "Tracey Ryniec"
    ],
    "summary": "Tracey is joined by Asif Suria, author of The Event-Driven Edge in Investing, to talk about how to get an edge from insider trading.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f2/1790.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998962"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.294027,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.047465",
        "ticker_sentiment_score": "0.173647",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.323078",
        "ticker_sentiment_score": "0.28436",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "Z",
        "relevance_score": "0.323078",
        "ticker_sentiment_score": "0.349073",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "YUMC",
        "relevance_score": "0.323078",
        "ticker_sentiment_score": "0.183017",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RH",
        "relevance_score": "0.279015",
        "ticker_sentiment_score": "0.443892",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.234006",
        "ticker_sentiment_score": "0.165931",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Top Stocks That Could Still Rocket Higher in 2024",
    "url": "https://www.fool.com/investing/2024/10/04/3-stocks-that-could-still-rocket-higher-in-2024/",
    "time_published": "20241004T091700",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "Upcoming Food and Drug Administration decisions could push these stocks through the roof.",
    "banner_image": "https://g.foolcdn.com/editorial/images/792697/investor-doing-stuff-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.167715,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PTCT",
        "relevance_score": "0.276909",
        "ticker_sentiment_score": "0.112284",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.186738",
        "ticker_sentiment_score": "0.159279",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BBIO",
        "relevance_score": "0.186738",
        "ticker_sentiment_score": "0.24845",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.047092",
        "ticker_sentiment_score": "0.117583",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Superior Growth Stocks That Are Screaming Buys Right Now",
    "url": "https://www.fool.com/investing/2024/10/04/2-superior-growth-stocks-that-are-screaming-buys-r/",
    "time_published": "20241004T084500",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "These companies have plenty of growth runway left.",
    "banner_image": "https://g.foolcdn.com/editorial/images/792525/couple-at-home-budget-stocks.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.270129,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.448603",
        "ticker_sentiment_score": "0.284027",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.086245",
        "ticker_sentiment_score": "0.096681",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "This Healthcare Growth Stock Could Be a Steal of a Deal Right Now",
    "url": "https://www.fool.com/investing/2024/10/05/healthcare-growth-stock-could-be-steal-of-a-deal/",
    "time_published": "20241005T082500",
    "authors": [
      "David Jagielski"
    ],
    "summary": "CRISPR Therapeutics is trading around multiyear lows.",
    "banner_image": "https://media.ycharts.com/charts/31b7cbc5e9494a62b96e86ed65b53229.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.286612,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.060848",
        "ticker_sentiment_score": "0.172051",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( VRTX )  Registers a Bigger Fall Than the Market: Important Facts to Note",
    "url": "https://www.zacks.com/stock/news/2347145/vertex-pharmaceuticals-vrtx-registers-a-bigger-fall-than-the-market-important-facts-to-note",
    "time_published": "20241007T220022",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $448.16, signifying a -1.57% move from its prior day's close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default330.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      }
    ],
    "overall_sentiment_score": 0.120503,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.592095",
        "ticker_sentiment_score": "0.139981",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Zacks Market Edge Highlights: Vertex, Zillow RH, Super Micro Computer, Yum China",
    "url": "https://www.zacks.com/stock/news/2346460/zacks-market-edge-highlights-vertex-zillow-rh-super-micro-computer-yum-china",
    "time_published": "20241007T090800",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Vertex, Zillow RH, Super Micro Computer, Yum China have been highlighted in this Market Edge article.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/29/1920.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.291651,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.041682",
        "ticker_sentiment_score": "0.171764",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.285526",
        "ticker_sentiment_score": "0.259083",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "Z",
        "relevance_score": "0.285526",
        "ticker_sentiment_score": "0.31879",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "YUMC",
        "relevance_score": "0.285526",
        "ticker_sentiment_score": "0.166078",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RH",
        "relevance_score": "0.246167",
        "ticker_sentiment_score": "0.406634",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.206157",
        "ticker_sentiment_score": "0.150263",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Biotech Stocks to Buy Hand Over Fist in October",
    "url": "https://www.fool.com/investing/2024/10/09/2-biotech-stocks-to-buy-hand-over-fist-in-october/",
    "time_published": "20241009T141500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "These longtime leading biotech stocks still have plenty of upside ahead.",
    "banner_image": "https://g.foolcdn.com/editorial/images/792380/doctor-and-patient-talking.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.249476,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.208464",
        "ticker_sentiment_score": "0.272865",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.356317",
        "ticker_sentiment_score": "0.352272",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated  ( VRTX )  is a Trending Stock",
    "url": "https://www.zacks.com/stock/news/2348104/here-is-what-to-know-beyond-why-vertex-pharmaceuticals-incorporated-vrtx-is-a-trending-stock",
    "time_published": "20241009T130011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default28.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.623304"
      }
    ],
    "overall_sentiment_score": 0.226634,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.102013",
        "ticker_sentiment_score": "0.075767",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cathie Wood's Ark Invest Trades: Bets $14M On Amazon Shares - Dumps Robinhood Stock Worth $36M, Embraces Coinbase And Meta - ARK Fintech Innovation ETF  ( ARCA:ARKF ) , Amazon.com  ( NASDAQ:AMZN ) ",
    "url": "https://www.benzinga.com/markets/equities/24/10/41242937/cathie-woods-ark-invest-trades-bets-14m-on-amazon-shares-dumps-robinhood-stock-worth-36m-embrace",
    "time_published": "20241009T024949",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "Cathie Wood's Ark Invest made significant trades in Amazon.com Inc AMZN, Robinhood Markets Inc HOOD, and Coinbase Global Inc COIN. The Amazon Trade: Ark Invest purchased 76,505 shares of Amazon, despite recent concerns about the company's growth trajectory.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/08/Perch-Cathie-Wood-sta-puntando-su-AMD-e-.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.95493"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.314231,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.201523",
        "ticker_sentiment_score": "0.347151",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TXG",
        "relevance_score": "0.201523",
        "ticker_sentiment_score": "0.420885",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.201523",
        "ticker_sentiment_score": "0.031802",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VEEV",
        "relevance_score": "0.201523",
        "ticker_sentiment_score": "0.420885",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.201523",
        "ticker_sentiment_score": "0.420885",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "RXRX",
        "relevance_score": "0.201523",
        "ticker_sentiment_score": "0.420885",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "HOOD",
        "relevance_score": "0.201523",
        "ticker_sentiment_score": "0.166308",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.556298",
        "ticker_sentiment_score": "0.354689",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "COIN",
        "relevance_score": "0.47672",
        "ticker_sentiment_score": "0.32771",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "10th Annual Glow Ride for Cystic Fibrosis Surpasses Fundraising Goal",
    "url": "https://www.benzinga.com/pressreleases/24/10/g41281845/10th-annual-glow-ride-for-cystic-fibrosis-surpasses-fundraising-goal",
    "time_published": "20241010T204004",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Los Angeles, CA, Oct. 10, 2024 ( GLOBE NEWSWIRE ) -- Claire's Place Foundation, a non-profit organization providing support to children and families affected by cystic fibrosis ( CF ) , is thrilled to announce the success of its 10th Annual Glow Ride for CF, presented by Vertex Pharmaceuticals.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.406447,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.14131",
        "ticker_sentiment_score": "0.237617",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Biotech Stocks That Are Screaming Buys This Month",
    "url": "https://www.fool.com/investing/2024/10/12/2-biotech-stocks-are-screaming-buys-this-month/",
    "time_published": "20241012T123000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "They won't remain southbound forever.",
    "banner_image": "https://g.foolcdn.com/editorial/images/793077/patient-sitting-on-hospital-bed.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.211075,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MRNA",
        "relevance_score": "0.416516",
        "ticker_sentiment_score": "0.128677",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.062434",
        "ticker_sentiment_score": "-0.02913",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Got $1,000? 2 Magnificent Growth Stocks to Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/10/13/got-1000-2-magnificent-growth-stocks-to-buy-and/",
    "time_published": "20241013T130000",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "These profitable companies are facing long-term growth runways.",
    "banner_image": "https://g.foolcdn.com/editorial/images/793586/getty-smiling-person-with-phone.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.997405"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.259239,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.070517",
        "ticker_sentiment_score": "0.078594",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UAL",
        "relevance_score": "0.035293",
        "ticker_sentiment_score": "0.194584",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PLTR",
        "relevance_score": "0.070517",
        "ticker_sentiment_score": "0.137766",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 No-Brainer Growth Stocks to Buy in October",
    "url": "https://www.fool.com/investing/2024/10/13/3-no-brainer-growth-stocks-to-buy-in-october/",
    "time_published": "20241013T111500",
    "authors": [
      "Keith Speights",
      "and Prosper Junior Bakiny",
      "David Jagielski"
    ],
    "summary": "These stocks look like slam-dunk picks for growth investors.",
    "banner_image": "https://g.foolcdn.com/editorial/images/793761/dog-with-owners-looking-at-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.163964,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.230235",
        "ticker_sentiment_score": "0.15936",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.154703",
        "ticker_sentiment_score": "0.212407",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.303644",
        "ticker_sentiment_score": "0.119385",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is CRISPR Therapeutics Stock a Buy?",
    "url": "https://www.fool.com/investing/2024/10/13/is-crispr-therapeutics-stock-a-buy/",
    "time_published": "20241013T103000",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "The markets this biotech is looking to enter could be extremely lucrative.",
    "banner_image": "https://g.foolcdn.com/editorial/images/793005/drug-development-pharmaceutical-pharma-research-researchers-doctors.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.905476"
      }
    ],
    "overall_sentiment_score": 0.231672,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.048919",
        "ticker_sentiment_score": "0.062599",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( VRTX )  Ascends But Remains Behind Market: Some Facts to Note",
    "url": "https://www.zacks.com/stock/news/2350280/vertex-pharmaceuticals-vrtx-ascends-but-remains-behind-market-some-facts-to-note",
    "time_published": "20241014T220022",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $484.94, moving +0.67% from the previous trading session.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default170.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      }
    ],
    "overall_sentiment_score": 0.193317,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.527969",
        "ticker_sentiment_score": "0.274647",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Check Out What Whales Are Doing With VRTX - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/insights/options/24/10/41342726/check-out-what-whales-are-doing-with-vrtx",
    "time_published": "20241015T190055",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Whales with a lot of money to spend have taken a noticeably bullish stance on Vertex Pharmaceuticals. Looking at options history for Vertex Pharmaceuticals VRTX we detected 13 trades.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1729018852_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.151214,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.665097",
        "ticker_sentiment_score": "0.155278",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Here's How Much $1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth Today - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/insights/news/24/10/41357653/heres-how-much-1000-invested-in-vertex-pharmaceuticals-5-years-ago-would-be-worth-today",
    "time_published": "20241016T140026",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Vertex Pharmaceuticals VRTX has outperformed the market over the past 5 years by 6.32% on an annualized basis producing an average annual return of 20.45%. Currently, Vertex Pharmaceuticals has a market capitalization of $125.03 billion.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1729087223_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.238974,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.9545",
        "ticker_sentiment_score": "0.384186",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Why I Keep Buying These 14 Incredible Growth Stocks",
    "url": "https://www.fool.com/investing/2024/10/16/why-i-keep-buying-these-14-incredible-growth-stock/",
    "time_published": "20241016T134500",
    "authors": [
      "George Budwell"
    ],
    "summary": "This diverse set of growth stocks offers tremendous opportunities in the fields of AI, space, biotech, and emerging industries.",
    "banner_image": "https://media.ycharts.com/charts/209551ba047e82fde683bf98365444c6.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.464946,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.087931",
        "ticker_sentiment_score": "0.207202",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVTS",
        "relevance_score": "0.087931",
        "ticker_sentiment_score": "0.301297",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.029363",
        "ticker_sentiment_score": "0.108736",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RKLB",
        "relevance_score": "0.087931",
        "ticker_sentiment_score": "0.197247",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ASPN",
        "relevance_score": "0.087931",
        "ticker_sentiment_score": "0.280991",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KTOS",
        "relevance_score": "0.058687",
        "ticker_sentiment_score": "0.164001",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LUNR",
        "relevance_score": "0.087931",
        "ticker_sentiment_score": "0.151986",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSM",
        "relevance_score": "0.087931",
        "ticker_sentiment_score": "0.258392",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DTII",
        "relevance_score": "0.029363",
        "ticker_sentiment_score": "0.154381",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ACHR",
        "relevance_score": "0.087931",
        "ticker_sentiment_score": "0.259438",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TM",
        "relevance_score": "0.029363",
        "ticker_sentiment_score": "0.103379",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GE",
        "relevance_score": "0.117057",
        "ticker_sentiment_score": "0.273936",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JOBY",
        "relevance_score": "0.087931",
        "ticker_sentiment_score": "0.121858",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HWM",
        "relevance_score": "0.087931",
        "ticker_sentiment_score": "0.308626",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PLTR",
        "relevance_score": "0.087931",
        "ticker_sentiment_score": "0.109185",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PRME",
        "relevance_score": "0.058687",
        "ticker_sentiment_score": "0.074984",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Market Whales and Their Recent Bets on VRTX Options - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/insights/options/24/10/41410913/market-whales-and-their-recent-bets-on-vrtx-options",
    "time_published": "20241018T200131",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Deep-pocketed investors have adopted a bullish approach towards Vertex Pharmaceuticals VRTX, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1729281688_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.137375,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.668128",
        "ticker_sentiment_score": "0.205807",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BNS",
        "relevance_score": "0.064449",
        "ticker_sentiment_score": "0.016054",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.064449",
        "ticker_sentiment_score": "0.016054",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Prediction: These 2 Stocks Will Beat the S&P 500 Through 2030",
    "url": "https://www.fool.com/investing/2024/10/19/prediction-these-2-stocks-will-beat-sp-500-through/",
    "time_published": "20241019T131500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "There's no need to change a winning formula.",
    "banner_image": "https://media.ycharts.com/charts/694d3b181e541420ab9c872a3c588833.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.297169,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MFCSF",
        "relevance_score": "0.060694",
        "ticker_sentiment_score": "0.001008",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.296582",
        "ticker_sentiment_score": "0.400101",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "HCA",
        "relevance_score": "0.405963",
        "ticker_sentiment_score": "0.303868",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Bargain Stocks to Buy in a Market That's Priced for Perfection",
    "url": "https://www.fool.com/investing/2024/10/19/3-bargain-stocks-to-buy-in-a-market-thats-priced-f/",
    "time_published": "20241019T113000",
    "authors": [
      "David Jagielski",
      "Keith Speights",
      "and Prosper Junior Bakiny"
    ],
    "summary": "Yes, bargains can still be found in the stock market.",
    "banner_image": "https://g.foolcdn.com/editorial/images/794517/light-bulb-question-marks-woman.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.938793"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.996023"
      }
    ],
    "overall_sentiment_score": 0.206517,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.044551",
        "ticker_sentiment_score": "0.072075",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BHVN",
        "relevance_score": "0.044551",
        "ticker_sentiment_score": "-0.020692",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.345073",
        "ticker_sentiment_score": "-0.050694",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXSM",
        "relevance_score": "0.304248",
        "ticker_sentiment_score": "0.282298",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why Vertex Pharmaceuticals  ( VRTX )  Dipped More Than Broader Market Today",
    "url": "https://www.zacks.com/stock/news/2354381/why-vertex-pharmaceuticals-vrtx-dipped-more-than-broader-market-today",
    "time_published": "20241021T220022",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $478.09, denoting a -1.02% change from the preceding trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default187.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.938793"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.148133,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.523451",
        "ticker_sentiment_score": "0.208558",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Looking Into Vertex Pharmaceuticals's Recent Short Interest - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/insights/short-sellers/24/10/41438660/looking-into-vertex-pharmaceuticalss-recent-short-interest",
    "time_published": "20241021T200026",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Vertex Pharmaceuticals's VRTX short percent of float has fallen 5.95% since its last report. The company recently reported that it has 4.08 million shares sold short, which is 1.58% of all regular shares that are available for trading.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1729540823_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.262256,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.209365",
        "ticker_sentiment_score": "0.079385",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why We Buy Stocks",
    "url": "https://www.fool.com/investing/2024/10/21/why-we-buy-stocks/",
    "time_published": "20241021T165200",
    "authors": [
      "Motley Fool Staff"
    ],
    "summary": "Is fear of missing out (FOMO) controlling your portfolio?",
    "banner_image": "https://g.foolcdn.com/editorial/images/794747/mfm_19.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.153645,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.014766",
        "ticker_sentiment_score": "0.087209",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.007383",
        "ticker_sentiment_score": "0.081913",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDNDF",
        "relevance_score": "0.007383",
        "ticker_sentiment_score": "0.070618",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.014766",
        "ticker_sentiment_score": "0.058703",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SFTBF",
        "relevance_score": "0.014766",
        "ticker_sentiment_score": "-0.012134",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.007383",
        "ticker_sentiment_score": "0.115356",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PLD",
        "relevance_score": "0.007383",
        "ticker_sentiment_score": "0.055227",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SCHW",
        "relevance_score": "0.022147",
        "ticker_sentiment_score": "0.068191",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HD",
        "relevance_score": "0.007383",
        "ticker_sentiment_score": "0.055227",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WINA",
        "relevance_score": "0.007383",
        "ticker_sentiment_score": "0.035585",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.007383",
        "ticker_sentiment_score": "-0.01142",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "BMY or VRTX: Which Is the Better Value Stock Right Now?",
    "url": "https://www.zacks.com/stock/news/2355104/bmy-or-vrtx-which-is-the-better-value-stock-right-now",
    "time_published": "20241022T154010",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "BMY vs. VRTX: Which Stock Is the Better Value Option?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default70.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.483813,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.550532",
        "ticker_sentiment_score": "0.481362",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.686739",
        "ticker_sentiment_score": "0.565639",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "EDIT Inks Collaboration Deal to Develop Novel Gene Editing Therapies",
    "url": "https://www.zacks.com/stock/news/2355099/edit-inks-collaboration-deal-to-develop-novel-gene-editing-therapies",
    "time_published": "20241022T153100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Editas signs a license agreement with Genevant Sciences to develop novel mRNA-LNP gene editing therapeutics. Shares rise in after-hours trading.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/62/5473.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.890401"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.149765,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ELEV",
        "relevance_score": "0.184834",
        "ticker_sentiment_score": "0.076689",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.184834",
        "ticker_sentiment_score": "0.167674",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ANIP",
        "relevance_score": "0.244723",
        "ticker_sentiment_score": "0.245032",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "EDIT",
        "relevance_score": "0.184834",
        "ticker_sentiment_score": "0.166216",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Investors Heavily Search Vertex Pharmaceuticals Incorporated  ( VRTX ) : Here is What You Need to Know",
    "url": "https://www.zacks.com/stock/news/2354609/investors-heavily-search-vertex-pharmaceuticals-incorporated-vrtx-here-is-what-you-need-to-know",
    "time_published": "20241022T130013",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default166.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.233287,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.103778",
        "ticker_sentiment_score": "0.036383",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the VanEck Biotech ETF  ( BBH ) ?",
    "url": "https://www.zacks.com/stock/news/2354481/should-you-invest-in-the-vaneck-biotech-etf-bbh",
    "time_published": "20241022T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default166.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.186298,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.071096",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.071096",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.071096",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings",
    "url": "https://www.zacks.com/stock/news/2355573/how-to-boost-your-portfolio-with-top-medical-stocks-set-to-beat-earnings",
    "time_published": "20241023T125011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default113.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999973"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.357473,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.338119",
        "ticker_sentiment_score": "0.269006",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ZTS",
        "relevance_score": "0.400265",
        "ticker_sentiment_score": "0.344661",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals Just Found Its Newest Blockbuster Drug. A $41 Billion Market Awaits",
    "url": "https://www.fool.com/investing/2024/10/24/vertex-pharmaceuticals-just-found-its-newest-block/",
    "time_published": "20241024T131500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Its latest report of clinical data suggests it has a winner on its hands.",
    "banner_image": "https://g.foolcdn.com/editorial/images/794810/doctors-with-investors.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.245103,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GLDAF",
        "relevance_score": "0.052112",
        "ticker_sentiment_score": "0.107545",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.104002",
        "ticker_sentiment_score": "0.188844",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright",
    "url": "https://www.zacks.com/commentary/2356709/5-biotech-stocks-likely-to-outperform-as-industry-prospects-look-bright",
    "time_published": "20241024T130600",
    "authors": [
      "Ekta Bagri"
    ],
    "summary": "New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position EXEL, BPMC, CRSP, FOLD and VRNA well in this volatile sector.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c2/53795.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.95493"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.261287,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "FOLD",
        "relevance_score": "0.076115",
        "ticker_sentiment_score": "0.175425",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRNA",
        "relevance_score": "0.050786",
        "ticker_sentiment_score": "0.099792",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.025406",
        "ticker_sentiment_score": "0.051695",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXEL",
        "relevance_score": "0.076115",
        "ticker_sentiment_score": "0.175425",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BPMC",
        "relevance_score": "0.050786",
        "ticker_sentiment_score": "0.099792",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.025406",
        "ticker_sentiment_score": "0.051695",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LBPH",
        "relevance_score": "0.025406",
        "ticker_sentiment_score": "0.051695",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Smartest Growth Stock to Buy With $500 Right Now",
    "url": "https://www.fool.com/investing/2024/10/25/the-smartest-growth-stock-to-buy-with-500-right-no/",
    "time_published": "20241025T094500",
    "authors": [
      "Keith Speights"
    ],
    "summary": "This stock might not be available for under $500 for long.",
    "banner_image": "https://g.foolcdn.com/editorial/images/794985/light-bulbs-with-dollar-sign-person-looking-up.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.658903"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.311901,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.107016",
        "ticker_sentiment_score": "0.209232",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MELI",
        "relevance_score": "0.053629",
        "ticker_sentiment_score": "0.195753",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.053629",
        "ticker_sentiment_score": "0.195753",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TTD",
        "relevance_score": "0.053629",
        "ticker_sentiment_score": "0.195753",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma",
    "url": "https://www.zacks.com/stock/news/2357442/zacks-industry-outlook-highlights-exelixis-blueprint-medicines-crispr-amicus-and-verona-pharma",
    "time_published": "20241025T085900",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma have been highlighted in this Industry Outlook article.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/86/1981.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.95493"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.858979"
      }
    ],
    "overall_sentiment_score": 0.272514,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "FOLD",
        "relevance_score": "0.097161",
        "ticker_sentiment_score": "0.138357",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRNA",
        "relevance_score": "0.121282",
        "ticker_sentiment_score": "0.150504",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.048671",
        "ticker_sentiment_score": "0.178941",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "EXEL",
        "relevance_score": "0.145291",
        "ticker_sentiment_score": "0.143112",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BPMC",
        "relevance_score": "0.07295",
        "ticker_sentiment_score": "0.043452",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.024347",
        "ticker_sentiment_score": "0.099757",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LBPH",
        "relevance_score": "0.024347",
        "ticker_sentiment_score": "0.099757",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "EQS-News: BB Biotech: Strategic reallocation of portfolio assets progressing",
    "url": "https://markets.businessinsider.com/news/stocks/eqs-news-bb-biotech-strategic-reallocation-of-portfolio-assets-progressing-1033890513",
    "time_published": "20241025T050015",
    "authors": [
      "markets.businessinsider.com"
    ],
    "summary": "BB Biotech: Strategic reallocation of portfolio assets progressing Portfolio of BB Biotech AG as at September 30, 2024 A key event during the period under review was the US Federal Reserve's decision in September to lower interest rates by 50 bps, marking its first rate cut in four years.",
    "banner_image": "https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&amp;application_id=2015565&amp;application_name=news&amp;site_id=finanzen_net~~~069d1026-6a45-454f-953c-2a2c4451f1d6",
    "source": "Business Insider",
    "category_within_source": "RSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999365"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.241981,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BHVN",
        "relevance_score": "0.036365",
        "ticker_sentiment_score": "0.117831",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CLDX",
        "relevance_score": "0.036365",
        "ticker_sentiment_score": "0.102599",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RLAY",
        "relevance_score": "0.072655",
        "ticker_sentiment_score": "0.085454",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EWTX",
        "relevance_score": "0.036365",
        "ticker_sentiment_score": "0.334274",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NBIX",
        "relevance_score": "0.036365",
        "ticker_sentiment_score": "-0.194075",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "WVE",
        "relevance_score": "0.108794",
        "ticker_sentiment_score": "0.12495",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALNY",
        "relevance_score": "0.036365",
        "ticker_sentiment_score": "0.26891",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.036365",
        "ticker_sentiment_score": "-0.02",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IONS",
        "relevance_score": "0.036365",
        "ticker_sentiment_score": "0.090391",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXEL",
        "relevance_score": "0.036365",
        "ticker_sentiment_score": "0.012019",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cathie Wood's Ark Sells $22M Worth Of Tesla Shares Following Blockbuster Q3 Rally - ARK Autonomous Technology & Robotics ETF  ( BATS:ARKQ ) , ARK Innovation ETF  ( ARCA:ARKK ) ",
    "url": "https://www.benzinga.com/markets/equities/24/10/41536387/cathie-woods-ark-sells-22m-worth-of-tesla-shares-following-blockbuster-q3-rally",
    "time_published": "20241025T023704",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "On Thursday, Cathie Wood-led Ark Invest made a series of trades, with the most prominent being the sale of Tesla Inc TSLA shares. Ark Invest sold 85,456 Tesla shares from its ARK Innovation ETF ARKK and ARK Autonomous Technology & Robotics ETF ARKQ, a transaction valued at $22.22 million based on ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/24/Cathie-Woods-Monday-Maneuvers-Ark-Invest.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.384609,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TER",
        "relevance_score": "0.247838",
        "ticker_sentiment_score": "0.41022",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CRSP",
        "relevance_score": "0.247838",
        "ticker_sentiment_score": "0.368803",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.730954",
        "ticker_sentiment_score": "0.566474",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.247838",
        "ticker_sentiment_score": "0.368803",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CERS",
        "relevance_score": "0.247838",
        "ticker_sentiment_score": "0.41022",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "OPTGF",
        "relevance_score": "0.12546",
        "ticker_sentiment_score": "-0.038892",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NTLA",
        "relevance_score": "0.247838",
        "ticker_sentiment_score": "0.41022",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "The Ultimate Biotech Stock to Buy With $50 Right Now",
    "url": "https://www.fool.com/investing/2024/10/26/the-ultimate-biotech-stock-to-buy-with-50/",
    "time_published": "20241026T103200",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "This company might be worth far more than many realize.",
    "banner_image": "https://media.ycharts.com/charts/77fb4721dcdbd8ad965ca4f86c05c498.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.955357"
      }
    ],
    "overall_sentiment_score": 0.187709,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.050679",
        "ticker_sentiment_score": "0.049024",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BLUE",
        "relevance_score": "0.050679",
        "ticker_sentiment_score": "-0.106985",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( VRTX )  Stock Drops Despite Market Gains: Important Facts to Note",
    "url": "https://www.zacks.com/stock/news/2359077/vertex-pharmaceuticals-vrtx-stock-drops-despite-market-gains-important-facts-to-note",
    "time_published": "20241028T220022",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex Pharmaceuticals (VRTX) closed at $476.37 in the latest trading session, marking a -0.28% move from the prior day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default127.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.176269,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.5341",
        "ticker_sentiment_score": "0.267592",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 5 Years - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/insights/news/24/10/41585226/heres-how-much-you-would-have-made-owning-vertex-pharmaceuticals-stock-in-the-last-5-years",
    "time_published": "20241028T193013",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Vertex Pharmaceuticals VRTX has outperformed the market over the past 5 years by 5.11% on an annualized basis producing an average annual return of 18.8%. Currently, Vertex Pharmaceuticals has a market capitalization of $122.70 billion.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1730143810_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.238974,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.9545",
        "ticker_sentiment_score": "0.384186",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Top Stocks To Buy Now? 2 Biotech Stocks To Watch",
    "url": "https://stockmarket.com/featured/top-stocks-to-buy-now-2-biotech-stocks-to-watch-2024-10-28",
    "time_published": "20241028T151546",
    "authors": [
      "Brett David"
    ],
    "summary": "The biotech sector represents companies developing innovative treatments and therapies using biological processes. These firms range from early-stage research companies to established pharmaceutical developers. Biotech stocks offer investment opportunities in companies working on groundbreaking ...",
    "banner_image": "https://u3j7m9h7.rocketcdn.me/wp-content/uploads/2020/06/VRTX-stock.jpg",
    "source": "StockMarket.com",
    "category_within_source": "n/a",
    "source_domain": "stockmarket.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999967"
      }
    ],
    "overall_sentiment_score": 0.165959,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "REGN",
        "relevance_score": "0.310843",
        "ticker_sentiment_score": "0.111399",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.310843",
        "ticker_sentiment_score": "0.208852",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( VRTX )  Earnings Expected to Grow: What to Know Ahead of Next Week's Release",
    "url": "https://www.zacks.com/stock/news/2358667/vertex-pharmaceuticals-vrtx-earnings-expected-to-grow-what-to-know-ahead-of-next-weeks-release",
    "time_published": "20241028T140117",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default238.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.156561,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.087663",
        "ticker_sentiment_score": "0.1249",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARQT",
        "relevance_score": "0.174272",
        "ticker_sentiment_score": "-0.024176",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "12 High-Growth Stocks That Could Deliver Parabolic Returns",
    "url": "https://www.fool.com/investing/2024/10/28/12-high-growth-stocks-that-could-deliver-parabolic/",
    "time_published": "20241028T140000",
    "authors": [
      "George Budwell"
    ],
    "summary": "These 12 innovative companies could deliver exponential returns over the next quarter century.",
    "banner_image": "https://media.ycharts.com/charts/05b4a537bf94811b3e862833313229be.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.955357"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.318995,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.085476",
        "ticker_sentiment_score": "0.288263",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVTS",
        "relevance_score": "0.085476",
        "ticker_sentiment_score": "0.181238",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.0428",
        "ticker_sentiment_score": "0.059232",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RKLB",
        "relevance_score": "0.085476",
        "ticker_sentiment_score": "0.167771",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LUNR",
        "relevance_score": "0.085476",
        "ticker_sentiment_score": "0.15742",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SERV",
        "relevance_score": "0.085476",
        "ticker_sentiment_score": "0.203014",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ACHR",
        "relevance_score": "0.085476",
        "ticker_sentiment_score": "0.070758",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SOUN",
        "relevance_score": "0.085476",
        "ticker_sentiment_score": "0.243522",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "APLD",
        "relevance_score": "0.085476",
        "ticker_sentiment_score": "0.171913",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SPCE",
        "relevance_score": "0.085476",
        "ticker_sentiment_score": "0.163266",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TM",
        "relevance_score": "0.0428",
        "ticker_sentiment_score": "0.007837",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JOBY",
        "relevance_score": "0.085476",
        "ticker_sentiment_score": "0.00825",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NTLA",
        "relevance_score": "0.085476",
        "ticker_sentiment_score": "0.024211",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PRME",
        "relevance_score": "0.085476",
        "ticker_sentiment_score": "0.134671",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "CRISPR Therapeutics to Report Q3 Earnings: Is a Beat in Store?",
    "url": "https://www.zacks.com/stock/news/2358537/crispr-therapeutics-to-report-q3-earnings-is-a-beat-in-store",
    "time_published": "20241028T123500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "On CRSP's third-quarter 2024 earnings call, investors will likely focus on the sales numbers of its recently approved gene therapy, Casgevy.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default217.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.998917"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.160914,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.116914",
        "ticker_sentiment_score": "0.175302",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.231332",
        "ticker_sentiment_score": "0.062253",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRSP",
        "relevance_score": "0.340915",
        "ticker_sentiment_score": "0.247697",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?",
    "url": "https://www.zacks.com/stock/news/2359751/vertex-gears-up-to-report-q3-earnings-is-a-beat-in-the-cards",
    "time_published": "20241029T151800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "VRTX's revenues in the third quarter of 2024 are likely to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/29/1920.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999756"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.191337,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.231332",
        "ticker_sentiment_score": "0.13681",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXEL",
        "relevance_score": "0.231332",
        "ticker_sentiment_score": "0.12761",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.231332",
        "ticker_sentiment_score": "-0.063645",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Earnings Preview: IDEAYA Biosciences, Inc.  ( IDYA )  Q3 Earnings Expected to Decline",
    "url": "https://www.zacks.com/stock/news/2359599/earnings-preview-ideaya-biosciences-inc-idya-q3-earnings-expected-to-decline",
    "time_published": "20241029T140107",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "IDEAYA Biosciences (IDYA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default89.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.117138,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.087824",
        "ticker_sentiment_score": "0.038066",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IDYA",
        "relevance_score": "0.259267",
        "ticker_sentiment_score": "-0.073619",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board - Skye Bioscience  ( NASDAQ:SKYE ) ",
    "url": "https://www.benzinga.com/pressreleases/24/10/g41595201/skye-bioscience-names-independent-director-paul-grayson-as-chairman-of-the-board",
    "time_published": "20241029T110000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "SAN DIEGO, Oct. 29, 2024 ( GLOBE NEWSWIRE ) -- Skye Bioscience, Inc. SKYE ( \"Skye\" ) , a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced the Board has appointed independent director Paul Grayson as Skye's new Chairman of ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.744043"
      }
    ],
    "overall_sentiment_score": 0.14002,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "FATE",
        "relevance_score": "0.04583",
        "ticker_sentiment_score": "0.043157",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.04583",
        "ticker_sentiment_score": "0.043157",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SKYE",
        "relevance_score": "0.136888",
        "ticker_sentiment_score": "0.06972",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why the Market Dipped But Vertex Pharmaceuticals  ( VRTX )  Gained Today",
    "url": "https://www.zacks.com/stock/news/2361146/why-the-market-dipped-but-vertex-pharmaceuticals-vrtx-gained-today",
    "time_published": "20241030T215019",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $475.08, representing a +1% change from its previous close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default330.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.990786"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.182107,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.595343",
        "ticker_sentiment_score": "0.285943",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.082963",
        "ticker_sentiment_score": "-0.046943",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex  ( VRTX )  Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures",
    "url": "https://www.zacks.com/stock/news/2360462/vertex-vrtx-q3-earnings-on-the-horizon-analysts-insights-on-key-performance-measures",
    "time_published": "20241030T131527",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Besides Wall Street's top -and-bottom-line estimates for Vertex (VRTX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default99.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.947132"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.220356,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.233556",
        "ticker_sentiment_score": "0.196823",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "T. Rowe Price Is 'One Of The Most Consistent' Companies: Cramer - CME Gr  ( NASDAQ:CME ) ",
    "url": "https://www.benzinga.com/news/24/10/41652163/jim-cramer-this-financial-stock-is-one-of-the-most-consistent-great-companies",
    "time_published": "20241031T123412",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "On CNBC's \"Mad Money Lightning Round,\" Jim Cramer said Vertex Pharmaceuticals Incorporated VRTX is a buy. \"This company is doing the lord's work,\" he added. On Wednesday, Oppenheimer analyst Hartaj Singh maintained Vertex Pharmaceuticals with an Outperform and lowered the price target from $550 ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/31/Jim-Cramer-perch-la-performance-di-Nvidi.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.252164,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MU",
        "relevance_score": "0.275867",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.519739",
        "ticker_sentiment_score": "0.268143",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CME",
        "relevance_score": "0.519739",
        "ticker_sentiment_score": "0.609791",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Thinking of Buying CRISPR Therapeutics Stock? Watch These 2 Key Numbers",
    "url": "https://www.fool.com/investing/2024/11/02/thinking-of-buying-crispr-therapeutics-stock-watch/",
    "time_published": "20241102T140000",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "It won't be able to be profitable without hitting its targets for both of these figures.",
    "banner_image": "https://g.foolcdn.com/editorial/images/795582/woman-stock-broker-investor-tracking-stocks.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.988915"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.176476,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.052918",
        "ticker_sentiment_score": "0.044914",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( VRTX )  Q3 Earnings and Revenues Top Estimates",
    "url": "https://www.zacks.com/stock/news/2363756/vertex-pharmaceuticals-vrtx-q3-earnings-and-revenues-top-estimates",
    "time_published": "20241104T221509",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex (VRTX) delivered earnings and revenue surprises of 6.05% and 3.62%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default255.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999953"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.141847,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GBIO",
        "relevance_score": "0.20997",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.140896",
        "ticker_sentiment_score": "0.09672",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Arcturus Gears Up to Report Q3 Earnings: Here's What to Expect",
    "url": "https://www.zacks.com/stock/news/2363525/arcturus-gears-up-to-report-q3-earnings-heres-what-to-expect",
    "time_published": "20241104T150500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "On ARCT's third-quarter 2024 earnings call, investors' focus is likely to be on the upcoming launch of its COVID-19 vaccine, Kostaive and other pipeline updates.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999953"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.165866,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.208017",
        "ticker_sentiment_score": "0.117398",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ACAD",
        "relevance_score": "0.208017",
        "ticker_sentiment_score": "-0.034914",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRSP",
        "relevance_score": "0.1568",
        "ticker_sentiment_score": "-0.005445",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARCT",
        "relevance_score": "0.531716",
        "ticker_sentiment_score": "0.058789",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Jim Cramer Says Vertex Doing 'Lord's Work': Can Q3 Earnings Outshine Bearish Charts? - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/general/biotech/24/11/41713478/jim-cramer-says-vertex-doing-lords-work-can-q3-earnings-outshine-bearish-charts",
    "time_published": "20241104T134810",
    "authors": [
      "Surbhi Jain"
    ],
    "summary": "Vertex Pharmaceuticals Inc VRTX will be reporting its third-quarter earnings on Monday. Wall Street expects $4.14 in EPS and $2.72 billion in revenues as the company reports after market hours.",
    "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/04083044/Screenshot-2024-11-04-at-5.45.49-PM.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.172639,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.468029",
        "ticker_sentiment_score": "0.125839",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Editas Medicine Announces Third Quarter 2024 Results and Business Updates",
    "url": "https://www.globenewswire.com/news-release/2024/11/04/2973941/0/en/Editas-Medicine-Announces-Third-Quarter-2024-Results-and-Business-Updates.html",
    "time_published": "20241104T123000",
    "authors": [
      "Editas Medicine",
      "Inc."
    ],
    "summary": "Achieved in vivo preclinical proof of concept of HBG1/2 editing in hematopoietic stem and progenitor cells ( HSPCs ) using Editas Medicine's proprietary targeted LNP in a key step to developing a novel in vivo treatment for sickle cell disease and beta thalassemia ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/03686b66-5cbc-40b5-9dfa-be0e7858ac97",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.150685,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.023259",
        "ticker_sentiment_score": "0.060203",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EDIT",
        "relevance_score": "0.295319",
        "ticker_sentiment_score": "0.136067",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DHTRF",
        "relevance_score": "0.023259",
        "ticker_sentiment_score": "0.060203",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MC",
        "relevance_score": "0.023259",
        "ticker_sentiment_score": "0.060203",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Spotlight on Vertex Pharmaceuticals: Analyzing the Surge in Options Activity - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/insights/options/24/11/41754262/spotlight-on-vertex-pharmaceuticals-analyzing-the-surge-in-options-activity",
    "time_published": "20241105T183210",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bullish stance on Vertex Pharmaceuticals VRTX. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1730831527_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.155829,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.637911",
        "ticker_sentiment_score": "0.186845",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BNS",
        "relevance_score": "0.060541",
        "ticker_sentiment_score": "0.073065",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Wall Street Rallies On Election Day, Palantir Skyrockets, Bitcoin Tops $70,000: What's Driving Markets Tuesday?",
    "url": "https://www.benzinga.com/markets/cryptocurrency/24/11/41753325/wall-street-rallies-on-election-day-palantir-skyrockets-bitcoin-tops-70-000-whats-driving-",
    "time_published": "20241105T175849",
    "authors": [
      "Piero Cingari"
    ],
    "summary": "Wall Street rallied on Tuesday as improved investor sentiment aligned with millions of Americans casting their votes for the 47th president. Betting markets leaned slightly toward Donald Trump, with CFTC-regulated Kalshi placing Trump's win probability at 56% compared to Kamala Harris's 44%.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/05/Wall-Street_2.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.372018,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TRGP",
        "relevance_score": "0.179121",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MPC",
        "relevance_score": "0.179121",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ILMN",
        "relevance_score": "0.179121",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NXPI",
        "relevance_score": "0.179121",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NYT",
        "relevance_score": "0.090134",
        "ticker_sentiment_score": "0.122448",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.179121",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EMR",
        "relevance_score": "0.179121",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.090134",
        "ticker_sentiment_score": "0.258633",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "APOS",
        "relevance_score": "0.090134",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "YUM",
        "relevance_score": "0.179121",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FANG",
        "relevance_score": "0.179121",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMI",
        "relevance_score": "0.179121",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AIG",
        "relevance_score": "0.179121",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PLTR",
        "relevance_score": "0.265859",
        "ticker_sentiment_score": "0.318517",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.265859",
        "ticker_sentiment_score": "0.304188",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.179121",
        "ticker_sentiment_score": "0.341066",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRYPTO:DOGE",
        "relevance_score": "0.179121",
        "ticker_sentiment_score": "0.341066",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "VRTX Q3 Earnings & Sales Trump Estimates, '24 Sales View Raised",
    "url": "https://www.zacks.com/stock/news/2364573/vrtx-q3-earnings-sales-trump-estimates-24-sales-view-raised",
    "time_published": "20241105T162500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex's third-quarter 2024 earnings and revenues beat estimates. The company raises its full-year product revenue guidance.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/29/1920.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999858"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.107027,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AVIR",
        "relevance_score": "0.120885",
        "ticker_sentiment_score": "0.08498",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOLD",
        "relevance_score": "0.090816",
        "ticker_sentiment_score": "0.09961",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.15078",
        "ticker_sentiment_score": "-0.027832",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Editas Q3 Loss Narrower Than Expected, Revenues Decrease Y/Y",
    "url": "https://www.zacks.com/stock/news/2364555/editas-q3-loss-narrower-than-expected-revenues-decrease-yy",
    "time_published": "20241105T160100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "EDIT reports mixed third-quarter 2024 results as earnings beat expectations while revenues miss the same.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/1076.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.150265,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ALLO",
        "relevance_score": "0.179454",
        "ticker_sentiment_score": "0.090913",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.090304",
        "ticker_sentiment_score": "0.107894",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EDIT",
        "relevance_score": "0.223248",
        "ticker_sentiment_score": "-0.017307",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DHTRF",
        "relevance_score": "0.045224",
        "ticker_sentiment_score": "0.127169",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "5 Top Stocks to Buy in November",
    "url": "https://www.fool.com/investing/2024/11/05/5-top-stocks-to-buy-in-november/",
    "time_published": "20241105T143200",
    "authors": [
      "Anders Bylund",
      "and Neha Chamaria",
      "Daniel Foelber",
      "Keith Speights",
      "Demitri Kalogeropoulos"
    ],
    "summary": "From blue chip dividend stocks to industry-leading growth stocks, there are plenty of bargains in today's market if you know where to look.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F796362%2Ffall-leaves-covering-money-1200x928-7a3bd5a.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.227878,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.159437",
        "ticker_sentiment_score": "0.150034",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.060135",
        "ticker_sentiment_score": "0.104309",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ROKU",
        "relevance_score": "0.237165",
        "ticker_sentiment_score": "0.133667",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.020062",
        "ticker_sentiment_score": "-0.046814",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.080121",
        "ticker_sentiment_score": "0.084366",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TTD",
        "relevance_score": "0.020062",
        "ticker_sentiment_score": "0.094978",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.080121",
        "ticker_sentiment_score": "0.06643",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PEP",
        "relevance_score": "0.020062",
        "ticker_sentiment_score": "0.109933",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "My 2 Favorite Growth Stocks to Buy Hand Over Fist in November",
    "url": "https://www.fool.com/investing/2024/11/05/my-2-favorite-growth-stocks-to-buy-hand-over-fist/",
    "time_published": "20241105T105300",
    "authors": [
      "Keith Speights"
    ],
    "summary": "The sky's the limit for these stocks.",
    "banner_image": "https://g.foolcdn.com/editorial/images/796428/happy-traders-wall-street-celebrating-profit-growth-win.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.977154"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.326856,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.107495",
        "ticker_sentiment_score": "0.037604",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.363768",
        "ticker_sentiment_score": "0.310924",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( VRTX )  Q3 2024 Earnings Call Transcript",
    "url": "https://www.fool.com/earnings/call-transcripts/2024/11/04/vertex-pharmaceuticals-vrtx-q3-2024-earnings-call/",
    "time_published": "20241105T014511",
    "authors": [
      "Motley Fool Transcribing"
    ],
    "summary": "VRTX earnings call for the period ending September 30, 2024.",
    "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.192688,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EVR",
        "relevance_score": "0.004885",
        "ticker_sentiment_score": "0.189254",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.004885",
        "ticker_sentiment_score": "0.14053",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.004885",
        "ticker_sentiment_score": "0.129992",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.004885",
        "ticker_sentiment_score": "0.14053",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.004885",
        "ticker_sentiment_score": "0.19572",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.004885",
        "ticker_sentiment_score": "0.129992",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.004885",
        "ticker_sentiment_score": "-0.033303",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ORINY",
        "relevance_score": "0.004885",
        "ticker_sentiment_score": "-0.03756",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( VRTX )  Just Overtook the 20-Day Moving Average",
    "url": "https://www.zacks.com/stock/news/2365163/vertex-pharmaceuticals-vrtx-just-overtook-the-20-day-moving-average",
    "time_published": "20241106T143503",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default22.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.310239,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.722944",
        "ticker_sentiment_score": "0.614268",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( VRTX )  Crossed Above the 50-Day Moving Average: What That Means for Investors",
    "url": "https://www.zacks.com/stock/news/2365203/vertex-pharmaceuticals-vrtx-crossed-above-the-50-day-moving-average-what-that-means-for-investors",
    "time_published": "20241106T143002",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Is it a good or bad thing when a stock surpasses resistance at the 50-day simple moving average?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default5.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.397012,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.807885",
        "ticker_sentiment_score": "0.615044",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "CRSP's Q3 Loss Narrower Than Expected, Sales Miss Estimates",
    "url": "https://www.zacks.com/stock/news/2364979/crsps-q3-loss-narrower-than-expected-sales-miss-estimates",
    "time_published": "20241106T132700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "CRISPR Therapeutics reports mixed third-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is progressing well.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.976913"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.101561,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "FOLD",
        "relevance_score": "0.222327",
        "ticker_sentiment_score": "0.122746",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.222327",
        "ticker_sentiment_score": "0.247218",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRSP",
        "relevance_score": "0.378777",
        "ticker_sentiment_score": "0.159047",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.167709",
        "ticker_sentiment_score": "0.16219",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Moderna Stock Rises on Q3 Earnings & Sales Beat, Reiterates View",
    "url": "https://www.zacks.com/stock/news/2366778/moderna-stock-rises-on-q3-earnings-sales-beat-reiterates-view",
    "time_published": "20241107T183100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "MRNA reports better-than-expected third-quarter earnings. It reiterates the guidance of product sales to between $3 billion and $3.5 billion for 2024.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/a1/7439.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.998311"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.1157,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "FOLD",
        "relevance_score": "0.19331",
        "ticker_sentiment_score": "0.074875",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.039033",
        "ticker_sentiment_score": "0.0918",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.537109",
        "ticker_sentiment_score": "0.102325",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.155201",
        "ticker_sentiment_score": "0.11182",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Biotech Stocks You Can Buy Hand Over Fist This Month",
    "url": "https://www.fool.com/investing/2024/11/08/2-biotech-stocks-you-can-buy-hand-over-fist-this/",
    "time_published": "20241108T150000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "Both stocks have made significant breakthroughs.",
    "banner_image": "https://media.ycharts.com/charts/41611407ab76c5939f43deda4b22261a.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.264762,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MRNA",
        "relevance_score": "0.271576",
        "ticker_sentiment_score": "0.248211",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.218817",
        "ticker_sentiment_score": "0.051505",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals Incorporated  ( VRTX )  Is a Trending Stock: Facts to Know Before Betting on It",
    "url": "https://www.zacks.com/stock/news/2367311/vertex-pharmaceuticals-incorporated-vrtx-is-a-trending-stock-facts-to-know-before-betting-on-it",
    "time_published": "20241108T140011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default185.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.239334,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.103778",
        "ticker_sentiment_score": "0.036383",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Biotechnology Market Value Set to Reach $2,667.36 Billion, Driven by 17.09% CAGR | Fact.MR Report",
    "url": "https://www.benzinga.com/pressreleases/24/11/g41875780/biotechnology-market-value-set-to-reach-2-667-36-billion-driven-by-17-09-cagr-fact-mr-report",
    "time_published": "20241111T123000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Rockville, MD, Nov. 11, 2024 ( GLOBE NEWSWIRE ) -- According to a new industry report by Fact.MR, a market research and competitive intelligence provider, the global biotechnology market is projected to reach a size of US$ 550.83 billion in 2024 and further touch US$ 2667.36 billion by the end ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/5570f77b-733f-4ab3-b5dd-e543a053beed/biotechnology-market.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.320652,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.039289",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.039289",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.039289",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.039289",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.039289",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.039289",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.039289",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "GILD or VRTX: Which Is the Better Value Stock Right Now?",
    "url": "https://www.zacks.com/stock/news/2369071/gild-or-vrtx-which-is-the-better-value-stock-right-now",
    "time_published": "20241112T164011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "GILD vs. VRTX: Which Stock Is the Better Value Option?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default282.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.470087,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.614479",
        "ticker_sentiment_score": "0.492395",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.73545",
        "ticker_sentiment_score": "0.565882",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics",
    "url": "https://www.globenewswire.com/news-release/2024/11/13/2980247/0/en/MaxCyte-Celebrates-25-Years-of-Innovation-Driving-Cell-Engineering-Based-Therapeutics.html",
    "time_published": "20241113T130500",
    "authors": [
      "MaxCyte",
      "Inc"
    ],
    "summary": "Since 1999, MaxCyte's non-viral cell engineering innovations have helped launch pioneering cell and gene therapy projects Since 1999, MaxCyte's non-viral cell engineering innovations have helped launch pioneering cell and gene therapy projects ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/8f0f0d48-fc4f-4d03-ac70-f4d096a780bd",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.235792,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MXCT",
        "relevance_score": "0.373611",
        "ticker_sentiment_score": "0.341983",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.048523",
        "ticker_sentiment_score": "0.135923",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Unstoppable Growth Stocks I'm Loading $25,000 Each Into by 2029",
    "url": "https://www.fool.com/investing/2024/11/13/3-unstoppable-growth-stocks-im-loading-25000-each/",
    "time_published": "20241113T113000",
    "authors": [
      "George Budwell"
    ],
    "summary": "These three emerging technology leaders are pioneering quantum computing, gene editing, and electric aviation.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F797566%2Fgrowth-trend.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.262889,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.054983",
        "ticker_sentiment_score": "0.102692",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ACHR",
        "relevance_score": "0.109705",
        "ticker_sentiment_score": "0.087417",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ANSS",
        "relevance_score": "0.054983",
        "ticker_sentiment_score": "0.134843",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JPNRF",
        "relevance_score": "0.054983",
        "ticker_sentiment_score": "0.161869",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.054983",
        "ticker_sentiment_score": "0.134843",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.054983",
        "ticker_sentiment_score": "0.079829",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.054983",
        "ticker_sentiment_score": "0.096826",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IONQ",
        "relevance_score": "0.217346",
        "ticker_sentiment_score": "0.181155",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Prediction: This Biotech Stock Is Heading for a Once-in-a-Generation Opportunity",
    "url": "https://www.fool.com/investing/2024/11/13/prediction-this-biotech-stock-is-heading-for-a-onc/",
    "time_published": "20241113T091500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Regulators are reviewing what could become a multi-billion-dollar drug.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F797520%2Fgettyimages-1253877215.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.106793,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.112008",
        "ticker_sentiment_score": "0.122022",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Where Will CRISPR Therapeutics Be in 3 Years?",
    "url": "https://www.fool.com/investing/2024/11/15/where-will-crispr-therapeutics-be-in-3-years/",
    "time_published": "20241115T104500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "CRISPR Therapeutics ( NASDAQ: CRSP ) made a name for itself by pioneering advanced gene therapies made with technologies that didn't exist a generation ago. Now, its challenge is to build on its prior successes to become a biotech powerhouse and prove to investors that it isn't a one-trick ...",
    "banner_image": "https://g.foolcdn.com/editorial/images/797558/lab-scientist-beaker.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.111634,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.048523",
        "ticker_sentiment_score": "0.138357",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More",
    "url": "https://www.fool.com/investing/2024/11/16/2-top-biotech-stocks-to-buy-now-and-hold-for-5-yea/",
    "time_published": "20241116T110000",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Biotechs often need several years to realize their visions, even after they have a drug approved for the first time. There's typically plenty of upside in store for enterprising and patient investors.Here are two such opportunities that are ripe for buying today, provided that you're willing to ...",
    "banner_image": "https://g.foolcdn.com/editorial/images/797895/scientists-doing-research-in-lab.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.337118,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.066414",
        "ticker_sentiment_score": "0.028318",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IOVA",
        "relevance_score": "0.132368",
        "ticker_sentiment_score": "0.021195",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "A Closer Look at Vertex Pharmaceuticals's Options Market Dynamics - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/insights/options/24/11/42047730/a-closer-look-at-vertex-pharmaceuticalss-options-market-dynamics",
    "time_published": "20241118T203021",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Whales with a lot of money to spend have taken a noticeably bearish stance on Vertex Pharmaceuticals. Looking at options history for Vertex Pharmaceuticals VRTX we detected 8 trades. If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with ...",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1731961818_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.125961,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.689458",
        "ticker_sentiment_score": "0.056772",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNS",
        "relevance_score": "0.067347",
        "ticker_sentiment_score": "0.038261",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Growth Stocks You Can Buy Right Now Without Any Hesitation",
    "url": "https://www.fool.com/investing/2024/11/18/3-growth-stocks-you-can-buy-right-now-without-any/",
    "time_published": "20241118T110300",
    "authors": [
      "Keith Speights",
      "and Prosper Junior Bakiny",
      "David Jagielski"
    ],
    "summary": "Many investors have a type of acrophobia ( the fear of heights ) . It's not that they're worried about standing at the top of a ladder. Instead, their concern is focused on putting money in stocks when the market is skyrocketing.Three Fool.com contributors think they've identified stocks that can ...",
    "banner_image": "https://g.foolcdn.com/editorial/images/797880/happy-stock-investor-holding-smartphone.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.993856"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.22085,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.221481",
        "ticker_sentiment_score": "0.148906",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.148731",
        "ticker_sentiment_score": "0.129861",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.326884",
        "ticker_sentiment_score": "0.248437",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BNXYF",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.007799",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals Incorporated  ( VRTX )  is Attracting Investor Attention: Here is What You Should Know",
    "url": "https://www.zacks.com/stock/news/2372043/vertex-pharmaceuticals-incorporated-vrtx-is-attracting-investor-attention-here-is-what-you-should-know",
    "time_published": "20241119T140012",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default67.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.223944,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.102449",
        "ticker_sentiment_score": "0.036245",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "CRISPR Therapeutics Stock Falls 7% in Two Weeks: Time to Hold or Sell?",
    "url": "https://www.zacks.com/stock/news/2372666/crispr-therapeutics-stock-falls-7-in-two-weeks-time-to-hold-or-sell",
    "time_published": "20241120T142100",
    "authors": [
      "Sundeep Ganoria"
    ],
    "summary": "The decline in CRSP's share price could be due to the beating the drug/biotech sector has been taking in the past couple of months, resulting from pipeline setbacks and guidance cuts.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.149,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BEAM",
        "relevance_score": "0.148426",
        "ticker_sentiment_score": "0.08433",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.197011",
        "ticker_sentiment_score": "0.242388",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "EDIT",
        "relevance_score": "0.099271",
        "ticker_sentiment_score": "0.076257",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "McKesson Stock Gains 34.1% YTD: What's Driving the Rally?",
    "url": "https://www.zacks.com/stock/news/2373606/mckesson-stock-gains-341-ytd-whats-driving-the-rally",
    "time_published": "20241121T180500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "MCK continues to gain because of robust segmental performance and raised fiscal 2025 guidance.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/34/973.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.967321"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.315387,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.05749",
        "ticker_sentiment_score": "0.058952",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MASI",
        "relevance_score": "0.171282",
        "ticker_sentiment_score": "0.117391",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSGR",
        "relevance_score": "0.114682",
        "ticker_sentiment_score": "0.063508",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GMED",
        "relevance_score": "0.171282",
        "ticker_sentiment_score": "0.158968",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MCK",
        "relevance_score": "0.483686",
        "ticker_sentiment_score": "0.33248",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HCSG",
        "relevance_score": "0.05749",
        "ticker_sentiment_score": "0.155988",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "MCK Stock Down Despite Latest Partnership to Boost SCD Treatment",
    "url": "https://www.zacks.com/stock/news/2373525/mck-stock-down-despite-latest-partnership-to-boost-scd-treatment",
    "time_published": "20241121T162800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The availability of the FDA-approved drug via McKesson's cell and gene therapies business is expected to give patients improved treatment options for SCD.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.199252,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.052455",
        "ticker_sentiment_score": "0.204668",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.104683",
        "ticker_sentiment_score": "0.248116",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.156461",
        "ticker_sentiment_score": "0.123686",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MCK",
        "relevance_score": "0.401331",
        "ticker_sentiment_score": "0.17615",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "COR",
        "relevance_score": "0.207571",
        "ticker_sentiment_score": "0.047318",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Got $500? 1 Biotech Stock to Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/11/22/got-500-1-biotech-stock-to-buy-and-hold-forever/",
    "time_published": "20241122T105100",
    "authors": [
      "Keith Speights"
    ],
    "summary": "Investing can sometimes require a significant amount of upfront cash. For example, you might need a lot of capital to buy real estate properties or launch a new business. However, even individuals without much money can invest in stocks.If you have $500, you should check out Vertex ...",
    "banner_image": "https://g.foolcdn.com/editorial/images/798512/scientists-looking-at-screen-with-icons.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      }
    ],
    "overall_sentiment_score": 0.172023,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.176287",
        "ticker_sentiment_score": "0.025053",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Monster Stocks in the Making",
    "url": "https://www.fool.com/investing/2024/11/23/3-monster-stocks-in-the-making/",
    "time_published": "20241123T113000",
    "authors": [
      "David Jagielski",
      "and Prosper Junior Bakiny",
      "Keith Speights"
    ],
    "summary": "Godzilla and King Kong surely weren't born big. They began small and grew over time to their gargantuan sizes even if the movies don't tell their childhood stories.Likewise, huge companies of today were once much smaller ( unless perhaps they were spin-offs ) .",
    "banner_image": "https://g.foolcdn.com/editorial/images/798646/scientist-looking-through-microscope.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.180921,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.043342",
        "ticker_sentiment_score": "0.159434",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AKESF",
        "relevance_score": "0.086556",
        "ticker_sentiment_score": "0.108188",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.296377",
        "ticker_sentiment_score": "0.07526",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMMT",
        "relevance_score": "0.214177",
        "ticker_sentiment_score": "-0.101086",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Down 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip?",
    "url": "https://www.fool.com/investing/2024/11/24/down-47-since-march-is-crispr-therapeutics-stock-a/",
    "time_published": "20241124T104700",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "On Nov. 21, shares of CRISPR Therapeutics ( NASDAQ: CRSP ) were down 47% from a peak they reached in March. This might be a little surprising to folks who have been following this developer of gene therapies. After all, it's been less than a year since regulators in the U.S. and E.U. approved its ...",
    "banner_image": "https://g.foolcdn.com/editorial/images/798604/smart-investor-studying-stock-charts-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.043741,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BEAM",
        "relevance_score": "0.047371",
        "ticker_sentiment_score": "-0.103003",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.187827",
        "ticker_sentiment_score": "0.028897",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.047371",
        "ticker_sentiment_score": "0.096024",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Looking Into Vertex Pharmaceuticals's Recent Short Interest - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/insights/short-sellers/24/11/42172011/looking-into-vertex-pharmaceuticalss-recent-short-interest",
    "time_published": "20241125T184515",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Vertex Pharmaceuticals's VRTX short percent of float has risen 5.42% since its last report. The company recently reported that it has 4.50 million shares sold short, which is 1.75% of all regular shares that are available for trading.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1732560311_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.287757,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.209365",
        "ticker_sentiment_score": "0.148634",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades.",
    "url": "https://www.fool.com/investing/2024/11/28/want-1-million-in-retirement-3-stocks-to-buy-now-a/",
    "time_published": "20241128T105000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "What you do in the present makes a huge difference in how successful you'll be in the future. This is true in a wide array of activities -- including investing.Do you want $1 million in retirement? Here are three stocks to buy now and hold for decades.Amazon ( NASDAQ: AMZN ) CEO Andy Jassy often ...",
    "banner_image": "https://g.foolcdn.com/editorial/images/799143/young-woman-smiling-hands-behind-head.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.905476"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.295471,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.101367",
        "ticker_sentiment_score": "0.113132",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.201105",
        "ticker_sentiment_score": "0.066991",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.050786",
        "ticker_sentiment_score": "0.346776",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.297661",
        "ticker_sentiment_score": "0.063606",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "GILD vs. VRTX: Which Stock Should Value Investors Buy Now?",
    "url": "https://www.zacks.com/stock/news/2377283/gild-vs-vrtx-which-stock-should-value-investors-buy-now",
    "time_published": "20241129T164013",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "GILD vs. VRTX: Which Stock Is the Better Value Option?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default117.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.505498,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.686739",
        "ticker_sentiment_score": "0.583398",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.743396",
        "ticker_sentiment_score": "0.598884",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More than 65%",
    "url": "https://www.fool.com/investing/2024/11/30/meet-the-beaten-down-stock-cathie-wood-loves/",
    "time_published": "20241130T093500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Ark Invest chief Cathie Wood is known for scooping up shares of innovators early in their growth stories and holding on for the long term. The idea is to get in on these players for a bargain price, and then benefit as they launch products and revenue gains momentum.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F799256%2Finvestor-smiling-computer.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.338476,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.054359",
        "ticker_sentiment_score": "0.008987",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RXRX",
        "relevance_score": "0.054359",
        "ticker_sentiment_score": "0.156811",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.054359",
        "ticker_sentiment_score": "0.088781",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TWST",
        "relevance_score": "0.054359",
        "ticker_sentiment_score": "0.156811",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "COIN",
        "relevance_score": "0.054359",
        "ticker_sentiment_score": "0.088781",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the iShares Biotechnology ETF  ( IBB ) ?",
    "url": "https://www.zacks.com/stock/news/2378017/should-you-invest-in-the-ishares-biotechnology-etf-ibb",
    "time_published": "20241203T112008",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default274.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      }
    ],
    "overall_sentiment_score": 0.189123,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.136499",
        "ticker_sentiment_score": "0.072027",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.136499",
        "ticker_sentiment_score": "0.072027",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.136499",
        "ticker_sentiment_score": "0.072027",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 High-Yield Dividend Growth Stocks to Buy in December and Hold for a Decade or Longer",
    "url": "https://www.fool.com/investing/2024/12/03/3-high-yield-dividend-growth-stocks-to-buy-in-dece/",
    "time_published": "20241203T092400",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "It's been a great couple of years for the stock market. From the end of 2022 through Nov. 29, the benchmark S&P 500 ( SNPINDEX: ^GSPC ) index rose a whopping 57.1% higher.During this bull run, stock prices have bounded forward much further than earnings from their underlying businesses.",
    "banner_image": "https://g.foolcdn.com/editorial/images/799277/board-room-chart-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999701"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.275012,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.049526",
        "ticker_sentiment_score": "0.156113",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RPRX",
        "relevance_score": "0.196212",
        "ticker_sentiment_score": "0.173649",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.196212",
        "ticker_sentiment_score": "0.163973",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.049526",
        "ticker_sentiment_score": "0.149845",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIPC",
        "relevance_score": "0.380736",
        "ticker_sentiment_score": "0.427828",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "FDA-Approved Sickle Cell Therapies From Bluebird Bio And Vertex Join Medicaid Innovation Program - bluebird bio  ( NASDAQ:BLUE ) , Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/24/12/42324351/fda-approved-sickle-cell-therapies-from-bluebird-bio-and-vertex-join-medicaid-innovation-program",
    "time_published": "20241204T193143",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "The Biden-Harris administration has announced an initiative to improve access to gene therapies for sickle cell disease under the Cell and Gene Therapy Access Model.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/04/FDA-Shutterstock.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.31305,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.255641",
        "ticker_sentiment_score": "0.17062",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BLUE",
        "relevance_score": "0.255641",
        "ticker_sentiment_score": "0.17062",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why Is Vertex  ( VRTX )  Down 8.6% Since Last Earnings Report?",
    "url": "https://www.zacks.com/stock/news/2379013/why-is-vertex-vrtx-down-86-since-last-earnings-report",
    "time_published": "20241204T163055",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default70.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.996675"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      }
    ],
    "overall_sentiment_score": 0.159014,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.043342",
        "ticker_sentiment_score": "-0.003973",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.043342",
        "ticker_sentiment_score": "0.058536",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Is Editas  ( EDIT )  Down 36.5% Since Last Earnings Report?",
    "url": "https://www.zacks.com/stock/news/2379037/why-is-editas-edit-down-365-since-last-earnings-report",
    "time_published": "20241204T163049",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default101.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.904684"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.105987,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.0699",
        "ticker_sentiment_score": "0.113516",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EDIT",
        "relevance_score": "0.0699",
        "ticker_sentiment_score": "-0.004057",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXEL",
        "relevance_score": "0.27432",
        "ticker_sentiment_score": "0.071595",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Investors Heavily Search Vertex Pharmaceuticals Incorporated  ( VRTX ) : Here is What You Need to Know",
    "url": "https://www.zacks.com/stock/news/2378771/investors-heavily-search-vertex-pharmaceuticals-incorporated-vrtx-here-is-what-you-need-to-know",
    "time_published": "20241204T140011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default298.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.228779,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.103331",
        "ticker_sentiment_score": "0.076054",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Forget Pfizer and Buy These Unstoppable Stocks Instead?",
    "url": "https://www.fool.com/investing/2024/12/05/should-you-forget-pfizer-and-buy-these-unstoppable/",
    "time_published": "20241205T121500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "Things aren't getting much better for Pfizer ( NYSE: PFE ) . The company is still suffering from the significant drop in sales of its coronavirus products and the less-than-impressive financial results it has produced during the past two years.",
    "banner_image": "https://g.foolcdn.com/editorial/images/799291/scientist-altering-dna-genome-project.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      }
    ],
    "overall_sentiment_score": 0.294612,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.422268",
        "ticker_sentiment_score": "0.48914",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.379291",
        "ticker_sentiment_score": "0.40492",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.289462",
        "ticker_sentiment_score": "0.244893",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 of the Best Growth Stocks You Can Buy for Less than $100",
    "url": "https://www.fool.com/investing/2024/12/05/3-of-the-best-growth-stocks-you-can-buy-for-less-t/",
    "time_published": "20241205T102700",
    "authors": [
      "David Jagielski"
    ],
    "summary": "It's getting harder these days to find great growth stocks trading for less than $100 a share. It almost seems like a higher price is one of the criteria. But investors should know that there are plenty of good growth stock options worth considering for the long haul that won't cost you a ...",
    "banner_image": "https://g.foolcdn.com/editorial/images/799427/a-family-meeting-with-an-advisor.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.752319"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.298301,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KBH",
        "relevance_score": "0.259451",
        "ticker_sentiment_score": "0.344398",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.052801",
        "ticker_sentiment_score": "0.092002",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CELH",
        "relevance_score": "0.40375",
        "ticker_sentiment_score": "0.37409",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "PEP",
        "relevance_score": "0.157483",
        "ticker_sentiment_score": "0.182355",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Biotech Stocks to Buy Hand Over Fist in December",
    "url": "https://www.fool.com/investing/2024/12/07/2-biotech-stocks-to-buy-hand-over-fist-in-december/",
    "time_published": "20241207T134500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The biotech industry has lagged the broader market so far in 2024. The SPDR S&P Biotech ETF, an industry benchmark, is up 9% this year compared to 28% for the S&P 500. Will that trend continue in 2025? It's hard to say, but many individual biotech stocks still look like solid long-term picks.That ...",
    "banner_image": "https://media.ycharts.com/charts/1021bfa811106ababba32d16e80d2a96.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      }
    ],
    "overall_sentiment_score": 0.251837,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.113062",
        "ticker_sentiment_score": "0.254694",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "EXEL",
        "relevance_score": "0.522854",
        "ticker_sentiment_score": "0.332785",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 No-Brainer Growth Stocks to Buy in December",
    "url": "https://www.fool.com/investing/2024/12/07/3-no-brainer-growth-stocks-to-buy-in-december/",
    "time_published": "20241207T114600",
    "authors": [
      "David Jagielski",
      "Keith Speights",
      "and Prosper Junior Bakiny"
    ],
    "summary": "Growth. It's what most investors want more than anything else from their stocks. Some stocks can deliver more of it than others.Three Motley Fool contributors think they've identified no-brainer growth stocks in the healthcare sector to buy in December.",
    "banner_image": "https://g.foolcdn.com/editorial/images/800044/excited-investor-looks-at-financial-charts-on-computer.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.190917,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.235823",
        "ticker_sentiment_score": "0.1895",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.197413",
        "ticker_sentiment_score": "0.013156",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.382925",
        "ticker_sentiment_score": "0.136836",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Has $5 Billion-Plus Opportunity In Pain And Kidney Disease Programs, Analyst Upgrades Stock - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/general/biotech/24/12/42396975/vertex-has-5-billion-plus-opportunity-in-pain-and-kidney-disease-programs-analyst-upgrades-stock",
    "time_published": "20241209T182336",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Jefferies has upgraded Vertex Pharmaceuticals Inc. VRTX, citing the company's robust cystic fibrosis base business and the additional upside from the new LNP/ mRNA therapy ( around $1 billion opportunity ) and \"triple pill\" regimens. The company's pipeline can potentially exceed expectations ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/09/Genetic-Research-And-Biotech-Science-Con.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.352179,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.328819",
        "ticker_sentiment_score": "0.35766",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology  ( ASH )  Annual Meeting",
    "url": "https://www.globenewswire.com/news-release/2024/12/09/2993974/0/en/CRISPR-Therapeutics-Presents-Data-at-the-2024-American-Society-of-Hematology-ASH-Annual-Meeting.html",
    "time_published": "20241209T170000",
    "authors": [
      "CRISPR Therapeutics AG"
    ],
    "summary": "-Preliminary data demonstrate that CTX112\u2122 has the potential to provide meaningful clinical benefit with a well-tolerated safety profile using a standard ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/5dac7d0d-131d-4047-bab7-db8e0719bf58",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.219504,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.039096",
        "ticker_sentiment_score": "0.12814",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRSP",
        "relevance_score": "0.058615",
        "ticker_sentiment_score": "0.119999",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is iShares Biotechnology ETF  ( IBB )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2380648/is-ishares-biotechnology-etf-ibb-a-strong-etf-right-now",
    "time_published": "20241209T112006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default87.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999981"
      }
    ],
    "overall_sentiment_score": 0.248169,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.121343",
        "ticker_sentiment_score": "0.068087",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.121343",
        "ticker_sentiment_score": "0.068087",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.121343",
        "ticker_sentiment_score": "0.068087",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 No-Brainer Stocks to Buy Before the End of 2024",
    "url": "https://www.fool.com/investing/2024/12/09/2-no-brainer-stocks-to-buy-before-the-end-of-2024/",
    "time_published": "20241209T105000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "I think the stock market's valuation has become frothy. And I'm in good company. Warren Buffett's actions show that he shares this opinion. The legendary investor continues to be a net seller of stocks, and has amassed a record-high cash stockpile for Berkshire Hathaway.",
    "banner_image": "https://g.foolcdn.com/editorial/images/800169/hands-behind-head-young-man.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.03878,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.116348",
        "ticker_sentiment_score": "0.140823",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.05833",
        "ticker_sentiment_score": "-0.064975",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNTX",
        "relevance_score": "0.339356",
        "ticker_sentiment_score": "-0.031755",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.05833",
        "ticker_sentiment_score": "0.07024",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( VRTX )  Falls More Steeply Than Broader Market: What Investors Need to Know",
    "url": "https://www.zacks.com/stock/news/2381816/vertex-pharmaceuticals-vrtx-falls-more-steeply-than-broader-market-what-investors-need-to-know",
    "time_published": "20241210T225011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $469.29, indicating a -0.99% shift from the previous trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default207.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.976913"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.129322,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.540358",
        "ticker_sentiment_score": "0.155512",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "The Ultimate Biotech Stock to Buy With $500 Right Now",
    "url": "https://www.fool.com/investing/2024/12/12/the-ultimate-biotech-stock-to-buy-with-500-right-n/",
    "time_published": "20241212T105100",
    "authors": [
      "Keith Speights"
    ],
    "summary": "Investing in biotech stocks isn't for everyone because the very nature of their business is fraught with risk. As a result, biotech stocks can be highly volatile.However, some exceptions aren't nearly as risky. A few are even practically no-brainer picks for long-term investors.",
    "banner_image": "https://g.foolcdn.com/editorial/images/800667/scientists-happy.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      }
    ],
    "overall_sentiment_score": 0.095614,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.183895",
        "ticker_sentiment_score": "0.071024",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/insights/news/24/12/42486614/100-invested-in-this-stock-20-years-ago-would-be-worth-this-much-today",
    "time_published": "20241213T154517",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Vertex Pharmaceuticals VRTX has outperformed the market over the past 20 years by 12.15% on an annualized basis producing an average annual return of 20.56%. Currently, Vertex Pharmaceuticals has a market capitalization of $118.76 billion.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1734104714_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.238974,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.9545",
        "ticker_sentiment_score": "0.384186",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors",
    "url": "https://www.globenewswire.com/news-release/2024/12/13/2996712/0/en/Monte-Rosa-Therapeutics-Appoints-Dr-Eric-A-Hughes-to-Board-of-Directors.html",
    "time_published": "20241213T120000",
    "authors": [
      "Monte Rosa Therapeutics",
      "Inc."
    ],
    "summary": "BOSTON, Dec. 13, 2024 ( GLOBE NEWSWIRE ) -- Monte Rosa Therapeutics, Inc. ( Nasdaq: GLUE ) , a clinical-stage biotechnology company developing novel molecular glue degrader ( MGD ) -based medicines, today announced the appointment of Eric A. Hughes, M.D, Ph.D., to its Board of Directors.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/20ed9999-454a-4e2a-aabc-217270a87d2d",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.055595,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GLUE",
        "relevance_score": "0.247838",
        "ticker_sentiment_score": "-0.044661",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.062926",
        "ticker_sentiment_score": "-0.033021",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.062926",
        "ticker_sentiment_score": "-0.033021",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors - Monte Rosa Therapeutics  ( NASDAQ:GLUE ) ",
    "url": "https://www.benzinga.com/pressreleases/24/12/g42481101/monte-rosa-therapeutics-appoints-dr-eric-a-hughes-to-board-of-directors",
    "time_published": "20241213T120000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "BOSTON, Dec. 13, 2024 ( GLOBE NEWSWIRE ) -- Monte Rosa Therapeutics, Inc. GLUE, a clinical-stage biotechnology company developing novel molecular glue degrader ( MGD ) -based medicines, today announced the appointment of Eric A. Hughes, M.D, Ph.D., to its Board of Directors.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.081964,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GLUE",
        "relevance_score": "0.230782",
        "ticker_sentiment_score": "-0.040284",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.058472",
        "ticker_sentiment_score": "-0.032999",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.058472",
        "ticker_sentiment_score": "-0.032999",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Things You Need to Know if You Buy CRISPR Therapeutics Today",
    "url": "https://www.fool.com/investing/2024/12/14/3-things-to-know-if-you-buy-crispr-therapeutics/",
    "time_published": "20241214T144500",
    "authors": [
      "Dan Victor"
    ],
    "summary": "CRISPR Therapeutics ( NASDAQ: CRSP ) is recognized as a pioneer in the field of gene therapy. This biotechnology has the potential to revolutionize medicine through precise modifications of a person's DNA to treat and cure genetic diseases.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F800738%2Fcrispr-stock-2025-cautious-outlook.png&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.218928,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BEAM",
        "relevance_score": "0.056275",
        "ticker_sentiment_score": "0.136929",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.056275",
        "ticker_sentiment_score": "0.191972",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NTLA",
        "relevance_score": "0.056275",
        "ticker_sentiment_score": "0.136929",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Unstoppable Stocks to Buy Right Now",
    "url": "https://www.fool.com/investing/2024/12/15/3-unstoppable-stocks-to-buy-right-now/",
    "time_published": "20241215T110700",
    "authors": [
      "Keith Speights",
      "David Jagielski",
      "and Prosper Junior Bakiny"
    ],
    "summary": "Some stocks sizzle, then fizzle. Others, though, build long-lasting momentum thanks to strong underlying business fundamentals. Three Motley Fool contributors believe they've found stocks in the latter category. Here's why they think AstraZeneca ( NASDAQ: AZN ) , Eli Lilly ( NYSE: LLY ) , and ...",
    "banner_image": "https://g.foolcdn.com/editorial/images/800812/smiling-person-with-cup-looking-at-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.255103,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GLDAF",
        "relevance_score": "0.047185",
        "ticker_sentiment_score": "-0.032449",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.321273",
        "ticker_sentiment_score": "0.135827",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.277433",
        "ticker_sentiment_score": "0.159379",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.364053",
        "ticker_sentiment_score": "0.290746",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why Vertex Pharmaceuticals  ( VRTX )  Outpaced the Stock Market Today",
    "url": "https://www.zacks.com/stock/news/2384210/why-vertex-pharmaceuticals-vrtx-outpaced-the-stock-market-today",
    "time_published": "20241216T225013",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex Pharmaceuticals (VRTX) closed at $468.09 in the latest trading session, marking a +0.94% move from the prior day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default76.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.160809,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.538782",
        "ticker_sentiment_score": "0.244908",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "BMY vs. VRTX: Which Stock Is the Better Value Option?",
    "url": "https://www.zacks.com/stock/news/2384104/bmy-vs-vrtx-which-stock-is-the-better-value-option",
    "time_published": "20241216T164013",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Bristol Myers Squibb ( BMY Quick QuoteBMY - ) or Vertex Pharmaceuticals ( VRTX Quick QuoteVRTX - ) . But which of these two stocks is more attractive to value investors?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default332.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.50411,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.739411",
        "ticker_sentiment_score": "0.582505",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.7887",
        "ticker_sentiment_score": "0.594153",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Tesla To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Monday - CNX Resources  ( NYSE:CNX ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",
    "url": "https://www.benzinga.com/24/12/42507587/tesla-to-rally-around-18-here-are-10-top-analyst-forecasts-for-monday",
    "time_published": "20241216T133729",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Stifel raised the price target for Vertex Pharmaceuticals Incorporated VRTX from $490 to $494.",
    "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16083522/image-126-1024x483.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.658903"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.222428,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MKSI",
        "relevance_score": "0.234307",
        "ticker_sentiment_score": "-0.122226",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.234307",
        "ticker_sentiment_score": "0.342577",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.308891",
        "ticker_sentiment_score": "0.347936",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.157483",
        "ticker_sentiment_score": "-0.091153",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RH",
        "relevance_score": "0.157483",
        "ticker_sentiment_score": "0.080903",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.234307",
        "ticker_sentiment_score": "0.005443",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.234307",
        "ticker_sentiment_score": "0.108503",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NKE",
        "relevance_score": "0.157483",
        "ticker_sentiment_score": "0.004048",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CNX",
        "relevance_score": "0.234307",
        "ticker_sentiment_score": "0.10674",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.234307",
        "ticker_sentiment_score": "0.224892",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DIS",
        "relevance_score": "0.157483",
        "ticker_sentiment_score": "0.086137",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.07913",
        "ticker_sentiment_score": "0.062884",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Prediction: These Could Be the Best-Performing Pharma and Biotech Stocks Through 2030",
    "url": "https://www.fool.com/investing/2024/12/16/prediction-best-performing-health-stocks-by-2030/",
    "time_published": "20241216T091500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Pharmaceutical and biotech stocks often are seen as steady and safe options for investors for one particular reason. Patients need their medications, so regardless of the economic environment, these companies generally see at least stability in revenue.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F801046%2Fgettyimages-1272759382.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.184547,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.103109",
        "ticker_sentiment_score": "0.147189",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.154125",
        "ticker_sentiment_score": "-0.041842",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.051663",
        "ticker_sentiment_score": "0.012003",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.051663",
        "ticker_sentiment_score": "0.012003",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.302553",
        "ticker_sentiment_score": "0.167298",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "4 Big Drug Stocks That May Continue to Outperform in 2025",
    "url": "https://www.zacks.com/stock/news/2384649/4-big-drug-stocks-that-may-continue-to-outperform-in-2025",
    "time_published": "20241217T150300",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Gilead, Eli Lilly, Vertex Pharmaceuticals and AbbVie have outperformed the industry this year and are likely to see continued momentum in 2025.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/cc/389.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.996675"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.196045,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.195025",
        "ticker_sentiment_score": "0.083643",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.065595",
        "ticker_sentiment_score": "0.057058",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.195025",
        "ticker_sentiment_score": "0.141608",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025",
    "url": "https://www.zacks.com/stock/news/2384457/3-biotech-stocks-with-promising-gene-therapies-to-watch-out-in-2025",
    "time_published": "20241217T135900",
    "authors": [
      "Ekta Bagri"
    ],
    "summary": "We have picked three biotech stocks with promising gene therapies in their portfolios/pipelines that are likely to perform well in 2025.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/75/76753.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.274741,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.04161",
        "ticker_sentiment_score": "0.204641",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRSP",
        "relevance_score": "0.285051",
        "ticker_sentiment_score": "0.186659",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.04161",
        "ticker_sentiment_score": "0.145899",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SRPT",
        "relevance_score": "0.285051",
        "ticker_sentiment_score": "0.349163",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VYGR",
        "relevance_score": "0.323608",
        "ticker_sentiment_score": "0.184838",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio?",
    "url": "https://www.fool.com/investing/2024/12/17/2-growth-stocks-that-could-rocket-higher-in-2025-a/",
    "time_published": "20241217T102900",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "Investors looking for stocks that can make dramatic gains can find some in the biopharmaceutical industry. Right now, there are a pair of biopharma stocks that Wall Street expects to rocket higher in 2025.The Food and Drug Administration ( FDA ) approved CRISPR Therapeutics' ( NASDAQ: CRSP ) ...",
    "banner_image": "https://g.foolcdn.com/editorial/images/801126/investors-evaluating-a-stock-purchase-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998356"
      }
    ],
    "overall_sentiment_score": 0.105103,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.042953",
        "ticker_sentiment_score": "0.00394",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IOVA",
        "relevance_score": "0.128363",
        "ticker_sentiment_score": "0.134745",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Check Out What Whales Are Doing With VRTX - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/insights/options/24/12/42562785/check-out-what-whales-are-doing-with-vrtx",
    "time_published": "20241218T203027",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bullish stance on Vertex Pharmaceuticals VRTX. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1734553827_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      }
    ],
    "overall_sentiment_score": 0.144014,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.662594",
        "ticker_sentiment_score": "0.183449",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Claire's Place Foundation Wraps up 2024 with Record-Breaking Events & Exciting Announcements for 2025",
    "url": "https://www.benzinga.com/pressreleases/24/12/g42554378/claires-place-foundation-wraps-up-2024-with-record-breaking-events-exciting-announcements-for-2025",
    "time_published": "20241218T143000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Los Angeles, CA, Dec. 18, 2024 ( GLOBE NEWSWIRE ) -- Claire's Place Foundation, a non-profit organization providing support to children and families affected by cystic fibrosis ( CF ) , celebrates an extraordinary 2024 and announces exciting plans for the year ahead.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.586966,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.097655",
        "ticker_sentiment_score": "0.391961",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals Incorporated  ( VRTX )  Is a Trending Stock: Facts to Know Before Betting on It",
    "url": "https://www.zacks.com/stock/news/2385163/vertex-pharmaceuticals-incorporated-vrtx-is-a-trending-stock-facts-to-know-before-betting-on-it",
    "time_published": "20241218T140012",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default51.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.246044,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.102668",
        "ticker_sentiment_score": "0.036268",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Is Vertex Pharmaceuticals Stock Trading Lower On Thursday After Back Pain Trial Data? - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/24/12/42599745/why-is-vertex-pharmaceuticals-stock-trading-on-thursday-lower-after-back-pain-trial-data",
    "time_published": "20241219T180632",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Thursday, Vertex Pharmaceuticals Incorporated VRTX announced results from its Phase 2 study of suzetrigine for painful lumbosacral radiculopathy ( LSR ) , a disorder that causes pain in the lower back and hip that radiates down the back of the thigh into the leg.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/19/VRTX.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": -0.026904,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.327366",
        "ticker_sentiment_score": "-0.389342",
        "ticker_sentiment_label": "Bearish"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals Inc.  ( VRTX )  Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/pressreleases/24/12/g42595404/vertex-pharmaceuticals-inc-vrtx-investigated-for-securities-fraud-block-leviton-encourages-investo",
    "time_published": "20241219T155018",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "BOSTON, Dec. 19, 2024 ( GLOBE NEWSWIRE ) -- Block & Leviton is investigating Vertex Pharmaceuticals Inc. VRTX for potential securities law violations. Investors who have lost money in their Vertex Pharmaceuticals Inc. investment should contact the firm to learn more about how they might recover ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.918141"
      }
    ],
    "overall_sentiment_score": -0.092962,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.400052",
        "ticker_sentiment_score": "0.039607",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Unstoppable Stocks to Buy and Hold for the Next Decade",
    "url": "https://www.fool.com/investing/2024/12/19/2-unstoppable-stocks-to-buy-and-hold-for-the-next/",
    "time_published": "20241219T092000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "What do Apple ( NASDAQ: AAPL ) and Vertex Pharmaceuticals ( NASDAQ: VRTX ) have in common? At first glance, not much. The former is a consumer tech leader while the latter operates in the biotech industry.One thing they do share, though, is that they've made their long-term shareholders happy.",
    "banner_image": "https://g.foolcdn.com/editorial/images/800686/person-holding-a-smartphone-and-a-mug.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.94762"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.299802,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.382088",
        "ticker_sentiment_score": "0.380135",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.382088",
        "ticker_sentiment_score": "0.299238",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "VRTX Down as Non-Opioid Drug Shows Similar Pain Reduction as Placebo",
    "url": "https://www.zacks.com/stock/news/2386433/vrtx-down-as-non-opioid-drug-shows-similar-pain-reduction-as-placebo",
    "time_published": "20241220T161300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex announces data from a phase II study evaluating its NaV1.8 pain signal inhibitor, suzetrigine, for treating painful lumbosacral radiculopathy. Shares down.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/37/2337.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.928139"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.089028,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.232996",
        "ticker_sentiment_score": "-0.149786",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTMX",
        "relevance_score": "0.232996",
        "ticker_sentiment_score": "0.032809",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPRO",
        "relevance_score": "0.232996",
        "ticker_sentiment_score": "0.045463",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CSTL",
        "relevance_score": "0.232996",
        "ticker_sentiment_score": "0.046557",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "1 big new Green Flag for CRISPR Therapeutics' Stock",
    "url": "https://www.fool.com/investing/2024/12/20/1-big-new-green-flag-for-crispr-therapeutics-stock/",
    "time_published": "20241220T143000",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "CRISPR Therapeutics ( NASDAQ: CRSP ) isn't a stock that's wanting for reasons to invest. Between the solid launch of its first commercialized therapy and a promising pipeline that's continuing to deliver, this biotech is on track for growth.",
    "banner_image": "https://g.foolcdn.com/editorial/images/801339/scientist-looking-at-microscope-in-lab1.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.209466,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.051774",
        "ticker_sentiment_score": "0.037007",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine",
    "url": "https://www.globenewswire.com/news-release/2024/12/20/3000627/0/en/Channel-Therapeutics-Highlights-Differences-Between-NaV1-7-and-NaV1-8-in-Light-of-Recent-Clinical-Data-on-Suzetrigine.html",
    "time_published": "20241220T140000",
    "authors": [
      "Channel Therapeutics Corporation"
    ],
    "summary": "FREEHOLD, N.J., Dec. 20, 2024 ( GLOBE NEWSWIRE ) -- Channel Therapeutics Corporation, ( \"Channel\" or the \"Company\" ) , ( NYSE American: CHRO ) , a pioneer in the development of non-opioid pain treatment therapeutics, is providing a statement regarding Vertex Pharmaceutical's recently announced ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/11b7ce12-2c43-4e68-af9d-fcf236872298",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.905476"
      }
    ],
    "overall_sentiment_score": -0.07834,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.051003",
        "ticker_sentiment_score": "-0.096001",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Fantastic Stocks That Could Enjoy a Santa Claus Rally",
    "url": "https://www.fool.com/investing/2024/12/21/3-fantastic-stocks-that-could-enjoy-a-santa-claus/",
    "time_published": "20241221T114800",
    "authors": [
      "Keith Speights",
      "and Prosper Junior Bakiny",
      "David Jagielski"
    ],
    "summary": "Santa Claus will soon be on his way delivering presents to kids around the world. But could the jolly gift-giver bring something for investors, too? So-called \"Santa Claus rallies\" can occur near the end of the year.Three Motley Fool contributors think they've identified fantastic stocks that ...",
    "banner_image": "https://g.foolcdn.com/editorial/images/801623/santa-claus-buggy-chart.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999186"
      }
    ],
    "overall_sentiment_score": 0.211687,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.167612",
        "ticker_sentiment_score": "-0.010377",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.327909",
        "ticker_sentiment_score": "0.311137",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.167612",
        "ticker_sentiment_score": "0.140496",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "1 Reason to Sell DexCom Stock, and 1 Reason to Buy",
    "url": "https://www.fool.com/investing/2024/12/21/1-reason-to-sell-dexcom-stock-and-1-reason-to-buy/",
    "time_published": "20241221T114500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "Shares of the medical-device maker DexCom ( NASDAQ: DXCM ) are down by 37% this year. The diabetes-focused healthcare company disappointed investors with its second-quarter results, leading to a massive drop in its stock price overnight.",
    "banner_image": "https://media.ycharts.com/charts/981d0dcca0bfef3de22b3932d9fb2620.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.228513,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.051663",
        "ticker_sentiment_score": "0.142477",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.600398",
        "ticker_sentiment_score": "0.351815",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "My Top 10 Stocks to Buy for 2025",
    "url": "https://www.fool.com/investing/2024/12/21/my-top-10-stocks-to-buy-for-2025/",
    "time_published": "20241221T090500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "It's that time of year again. I'm not referring to buying gifts and preparing holiday meals -- although that may be part of your agenda too. It's time to look back on your portfolio's performance and plan for the year ahead.It's been a solid year for many, with all three indexes heading for ...",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F801386%2Fgettyimages-1070239362.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.294166,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.057698",
        "ticker_sentiment_score": "0.101011",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRMNF",
        "relevance_score": "0.028868",
        "ticker_sentiment_score": "0.271297",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.057698",
        "ticker_sentiment_score": "0.189079",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.057698",
        "ticker_sentiment_score": "0.125112",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRWD",
        "relevance_score": "0.115094",
        "ticker_sentiment_score": "0.172189",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ETSY",
        "relevance_score": "0.199977",
        "ticker_sentiment_score": "0.029445",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.057698",
        "ticker_sentiment_score": "0.239009",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.115094",
        "ticker_sentiment_score": "0.231631",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.171892",
        "ticker_sentiment_score": "0.119767",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.115094",
        "ticker_sentiment_score": "0.101426",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PLTR",
        "relevance_score": "0.057698",
        "ticker_sentiment_score": "0.025011",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "This Beaten-Down Biotech Stock Just Got Some Good News: Time to Buy?",
    "url": "https://www.fool.com/investing/2024/12/22/this-beaten-down-biotech-stock-just-got-some-good/",
    "time_published": "20241222T172500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "What's going on with CRISPR Therapeutics ( NASDAQ: CRSP ) ? The company's shares have been southbound for the better part of three years. And despite major regulatory wins since late 2023, the biotech hasn't recovered: The stock is down 23% year to date.Can CRISPR Therapeutics bounce back?",
    "banner_image": "https://g.foolcdn.com/editorial/images/800098/physician-giving-a-high-five-to-a-young-patient.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.17384,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.109956",
        "ticker_sentiment_score": "0.031605",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BLUE",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "-0.11384",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025?",
    "url": "https://www.fool.com/investing/2024/12/22/should-you-buy-vertex-on-dip-before-2025/",
    "time_published": "20241222T093000",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Vertex Pharmaceuticals ( NASDAQ: VRTX ) was on track to become one of this year's biotech winners, with the shares climbing 27% from January through a peak in November. The company, the global leader in cystic fibrosis ( CF ) treatments, has established a long track record of earnings growth ...",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F801725%2Fgettyimages-research-team-smiles-in-lab.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.112727,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.109956",
        "ticker_sentiment_score": "0.231112",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek",
    "url": "https://www.zacks.com/stock/news/2387103/vertex-secures-fda-approval-for-new-cystic-fibrosis-drug-alyftrek",
    "time_published": "20241223T184400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The FDA's nod is based on late-stage data, which show that treatment with VRTX's Alyftrek enhances patient benefit compared to the blockbuster drug Trikafta.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/29/1920.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.055168,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.324495",
        "ticker_sentiment_score": "-0.007095",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTMX",
        "relevance_score": "0.165788",
        "ticker_sentiment_score": "0.038087",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.165788",
        "ticker_sentiment_score": "-0.149455",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CSTL",
        "relevance_score": "0.219809",
        "ticker_sentiment_score": "0.130208",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals: Alyftrek Is An 'Accretive Opportunity' On Top- And Bottom-Lines, Says Bullish Analyst - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
    "url": "https://www.benzinga.com/24/12/42652152/vertex-pharmaceuticals-alyftrek-is-an-accretive-opportunity-on-top-and-bottom-lines-say-bullish-analyst",
    "time_published": "20241223T161358",
    "authors": [
      "Priya Nigam"
    ],
    "summary": "Vertex Pharmaceuticals Inc VRTX last week announced that the Phase 2 study of suzetrigine for painful lumbosacral radiculopathy ( LSR ) had met its primary endpoint.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/23/Vertex-jpg.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.219509,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.142565",
        "ticker_sentiment_score": "0.108374",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.791422",
        "ticker_sentiment_score": "-0.203473",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Microsoft To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Monday - Datadog  ( NASDAQ:DDOG ) , Carnival  ( NYSE:CCL ) ",
    "url": "https://www.benzinga.com/24/12/42651617/microsoft-to-rally-around-26-here-are-10-top-analyst-forecasts-for-monday",
    "time_published": "20241223T160002",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Loop Capital increased Microsoft Corporation MSFT price target from $500 to $550.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/23/Amazon-and-Microsoft-Join-the-Rally.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999186"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.215986,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.237358",
        "ticker_sentiment_score": "0.20806",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.159569",
        "ticker_sentiment_score": "-0.010925",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HUMA",
        "relevance_score": "0.237358",
        "ticker_sentiment_score": "0.225439",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SOUN",
        "relevance_score": "0.237358",
        "ticker_sentiment_score": "0.188856",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UNIT",
        "relevance_score": "0.237358",
        "ticker_sentiment_score": "0.107859",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LEN",
        "relevance_score": "0.237358",
        "ticker_sentiment_score": "0.036334",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNOW",
        "relevance_score": "0.237358",
        "ticker_sentiment_score": "0.113164",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DDOG",
        "relevance_score": "0.237358",
        "ticker_sentiment_score": "0.20806",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SLB",
        "relevance_score": "0.080188",
        "ticker_sentiment_score": "-0.048411",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.237358",
        "ticker_sentiment_score": "0.200862",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.159569",
        "ticker_sentiment_score": "0.02698",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( VRTX )  Gains But Lags Market: What You Should Know",
    "url": "https://www.zacks.com/stock/news/2387744/vertex-pharmaceuticals-vrtx-gains-but-lags-market-what-you-should-know",
    "time_published": "20241224T225019",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $408.18, denoting a +0.72% change from the preceding trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default273.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.972476"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.174632,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.656549",
        "ticker_sentiment_score": "0.318438",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Top Stock Reports for T-Mobile, Toyota Motor & Vertex Pharmaceuticals",
    "url": "https://www.zacks.com/research-daily/2387573/top-stock-reports-for-t-mobile-toyota-motor-vertex-pharmaceuticals",
    "time_published": "20241224T194200",
    "authors": [
      "Mark Vickery"
    ],
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc. (TMUS), Toyota Motor Corporation (TM) and Vertex Pharmaceuticals Incorporated (VRTX), as well as two micro-cap stocks BK Technologies Corporation (BKTI) and Servotronics, Inc. (SVT).",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/86/3444.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.94762"
      }
    ],
    "overall_sentiment_score": 0.181167,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.052226",
        "ticker_sentiment_score": "-0.086945",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TM",
        "relevance_score": "0.052226",
        "ticker_sentiment_score": "0.182924",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should You Invest in the VanEck Biotech ETF  ( BBH ) ?",
    "url": "https://www.zacks.com/stock/news/2387268/should-you-invest-in-the-vaneck-biotech-etf-bbh",
    "time_published": "20241224T112006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default63.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.161328,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.071096",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.071096",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.071096",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 No-Brainer Stocks to Buy on the Latest Sell-Off",
    "url": "https://www.fool.com/investing/2024/12/24/3-no-brainer-stocks-to-buy-on-the-latest-sell-off/",
    "time_published": "20241224T102500",
    "authors": [
      "Keith Speights"
    ],
    "summary": "Warren Buffett's mentor Benjamin Graham once said, \"In the short run, the market is a voting machine but in the long run, it is a weighing machine.\" He understood that stocks are largely driven by investor sentiment, which is inherently fickle over the near term.",
    "banner_image": "https://g.foolcdn.com/editorial/images/801947/stock-chart-falling-with-man-holding-hand-to-head.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.875462"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.230697,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.093108",
        "ticker_sentiment_score": "-0.259425",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.093108",
        "ticker_sentiment_score": "0.136288",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNXYF",
        "relevance_score": "0.046633",
        "ticker_sentiment_score": "0.072892",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.230017",
        "ticker_sentiment_score": "0.143534",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights T-Mobile, Toyota Motor, Vertex Pharmaceuticals, BK Technologies and Servotronics",
    "url": "https://www.zacks.com/stock/news/2388293/the-zacks-analyst-blog-highlights-t-mobile-toyota-motor-vertex-pharmaceuticals-bk-technologies-and-servotronics",
    "time_published": "20241226T144300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "T-Mobile, Toyota Motor, Vertex Pharmaceuticals, BK Technologies and Servotronics are part of the Zacks top Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e3/536.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.94762"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.160549,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TMUS",
        "relevance_score": "0.162528",
        "ticker_sentiment_score": "0.04384",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.202366",
        "ticker_sentiment_score": "0.007921",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TM",
        "relevance_score": "0.202366",
        "ticker_sentiment_score": "0.108019",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip",
    "url": "https://www.fool.com/investing/2024/12/26/vertex-pharmaceuticals-stock-is-down-13-heres-why/",
    "time_published": "20241226T133000",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Vertex Pharmaceuticals ( NASDAQ: VRTX ) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to doubt the long-term potential of this stock, this setback is an opportunity to buy the dip for ...",
    "banner_image": "https://g.foolcdn.com/editorial/images/801997/two-investors-consider-a-stock-with-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.082514,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.115787",
        "ticker_sentiment_score": "-0.080865",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why This Beaten-Down Growth Stock Is a No-Brainer Buy on the Dip",
    "url": "https://www.fool.com/investing/2024/12/28/why-this-beaten-down-growth-stock-is-a-no-brainer/",
    "time_published": "20241228T130000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "Every investor has heard the phrase \"buy low, sell high.\" It's a simple enough piece of advice that's less simple to apply. What exactly qualifies as \"low\"? One possible answer is when a company's shares fall significantly in one day following a setback that barely affects its long-term ...",
    "banner_image": "https://media.ycharts.com/charts/e547416f3b01d6687f000b812007b864.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.043965,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.333257",
        "ticker_sentiment_score": "-0.075738",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is the Options Market Predicting a Spike in Vertex Pharmaceuticals  ( VRTX )  Stock?",
    "url": "https://www.zacks.com/stock/news/2389326/is-the-options-market-predicting-a-spike-in-vertex-pharmaceuticals-vrtx-stock",
    "time_published": "20241230T133000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Investors need to pay close attention to Vertex Pharmaceuticals (VRTX) stock based on the movements in the options market lately.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.064363,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.567746",
        "ticker_sentiment_score": "0.092605",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vertex Pharmaceuticals  ( VRTX )  Advances While Market Declines: Some Information for Investors",
    "url": "https://www.zacks.com/stock/news/2390247/vertex-pharmaceuticals-vrtx-advances-while-market-declines-some-information-for-investors",
    "time_published": "20241231T230022",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $402.70, marking a +0.84% move from the previous day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default273.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.136465,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.531019",
        "ticker_sentiment_score": "0.179318",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  }
]